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Abstract 
Chronic inflammation and oxidative stress are two common biological processes 
known to play significant roles in the mechanisms underlying the pathogenesis of 
many human inflammatory and neurodegenerative diseases such as atherosclerosis, 
rheumatoid arthritis, Parkinson’s disease, and some cancers. As a wider strategy 
towards developing new therapeutics for managing chronic inflammation and 
oxidative stress-related diseases/disorders, this project employed the pharmacophore 
hybridization strategy to design, synthesize and evaluate the therapeutic efficacy of 
novel potential hybrid nitroxide-based antioxidants that may regulate multiple 
biological targets simultaneously (dual-acting). The approach combines various 
nitroxide compounds with known pharmacophores - mainly the NSAID and 
sympathomimetic stimulants class of drugs. The hybrid agents were constructed by 
either merging/overlapping the two structural subunits or via cleavable (ester and 
amide bonds) and non-cleavable (amine bond) linkers. 
Three novel, potential dual action nitroxide-salicylate hybrids were successfully 
synthesized by overlapping similar structural subunits of the parent molecules. The 
merged analogues displayed moderate antioxidant and anti-inflammatory effects by 
inhibiting the MPO-mediated hypochlorous acid production system and the 
cyclooxygenase (COX) enzymes respectively. Although the results are encouraging, 
notably, the COX inhibitory effects were only significant after longer incubation 
times. 
In addition to the merged hybrid nitroxide-salicylates, thirty novel cleavable (ester 
and amide bond linkers) and non-cleavable nitroxide-NSAID conjugates (amino 
linker) were synthesized. The hybrid nitroxide-NSAID conjugates displayed 
significant antioxidant and anti-inflammatory effects on the A549 Non-Small Cell 
Lung Cancer cells. Notably, the ester-linked nitroxide conjugate 140 possessed better 
anti-inflammatory effects (inhibitory effects on the COX enzyme) than parent aspirin 
136, and showed a better ROS scavenging activity than the versatile antioxidant, 
TEMPOL 102. In addition to the antioxidant and anti-inflammatory effects, the 
hybrid conjugates also displayed promising anticancer effects. The nitroxide-NSAID 
  v 
conjugates were shown to inhibit the proliferation of A549 Non-Small Cell Lung 
Cancer cells. Clonogenic assay studies of A549 cells indicated that combining the 
nitroxide-NSAID conjugates with anticancer agents such as gefitinib produced a 
synergistic effect on inhibiting A549 cells growth. 
Although the key and ultimate step (dirhodium-catalyzed intermolecular C-H 
insertion of methyl phenyldiazoacetate) in the synthesis of the Ritalin-nitroxide 
analogue was unsuccessful, the Schöllkopf’s bis-lactim ether asymmetric synthesis 
of α-amino acids approach was successfully employed to synthesize the target L-
Dopa nitroxide derivative. By combining the Schöllkopf’s methodology with the 
palladium-catalyzed Sonogashira coupling reaction, a rigid alkyne-linked chiral α-
amino acid site directed spin label (SDSL) was also synthesized. The alkyne-linked 
α-amino acid was designed for studying the structure and conformational dynamics 
of peptides and proteins, and for monitoring ROS-induced cellular oxidative stress in 
diseases such as PD by both EPR and fluorescence techniques. 
The synthesis of a series of isoindoline-based (tetramethyl and tetraethyl-substituted) 
catecholamine and benzodioxole compounds and their nitroxide derivatives is also 
described. As the first class of catechol-based nitroxides, the target nitroxide-
catecholinic-hybrids were mainly designed as potential dual-acting antioxidant-
sympathomimetic agents which could also be readily employed as synthetic 
templates/precursors for building functional materials. Since the therapeutic benefits 
of common catechol and benzodioxole-based pharmacophores (such as dopamine 
and L-Dopa) have been limited by the oxidative stress-induced cellular damage, the 
hybrid catecholic-nitroxides could provide effective antioxidant intervention (in 
addition to their potential sympathomimetic effects). The hybrid catecholinic 
compounds are also designed as potential substrates for building new nanocomposite 
drug delivery systems, sensing and electronic devices, metal complexes, catalysis 
and for (bio)chemical reactions. 
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Chapter 1: Introduction 
1.1 Free Radicals in Biology- Oxidative stress (OS) 
Free radicals are essential components of chemical processes that take place in 
biological systems such as energetics, cellular metabolism and carcinogenesis.1 
Decades since it was first proposed, the Haber-Weiss reaction (Scheme 1.1) is 
thought to be an integral component of the mechanism underlying biological 
processes involved in both normal cellular function and disease related processes.1-4 
 
Scheme 1.1. Harber-Weiss reaction. 
Under normal physiological conditions, free radicals, mainly reactive oxygen species 
(superoxide, hydrogen peroxide, hydroxyl radical), are associated with many cellular 
processes including cell-signalling pathways.1,3,5,6 However, these processes require 
tight regulation of the production and bioactivity of reactive oxygen species (ROS) in 
the cell.7 
Abnormal levels of free radicals can cause significant damage to biomolecules.4 Free 
radicals are involved in many chronic diseases and aging processes that affect the 
quality of life. Abnormal levels of free radicals result from exposure to 
environmental pollution, ultraviolet light and various illnesses.1 The harmful state of 
abnormal ROS levels is known as oxidative stress (OS).8 OS exerts its harmful effect 
in host cells by damaging cellular DNA, proteins, and lipids, thereby inhibiting their 
normal functions.1 ROS are implicated in many pathological processes including 
cancer, schizophrenia, aging, Alzheimer’s and Parkinson’s diseases.2,3,9 
For normal cell function, an equilibrium between ROS and the antioxidant defence 
system within cells is required. Thus, cells living under aerobic conditions are always 
faced with an oxygen dilemma - at physiological levels, they need oxygen to survive, 




but toxic reactive oxygen species, which are generated from oxygen, can cause 
damage to the cells. 
1.2 Endogenous Antioxidant Defence Systems 
Under normal cellular redox equilibrium, cells are protected from ROS-induced 
damage by antioxidant defence mechanisms. Endogenous antioxidants either remove 
harmful oxidants (ROS) soon after they form, or repair damage caused by ROS.10 
They include components of membranes and DNA, enzymes and other radical 
scavenging molecules.5 For instance, superoxide dismutase (SOD) is an antioxidant 
enzyme that catalyzes the decomposition of the superoxide radical into hydrogen 
peroxide (Scheme 1.2).5,11 SOD-mimetic therapeutics show promising efficacy in 
disease states such as rheumatoid arthritis, reperfusion injury, inflammation and 
hyperoxia.12 
 
Scheme 1.2. SOD catalyzed dismutation of the superoxide radical. 
The “chain-breaking" antioxidants like vitamin E block free radical chain reaction 
processes that propagate the peroxidation cascade along a membrane.7 Ascorbate 
(vitamin C) can reduce free radicals to form the water soluble dehydroascorbate. 
Glutathione (GSH), a versatile nucleophile and a reductant, can react with oxygen 
free radicals in various ways with transferases as a catalyst.13-16 
To date, the search to develop potent antioxidant therapeutics is attracting more 
research interest because we have a better understanding of the mechanisms 
underlying free radical processes. Despite the progress, free radical induced tissue 
damage remains the primary mechanism that initiates and propagates many human 
pathophysiological conditions. One class of antioxidant compounds studied for their 
effect in both in biology and material science, is the stable nitroxide compounds. 




1.3 Stable Nitroxide Radicals 
Nitroxides are stable radical derivatives of nitrogen oxide that contain a disubstituted 
nitrogen atom linked to a single-valent oxygen atom.17 The presence of the unpaired 
electron is the key paramagnetic property that allows the use of nitroxides as 
biophysical tools in electron paramagnetic (spin) resonance (EPR) spectroscopy.9,18 
The most stable nitroxides occur in the form of sterically hindered cyclic compounds 
with oxazolidines, pyrrolidines, pyrrolines, piperidines and isoindolines among the 
most common ring classes of cyclic nitroxides (Figure 1.1). However, a significant 
number of acyclic forms also exist.19 
 
Figure 1.1. Common ring classes of stable nitroxide compounds: oxazolidine 1, 
pyrrolidine 2, pyrroline 3, piperidine 4 and isoindoline 5. 
Despite the diverse nature of many of these structures, each stable nitroxide molecule 
has two common structural characteristics that influence its properties within organic 
synthesis, biomedicine and materials science: the effect of substituents in the 
immediate proximity of the nitroxide moiety and the resonance delocalization of the 
three-electron N-O bond. 
1.3.1 Stability of Nitroxide Radicals 
Like most radical species, nitroxide free radicals have an open-shell electronic 
configuration with an odd number (single unpaired) of higher energy valence 
electrons. Though free radicals are generally highly reactive and short-lived, 
hindered nitroxide radicals are remarkably stable. This property has allowed organic 
chemists to synthesize, characterize and store them under normal laboratory 
conditions over long time without any extra precaution. Hence, a number of nitroxide 





















compounds are commercially available and have been used extensively as 
biophysical tools and in materials science.18,20 Such exceptional stability is partly 
because of the strong delocalized three-electron bond within the radical centre, 
between the nitrogen and the oxygen atoms. In general, the spin density of the 
nitroxide moiety is slightly concentrated on the nitrogen atom.21 The high 
delocalization energy within this bond increases the thermodynamic stability at the 
radical centre (Scheme 1.3).22 This makes a pair of nitroxide radicals essentially 
unreactive toward one another. Thus, dimerization, a common radical-to-radical 
termination reaction, is highly unlikely to occur between nitroxide radicals (Scheme 
1.4).22,23 
 
Scheme 1.3. Resonance structures of the nitroxide moiety. 
 
Scheme 1.4. Reversible dimerization of nitroxides. 
Nitroxides are also stabilized significantly by steric hindrance and the polarity of 
substituents around the radical centre, particular at the α-carbon.24-27 In general, 
saturating the α-carbon with bulky substituents confers kinetic stability at the radical 
centre. As a result, the prospect of many common radical mediated degradation 
pathways such as hydrogen abstraction is significantly diminished. As a practical 
example, tetraethyl substituted nitroxides are reduced more slowly by ascorbic acid 
than their tetramethyl counterparts.28,29 Similar trends are observed in biological 
environments. Moreover, having an electron withdrawing group at the α-carbon 
increases the electron density of the oxygen atom on the resonance structure A2.30 





































This consequently increases the nucleophilicity of the oxygen atom, which in turn 
increases the ease of reduction of the nitroxide group. 
1.3.2 General Synthetic Methodologies of Stable Nitroxides 
Nitroxides are generated from a number of functional precursors (Scheme 1.5). 
However, stable nitroxides are prepared from the corresponding amines (secondary 
and tertiary) and hydroxylamines. These precursors undergo oxidation reactions in 
the presence of a number of oxidizing agents to form stable nitroxide radical-
containing compounds. 
 
Scheme 1.5. Synthetic precursors for generating nitroxide radicals. 
1.3.4.1. Oxidation of Secondary Amines 
Oxidation of hindered secondary amines is the most common approach used to 
generate nitroxides. There are a variety of reagents currently employed to achieve 
this transformation. Amongst them, aqueous hydrogen peroxide is the main reagent 
used to oxidize secondary amines to nitroxides.31 The reaction is performed in the 
presence of sodium tungstate and an inorganic weak base (e.g. sodium bicarbonate). 
There are also examples within the literature where sodium tungstate has been 
successfully replaced with phosphotungstic acid.32,33 With either reagent, the 











































Despite being the most cost effective reagent of choice, hydrogen peroxide/sodium 
tungstate oxidation conditions require the use of excess reagents and longer reaction 
times. Such reaction conditions may affect the stability of other labile functional 
groups present. For instance, under such conditions, the oxidation of aldehyde 6 to 
the corresponding nitroxide 7 is accompanied by simultaneous oxidation of the 
aldehyde functional group to its acid derivative 8 (Scheme 1.6).34 Limitations such 
as this can be overcome either by designing appropriate synthetic sequences for 
introducing the desired functionalities or by employing protecting group strategies. 
 
Scheme 1.6. Oxidation of amino formyl 6 to the corresponding nitroxide 7. Reagents 
and conditions: a. H2O2, Na2WO4, NaHCO3, MeOH (depending on the reaction 
time, ≥20% of compound 8 can be obtained). 
Peracids, most commonly m-chloroperoxybenzoic (mCPBA) and sometimes m-
nitroperoxybenzoic acid are the second most widely used reagents for oxidizing 
secondary amines in high yields.35-37 Unlike the hydrogen peroxide-tungstate system, 
the peracid oxidation reactions are conducted in an organic solvent, mainly 
dichloromethane (DCM), with much shorter reaction times (30 mins to a few hours). 
The resulting m-chlorobenzoic acid by-product can be removed via extraction with 
base, or separated from the desired product by use of chromatographic techniques or 
trituration. 
Generating nitroxides from secondary amines can also be achieved in high yields 
with at least two molar equivalent of dimethyldioxirane. This reagent was first 
investigated by Murray and co-workers when a variety of hindered secondary amines 
were each treated with 2 molar equivalents of dimethyldioxirane stock solution.38 
The authors proposed a reaction mechanism in which the amine is first oxidized to 















second molar equivalent then easily oxidizes the resulting hydroxylamine to the 
desired nitroxide. A slight modification to the Murray procedure conducted by Brik 
involves an in-situ generation of dimethyldioxirane by reacting peroxomonosulfate 
with acetone under phase-transfer conditions in a biphasic media.39 Both studies 
support the superiority of this reagent because of its versatility, shorter reaction time 
(30 minutes), convenience and high yields. With this method, the aldehyde nitroxide 
7 in Scheme 1.6 above was obtained directly from its amine precursor 6 in 95% 
yield. 
1.3.4.2. Oxidation of Tertiary Amines 
Hindered tertiary amines are another type of functional group used as direct 
precursors for generating nitroxides. Although they are comparatively less common 
than their secondary amine counterparts, there are some examples in the literature 
where tertiary amines have been successfully oxidized to the corresponding 
nitroxides in moderate to high yields. The N-alkyl type tertiary amines are usually 
employed as protecting groups under incompatible reaction conditions with respect 
to either the nitroxide moiety, or other intermediate functionalities.  
As with secondary amines, the H2O2/Na2WO4 oxidation system is used to convert 
some heterocyclic hindered tertiary amines into nitroxides.40,41 One drawback to this 
method is the longer reaction times (days). There are a number of literature examples 
where this methodology has failed to yield the desired nitroxide product. For 
example, Grigor’ev et al. used this method to oxidize the amide version of N-methyl-
3-imidazoline compound 9 to the nitroxides 10 but was unsuccessful with the 
carboxylic acid and ester derivatives 11 (Scheme 1.7).40  
For the oxidation of N-benzyl type hindered tertiary amines to nitroxides, mCPBA is 
the reagent of choice. In Scheme 1.8 below, the hindered N-benzyl azaphenalenes 12 
were successfully oxidized to the corresponding nitroxides 13 with excess mCPBA.42  
Even the more sterically hindered tetraphenylisoindoline compounds 14 were 



























Scheme 1.7. Peroxy acid oxidation of N-methyl 3-imidazolines 9 to the 
corresponding nitroxides. Reagents and conditions: a. H2O2, Na2WO4, NaHCO3. 
 
Scheme 1.8. Peroxy acid oxidation of N-benzyl azaphenalenes to the corresponding 
nitroxides. Reagents and conditions: a. mCPBA, DCM, 1 d, R = H (90%), NO2 
(65%). 
 
Scheme 1.9. Peroxy acid oxidation of N-benzylisoindolines to the corresponding 
nitroxides. Reagents and conditions: a. mCPBA, DCM, 1-6 d, R = Ph (71%), 
(CH2)3Ph (54%); b. H2, 10% Pd/C, R = Me (92%), Et (99%), n-Pr (83%), n-Bu 


























Alternatively, the N-benzyl type tertiary amines 14 were reduced to the secondary 
amines 16 by hydrogenolysis. Then, the resulting secondary amines 16 were easily 
oxidized to the desired nitroxides 15 with the H2O2/Na2WO4 system or mCPBA 
(Scheme 1.9.b.c.).44 This route gave higher yields over the two steps and the reaction 
times were reduced significantly. 
1.3.4.3. Oxidation of Hydroxylamines 
Hindered hydroxylamines are the most easily oxidized precursors to nitroxides - so 
much so that it is highly unlikely that they are isolated in their pure form without 
their nitroxide derivatives as an impurity. Often, even brief exposure to oxygen in the 
atmosphere is enough to oxidize hydroxylamines to nitroxides.45,46 There are some 
examples however, where the hydroxylamine derivatives are very stable and their 
oxidation requires more aggressive reaction conditions. For example, attempts to 
oxidize the dibromo hydroxylamine compound 17 with common oxidizing agents 
such as PbO2, MnO2, and H2O2/Na2WO4 proved unsuccessful. The oxidation was 
successful only when nitrous acid was employed (Scheme 1.10).47 
 
Scheme 1.10. Nitrous acid oxidation of hydroxylamine 17 to the nitroxide 18. 
Reagents and conditions: a. HNO2. 
As a general rule, it becomes more difficult to oxidize hydroxylamine compounds 
when the number of electron withdrawing substituents around the radical centre 
increases. Some other metal salts have also been used as oxidizing agents for 
hydroxylamines.48 Careful choice of oxidizing agent is required when oxidizing 
hydroxylamines to nitroxides. This is because certain oxidizing agents like Br2 can 
further oxidize the desired nitroxide to the oxoammonium ion: with Br2, the 












Scheme 1.11. Bromine oxidation of nitroxide 19 to the oxoammonium salt 20. 
Reagents and conditions: a. Br2, -30 oC, quantitative. 
1.3.4.4. Oxidation of Alkoxyamines 
In controlled radical polymerization, homolytic cleavage of NO-C of alkoxyamines 
to generate nitroxides is common,20,51,52 but synthetically, it is less common to 
synthesize nitroxides from alkoxyamines.53 Recently, Bottle et al. examined the 
oxidative cleavage of a range of functionalized N-methoxy type alkoxyamines to 
generate the corresponding nitroxides.54 The methoxyamine is a robust protecting 
group for the nitroxide moiety that can be used in synthesis and other comparative 
studies. Interestingly, they found that nitroxide compounds 26-30 could be generated 
quantitatively from the methoxyamine derivatives 21-25 with mCPBA as the oxidant 
under mild reaction conditions (Scheme 1.12).  
 
Scheme 1.12. mCPBA oxidation of N-methoxyamines to nitroxides. Reagents and 
conditions: a. mCPBA, DCM, 0 oC, 30 min -1 h; 70-90% yield. 
Complete conversion to the nitroxide was observed at room temperature within an 
hour. There are other examples in the literature where mCPBA was used to cleave 
the NO-C bond of a range of alkoxyamines during aldehyde synthesis. In these cases 
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R = Me (21, 26), CHO (22, 27), Br (23, 28), NO2 (24, 29), 





1.3.4.5. Other Methods for Nitroxide Synthesis 
Nitroxides are also generated from nitrones. Like nitroxides, nitrone compounds are 
regularly employed as spin traps for the identification of short-lived radicals 
including hydroxyl and carbon centred radicals.62,63 In the process of capturing short-
lived radicals, nitrones are converted to more persistent nitroxide radical species that 
are often analyzed by EPR spectroscopy. For instance, the spirolactonyl nitroxide 
spin adducts 32 were generated from the reaction of nitrone 31 with respective 
radicals (Scheme 1.13).64 Also, when nitrones are alkylated with Grignard reagents, 
the resulting hydroxylamines can be oxidized in air, or in the presence of other 













X=SO3, CO2, CH3CHOH, tBuO, OH and  O2  
Scheme 1.13. Generation of nitroxides via radical spin trapping by nitrones. 
Reagents and conditions: phosphate buffer saline, H2O2, UV, and the respective 
radical sources NaHCO3, Na2SO3, EtOH, (tBuO)2, KO2 and DMSO. 
 
Scheme 1.14. Generation of nitroxides via alkylation of nitrones with Grignard 
reagents. Reagents and conditions: RMgBr, THF, N2, 1 h, then NH4Cl, air, 46-82%. 
Nitroxide compounds are also generated from nitroso compounds, mainly the tertiary 
aliphatic and aromatic nitroso compounds. As shown in Scheme 1.15 below, when 9-
bromo-10-phenylanthracene 35 is lithiated with t-butyllithium, the resulting anion 












X = H, Cl, OMe R = Ph, Bn
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hydroxylamine intermediate was then spontaneously oxidized in air to the 
corresponding nitroxide 36 in 52% yield.66 
 
Scheme 1.15. Synthesis of nitroxides from tertiary nitroso compounds. Reagents and 
conditions: a. 1. tBuLi; 2. tBuNO; 3. Air, 52%. 
1.3.3 Nitroxide Design and Applications 
There are many literature reports that support the robust nature of the nitroxide 
moiety under diverse chemical reaction conditions. As the applications of nitroxides 
in biology and material science continue to expand, it is desirable to synthesize new 
nitroxide compounds that can be used to make functional materials. This section is 
aimed at highlighting synthetic transformations carried out within the past 10-15 
years to design functional nitroxide compounds. The first consideration is that there 
are certain reaction conditions under which the nitroxide moiety can react. Other 
undesirable reaction conditions can produce side products, lower yields of the 
desired product, or stop product formation completely. 
Reactions at the nitroxide radical centre, beside their ability to recombine with short-
lived radical species, commonly involve a reversible redox triad between the nitroxyl 
radical A, its hydroxylamine B and oxoammonium ion C derivatives (Scheme 
1.16).67 In the presence of strong oxidizing agents, the nitroxide (A) undergoes a 
single-electron oxidation to its oxoammonium salt (C). The oxidation potential and 
stability of the resulting oxoammonium ion mainly depends on the nitroxide ring 











Scheme 1.16. Reversible redox cycle between nitroxide (A), hydroxylamine (B) and 
oxoammonium (C). 
The nitroxide moiety is a weak oxidant in itself.44 Hence, the nitroxide moiety is 
reduced readily to its hydroxylamine derivative by a variety of reducing agents 
including some metals, metal salts,68 hydrazines,69-71 ascorbic acid,72-74 and 
hydrogen/catalyst. Because of the efficient reducing power and the strong 
nucleophilicity of hydrazines, it is not recommended, and is highly unlikely, to have 
a compound that contains both nitroxide and hydrazine functionalities. Most 
common metal hydrides have been employed successfully to reduce other functional 
groups in the presence of the nitroxide moiety.75-77 This, however, depends on the 
nitroxide ring class. The reduction of a nitroxide to its hydroxylamine is reversible, 
oxidation of the hydroxylamine back to the nitroxide is often achieved by exposing it 
to air. Organometallic reagents can also reduce nitroxides. The products isolated 
when the piperidine nitroxide 37 (TEMPO) was treated with n-butyllithium included 
the hydroxylamine 38, amine 39 and alkoxyamine 40 derivatives (Scheme 1.17).78,79 
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Because of the weak basic character of the nitroxyl group (pKH+ = -5.8),80 nitroxides 
disproportionate in strong acid media to form the oxoammonium ion and the 
protonated hydroxylamine.25,81-83 The reversibility of the acid catalyzed 
disproportionation process depends on the pH and the excess acidity function. In 
concentrated strong acid media, the equilibrium is completely shifted toward the 
oxoammonium salt and the protonated hydroxylamine, but the nitroxide is usually 
regenerated if such concentrated acid media is diluted, neutralized or basified.25  
Most oxoammonium ions are unstable and highly reactive towards other functional 
groups.84,85 The oxoammonium ion is a strong oxidizing agent. It is used in catalytic 
or stoichiometric amounts to oxidize a number of substrates under acidic, neutral or 
basic conditions.  
In Scheme 1.18 below, the oxoammonium salts of TEMPO and 4-acetylamino-
TEMPO derivatives (compounds 41 and 42) oxidize alcohols to aldehydes,86 
ketones,87-89 esters,90 or carboxylic acids;86 aldehydes to esters91 or carboxylic 
acids;86 diketones to triketones;92 primary amines to nitriles;93 N-alkylanilines to 
dihydroquinazolines and quinolones;94,95 and perform oxidative cleavage of silyl enol 
ethers89 and benzylic related ethers.96 
Evidently, being aware of the reaction conditions under which the nitroxide moiety 
can react and its functional group tolerance characteristic could be helpful in the 





Scheme 1.18. Synthetic applications of oxoammonium salts. Reagents and 
conditions: a. Fe(OTf)2, DCM, 60 oC, 24 h, 15 examples, 30-70%; b. FeCl3, 
appropriate styrene, DCM, 60 oC, 24 h, 15 examples, 30-86%; c. 2,6-lutidine, DCM, 
RT, 20 examples, 49-99%; d. Pyridine, DCM, RT, 15 examples, 75-95%; e/g. 
MeCN, 10 examples each, 36-93%; f. (CF3)2CHOH, pyridine, DCM, RT, 26 
examples, 68-96%; h. 2-azaadamantane-N-oxyl oxoammonium ion, MeCN, -78 oC, 1 
h, 16 examples, 6-88%;  (R = H (41), NHAc (42)). 
1.3.4 Functional Nitroxides 
When functionalizing a molecule containing the nitroxide moiety, the process is not 
restricted to reactions conducted only in the presence of the radical species. In many 
instances, functional groups are introduced in the molecular framework of nitroxide 

























































groups, such as the acetyl-protecting group, can be used to mask the radical centre if 
necessary. 
Aromatic substitution reactions are synthetic transformations commonly used in 
organic chemistry. Hence functionalizing nitroxide compounds with a range of 
aromatic substitution reaction conditions is essential. 
In the synthesis of the terminal acetylenic sulfone linked to a pyrroline nitroxide, the 
intermediate nitroxide sulfonyl chloride 58 (Scheme 1.19) was obtained after 
electrophilic aromatic sulfonation of 57 with chlorosulfonic acid at 0 oC.97 Because 
of the strong acid content of the reaction media, PbO2 was employed to oxidize any 
pre-formed hydroxylamine (by acid disproportionation of nitroxide) back to the 
target nitroxide. 
 
Scheme 1.19. Electrophilic aromatic sulfonation of nitroxide 57. Reagents and 
conditions: a. HSO3Cl, 0 oC to RT, 2 h, then PbO2, O2, 10 min, 73% yield. 
The isoindoline class of nitroxides are readily functionalized on the aromatic ring, 
mainly at the 5- and 6-positions. Like most aromatic compounds, introducing a 
halide group on the aromatic ring can increase the synthetic versatility of the 
substrate. Whereas direct ring bromination (with both single or double substitution 
available at the 5 and 6 positions) has been shown in a number of examples in the 
literature,98 it is only recently that the direct iodination of isoindoline nitroxides was 
established. Di-iodination of both tetramethyl and tetraethyl substituted isoindoline 
were successfully achieved with periodic acid and potassium iodide as a source of a 
strongly electrophilic iodonium ion, in concentrated sulfuric acid (Scheme 1.20).99 
For tetraethyl isoindoline nitroxide, the authors reported the isolation of 13% of 
iodinated nitrones 65 (Scheme 1.21). The nitrones 65 formation was attributed to the 










ions 64 under such strong acidic reaction conditions. Under the same reaction 
conditions, selective single iodidations were accompanied by the formation of the 
small amount of the di-iodo counterparts. The products were separated by flash 
column chromatography. These reaction conditions were also used on the secondary 
amine precursors successfully. 
 
Scheme 1.20. Direct iodination of isoindoline nitroxides. Reagents and conditions: a. 
H5IO6, KI, conc. H2SO4, 0 °C to RT. 3 h, 61 (48%); 62 (82%); 63 (37%). 












Scheme 1.21. Acid-catalyzed decomposition of tetraethylisoindoline oxoammonium 
salts to nitrones. 
The 5-bromoisoindoline compound 66 is a versatile nitroxide precursor used in a 
variety of synthetic transformations. Scheme 1.22 displays some useful synthetic 
transformations carried out with compound 66. The reactions include formylation,100 
cyanation,101 iodination,102 nitration,103 carboxylation,100 copper-catalyzed 
nucleophilic methoxylation,42 palladium-catalyzed and Heck coupling reactions.104  
The intermediate dianion formed when compound 66 is treated with two molar 
equivalents of n-butyllithium can be quenched with iodine, dry CO2, or DMF to give 
the iodo 68, carboxylic acid 70, or aldehyde 73 derivatives respectively. In the 
synthesis of potential antioxidant isoindoline nitroxide-resveratrol analogue 75, the 
















triphenylmethylphosphonium iodide in the presence of K2CO3, KOH and 18-crown-
6 in refluxing dioxane to give the styrene nitroxide derivative 74.105 
 
Scheme 1.22. Synthetic utility of bromoamine precursor 66. Reagents and 
conditions: a. HNO3, H2SO4, 0 °C to RT, 3 h, 56%; b. nBuLi, THF, -78 oC, then I2, 
70%; c. mCPBA, DCM, 3 h, RT, then NaOMe, CuI, EtOAc, MeOH, reflux, 16 h, 
88%; d. nBuLi, THF, -78 oC, then CO2, then H2O2, Na2WO4.7H2O, NaHCO3, 62%; 
e. CuI, nBulmi, K4[Fe(CN)6], o-xylene, 180 oC, 4 d, 78%; f. K2CO3, methyl 
acrylate, Pd(OAc)2, PPh3, DMF, 120 oC, 72 h, 62%; g. nBuLi, THF, -78 oC, then 
DMF, 100%; h. mCPBA, DCM, 72%; i. PCH3Ph3I, K2CO3, KOH, 18-crown-6, 
dioxane, reflux, 48 h, 62%; j. KOAc, 5-iodo-1,3-phenylene diacetate, Pd(OAc)2, 
Bu4NBr, DMF, 80 oC, 10 h, then NaOMe (0.1 equiv), MeOH, 1 h, RT, 78%. 
Piperidine type nitroxides are commonly functionalized at the 4-position. Two stable 
Schiff base piperidine nitroxide derivatives of benzothiazole and benzoxazole-based 

















































reacted in an alcohol solution with compound 77 in the presence of a catalytic 
amount of acetic acid (Scheme 1.23).106 
 
Scheme 1.23. Synthesis of Schiff base piperidine nitroxide derivatives. Reagents and 
conditions: a. AcOH, EtOAc, reflux, 2 h; 78 (X = S, 83%) and 79 (X = O, 81%). 
Nitroxides have also been incorporated into Fischer-type carbene complexes to give 
novel organometallic nitroxide spin systems (Scheme 1.24).107 Aminolysis of 
ferrocenyl methoxy carbene 80 with excess 4-amino-TEMPO 76 afforded the 
TEMPO-linked ferrocenyl methoxy carbene complex 81. Complex 81 is quite stable 
and contains two redox systems, namely the nitroxide and ferrocenyl groups. Thus, 
complex 81 could be further explored as potential antioxidant therapeutics or for use 
in charge-storage devices. 
 
Scheme 1.24. Synthesis of 4-amino-TEMPO-linked ferrocenyl methoxy carbene 
complex 81. Reagents and conditions: a. THF, RT, 2 d, 58%. 
Organoselenium compounds are useful building blocks for functional materials and 
as potential pharmaceutical agents. In the synthesis of some functionalized selenium-
nitroxide compounds, 4-amino-TEMPO 76 was successfully transformed to a range 





























the reaction of 76 with excess ethyl formate to give the 4-aminoformyl derivative 82. 
Then, compound 82 was dehydrated with gaseous phosgene to give the 4-isocyano 
derivative 83. Selenation of 83 with metallic selenium gave the 4-isoselenocyanato 
84, which was subsequently reacted with a series of amines and alcohols to give 
selenoureas and selenocarbamates 85. 
 
Scheme 1.25. Synthesis of organoselenium nitroxides. Reagents and conditions; a. 
HCO2Et, reflux, 5 h, (96%); b. COCl2 or ClCOOCCl3, TEA, DCM, 0 oC, (78%); c. 
Se, CHCl3, 61 oC 70 h, 38%; d. HX/NaX, benzene, 19-87%. 
Recently, Turro and co-workers reported a synthetic procedure for making multi-spin 
systems via nucleophilic aromatic substitution of fluorides with the alkoxide anion of 
4-hydroxy-2,2,6,6-tetramethylpiperidin-1-yloxyl (TEMPOL) 86 (Scheme 1.26).109 
With a range of multi-fluorinated aromatic cores 87, the authors selectively 
introduced mono, di, tri and tetranitroxides 88 under appropriate reaction conditions. 
In contrast to mononitroxide compounds, multi-spin nitroxide compounds like 88 
have good electron-electron spin-exchange between individual nitroxide moieties. 
This enables their use as efficient paramagnetic relaxation agents and electron spin 
agents for dynamic nuclear polarization experiments. 
Copper-catalyzed azide alkyne cycloaddition (CuAAC) reactions are another useful 
synthetic approach currently employed to produce functionalized nitroxides. Figure 


















X = N(CH3)2, N(C2H5)2, N(n-C2H7)2,
 
































Scheme 1.26. Synthesis of tetranitroxides 88 via nucleophilic aromatic substitution 
of fluorides. Reagents and conditions; a. DMI, NaNH2, 0 oC-RT-80 oC, 37-81%. 
 
Figure 1.2. Common azide and acetylene nitroxides. 
Compound 99, a triazole coumarin-based profluorescent nitroxide which 
significantly suppressed fluorescence, was synthesized via a copper-catalyzed azide 
alkyne 1,3-dipolar cycloaddition reaction of 3-azido-7-diethylamine coumarin 98 and 
alkyne TMIO (tetramethylisoindolin-2-yloxyl) 90 (Scheme 1.27).111 The 
fluorescence of the coumarin fluorophore was restored when 99 was converted to its 





















































Scheme 1.27. Copper-catalyzed azide alkyne cycloaddition of nitroxides. Reagents 
and conditions: a. CuSO4, NaAsc, EtOH/H2O, 16 h, RT, 60-90%; b. H2O2, 
FeSO4.7H2O, DMSO, 30 min, 78-90%. 
A number of examples of nitroxides grafted to carbon-based surfaces to give carbon-
polymer composite materials have been reported. In an attempt to design higher 
capacity next generation lithium ion batteries, graphene 101 (graphene oxide, GO) 
was grafted with TEMPOL 102 via the conventional esterification of its carboxylic 
acid groups (Scheme 1.28).115 The resulting hybrid nitroxide-graphene anode 
conjugate material 103 possesses superior lithium storage capacity because it has a 
dual redox system that comprises of graphene and the reversible redox cycling 
nitroxide. 
Yan and co-workers also grafted isoindoline nitroxide to fullerene (C60 and C70) 
cages.116 In Scheme 1.29 below, the nitroxide-linked nanoparticle 105 (TMIO-C60) 
was prepared by refluxing fullerene 104 and formyl TMIO 27 in the presence of 
sarcosine. Along the same line, Bingel–Hirsch reaction of fullerene 104 and the 





Scheme 1.28. Grafting of nitroxides to graphene surfaces. Reagents and conditions: 
a. SOCl2, 102, DMF, 70 oC, 24 h; then TEA, 100 oC, 60 h, NaHCO3. 
 
Scheme 1.29. Grafting of nitroxides to fullerene cages. Reagents and conditions: a. 

















































Blinco et al. synthesized the novel diazonium-based isoindoline nitroxide 109 from 
its 5-amino-TMIO precursor 108 (Scheme 1.30) and grafted it to a number of 
different carbon allotropes (single and multi-walled carbon nanotubes, graphene, 
glassy carbon and carbon fibre).118 This was achieved by either an electrochemical 





















Scheme 1.30. Grafting of diazonium-based nitroxide to carbon allotropes. Reagents 
and conditions: a. NOBF4, MeCN; b. grafting of diazonium 109. 
Incorporating nitroxides into complex biomolecules is an effective technique 
commonly used to obtain useful structural information. Recently, isoindoline based 
nitroxides were synthesized and incorporated into duplex DNA as spin labels. In one 
instance, CuAAC of an azide functionalized isoindoline nitroxide 89 with 5-ethynyl-
2′-deoxyuridine oligomers 110 afforded the triazole-linked spin labelled 
oligonucleotide derivatives 111 (Scheme 1.31).113 
Along the same line, novel isoindoline nitroxide spin-labelled benzimidazole and 
benzoxazole nucleosides 115 were successfully synthesized when 3’,5’-di-o-acetyl-
5-formyl-2’-deoxyuridine 113 was reacted with isoindolines 112 in the presence of 
potassium ferricyanide, followed by oxidation of the resulting amine intermediate 
114 (Scheme 1.32).119 These nitroxide-based nucleosides 115 were incorporated into 




Scheme 1.31. Synthesis of triazole-linked nitroxide-oligonucleotide spin label 111 



























X = OH, NH2













X = O, NH
 
Scheme 1.32. Synthesis of triazole-linked nitroxide-benzimidazole and benzoxazole-
based spin label nucleosides. Reagents and conditions: a. K3Fe(CN)6, MeOH, 40% 
(X = O); Iodobenzene diacetate, 47% (X = NH); b. mCPBA, 50-56%. 
In general, the structure and paramagnetic properties of nitroxide containing 

































understanding of the chemistry of stable nitroxides, a variety of synthetic 
transformations have been used to design novel functional nitroxide compounds. 
Recently, the therapeutic application of stable nitroxide compounds as potent 
antioxidants has gained significant research interest and is quite promising. 
1.3.5 Antioxidant Nitroxides 
Although stable nitroxide compounds have been used for many years as biophysical 
tools, it is only within the past two decades that their therapeutic applications have 
been explored.6,7,13,19,112,120-130 Stable nitroxides have antioxidant actions and thus 
protect biological tissues against oxidative stress.131 The antioxidant action of 
nitroxides is mainly attributed to the redox cycle (Scheme 1.16) that involves the 
nitroxide and its oxoammonium ion and hydroxylamine derivatives. In cellular 
environments, the equilibrium of this redox triad depends mainly on the redox-status 
of the surrounding cellular components. 
As stable free radicals, nitroxides directly scavenge ROS type radicals that cause 
damage to biomolecules.132,133 pH-responsive TEMPAMINE-linked nanoparticles 
116 scavenge ROS and offer renal protection in ischemia-reperfusion acute kidney 
injury model in mice (Figure 1.3).132 
 
Figure 1.3. ROS scavenging pH-responsive TEMPAMINE-linked nanoparticles 116. 
Under aerobic conditions, the hypoxanthine/xanthine oxidase system can generate 












When Chinese hamster V79 lung fibroblasts were exposed to hypoxanthine/xanthine 
oxidase, a dose-dependent decrease in survival of V79 cells was observed.135 
However, in the presence of several nitroxide compounds, the V79 cells survived the 
cytotoxicity induced by the hypoxanthine/xanthine oxidase-derived oxidative stress. 
In comparison to endogeneous antioxidants such as SOD, the V79 cell protection 
effect of TEMPOL 102 was superior. 
Nitroxides also possess a metal-free SOD-mimetic action; i.e. they catalyze the 
dismutation of superoxide radicals.16,136,137 In in vitro and in vivo studies, TEMPOL 
102 appeared to protect mammalian cells against oxidative damage, both by an SOD-
mimetic action.138,139 In Scheme 1.33 below, the nitroxide TEMPOL 102 and its 
hydroxylamine derivative TEMPOL-H 117 can both offer protection against 
cytotoxic oxidants via redox processes in which the nitroxide can be regenerated. 
 
Scheme 1.33. SOD mimetic-like action of TEMPOL 102. 
As stable free radicals, nitroxides also exert their antioxidant action by inhibiting 
lipid peroxidation process. Lipid peroxidation is a common free radical related  
process by which damage to tissues occurs.123,125,129 Lipid peroxidation modifies 
lipid-containing biological macromolecules such as proteins and membrane lipid 
bilayers to produce toxic pro-oxidants. 
In addition to inducing chemical change in lipid membranes and proteins that 
compromises their biophysical properties, free radicals and ROS can damage 
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sensitive neurones. Although the mechanism underlying most neurodegenerative 
diseases is not fully understood, clearly oxidative stress is involved in the pathway 
through which neuronal damage occur.140-143 Nitroxides have also been reported to 
offer neuroprotection to neuronal cells that are under oxidative stress associated with 
neurodegenerative diseases.144,145 In in vitro Parkinson’s disease studies, nitroxides 
were reported to protect dopaminergic neurons from 6-hydroxydopamine-induced 
apoptosis.146 
Stable nitroxide compounds have also been reported to possess anti-cancer activities. 
Such promising redox-chemotherapeutic effects have been associated with the ability 
of the nitroxide radical to disrupt some tumor related redox chemistry.122,147-149 
Ataxia-telangiectasia (AT) is a genetic disorder that is commonly associated with 
cancer predisposition, immunodeficiency, growth retardation, infertility, neurological 
degeneration and sensitivity to ionizing radiation. When the tumor prone AT-mutated 
(Atm)-deficient mice were fed high dose of nitroxides, Wynshaw-Boris and co-
workers observed that the nitroxides significantly increased the lifespan of the mice 
by delaying the start of thymic lymphomas.149 The Atm-deficient mice are a murine 
model for the human disease AT. Such anti-cancer activity of nitroxides was 
attributed to the antioxidant action in reducing oxidative stress.  
Recently, some stable nitroxide compounds were shown to inhibit the action of the 
myeloperoxidase (MPO)-mediated hypochlorous acid production system.130 The 
MPO system is implicated in a number of inflammatory diseases. The inhibitory 
action of nitroxides involves a competing one-electron oxidation of nitroxides by the 
so-called compound I state of MPO which subsequently prevents the oxidation of 
chloride, and the MPO reduction by superoxides. As the number of disease states 
increases where nitroxides display therapeutic value, there is a need for the design 
and synthesis of novel antioxidant nitroxides that are based on specific biological 
targets. 
Stable antioxidant nitroxides have also been reported to possess promising 
radioprotective, antihypertensive, anti-aging, anti-inflammatory, and weight control 
activity.122,150 Such widespread applications of stable nitroxides make the effort to 
design and synthesize novel antioxidant nitroxides a key area of current research 
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interest. Thus, a rational drug design and development strategy could be used as an 
attractive approach for the development of novel nitroxide-based antioxidant 
therapeutics. 
1.4 Modern Drug Discovery 
At a cellular level, the human body continuously undergoes countless complex 
chemical reactions. These chemical reactions regulate our growth, maintenance and 
daily activities but they are also involved with the changes in cellular functions 
associated with disease conditions. For instance, chemical imbalance can trigger a 
cascade of undesired events that disturb the normal function of a specific protein 
which could lead to a disease state. Drugs administered to manage disease conditions 
often work by interacting with endogenous target molecules to either restore a 
balanced physiological state or reverse the disease state. The process and effort to 
develop drugs on as rational a basis as possible, that minimizes trial-and-error 
factors, is known as drug design.151 
Advances in modern drug discovery are a product of collective research effort from 
government, academia, and pharmaceutical industries. The modern drug discovery 
process is an interdisciplinary endeavour that involves clinicians, pharmacologists, 
biochemists and medicinal chemists.152,153 Modern techniques such as high-
throughput screening methods, combinatorial chemistry, rapid DNA sequencing and 
new computing methods are used to identify promising “lead” compounds. This has 
led to the development of a number of successful drug candidates in modern 
medicine.154 However, the modern drug discovery and development process remains 
challenging. The process of discovering and developing a drug and releasing it to the 
market takes approximately 15 years and costs up to $2 billion.152,155-157 The success 
rate of this process is low with only one in every 5,000-10,000 developed drug 
candidates receiving approval. This ratio continues to decrease because of the strict 
regulations required for a new drug to be accepted for use. Thus, to have an 




1.4.1 Single Hit Drugs 
Small molecule drug design is an attractive approach broadly pursued by medicinal 
chemists.158-162 Single small molecule drugs that are produced by the single-drug-to-
single-target approach can manage disease states effectively by acting selectively on 
a single target molecule. This monotherapeutic approach has succeeded in 
developing new, safe and effective medicines that are currently on the market. For 
instance, Tamsulosin 118 (Figure 1.4) is a selective α1a-adrenoceptor antagonist 
single hit drug used to treat the symptoms of benign enlargement of the prostate 
(BPH).163 BPH is a disorder prevalent in older men and is characterized by the 
enlargement of the prostate which often results to symptoms of urinary dysfunction. 
The development and clinical success of Glivec 119 (STI571, Imatinib) was a 
highlight for the therapeutic benefit of single molecular targeted therapies.164,165 
Glivec is the first tyrosine kinase-specific inhibitor approved for the treatment of 
chronic myeloid leukemia - a type of cancer in which the bone marrow makes too 






















Figure 1.4. Examples of single hit drugs: Tamsulosin 118 and Glivec 119. 
The therapeutic success of single target drugs is however, hampered by their 
vulnerability to drug resistance.167-169 Also, many diseases (especially cancer) are 
complex because they have multiple pathophysiological pathways.170 The pathways 
have diverse therapeutic targets which may not be managed effectively by a single-
target-drug. Also, single hit drugs are unlikely to manage secondary drug targets 
associated with a disease state.171  
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1.4.2 Combination Drug Therapy 
One approach currently used to overcome the limitations of the ‘single hit’ drug 
paradigm is combination drug therapy. The combination drug therapy approach 
combines two or more known pharmacophores into a single formulation that 
regulates multiple drug targets at the same time. Combination drugs are the standard 
of care for complex diseases like cardiovascular diseases,172 HIV,173 cancer,174 and 
Type 2 diabetes (Figure 1.5).175-177 For example, Actoplus Met (120 + 121) is a 
fixed-dose combination drug approved for the treatment of type 2 diabetes.176 
Treating patients with combination drugs minimizes the side effects associated with 
most single hit drug therapies. Despite the benefits of combination drug therapy, 
there still remain rational objections to it because of setbacks experienced in the 
formulation process and in the therapeutic outcomes.178,179 That two separate drugs 
work on one or more targets in a disease state is not a guarantee that their efficacies 













































Figure 1.5. Examples of combination drugs: Actoplus Met (pioglitazone 120 + 
metformin 121), BiDil (isosorbide dinitrate 122 + hydralazine hydrochloride 123) 
and Cambivir (zidovudine 124 + lamivudine 125). 
For instance, combined drugs may interact with each other.180 Such drug-to-drug 
interaction can either enhance or reduce the therapeutic efficacy of the combined 
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drugs. The combined drugs may compete with each other for binding sites in the 
blood plasma and within target compartments. Thus, the effective therapeutic dose of 
a low affinity drug may be reduced if administered in combination with a high 
affinity drug. 
The effective dose of combined drugs can also diminish during passive diffusion-
dependent processes such as uptake, distribution and elimination. Therefore if two 
drugs differ significantly in solubility, how each drug gets absorbed and released into 
the blood stream may affect their effective dose. 
Each component of a combination drug (or single hit cocktail) has a distinct 
biological half-life. The half-life of each drug molecule dictates how its steady-state 
level of accumulation changes within a specific dose interval.151,181 If over a given 
dose interval, the rate of elimination of one compound is slower than its uptake rate, 
then the concentration of that compound will gradually increase over time, which in 
turn causes an increase in the steady state level of accumulation of that component. 
For combination and multiple single hit drug therapy, it is difficult to precisely 
predict the pharmacokinetic and pharmacodynamic properties of an individual drug. 
The pharmacokinetic and pharmacodynamic properties of a drug provide useful 
information on how a drug works, its toxicity, and patient compliance.182 
To address the limitations and difficulties associated with both single hit and 
combination drugs, Morphy and co-workers183 proposed a rational drug design 
approach commonly referred to as pharmacophore hybridization. 
1.4.3 Pharmacophore Hybridization 
Pharmacophore hybridization (PH), also referred to as molecular hybridization, is a 
novel drug design concept that represents a promising alternative to both the 
combination and single hit drug design processes. In PH, functional moieties from 
two or more pharmacophores are chemically linked to produce a single, non-
identical, dual hybrid drug that retains the therapeutic actions of its parent 
templates.183-186 Hybrid pharmacophores, like the dual action agents, can modulate 
one or more drug targets simultaneously. The PH strategy targets bioactive 
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compounds that are either on the drug market or considered promising drug 
candidates. Hybrid pharmacophores are less prone to resistance and side effects 
because of their multi-target action. The pharmacokinetic and pharmacodynamic 
properties of a hybrid drug are easier to predict than combination drugs. In biological 
systems, the solubility of a hybrid drug is measured for the whole molecule rather 
than individual active components. Hence, the relative bioavailability and effective 
dose of each functional moiety of the hybrid remains undiminished during passive 
diffusion processes like uptake and distribution. One benefit observed with hybrid 
drugs is how each component boosts the therapeutic potential of the other.187,188 
Hybrid pharmacophores are classified based on the how the components are joined 
together and the degree of integration. The four common ways by which the 
pharmacophores can be linked together are discussed below.183,189,190 
1.4.3.1 Cleavable Linker Hybrids 
With cleavable hybrids, the functional moieties are linked directly by hydrolyzable 
bonds, most commonly in the form of esters, amides, carbamates, and disulfides 
(Figure 1.6).191-195 In biological systems, the individual active component is released 






























Figure 1.6. Cleavable conjugates: NO-aspirin (NCX4016) 126, ibuprofen-furoxan 
NSAID hybrid 127, and disulfide-based cleavable conjugate RB101 (128). 
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For instance, hybrids of nitric oxide (NO)-releasing agents linked with known anti-
inflammatory agents, 126 and 127, displayed promising synergism by retaining the 
therapeutic potential of parent templates and at the same time reducing their side 
effects such as NSAID-induced gastrotoxicity. The disulfide-linked hybrid inhibitor 
RB101 128 displays good analgesic properties with longer pharmacological effect.196 
1.4.3.2 Non-Cleavable Linker Hybrids 
Non-cleavable conjugates are linked by a non-hydrolyzable chemical bond or spacer. 
These agents are more stable and are not generally cleaved by biological enzymes. 
Notable examples of such conjugates (Figure 1.7) work on either the same target, or 
they may affect two or more closely related targets independently. The platinum–
acridine conjugate 129 has a non-cleavable Pt–S linkage that is resistant to 
nucleophilic attack by the nitrogen atom of a nucleobase.197,198 This hybrid platinum–
acridine compound 129 is a new type of DNA-targeted cytotoxic agent that acts 
selectively on many cancer cell types - in particular, glioblastoma multiforme (the 
most aggressive form of metastatic brain tumor).199 The hybrid phenylindole (2-PI)–
aniline mustard 130 consists of two pharmacophore subunits. The phenylindole 
component is a synthetic ligand for estrogen receptor and the aniline mustard 
component is a DNA damaging agent. This hybrid 130 is a promising 






























1.4.3.3 Merged and Overlapped Hybrids   
The most common type of pharmacophore hybridization involves merging or 
overlapping structural moieties/elements from two or more pharmacophores. The 
approach takes advantage of similar structural elements within the parent 
pharmacophore. Such hybrids range from slightly overlapped to highly integrated 
systems in which the new hybrid may be completely different in structure to the 
parent templates. Scheme 1.34 below depicts an example of how a 
merged/overlapped pharmacophore hybridization strategy was used to rationally 
design and synthesize a series of prototype analgesic and antipyretic agents 134 by 
taking advantage of the structural similarities of the parent analgesic templates (131-
133).201,202 This series of hybrid analgesic agents 134 combines the isochromanyl, 
imesulide and acylarylhydrazone biologically relevant functional subunits of parent 




























Scheme 1.34. Synthesis of a series of merged-prototype NSAIDs via pharmacophore 
hybridization strategy. R = H, Br, OH, NO2, SCH3, SOCH3, SO2CH3, N(CH3)2. 
These examples give insight into how useful and attractive the pharmacophore 
hybridization strategy is in modern drug design for the development of novel 
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therapeutics that can modulate complex diseases with multiple-target mechanisms. In 
most complex disease states such as cancer, arthritis, atherosclerosis and 
Alzheimer’s, the mechanisms underlying such disease states, at the molecular level, 
are not fully understood. However, both chronic inflammation and oxidative stress 
(OS) have been established as the major contributors to the multiple pathways 
through which most cellular damages associated with these complex diseases 
occur.138,203,204 Thus, by use of PH strategy, multi-target antioxidant and anti-
inflammatory agents are designed to effectively modulate chronic inflammatory and 
reactive oxygen species-induced cellular damage. 
1.5 Project Proposal 
Pharmacophore hybridization is an effective and rational drug discovery and 
development strategy that is currently pursued in both academia and the 
pharmaceutical industry in the search for new drug candidates. This PhD project uses 
the pharmacophore hybridization strategy to synthesize new hybrid molecules as 
potential therapeutics for diseases associated with oxidative stress. The aim was to 
synthetically combine antioxidant nitroxides with known pharmacophore subunits to 
produce hybrid agents that may regulate multiple biological targets simultaneously. 
As oxidative stress, whether drug–induced or from a pathophysiology of a disease 
state, contributes to the mechanism underlying the pathophysiology of chronic 
inflammatory diseases and neurodegenerative disorders, the successful fusion of 
antioxidant nitroxides with parent therapeutics may produce hybrid molecules that 
minimize oxidative stress and at the same time retain the therapeutic benefits of the 
parent structure. The non-steroidal anti-inflammatory drugs and the amphetamine-
stimulant therapeutics were the main drug classes of interest. 
Chapter 2 of this thesis explores the synthesis of overlapped hybrid conjugates that 
incorporate antioxidant nitroxides with the salicylate class of nonsteroidal anti-
inflammatory drugs. Taking advantage of the structural similarities of the parent 
templates (Figure 1.8), Chapter 2 aims to merge the pyrroline nitroxide 3 with 
salicylic acid 135 and acetylsalicylic acid 136 (aspirin) to produce new hybrid 
nitroxide-salicylate molecules 5-carboxy-6-hydroxy-1,1,3,3-tetramethylisoindolin-
2yloxyl 137 (salicylic acid-TMIO) and 5-carboxy-6-acetoxy-1,1,3,3-
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tetramethylisoin-2-yloxyl 138 (aspirin-TMIO) shown in Figure 1.9. The o-acetamide 
benzoic acid derivative 139 was the ultimate target compound. Compound 139 
provides means to compare the biological efficacy of amides to esters. Some 
preliminary biological data for the antioxidant and anti-inflammatory activities of the 














Figure 1.8. Structures of parent molecular templates: pyrroline nitroxide 3, salicylic 



















Figure 1.9. Structures of merged-hybrid target molecules: salicylic acid TMIO 137, 
aspirin TMIO 138 and o-acetamide benzoic acid TMIO 139. 
Chapter 3 probes the synthesis of cleavable and non-cleavable hybrid nitroxide 
conjugates of non-steroidal anti-inflammatory drugs, mainly salicylates and 
indomethacin. The nitroxide moieties were linked to the parent drugs through ester, 
amide and amine linkages. To obtain more structural activity relationship data, the 
nitroxides were tethered to the parent pharmacophores at various positions (Figure 
1.10). The common cyclic nitroxide ring classes (pyrroline, piperidine and 
isoindolines) were used in the synthesis. As steric bulk around the nitroxide moiety 
influences the rate of biological reduction, the synthesis of tetramethyl and tetraethyl 
conjugates was also undertaken. To compare the antioxidant potential of the various 
NSAID-nitroxide conjugates, the conjugates of some common antioxidants (Trolox 
and Cinnamic acid) were also synthesized (145 and 146). Preliminary biological data 





























































Figure 1.10. Representative targets of cleavable and non-cleavable NSAID-nitroxide 
conjugates. 
Chapter 4 focuses on the enantioselective synthesis of overlapped nitroxide hybrids 
of the sympathomimetic amine stimulants L-Dopa 147 and Ritalin 148 (Figure 1.11). 
L-Dopa and Ritalin are the main therapeutic agents used to treat Parkinson’s disease 











147 3 148  
Figure 1.11. Parent templates: L-Dopa 147, pyrroline nitroxide 3 and Ritalin 148. 
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As oxidative stress contributes to the pathophysiology of Parkinson’s disease and 
ADHD, the target hybrid nitroxide molecules 149 and 150 (Figure 1.12) could serve 
as effective therapeutic agents that reduce oxidative stress by the antioxidant action 
















Figure 1.12. Chemical structures of target compounds: merged psychostimulant-
nitroxide target conjugates (L-Dopa TMIO 149 and Ritalin TMIO 150) and the rigid 
alkyne-linked chiral α-amino acid nitroxide spin label 151. 
The rigid alkyne-linked chiral α-amino acid nitroxide 151 is the final target 
compound of Chapter 4. Unlike the L-Dopa and Ritalin nitroxide analogues (149 
and 150), compound 151 is designed as a site directed spin label for studying the 
structure and structure and conformational dynamics of peptides and proteins. The 
preparation of 151 will be carried out by taking advantage of similar asymmetric α-
amino acid synthetic approach that will be employed for the synthesis of the L-Dopa 
nitroxide analogue 159. Due to its rigidness, chirality and enantiopurity, compound 
151, if incorporated into a peptide, could provide relevant structural and dynamic 
information by EPR spectroscopy without any drawback associated with rotational 
mobility, isomerization, multiple conformers, and achiral effects. 
Chapter 5 presents the synthesis of the novel isoindoline catechol and benzodioxole 
amines, and their corresponding nitroxides. The target compounds are designed for 
potential use in biology as antioxidants but they could also have applications in 
material science as building blocks for nitroxide-functional materials. The 
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tetramethyl and tetraethyl substituted isoindoline derivatives 154-161 of each parent 









Figure 1.13. Parent pharmacophores: dopamine 152 and 3,4-methylenedioxy-
































Figure 1.14. Target compounds: Catecholamines tetramethylisoindoline (TMI) 154 
and tetraethylisoindoline (TEI) 158; catechol TMIO 156 and TEIO 
(tetraethylisoindolin-2-yloxyl) 160, benzodioxole TMI 155 and TEI 159; 
benzodioxole TMIO 157 and TEIO 161. 
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Chapter 2: Merged Dual-Action Nitroxide-
Aspirin Hybrids 
2.1 Background: Cellular Inflammation- Friend or Foe? 
Cells in our body are under constant attack from invading pathogens. Changes 
occurring at the molecular level that arise from such attacks can lead to cell and 
tissue damage or the death of the cell.1-4 However, the immune system, comprising 
innate and acquired defences, limits the harmful effects of pathogens and injuries.5 
Regardless of the stimuli, innate cellular defence systems rapidly respond to 
infections and tissue damage through a complex cascade of events aimed at restoring 
physiological homeostasis. An integral component of these defence systems is the 
cellular inflammatory response. Primarily triggered by tissue damage (caused by 
trauma or infection), controlled-cellular inflammatory response (acute inflammation) 
facilitates pathogen clearance, tissue recovery and regeneration processes at infected 
or damaged sites.5 The response is characterized by the action of a diverse range of 
inflammatory mediators (such as prostaglandins (PGs), leukotrienes, bradykinin, 
platelet-activating factor, cytokines and interleukin-1 and several more broadly 
acting processes such as vasodilation and coagulation.6,7 Coagulation, for example, 
minimizes the loss of blood from damaged vessels by forming platelet aggregates at 
the injured sites. While neutrophils initiate pathogen killing by phagolysosomes, 
macrophages on the other hand, clear all matrix and cell debris and release 
inflammatory mediators that act as regulatory tissue-repair signalling 
molecules.8 However, when an acute inflammatory response is not properly 
regulated, it can transform into a chronic inflammatory response. Chronic 
inflammation is mainly characterized by oxidative stress and prolonged and 
excessive inflammation which may translate into an irreparable damage to host 
tissues and, in severe situations, organ malfunction or death.9,10 Chronic 
inflammation is a significant contributing factor to numerous pathophysiological 
conditions including rheumatoid arthritis, cancer, neurodegeneration and 
cardiovascular diseases. 7,8,11-18 
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Rheumatoid arthritis, is an autoimmune disease that afflicts about 1% of the world’s 
population.19 The symptoms and mechanism of progression of rheumatoid arthritis 
are mainly characterized by chronic inflammation of the synovial joints. This results 
in lingering pain, loss of function and disability. In general, nonsteroidal anti-
inflammatory drugs (NSAIDs) are the most common therapeutic agents used to 
manage inflammatory symptoms.17,20-22 NSAIDs are a structurally diverse group of 































Figure 2.1. Common NSAIDs: aspirin 136, Vioxx 162, ibuprofen 163, indomethacin 
164, antipyrine 165 and celecoxib 166. 
NSAIDs exert their therapeutic action mainly as antipyretics (drugs used to manage 
fever), anti-inflammatories and analgesics (pain relief medications), by inhibiting the 
activity of several enzymes and ion channels.3,6,7,21-29 The main target enzyme for 
NSAIDs is the cyclooxygenase (COX) enzyme. COX is a membrane-bound 
hemoprotein and glycoprotein present primarily in the endoplasmic reticulum of 
prostanoid-forming cells.6,7 It has two main isoforms (COX-1 and COX-2) which 
have similar active sites, but differ slightly in size. COX-1 is the constitutionally 
expressed isoform present in almost every tissue. Under physiological conditions, 
COX-1 catalyzes the production of prostaglandins (PGs) involved in basic 
cytoprotective functions such as maintaining the gastrointestinal (GI) mucosal 
integrity, vascular homeostasis, and renal regulation. COX-2 is the inducible 
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expressed isoform involved in producing PGs mainly in response to inflammatory 
stimuli from infections or injuries.7,17,20 The problem with most traditional NSAIDs 
such as indomethacin and aspirin is they inhibit both COX-1 and COX-2 enzymes 
(Figure 2.2).30,31 
 
Figure 2.2. COX-catalyzed biosynthesis of prostanoids and their roles in 
inflammation and normal cell physiology: COX catalyzes the metabolism of 
arachidonic acid (AA, released from phospholipid bilayer) to various prostanoids 
including thromboxane A (TXA2), prostaglandin D2 (PGD2), prostaglandin F2α 
(PGF2α), prostaglandin E2 (PGE2) and prostacyclin (PGI2)- that are involved in 
numerous cellular and inflammatory processes. Adapted and modified from 
Cipollone et al.30 
Such inevitable nonselectivity by conventional NSAID therapy leads to adverse side 
effects- notably gastrointestinal ulceration and bleeding, platelet dysfunction and 
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prostaglandins.32 Logically, selective COX-2 inhibitors (Coxibs) were developed as 
effective inflammatory agents without the adverse side effects normally associated 
with chronic use of conventional NSAIDs.33 Celecoxib (marketed by Pfizer under the 
brand name Celebrex) and rofecoxib (Vioxx) are two licensed selective COX-2 
inhibitors that have been marketed for the treatment of acute pain, osteoarthritis and 
rheumatoid arthritis.34,35 However, the use of most COX-2 selective inhibitors has 
been hampered by the increased risks of cardiovascular disorders observed in 
patients.36-38 As a result, some selective COX-2 inhibitors have been removed from 
the drug market following legal action.39 
As described previously, oxidative stress is a major contributor to inflammatory 
diseases.40-42 Also, endoscopic studies have shown that elevated levels of reactive 
oxygen species (ROS) are a key factor in both the pathogenesis and the propagation 
mechanism underlying NSAID-induced gastric mucosa ulceration.43 The abnormal 
level of ROS produced during NSAID-induced ulceration is linked to the increase in 
the activity of the myeloperoxidase enzyme. During NSAID-induced ulceration, 
gastrointestinal endothelial cells also show significant suppression (to below 
physiological levels) of endogenous antioxidant systems such as superoxide 
dismutase (SOD) and glutathione. Such high levels of ROS cause mucosa damage 
either directly or via ROS-induced lipid peroxidation. This in turn leads to increased 
production of ROS oxidants. Thus, to effectively manage chronic inflammatory 
diseases and the associated NSAID-induced damage, there is a clear need for both an 
effective anti-inflammatory and an antioxidant intervention. This project explores the 
design of novel, potential dual-action based pharmacophores that contain both anti-
inflammatory and antioxidant functional subunits. Using the pharmacophore 
hybridization strategy, the aim was to combine antioxidant nitroxides with the 
salicylate type NSAIDs by taking advantage of structural similarities of the parent 
compounds. Specifically, drug candidates were designed whereby a pyrroline 
nitroxide 3 was merged with salicylic acid 135 and aspirin 136 pharmacophores 
(Figure 2.3) to produce new hybrid nitroxide-salicylate molecules 5-carboxy-6-
hydroxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 137 (salicylic acid TMIO) and 6-
acetoxy-5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 138 (aspirin TMIO) shown 
in Figure 2.4 below. In addition, the o-acetamide benzoic acid derivative 139 was 
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also conceived as a target as it differs structurally from aspirin TMIO 138 by having 
an ortho-acetamide group instead of an ortho-acetate. This variation has the potential 
to provide structural-reactivity relationship information that could provide insight on 
the process and mechanisms of competitive inhibition of the COX enzyme by the 
compounds. Also, the mechanism of action of aspirin is thought to involve an 














Figure 2.3. Structures of parent molecular templates: pyrroline nitroxide 3, salicylic 



















Figure 2.4. Structures of target hybrid molecules: salicylic acid TMIO 137, aspirin 
TMIO 138 and o-acetamide benzoic acid TMIO 139. 
Such transesterification of the acetate (present in target compound 138) would not be 
possible for the target amide nitroxide 139. Therefore any efficacy of the structurally 
similar acetamide 139 would arise purely from either the nitroxide moiety or by a 
time-dependent reversible hydrogen bonding, ionic, van der Waals or hydrophobic 
interactions with distinct amino acid residues of the COX.45 The synthesis and 
preliminary biological results of these novel compounds are discussed in the next 
section. 
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2.2 Results and Discussion 
2.2.1 Synthesis of Salicylic Acid and Aspirin TMIO 
Scheme 2.1 below outlines the synthetic route that was proposed for the synthesis of 
salicylic acid and aspirin TMIO conjugates 137 and 139. Dashed arrows represent 
























































Scheme 2.1. Overall route for the synthesis of salicylic acid TMIO 137 and aspirin 
TMIO 138. Reagents and conditions: a. BnNH2, AcOH, reflux, 1 h, 98%; b. MeMgI, 
Et2O, toluene, reflux, 3 h, 27%; c. Br2, AlCl3, DCM, then NaHCO3, H2O2, MeOH, 
1h, 90%; d. NaOMe, DMF, MeOH, reflux; e. Br2, AlCl3, DCM; f. H2O2, MeOH; g. 
K4[Fe(CN)6], nBulmi, CuI, toluene; h. mCPBA, DCM; i. NaOH, H2O reflux; j. 
BBr3, DCM; k. AcCl, TEA, THF. 
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2.2.1.1.  Synthesis of 5-Bromo-1,1,3,3-tetramethylisoindoline 66 
The 5-bromo-1,1,3,3-tetramethylisoindoline 66 precursor was synthesized in three 
steps from phthalic anhydride 167 by following previous established literature 
procedures.46 Thus, commercially available phthalic anhydride 167 was reacted with 
excess benzylamine and the resulting reaction mixture was refluxed in acetic acid to 
give a crude residue that was recrystallized from ethanol to afford N-
benzylphthalimide 168 as white fluffy crystals in 98% yield. The melting range (116-
117 oC) was consistent with that reported in the literature.47 The synthesis of N-
benzyl-1,1,3,3-tetramethylisoindoline 169 was then performed using freshly prepared 
methyl magnesium iodide. In this case, N-benzylphthalimide 168 was 
tetramethylated by reacting with six equivalents of freshly prepared methyl Grignard 
reagent in refluxing toluene. The crude product residue obtained was purified by 
filtering through Celite and a short silica gel column, followed by recrystallization 
from methanol to give N-benzyl-1,1,3,3-tetramethylisoindoline 169 as a white 
crystalline solid in a typical modest yield of 27%. The low yield was attributed to the 
formation of a large amount of intractable purple material that was separated from 
169 at the basic alumina filtration step.48-50 All physical data obtained for compound 
169 were in agreement with that previous reported in the literature.51 
To synthesize bromoamine precursor 66 from compound 169, a combined oxidative 
debenzylation and selective ring mono-bromination reaction was carried out 










Scheme 2.2. Synthesis of bromoamine precursor 66.  Reagents and conditions: a. 
Br2, AlCl3, DCM, 0 oC, 1 h; b. NaHCO3, H2O2, MeOH, (90% over the two steps). 
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When compound 169 was treated with an almost stoichiometric amount of bromine 
(2.1 equiv.) in the presence of anhydrous aluminium trichloride, the crude product 
obtained, predominantly as the 2,5-dibromo 176 intermediate, was then reduced to 
the desired bromoamine 66 using hydrogen peroxide in the presence of sodium 
bicarbonate. Pure bromoamine 66 was obtained as a pale white solid in 90% yield 
with all characteristic data obtained matching those reported in the literature.46 
2.2.1.2. Copper-Catalyzed Methanolysis of Bromoamine 66 
The only literature procedure to describe the synthesis of the 5-methoxyamine 
intermediate 170 was reported in a patent by Haj-Yehia and coworkers.52 In their 
work, compound 170 was prepared in three steps from dimethyl 4-methoxyphthalate 
177 (Scheme 2.3). Although it is commercially available, compound 177 is 
expensive when compared to other phthalate precursors such as the phthalic 





















Scheme 2.3. Synthesis of 5-methoxyamine 170 from 4-methoxyphthalate 177. 
Reagents and conditions: a. BnNH2, PhMe, reflux; 111°C; b. MeMgI, Et2O, RT, 
then PhMe 4-6 h, 111°C; c. H2, Pd/C, EtOH, 15 h, RT, 50 psi: (no yields reported).52  
However, the nitroxide derivative of 170 was previously synthesized by Benjamin 
Morrow of the Bottle research group here at QUT (Scheme 2.4).53 In this case, the 5-
bromo nitroxide 28 was subjected to a copper (I) catalyzed methanolysis reaction 
developed by Capdevielle and Maumy.54 The method involves refluxing aryl halides 
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in 5 M sodium methoxide solution in the presence of catalytic amount of copper (I) 
bromide and ethyl acetate as a co-catalyst. 
 
Scheme 2.4.  Copper-catalyzed methanolysis of bromonitroxide 28. Reagents and 
conditions: a. NaOMe, CuI, EtOAc, MeOH, reflux, 16 h, 88%.53 
Since most transition metal catalyzed methoxylations (nucleophilic aromatic 
substitution with aryl halides) have drawbacks such as difficulties in initiation and 
low conversion,55-57 ethyl acetate is often used as an effective co-catalyst to enhance 
the methanolysis reaction particularly for deactivated aryl halide substrates. Ethyl 
acetate stabilizes and increases the solubility of the cuprous salts by first forming a 
stable tetrahedral complex (i) with the methoxide ion (Scheme 2.5).  
 
Scheme 2.5. Proposed mechanism for the copper-catalyzed methoxylation of 28.54 
The tetrahedral intermediate (i) is a strong ligand that effectively binds to the Cu(I)-
catalyst to generate Cu(I)-complex (ii) which assists the substitution process. If no 
co-catalyst is used, an insoluble yellow copper (I) methoxide is usually formed.54 
Such salts (Cu(I)-methoxide) disproportionate quickly to form some Cu0 and Cu2+ 
salts. This in turn slows down the catalytic cycle and eventually stops it.  
The copper-catalyzed methanolysis method was employed herein for the synthesis of 
the methoxyamine 170. However, when bromoamine 66 was refluxed under similar 
methanolysis conditions, less than 10% conversion of 66 to 170 was observed by 1H 
NMR spectroscopic analysis. The conversion could not be improved by prolonged 
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in place of copper (I) bromide (Table 2.1). In a mechanistic study of the copper (I)-
catalyzed methanolysis of aryl halides, Aalten and co-workers used N,N-
dimethylformamide (DMF) as a suitable co-catalyst (or co-solvent) to quantitatively 
obtain aryl methyl ethers from the corresponding aryl bromides.58 Like ethyl acetate, 
DMF stabilizes and increases the solubility of the cuprous-catalyst by forming a Cu-
DMF complex.59,60 







CuBr 10/20 - - 
CuI 10/20 - <5 
CuBr 10/20 EtOAc - 
CuI 10/20 EtOAc <10 
CuBr 10/20 DMF <5 
CuI 12 DMF 100 
However, in this case no conversion was observed when bromoamine 66 was 
refluxed in sodium methoxide in the presence of DMF and copper (I) bromide. When 
copper (I) iodide was used instead of copper (I) bromide however, the methanolysis 
proceeded smoothly with complete conversion of 66 to 170 achieved after refluxing 
overnight. This is thought to be because of the higher reactivity of the copper (I) 
iodide with DMF as co-solvent. The crude product obtained was determined to be 
pure enough by NMR spectroscopy to be used in the subsequent step. It could be 
further purified if necessary by silica gel column chromatography to afford 
compound 170 in 88% yield. The purity of 170 was assessed by HPLC analysis to be >95%. Pure compound 170 could also be obtained after acid/base washes of the 
crude product. The most diagnostic feature was the characteristic methoxy protons 
(OMe) signal at 3.87 ppm in the 1H NMR spectrum of 170. Other characteristic data 
obtained for 170 included 13C NMR, FTIR, and HRMS spectra (see experimental 
section for details). 
Merged Dual-Action Nitroxide-Aspirin Hybrids 
 63 
2.2.1.3. Synthesis of 5-Bromo-6-methoxy-1,1,3,3-tetramethylisoindoline 
172 
The next step developed in this synthetic approach involved the selective 
bromination of 170 at the 6-position to give the bromo ether 172. This was achieved 
using similar bromination conditions as were employed for the synthesis of 
compound 66 (Scheme 2.2). Thus, when compound 170 was treated with 2.5 molar 
equivalents of bromine in the presence of anhydrous aluminium trichloride, a crude 
fraction of 2,5-dibromo compound 171 was obtained as a light brown oil after 
extraction and evaporation of the organic solvent (Scheme 2.6).  
 
Scheme 2.6. Synthesis of bromomethoxyamine 172 via selective bromination of 
methoxyamine 170. Reagents and conditions: a. Br2, AlCl3, DCM, 0 oC, 1 h, 87%; b. 
NaHCO3, H2O2, MeOH, 98%. 
Though the Lewis acid catalyst, aluminium trichloride would typically be expected 
to be required to brominate the aromatic ring, the N-bromination proceeds readily 
even in the absence of the catalyst. The crude residue was triturated with methanol to 
give 171 as a yellow solid in 87% yield. Despite the presence of the activating 
methoxy group, only mono bromination was observed. This is presumably because 
of the steric hindrance at the 1 and 3-positions. The structure of compound 171 was 
confirmed by 1H and 13C NMR and FTIR spectroscopy. In the 1H NMR spectrum of 
171, two singlets were observed for the two aryl protons at 6.66 and 7.30 ppm. 
Compound 171 was >93% pure by HPLC and had a melting range of 97-98 oC. 
It was then determined that compound 171 could be subsequently reduced to the 
secondary amine derivative, 5-bromo-6-methoxy-1,1,3,3-tetramethylisoindoline 172, 
by aqueous hydrogen peroxide in the presence of sodium bicarbonate. A weak N-H 
stretching frequency was observed in the FTIR spectrum of 172 at 3307 cm-1. The 
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atom with the molecular ion plus proton [M + H]+ mass observed for both isotopes at 
284 and 286. Although hydrogen peroxide was used to reduce 171 to the secondary 
amine derivative 172, the reduction (without hydrogen peroxide) was observed to 
occur slowly even after 171 was left in a sealed vessel of methanol for 3-7 days. 
2.2.1.4. Synthesis of 5-Cyano-6-methoxy-1,1,3,3-tetramethylisoindoline 
173 via Copper-Catalyzed Cyanation 
Typically, aryl nitriles are synthesized from five general precursors (Scheme 2.7).61 
Choosing a route to a particular aryl nitrile mainly depends on the precursor 
available, how stable other functional groups are to the chosen reaction conditions, 
and the prospective overall yield of the route. 
 
Scheme 2.7. Common precursors to aryl nitriles. 
The use of aryl halides to synthesize aryl nitriles is an attractive methodology 
because aryl halides are versatile and readily available stable precursors. The 
Rosenmund-von Braun reaction of aryl halides with CuCN is the conventional 
method used to synthesize benzonitriles.57,62 The drawback to this reaction is that it is 
relatively less reactive to aryl chlorides and bromides and requires the use of excess 
CuCN under somewhat demanding reaction conditions. To circumvent these 
limitations, it was decided to exploit a copper-catalyzed cyanation of aryl bromides 
as reported by Schareina et al.63 In this case the cyanation of 5-bromo-6-methoxy-







Merged Dual-Action Nitroxide-Aspirin Hybrids 
 65 
hexacyanoferrate(II), as the cyanide source, in the presence of a catalytic amount of 
CuI with N-butylimidazole as a co-solvent (Scheme 2.8). 
 
Scheme 2.8. Copper-catalyzed cyanation of bromomethoxyamine 172. Reagents and 
conditions: a. K4[Fe(CN)6], nBulmi, CuI, o-xylene, 180 oC, 3 d, 78%. 
Unlike most transition metal-catalyzed cyanation methods which use more toxic 
cyanide sources (KCN, NaCN, Zn(CN)2, and TMSCN),61,64-68 potassium 
hexacyanoferrate (II) is the least toxic cyanide source available and is relatively 
inexpensive. In addition, the Schareina method is tolerant to many functional groups 
and gives excellent yields with both electron deficient and electron rich substrates. 
Also, with most other metal-catalyzed aryl halide cyanations, the cyanide sources 
usually form stable complexes with the metal centre. Such complexes are known to 
deactivate the catalytic process and result in an inefficient cyanation. Using N-
butylimidazole can prevent the formation of such undesirable cyano-metal 
complexes.  The N-butylimidazole acts as a superior ligand that effectively binds to 
the metal centre to generate an active cyanation catalyst that is stable enough and 
selective towards the targeted substrates. When compound 172 was however, 
refluxed for three days under these conditions at 150 oC in toluene, the crude residue 
obtained was at best a 1:1 mixture of the desired product 173 and the unreacted 
starting material 172 (determined by 1H NMR spectroscopy). Attempts to separate 
these compounds by conventional separation techniques (column chromatography 
and recrystallization) were unsuccessful. The ratio could not be improved even with 
increased molar equivalents of reagents and prolonged reaction time (1 week). 
However, complete conversion was achieved after three days when o-xylene was 
used in place of toluene as solvent. This allowed for the reaction temperature to be 
raised to 180 oC. Using this solvent, compound 173 was obtained as a white solid in 
78% yield after purification by column chromatography, followed by 
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Though the residual Cu-N-butylimidazole-complex was removed by recrystallization 
(or sometimes by trituration), its presence did not affect the next reaction and could 
be readily removed in the workup of the reaction by acid extraction. The FTIR 
spectrum of 173 showed a distinct sharp and strong C≡N vibration stretch at 2221 
cm-1. In addition, the extra (1 more carbon than 172) carbon signal at 100.8 ppm in 
the 13C NMR spectrum of 173 supported the presence of a nitrile group. The 
expected molecular ion plus proton [M + H]+ was observed at m/z 231 in the HRMS 
spectrum of 173. As expected, the characteristic isotopic pattern of a single bromine 
atom (of the starting material 172) was not observed. The product had a melting 
range 138-139 oC and its purity was assessed by HPLC to be >99%. 
2.2.1.5. Synthesis of 5-Cyano-6-methoxy-1,1,3,3-tetramethylisoindolin-
yloxyl 174 
After the successful synthesis and characterization of the aminonitrile 173, the next 
step was to oxidize 173 to the corresponding nitrile nitroxide 174. This can be 
achieved using mCPBA or hydrogen peroxide oxidation conditions. Thus, compound 
173 was converted to the nitroxide derivative 174 by reacting with 1.2 molar 
equivalents of mCPBA in dichloromethane (Scheme 2.9). 
 
Scheme 2.9. m-Chloroperoxybenzoic acid oxidation of aminonitrile 173. Reagents 
and conditions: a. mCPBA, DCM, 0 oC-RT, 2 h, 90%. 
After successive acid and base washes to remove any residual N-butylimidazole and 
m-chlorobenzoic acid respectively, compound 174 was obtained as a yellow solid 
which was determined by HPLC analysis to be pure enough (>95%) to be used in 
the next step. However, high purity (>99% by HPLC) 174 was obtained after 
recrystallization from ethanol to give bright yellow crystals in 92% yield. No NMR 
spectroscopic data was obtained for compound 174 because of the paramagnetic 
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the presence of the free radical). However, FTIR, HRMS and HPLC analysis further 
supported the structural assignment and purity. The loss of the weak N-H stretch at 
3326 cm-1 in the FTIR spectrum of 174 supported the transformation. In addition, a 
sharp C≡N stretch was observed at 2231 cm-1. The mass of the molecular ion plus 
sodium [M + Na]+ was observed at m/z 268 in the HRMS spectrum of 174. The 
melting range determined for 174 was 200-201 oC. 
2.2.1.6. Synthesis of 5-Carboxy-6-methoxy-1,1,3,3-tetramethylisoindolin-
2-yloxyl 163 
Nitrile hydrolysis is a common synthetic method used to generate amides and 
carboxylic acids.  In general, organic nitriles are hydrolyzed readily in strong acids 
(e.g. hydrochloric acid, sulfuric acid) or strong alkaline (sodium hydroxide) 
solutions. In either case, the reaction proceeds by first forming the amide which is 
further hydrolyzed, in situ, to the carboxylic acid (Scheme 2.10). 
 
Scheme 2.10. Hydrolysis of nitriles to the corresponding carboxylic acids. 
However, because nitroxides may disproportionate in strongly acidic solutions,69 
hydrolysing the nitrile nitroxide 174 by refluxing in acid was not attempted. Instead, 
nitrile nitroxide 174 was readily converted to the carboxylic acid derivative 175 by 
refluxing in 5 M sodium hydroxide solution (Scheme 2.11). Ethanol was used as a 
co-solvent in order to increase solubility of the nitrile 174. 
 
Scheme 2.11. Basic hydrolysis of nitrile nitroxide 174. Reagents and conditions: a. 5 
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The desired carboxylic acid nitroxide 175 was obtained in 89% yield as a bright 
yellow crystalline solid following recrystallization from H2O/EtOH. The FTIR 
spectrum of 175 confirmed the disappearance of the sharp C≡N stretch of the 
starting material 174 at 2231 cm-1. The strong-broad O-H and strong C=O stretching 
frequencies, observed at 3400 and 1675 cm-1 respectively, supported the formation of 
a carboxylic acid functional group. The paramagnetic broadening effect of the 
nitroxide radical moiety of 175 limited the use of NMR spectroscopy for the 
characterization of compound 175. The molecular ion plus sodium [M + Na]+ and the 
molecular ion plus potassium [M + K]+ for 175 were observed at m/z 287 and 303 
respectively in the HRMS spectrum. 
2.2.1.7. Synthesis of Salicylic Acid-TMIO 137 via Boron Tribromide 
Demethylation of 175 
A variety of reagents are known to cleave ethers.70 The most common ether cleavage 
reagents include the Bronsted acids (HCl, HBr), Lewis acids (aluminium and boron 
trihalides), basic reagents (alkali metals, hydroxides and amides), and miscellaneous 
reagents like the halogen trimethylsilanes. These reagents differ in their comparative 
reactivities for ether cleavage. They can have limitations with respect to the structure 
of the substrate and their tolerance to other functional groups present. Because of 
this, boron tribromide (BBr3) is the reagent of choice for the cleavage of ethers. Its 
widespread use in this context is because the reactions are generally carried out under 
mild conditions (-78 oC to RT) and the cleavage usually does not affect other 
functional groups. Boron tribromide is a moisture-sensitive liquid that decomposes in 
air to give hydrobromic acid. As a strong Lewis acid, boron tribromide complexes to 
the ethereal oxygen atom and promotes the ether cleavage (Scheme 2.12).71 For 
optimum ether cleavage, typically at least one molar equivalent of BBr3 is used for 
each ether group and an extra equivalent is added for each functional group that 
contains lone pairs of electrons that could complex with BBr3. 
Thus, three molar equivalents of BBr3 were added to a solution of carboxylic acid 
175 in dichloromethane at -78 oC and the reaction mixture was allowed to return to 
room temperature while stirring overnight (Scheme 2.13). After work-up, which 
involved hydrolysis of the alkoxyborane with water and extraction with 
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dichloromethane, the desired salicylic acid-TMIO 137 was obtained as a yellow 
crystalline solid in 40% yield after recrystallization. The FTIR spectrum of the 
product displayed a medium-broad OH stretching frequency (3400-2500 cm-1) along 
with a strong C=O stretch (1674 cm-1). Compound 137 was of high purity (>99% 
pure by HPLC) with a melting range of 207-208 oC. 
 
Scheme 2.12. Proposed mechanism for BBr3-mediated ether cleavage. 
 
Scheme 2.13. Boron tribromide demethylation of 175. Reagents and conditions: a. 
BBr3, DCM, -78 oC-RT, 18 h, 40%. 
The low yield could be attributed to the potential formation of a complex between 
BBr3 and the nitroxide moiety. Evidence to support the proposed nitroxide-BBr3 
complexation is reported by the work of Renaud et al. in which TEMPO was shown 
to complex with β-alkylcatecholboranes under mild radical hydroxylation conditions 
(Scheme 2.14).72-75 Such nitroxide-BBr3 complex formation could initiate multiple 
degradation pathways for both the starting material and the desired nitroxide 
compounds. To optimize the demethylation, an alternative approach was undertaken 
using a protecting group strategy for the nitroxide moiety. 
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Scheme 2.14. Reaction of β-alkylcatecholborane with nitroxide radicals. Adopted 
and modified from Renaud et al.72,73 
2.2.1.8. Alternative Synthetic Route to Salicylic Acid-TMIO 137 from 175 
One potential means to avoid such nitroxide-BBr3 complexation (and, ultimately, to 
improve the yield) is to use a protecting group for the nitroxide moiety. The acetyl 
group is a simple nitroxide protecting group that is easily introduced and removed 
with no significant loss in yield.51 The acetyl protection of 175 was carried out in a 
two-step one-pot synthesis (Scheme 2.15). 
 
Scheme 2.15. Alternative route to 137 via protection of the nitroxide moiety of 175. 
Reagents and conditions: a. 1 M BBr3, DCM, -78 oC-RT, 1 d, 40%; b. H2, Pd/C, 
THF, 15 min; c. TEA, AcCl, 0 oC-RT, 1.5 h, 96%; d. MeOH, 2 h; e. 1 M BBr3, 





























































Merged Dual-Action Nitroxide-Aspirin Hybrids 
 71 
First, compound 175 was reduced to its corresponding hydroxylamine 183 via 
palladium-catalyzed hydrogenation. Then, the in situ generated hydroxylamine 183 
was allowed to react with acetyl chloride in the presence triethylamine. The acetyl-
protected intermediate 185 was obtained as a mixture with 10% of the anhydride 184 
as determined by 1H NMR spectroscopy. However, the anhydride 184 was easily 
hydrolyzed back to carboxylic acid 185 when the crude mixture was stirred in 
methanol for 2 hours. Compound 185 was obtained as a white crystalline solid in 
96% yield after purification by chromatography and recrystallization. The singlets at 
2.2 (3 protons), 4.1 (3 protons) and 10.8 ppm (br, 1 proton) observed in the 1H NMR 
spectrum of 185 are characteristic protons of the acetyl, methoxy and carboxylic acid 
groups respectively. The two strong FTIR spectroscopy stretching frequencies at 
1709 and 1772 cm-1 are consistent with the presence of the carboxylic acid and acetyl 
functionalities respectively. 
The acetyl-protected compound 185 was then subjected to the same mild boron 
tribromide mediated demethylation reaction conditions used in the preceding section 
(Section 2.2.1.7). This afforded the desired N-acetoxy salicylic acid 186 in excellent 
yield (85%). Evidence for successful demethylation of 185 was given by the 
disappearance of the methoxy proton and carbon peaks at 4.1 and 64 ppm in the 1H 
and 13C NMR spectra respectively. Though the phenolic proton could not be detected 
in the 1H NMR spectrum (possibly due to strong hydrogen bonding with the ortho-
carboxylic acid group or residual water) all characterization data obtained support the 
successful synthesis of 186. 
The acetyl-protecting group was removed following basic hydrolysis of compound 
186 with lithium hydroxide to give the target salicylic acid-TMIO 137 in 92% yield. 
In comparison to the 40% yield obtained from direct demethylation of 175 (Scheme 
2.15.a), the overall yield over the three steps (protection, demethylation and 
deprotection) was 75%. 
Thus, the use of the acetyl protecting group clearly satisfies the prerequisites of a 
good protecting group: it was introduced easily in high yield, was stable under the 
boron tribromide demethylation conditions, did not interfere with the reaction, and 
was easily removed in high yield. 
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2.2.1.9. Synthesis of Aspirin-TMIO 138 from Salicylic acid-TMIO 137 
The second target compound, aspirin-TMIO 138, was readily synthesized by 
acetylating salicylic acid-TMIO 137 with acetyl chloride in the presence of 
triethylamine (TEA, Scheme 2.16). The target aspirin-TMIO 138 was obtained 
almost quantitatively as a bright yellow crystalline solid after recrystallization from 
water/ethanol. The acetyl and carboxylic acid C=O groups were observed as strong 
bands at 1765 and 1695 cm-1 respectively in the FTIR spectrum. The carboxylic acid 
stretching frequency was observed at 3400-2600 cm-1 as a medium broad band. 
Compound 138 was determined to be >95% pure by HPLC and decomposed at 
temperatures above 206-207 oC. 
 
Scheme 2.16. Synthesis of aspirin TMIO 138. Reagents and conditions: a. TEA, 
AcCl, THF, 0 oC-RT, 3 h, 91%. 
With both salicylic acid and aspirin-containing TMIO compounds (137 and 138) in 
hand, the next section details the synthesis of the last target compound 6-
acetylamino-5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 139. 
2.2.2 Synthesis of 6-Acetamido-5-carboxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl 139 
This section explores the synthesis of the final target compound in this chapter, N-
acetylanthranilic acid-TMIO 139. This analogue differs structurally from aspirin-
TMIO 138 by having an ortho-N-acetyl group instead of an ortho-O-acetyl group. 
Such structural variation may provide means to compare the biological efficacy of 
the amide to the ester derivatives in inhibiting the MPO and COX enzymes. Scheme 
2.17 below outlines the synthetic route undertaken for the synthesis of compound 
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Scheme 2.17. Synthesis of N-acetylanthranilic acid-TMIO 139. Reagents and 
conditions: a. HNO3, H2SO4, 0 oC, 5 h, 55%; b. K4[Fe(CN)6], nBulmi, CuI, toluene, 
160 oC, 2 d, 68%; c. mCPBA, DCM, 0 oC-RT, 2 h, 93%; d. SnCl2.2H2O, HCl, 0 oC-
RT, 3 h, 69%; e. KOH, H2O/EtOH, reflux, 16 h, 75%; f. AcCl, TEA, THF, 0 oC, 3 h, 
88%. 
The starting bromoamine compound 66 was prepared in three steps from phthalic 
anhydride as detailed in Section 2.2.1.1. Nitration of aromatic compounds is 
generally a useful synthetic route to aromatic nitrogen containing compounds. It 
requires a strong electrophile, most commonly, a nitronium ion. The nitronium ion is 
formed by reacting concentrated sulfuric acid with nitric acid. When three 
equivalents of concentrated nitric acid were added to an ice-cold solution of 
bromoamine 66 in concentrated sulfuric acid, the reaction afforded the nitroamine 67 
in 56% yield. Although excess nitric acid was used, only a single ring-nitration 
product was obtained as expected when a deactivating nitro group is added to the 
ring.  
Using copper-catalyzed cyanation reaction conditions similar to those discussed in 
Section 2.2.1.4, a reaction mixture of compound 67, potassium hexacyanoferrate (II), 
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give crude cyano nitroamine 187. Compound 187 was obtained as an off white solid 
in 68% yield after purification by flash column chromatography. The cyano 
nitroamine 187 was then oxidized to the nitroxide derivative 188 by allowing it to 
react with mCPBA in DCM. The nitroxide 188 was obtained as a bright orange solid 
in 93% yield after purification by column chromatography and recrystallization from 
ethanol. The melting range determined for 188 (230-231 oC) was in agreement with 
that reported in literature.51 
The next step was to selectively reduce the nitro group of compound 188 to the 
amine derivative 189. The reduction of nitro groups to their corresponding amine 
derivatives is most commonly carried out using tin chloride/hydrochloric acid 
(SnCl2/HCl) or by catalytic hydrogenation. However, the nitrile group of 188 could 
also be reduced to the amine or the aldehyde derivative by hydrogenation. Although 
tin chloride reduces nitriles, such reduction reactions are usually carried out under 
anhydrous conditions with gaseous HCl.76,77 Therefore in this case the nitro group of 
compound 188 was selectively reduced to the aminonitrile 189 using SnCl2 in 2 M 
aqueous HCl solution. Although some nitroxides are reduced to amines by tin 
chloride, this did not occur with compound 188 under these aqueous conditions. The 
aminonitrile nitroxide 189 was obtained as a yellow solid in 69% yield after 
purification by flash column chromatography and recrystallization from ethanol. 
Basic hydrolysis of the aminonitrile 189 with 5 M potassium hydroxide solution 
afforded the β-amino acid nitroxide 190 in 75% yield. The amino acid 190 was 
obtained as bright yellow crystals and decomposed at temperatures above 230 oC. 
This was consistent with that of the literature.51 
The target N-acetylanthranilic acid-TMIO 139 was synthesized by acetylation of β-
amino acid nitroxide 190 with acetyl chloride in the presence of triethylamine. The 
crude product was purified by recrystallization from water/methanol to give a yellow 
crystalline solid of N-acetylanthranilic acid-TMIO 139 in 88% yield. The presence of 
two strong carbonyl stretching frequencies at 1681 and 1590 cm-1 in the FTIR 
spectrum of 139 supported the presence of the carboxylic acid and acetamide groups 
respectively. In addition, a strong broad OH stretch was also observed (3340-2600   
cm-1) in the FTIR spectrum of 139. Further structural confirmation for 139 was 
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obtained by the presence of the molecular ion plus proton [M + H]+ mass at m/z 292 
in the HRMS spectrum.  
All of the synthesized compounds were determined to be of sufficient purity for 
biological screening, being >95% pure by HPLC. 
2.2.3 Preliminary Biological Results 
Following the synthesis of the target nitroxide-aspirin analogues, the next step in this 
project was to study the in vitro anti-inflammatory and antioxidant potentials of these 
new analogues. Preliminary antioxidant and anti-inflammatory activity studies on 
newly synthesized merged nitroxide-aspirin hybrids involved evaluating their 
inhibitory action on the MPO system and two isoforms of the COX enzyme (COX-1 
and COX-2) respectively. Collaborators at the Australian Heart Research Institute 
(HRI) conducted both the initial antioxidant and anti-inflammatory experiments. 
Results discussed herein were obtained from studies conducted with the merged 
salicylic acid TMIO 137 and aspirin TMIO 138 hybrids. Compound 139 is currently 
being investigated for its antioxidant and anti-inflammatory effects. 
2.2.3.1 Inhibitory Effects of Hybrid Salicylate-Nitroxides on the 
Myeloperoxidase Enzyme 
The myeloperoxidase (MPO)-mediated hypochlorous acid production system is well-
known therapeutic target due to its involvement in the progression of 
neurodegenerative and chronic inflammatory diseases.1,4 Nitroxides and other potent 
antioxidants have been previously shown to inhibit the MPO system.78-82 In these 
studies, the MPO system used to produce the strong hypochlorous acid oxidant 
comprised of MPO (10–500 nM), Cl- (100 mM) and H2O2 (10–50 μM).83 The 
enzyme was incubated either alone (control) or with each nitroxide and the reactions 
were initiated by the addition of H2O2. The reactions were performed at 25 oC at or 
near the physiological pH of 7.4. Each experiment was performed in the presence of 
taurine and a bovine liver catalase was used to stop the reactions. Taurine is a 𝛽-
amino acid which rapidly traps hypochlorous acid produced by the MPO system to 
form the stable oxidant taurine chloroamine (Tau-Cl). Taurine chloroamine 
subsequently reacts with 5-thio-2-nitrobenzoic acid (which has a strong absorbance 
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at 412 nm) to produce the colourless compound 5,5’-dithio-bis(2-nitrobenzoic acid) 
199 (DTNB). The MPO inhibition activity of each compound is inversely 
proportional to the decrease in DNB absorbance which in turn is proportional to the 
amount of Tau-Cl generated. Aspirin and salicylic acid-TMIO based compounds 137 
and 138 were evaluated along with the parent aspirin compound 136. 
As shown in Figure 2.5 below, the parent aspirin 136 displayed no inhibitory effect 
on the MPO system even at higher concentration. With respect to the hybrid 
nitroxides, neither CTMIO 70, salicylic acid-TMIO 137, nor aspirin-TMIO 138 
could inhibit the production of hypochlorous acid at 10 μM concentrations (Figure 
2.6, Figure 2.7 and Figure 2.8). At concentrations ≥ 100 μM however, a gradual 
decrease in the amount of Tau-Cl generated was observed for each hybrid nitroxide.  
 
Figure 2.5. Parent aspirin 136 inhibitory action of MPO-system. 
 
 




















Figure 2.8. Aspirin TMIO 138 inhibition of MPO (*** denotes marked inhibitory 
effect). 
The IC50 values from each dose-response curve were 116, 430 and >1000 μM for 
CTMIO 70, aspirin-TMIO 138 and salicylic acid-TMIO 137 respectively. The results 
indicated a dose-dependent inhibitory effect of the hybrid nitroxide salicylate 
compounds on the MPO system. 
The fact that these novel nitroxides do inhibit the myeloperoxidase system albeit at 
higher concentration was encouraging and demonstrated a clear antioxidant capacity 
for these hybrids. The inhibitory effect however is modest when compared to amino-
TEMPO nitroxide (currently the most potent nitroxide inhibitor of MPO reported) 
which has an IC50 value of 1 μM.78 This is likely to be size-related, since previous 
studies have shown that the extent of nitroxide-mediated MPO inhibition largely 
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site).78 Nevertheless, these results do support, at least in part, our hypothesis that 
these novel analogues may have potential to function as therapeutic antioxidant in 
biological environments with particular targets such as the gastrointestinal mucosa 
linings. 
The next section details some preliminary COX inhibition results for the novel 
hybrid compounds. 
2.2.3.2 Inhibitory Effects of Hybrid Salicylate-Nitroxides on Cyclooxygenase 
Enzymes 
In order to evaluate the anti-inflammatory action of the novel nitroxide analogues, 
inhibitory studies were carried out on both isoforms of the COX enzyme, COX-1 and 
COX-2. 
2.2.3.2.1. COX Inhibitory Studies using the Amplex Red Fluorescent Inhibitor 
Screening Assay 
Preliminary studies were carried out using the COX Fluorescent Inhibitor Screening 
Assay Kit (Cayman Chemical, Item No. 700100). Following a phospholipase H2-
catalyzed liberation of arachidonic acid from the phospholipids of the cell 
membrane, each isoform of the COX enzyme can cyclize arachidonic acid and add 
the 15-hydroperoxy group to form prostaglandin G2 which in turn decomposes to 
various prostanoids involved in both normal cell function and inflammation (Figure 
2.2). The peroxidase component of the COX enzyme uses a range of substrates to 
provide the required pair of electrons.84 The fluorescent inhibitor screening assay is 
designed to monitor the reactions that occur at the peroxidase active site of the COX 
enzyme. It uses 10-acetyl-3,7-dihydroxyphenoxazine 191 (ADHP or Amplex Red) as 
a fluorogenic peroxidase substrate (Scheme 2.18).85 In the presence of peroxidase, 
ADHP (a nonfluorescent compound) is converted to the highly fluorescent resorufin 
that has maximum excitation and emission of approximately 571 and 585 nm 
respectively. 
The COX inhibition experiments were carried out in duplicate wells, in duplicate 
experiments (with the exception of TEMPO, n=1). As expected, aspirin 136 
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significantly inhibited the COX-1 enzyme at 750 μM (Figure 2.9). TEMPO 38, at 
750 μM, displayed some COX-1 inhibition but not as much as aspirin. TEMPO 38 in 
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Scheme 2.18. Peroxidase/H2O2 oxidation of Amplex Red. Peroxidase converts 
ADHP 191 to resorufin 192, a highly fluorescent compound which can be analyzed 


























Figure 2.9. COX inhibitory studies of nitroxides using the Amplex Red assay (* 
denotes marked inhibitory effect). 
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Although CTMIO 70 displayed moderate inhibitory action of the COX-1 enzyme, 
neither the salicylic acid-TMIO 137 nor the aspirin-TMIO 138 hybrids had any 
significant inhibitory effect on the COX-1 enzyme. From the COX-2 study, TEMPO 
38 had the most significant inhibitory effect at 750 μM. However, CTMIO 70 and the 
hybrid salicylic acid and aspirin nitroxide compounds (137 and 138) also displayed 
good COX-2 inhibition, but not as much as TEMPO 38. 
Although the results seem promising, the important caveat in this study is that aspirin 
(known to inhibit both COX isoforms) did not inhibit the COX-2 enzyme in this 
specific assay.86 Also, the combination of aspirin 136 with TEMPO 38 appears to 
have a lesser inhibitory effect than TEMPO 38 alone. Furthermore, the significant 
inhibitory effect of TEMPO 38 on both COX isoforms was surprising as TEMPO 38 
has no structural functionality, besides the nitroxide moiety, that would give rise to 
this inhibitory capacity. 
One possible explanation for this observation could be that the nitroxide radical 
centre is interfering with the Amplex Red assay and thus giving a false positive COX 
inhibitory effect. In a recent study, Serrano et al. observed that dietary antioxidants 
(such as gallic acid, epicatechin, quercetin, vanillic acid and ascorbic acid) could 
interfere with the Amplex Red probe/ horseradish peroxidase assay.87 Although the 
mechanism for such interactions is complex, they proposed that it involves direct 
redox interactions of dietary antioxidants with the ferric centre of the peroxidase 
enzyme. This subsequently results in the production of antioxidant radicals which in 
turn act as competitive substrates for the peroxidase enzyme. 
Similarly, the antioxidant nitroxide moiety could be acting as a substrate that 
competes with the non-fluorescent ADHP 191 for the peroxidase enzyme of the 
Amplex Red assay. This leads to less resofurin production and therefore less 
fluorescence would be observed, thus explaining the strong inhibitory effect of 
TEMPO 38 that was observed. It is likely in such a case that the nitroxide moiety is 
either reduced to the hydroxylamine or oxidized to the oxoammonium derivative. 
The case of nitroxide reduction (or oxidation) can depend on the nitroxide ring class. 
This is a possible explanation for the observed difference between COX inhibitory 
effect of TEMPO 38 (a piperidine type nitroxide) and the isoindoline hybrids 
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(CTMIO 70, salicylic acid TMIO 137 and aspirin-TMIO 138). To determine the 
potential for the nitroxide to interfere with the Amplex Red assay, the non-radical 
methoxyamines were synthesized and assessed. 
2.2.3.2.2. Synthesis of Alkoxyamine Derivatives of Salicylic Acid TMIO and 
Aspirin TMIO 
To assess the possibility that the nitroxide moiety interferes with the Amplex Red 
reaction, additional experiments were carried out, this time with the nitroxide moiety 
of each analogue converted to the corresponding methoxyamine derivative. These 
derivatives were synthesized as outlined in Scheme 2.19 below. Methyl radicals 
generated by Fenton chemistry (from dimethyl sulfoxide, ferrous ions and hydrogen 
peroxide) were allowed to react with aspirin TMIO 138 to afford the diamagnetic N-


















Scheme 2.19. Synthesis of methoxyamine derivatives of salicylic acid-TMIO and 
aspirin-TMIO. Reagents and conditions: a. H2O2, FeSO4.7H2O, DMSO, 1 h, 64%; 
b. 2 M NaOH, 3 h, 96%. 
In the 1H NMR spectrum of 193, the singlets at 2.2 ppm and 3.8 ppm, each 
integrating for 3 protons, represent the OAc and N-OMe protons respectively. The 
carboxylic acid proton of 193 resonated as a weak, broad singlet at 10.7 ppm. In the 
FTIR spectrum of 193, two strong carbonyl (C=O) stretching frequencies were 
observed at 1690 and 1689 cm-1 which account for the acetyl and carboxylic acid 
groups respectively. A strong, broad O-H band stretching from 3400 to 2800 cm-1 of 
the COOH group was also observed. 
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Basic hydrolysis of 193 afforded the salicylic acid derivative 194 quantitatively. 
Although the phenolic proton could not be assigned in the 1H NMR spectrum 
(possibly due to a strong hydrogen bonding with the ortho carboxylic acid group or 
residual water), other characteristic data obtained to support the successful synthesis 
of 194 included FTIR and 13C NMR spectra and HRMS. 
Initial attempts to synthesize the alkoxyamine 194 directly from the nitroxide 
counterpart 137 (salicylic acid-TMIO) using the Fenton chemistry produced a 
mixture of the desired product (≤ 40 yield, after purification) and other 
uncharacterized side products. This could be attributed to a likely reaction of the 
phenolic groups of 137 and 194 with the methyl radicals. 
The methoxyamine derivatives 193 and 194 were tested for their inhibitory activity 
of the COX enzyme along with their nitroxide counterparts using the Amplex Red 
peroxidase fluorescence assay kit. As shown in Figure 2.10 below, at 700 μM 
concentrations, neither alkoxyamine derivatives 193 or 194 had any significant 












Figure 2.10. COX inhibition results for methoxyamine derivatives 193 and 194. 
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While this result reinforced the claim for a potential nitroxide interference with the 
Amplex Red assay, it is difficult to determine whether any interference 
predominantly gave rise to the observed COX inhibitory activity by TEMPOL and 
the hybrid salicylates and that the mechanism of inhibition of nitroxides (TEMPO 38, 
CTMIO 70, salicylic acid TMIO 137 and aspirin TMIO 138) arises at least in part, 
perhaps in a large part, from their antioxidant activity. Thus, the measured inhibitory 
effect could either arise from the nitroxide interference with the Amplex Red assay 
or from actual inhibitory effect from the nitroxide moiety, or a combination of both. 
In other words, the Amplex Red fluorescence assay could be measuring the COX 
inhibitory activity of hybrid nitroxide compounds while at the same time its 
peroxidase component is involved in a radical-mediated interaction with the 
nitroxide moiety. 
Although the Amplex Red results are not conclusively showing NSAID character, 
they still however, confirm the potent redox character of these compounds. Although 
the results link the significant COX inhibition observed for TEMPO (and other 
nitroxides) to the redox interference of the nitroxide moiety, the extent of such 
interference remains unknown. Thus, using other COX inhibitory assays with no 
prior reported antioxidant interference is required. One assay suitable for this 
purpose is the COX (ovine) inhibitor screening assay kit in which the enzyme-linked 
immunosorbent assay (ELISA) is employed to quantify the COX-induced PGs 
production. The next section discusses the technique and results obtained with the 
ELISA method.  
2.2.3.2.3. COX Inhibition Studies using the Enzyme-Linked Immunosorbent 
Assay (ELISA) 
Other methods used to quantify the inhibitory action of potent anti-inflammatories on 
the COX enzyme include monitoring the rate of oxygen consumption (from the 
double oxygenation of the arachidonic acid) or by quantitative measurement of the 
prostaglandins produced during the COX reaction. The most convenient COX 
(ovine) inhibitor screening assay however uses ELISA to directly measure the 
quantity of each PG produced from the COX reaction. 
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This high throughput method uses tin (II) chloride to reduce the COX-derived PGH2 
non-enzymatically to a variety of primary prostanoids. Before the COX reaction is 
started (by the addition of arachidonic acid), target compounds are pre-incubated 
with both isoforms of the COX enzyme. The prostanoid products derived from the 
COX reaction are then quantified using ELISA. The ELISA kit uses a specific 
antiserum that binds to all major bioactive PG products (Scheme 2.20).88 Also, it 
requires a constant concentration of PG-acetylcholinesterase 196 (AChE) tracer 
(obtained by covalent coupling of PG to pure AChE) that competes with PG 
(produced from COX reaction) for a limited amount of PG antiserum.  
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Scheme 2.20. ELISA method for detecting COX activity by quantification of PGs: a. 
Schematic of the quantification process; b. AChE (196)-catalyzed hydrolysis of 
acetylthiocholine 195 and subsequent reduction of Ellman’s reagent. 
The PG-AChE tracer which is bound to the antiserum is quantified by reaction with 
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dithio-bis(2-nitrobenzoic acid) 199 (DTNB) substrates. Acetylthiocholine 195 is 
hydrolyzed by AChE 196 to produce thiocholine 198 which in turn reacts with 
DTNB 199 to produce 5-thio-2-nitro-benzoic acid 200. 5-Thio-2-nitro-benzoic acid 
200 has a strong absorbance at 412 nm. The intensity of the coloured 200 is 
proportional to the amount of the tracer bound to the antiserum which is inversely 
proportional to the amount of PG produced from the COX reaction. 
Results obtained from duplicated experiments with pre-incubation times of 2 minutes 
are shown in Figure 2.11 below. At 10 μM, neither the parent aspirin nor the novel 
nitroxide derivatives could inhibit the COX-1 enzyme. At 100 μM and 500 μM, 



























Figure 2.11. COX inhibitory action of nitroxides after 2 minutes incubation (Cpd 
No. refers to compound numbers). 
However, none of the nitroxide compounds (38, 70, 137 and 138) displayed any 
significant inhibitory effects towards either COX isoform even at 500 μM. Most 
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notably, TEMPO 38, which with the Amplex Red assay indicated strong inhibitory 
effects of both COX isoforms, had no effect on both COX enzymes with this assay. 
This further supports the proposed redox interaction of the nitroxide compounds with 
the Amplex Red assay. 
Several studies have now determined that aspirin irreversibly deactivates the COX 
enzyme by rapidly blocking the entry of arachidonic acid to the COX active site by 
acetylating amino acid serine 530.44,89 Unlike aspirin however, most NSAIDs such as 
indomethacin and celecoxib harness their inhibitory action by either hydrogen 
bonding, ionic, van der Waals or hydrophobic interactions (or a combination) with 
distinct amino acid residues within the long, narrow hydrophobic region of the COX 
enzyme.45 Thus, most NSAIDs are slow time-dependent inhibitors of the COX 
enzyme. 
To test whether the hybrid nitroxide derivatives could be slow time-dependent COX-
inhibitors, further COX inhibitory experiments were therefore conducted with longer 
pre-incubation times (20 min, Figure 2.12). As expected, aspirin 136 inhibited both 
COX isoforms at 20 minutes. Neither aspirin-TMIO 138 nor the methoxyamine 
derivative 193 showed any inhibitory activity on the COX enzymes. Likely, the 
constrained nature of the hydrophobic inhibition region of the COX enzyme limits 
access to serine 530 by the acetyl group of aspirin TMIO 138 through steric 
constraints.89 In contrast, salicylic acid-TMIO 137 possessed moderate inhibitory 
action on both COX enzymes after a 20-minute incubation. Such moderate inhibitory 
action after longer incubation is promising and suggests that the hybrid nitroxide 
compounds could be slow-time dependent COX inhibitors. 
Hence, prolonging the incubation (up to hours) may be necessary to fully deduce the 
anti-inflammatory action of these hybrid nitroxides. Notably, the methoxyamine 
derivative of salicylic acid-TMIO 194 had very little inhibitory effect on the COX 
enzymes. Thus the moderate COX inhibitory action displayed by salicylic acid-
TMIO 137 could arise from the antioxidant nitroxide moiety instead of the salicylate 
group. Although the methoxyamine derivatives (193 and 194) give a rough estimate 
of the COX inhibitory effect in the absence of the nitroxide moiety, it is important to 
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Figure 2.12. COX Inhibitory action of nitroxides (20 min incubation). 
Thus an alternative explanation is that the conversion of the more polar nitroxide to 
the less polar methoxyamine interferes with a critical element required for binding in 
the COX active site. The restricted nature and critically important electron density of 
the hydrophobic region of the COX active site means the alkoxyamine derivatives 
could have a different mode of interaction in the inhibitory region in comparison 
with parent nitroxides. Further studies using non-radical secondary amines may help 
to elucidate this point. 
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2.3 Summary of Results 
Using the pharmacophore hybridization strategy, three novel, potential dual action 
nitroxide-salicylate hybrids were successfully synthesized by overlapping similar 
structural subunits of the parent molecules. The following preliminary conclusions 
can be deduced from the results obtained from all biological evaluations (on both 
MPO and COX) performed to date. 
CTMIO 70, salicylic acid-TMIO 137 and aspirin-TMIO 138 showed moderate 
inhibition of MPO activity. This reinforces one of their several modes of antioxidant 
capacity (that may include their SOD mimetic action, lipid peroxidation inhibition, 
and radical scavenging potential), despite their moderate IC50 values when compared 
to amino-TEMPO 76. This is likely to be related to the nitroxide structure (size and 
ring class). 
Studies to evaluate the anti-inflammatory actions of the hybrid nitroxide-salicylate 
derivatives were first carried out with the PG-Amplex Red COX inhibitor assay. 
Initial results obtained from these experiments suggested potent COX inhibitory 
effect of the hybrid nitroxide-salicylate derivatives and, in particular, TEMPO 38. 
However, further studies with the alkoxyamine derivatives (193 and 194) of these 
hybrids indicated that the nitroxide moiety is likely acting as a substrate for the PG-
Amplex Red assay, thus leading to a false positive result. Since dietary antioxidants 
are known to interfere with the PG-Amplex Red assay, the proposed similar nitroxide 
reaction with the PG-Amplex Red assay supports the antioxidant action of the novel 
nitroxide compounds detected by this methodology. To obtain more insight into the 
COX inhibitory effect of these compounds, further experiments were conducted with 
the ELISA assay. The results indicate that salicylic acid-TMIO 137, but not aspirin-
TMIO 138, had moderate inhibitory effect on both isoforms of the COX enzyme but 
only after prolonged incubation (20 min). This, therefore, suggests that the hybrid 
nitroxide-salicylate derivatives are likely to be slow-time dependent COX inhibitors. 
The preliminary results for the inhibition of both MPO and COX enzymes by 
nitroxide compounds are encouraging. They indicate that combining antioxidant 
nitroxides with known pharmacophores (such as aspirin) is, evidently, an attractive 
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approach for developing potent novel dual action (antioxidant and anti-
inflammatories) therapeutics for chronic inflammatory diseases. However, further 
studies are still required in order to have a clear understanding of the structure-
activity relationships for these hybrid nitroxide agents. The next chapter, through 
pharmacophore hybridization, further expands on the dual drug design approach by 
exploring the synthesis and biological evaluation of a different series of nitroxide-
NSAID conjugates including compounds 140-146. 
2.4 Experimental 
The syntheses reported in this project were carried out at the Queensland University 
of Technology (QUT), Brisbane, Australia. 
  All air-sensitive reactions were carried out under ultra-high pure argon. Diethyl 
ether and toluene were dried by storing with sodium wire. All other solvents were 
dried using the Pure Solv Micro 4 L solvent purification system (PSM-13-672). 
Solvents used for extractions and silica gel column chromatography were AR grade. 
Crystalline K4[Fe(CN)6]·3H2O was ground to a fine powder and then dried at 80 °C at 
0.5 Torr for 10 h. All other reagents were purchased from commercial suppliers and 
used without further purification 1H and 13C NMR spectra were recorded with Bruker 
Avance 600 MHz, 400 MHz or Varian 400 MHz spectrometers and referenced to the 
relevant solvent peak. HPLC was performed with a HP Agilent 1100 HPLC 
instrument. HRMS was performed with an Agilent accurate mass QTOF LC-MS 
spectrometer. Formulations were calculated by elemental analysis using a Mass Lynx 
4.0 or Micromass Opus 3.6 instrument. FTIR spectra were recorded with a Nicolet 
870 Nexus Fourier Transform Infrared Spectrometer equipped with a DTGS TEC 
detector and an ATR objective. Melting points were measured by Buchi Melting 
Point M-565 apparatus. 
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Phthalic anhydride 167 (10 g, 67.51 mmol, 1 equiv.) was dissolved in glacial acetic 
acid (50 mL). To this was added benzylamine (10.94 mL, 101.3 mmol, 1.5 equiv.) 
and the resulting solution refluxed for 1 hr. The reaction mixture was cooled to room 
temperature, poured onto ice/water (150 mL) and stirred to give a white precipitate 
which was then filtered and recrystallized from ethanol to give fluffy white crystals 
of N-benzylphthalimide 168 (15.7 g, 98%). Mp. 116 oC (Lit.,50 115-116 oC). 1H 
NMR (CDCl3, 400 MHz) δ = 4.87 (s, 2 H, CH2), 7.27-7.36 (m, 3 H, Ar-H), 7.46 (d, 
2 H, J = 7.2 Hz, Ar-H), 7.73 (d, 2 H, J = 5.6 Hz, 4 Hz, Ar-H), 7.87 (d, 2 H, J = 5.6 
Hz, 4 Hz, Ar-H) . 13C NMR (100 MHz, CDCl3) δ = 41.62 (CH2), 123.35 (Ar-C), 
127.34 (Ar-C), 128.63 (Ar-C), 128.69 (Ar-C), 132.14 (Ar-C), 133.99 (Ar-C), 136.39 
(Ar-C), 168.05 (C=O). The obtained NMR data were consistent with that previously 
reported in the literature.50 
2.4.2 Synthesis of N-Benzyl-1,1,3,3-tetramethylisoindoline 169 
 
Magnesium turnings (37.5 g, 1.48 mol, 7 equiv.) and all glassware were placed in an 
oven at 80 oC and dried overnight before the reaction. The Mg turnings with a couple 
of iodine crystals were placed in a 2 L three-neck flask fitted with a thermometer, a 
dropping funnel, and a Dean Stark apparatus connected, through a condenser, to an 
Ar and vacuum lines. The flask was heated carefully with a heat gun under high 
vacuum to evacuate remaining moisture and then allowing the flask to cool to RT. 
The flask was placed under Ar and dry Et2O (500 mL) was added through a dropping 
funnel. The reaction mixture was stirred gently and few drops of the MeI (78.7 mL, 
1.26 mol, 6 equiv.) were added to start the reaction. As the reaction mixture began to 
turn grey and the Et2O started to boil, the remaining MeI was added slowly at a 
steady rate to keep the Et2O boiling constant. After addition of all the MeI, complete 
formation of the MeMgI Grignard reagent was indicated by the time when the Et2O 
stopped boiling. A solution of N-benzylphthalimide 168 (50 g, 211 mmol) in dry 
toluene (500 mL) was added with care and the resulting solution was heated to 80 oC 
to remove the Et2O. The solution was refluxed for 4 h and then allowed to cool to 
N Bn
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RT. Hexane (400 mL) was added and the mixture filtered through Celite with the 
solid residue washed several times with hexane and filtered. Air was bubbled through 
the filtrate until it was almost dry. The filtrate was dissolved in hexane and filtered 
through a basic alumina column to separate the product from the purple intractable 
material. The column was washed several times with hexane and the combined 
filtrate was concentrated in vacuo. The residue was recrystallized from methanol to 
give white needles of N-benzyl-1,1,3,3-tetramethylisoindoline 169 (2.88 g, 27%). 
Mp. 63-64 oC (lit.,50 63-64 oC). 1H NMR (400 MHz, CDCl3): δ = 1.32 (s, 12 H, 
CH3), 4.02 (s, 2 H, CH2), 7.17 (dd, 2 H, Ar-H) 7.26 (dd, 2 H, Ar-H), 7.24-7.36 (m, 3 
H, Ar-H), 7.51 (dd, 2 H, Ar-H). 13C NMR (100 MHz, CDCl3) δ = 28.4 (CH3), 46.4 
(CH2), 65.4 (CCH3), 121.3 (Ar-C), 126.35 (Ar-C), 127.0 (Ar-C), 127.7 (Ar-C), 
128.2 (Ar-C), 143.4 (Ar-C), 147.8 (Ar-C). 
2.4.3 Synthesis of 5-Bromo-1,1,3,3-tetramethylisoindoline 66 
 
A solution of N-benzyl-1,1,3,3-tetramethylisoindoline 169 (6 g, 22.7 mmol, 1 equiv.) 
in DCM (60 mL) was placed under Ar and cooled to 0 oC. To that was added a 
solution of bromine (2.43 mL, 47.5 mmol, 2.1 equiv.) in DCM (10 mL) dropwise, 
followed immediately by the addition of anhydrous aluminium trichloride (AlCl3) 
powder (10.6 g, 79.5 mmol, 3.5 equiv.). The reaction was stirred for 1 hr at 0 oC and 
the resulting mixture poured onto ice and stirred vigorously for a further 10 minutes. 
The solution was then basified to or above pH 12 with aqueous NaOH (10 M) 
solution and then extracted with DCM. The combined DCM extracts were washed 
with brine solution and concentrated under reduced pressure to give golden oil. This 
oil was taken up in methanol and sodium bicarbonate (200 mg) added. A solution of 
aqueous hydrogen peroxide (30%) was then added dropwise until the observed 
effervescence ceased, and ensuring that some sodium bicarbonate remained. A 
solution of H2SO4 (2 M) was cautiously added and the resulting solution extracted 
with DCM (20 mL x 3). The combined DCM extracts were extracted further with 
H2SO4 (2 M, 20 mL x 4). The combined acidic layers were washed with DCM and 
NH
Br
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basified at 0 oC to pH 12. The resulting basic aqueous layer was extracted with DCM 
and the combined DCM layers were washed with brine, dried over anhydrous 
Na2SO4 and concentrated under reduced pressure to give 5-bromo-1,1,3,3-
tetramethylisoindoline 66 as a clear oil which rapidly solidified upon standing in air 
(5.19 g, 90%). 1H NMR (CDCl3, 400 MHz): δ = 1.43 (s, 6 H, CH3), 1.45 (s, 6 H, 
CH3), 6.98 (d, 1 H, Ar-H), 7.23 (d, 1 H, Ar-H), 7.34 (dd, 1 H, Ar-H). 13C NMR 
(CDCl3, 100 MHz): δ = 31.7 (CH3), 62.5 (CCH3), 62.6 (CCH3), 121.2 (Ar-C), 123.1 
(Ar-C), 124.7 (Ar-C), 130 (Ar-C), 147.7 (Ar-C), 151.2 (Ar-C). The obtained NMR 
data was consistent with that previously reported in the literature.3 
2.4.4 Synthesis of 5-Methoxy-1,1,3,3-tetramethylisoindoline 170 
 
CuI (56.25 mg, 0.2 equiv.) was added to a solution of 5-bromo-1,1,3,3-
tetramethylisoindoline 66 (500 mg, 1.967 mmol, 1 equiv.) in DMF (3 mL) and 
NaOMe (5 M in MeOH, 12 mL) under Ar. The reaction mixture was refluxed for 15 
h and allowed to return to RT. It was then diluted with H2O and extracted with Et2O. 
The combined Et2O (40 mL x 4) extracts were washed with brine (50 mL), dried 
over anhydrous Na2SO4 and concentrated under reduced pressure. The resulting 
solid residue was purified by silica column chromatography (CHCl3/EtOH, 10:0.5) 
to give 5-methoxy-1,1,3,3-tetramethylisoindoline 170 as a pale white oil-solid (343.3 
mg, 85%). Mp. 57-58 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 
1.45 (s, 6 H, CH3), 1.47 (s, 6 H, CH3), 3.87 (s, 3 H, OCH3), 6.65-7.39 (m, 3 H, Ar-
H). 13C NMR (CDCl3, 100 MHz): δ = 31.9 ( C-CH3), 32.0 (C-CH3), 55.4 (OCH3), 
62.5 (CCH3), 62.8 (CCH3), 112.8 (Ar-C), 123.3 (Ar-C), 125.7 (Ar-C), 140.0 (Ar-C), 
147.2 (Ar-C), 157.4 (Ar-C). HRMS (ES): m/z (%) = 206.1574 (100) [M + H]+, calcd. 
for C13H19NO: 205.1467; found 105.1470. ATR-FTIR: υmax= 3415 (s, N-H), 1154 
(s, C-N), 1042 (C-O) cm-1. 
NH
MeO
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2.4.5 Synthesis of 2,5-Dibromo-6-methoxy-1,1,3,3-tetramethylisoindoline 171 
 
A solution of 5-methoxy-1,1,3,3-tetramethylisoindoline 170 (1.50 g, 731 μmol, 1 
equiv.) in DCM (25 mL) under Ar was cooled to 0oC. A solution of bromine (942 
μL, 1.83 mmol, 2.5 equiv.) in DCM (10 mL) was added dropwise followed by 
addition of anhydrous aluminium trichloride (3.48 g, 2.56 mmol, 3.5 equiv.). The 
reaction mixture was stirred for 1 hr at 0 oC, then poured onto ice (40 mL) and stirred 
vigorously for further 20 min. The solution was then basified to or above pH 12 with 
aqueous NaOH (10 M) solution and stirred for 10 min. The mixture was extracted 
with DCM (50 mL x 4) and the combined DCM extracts were washed with brine (50 
mL), and the solvent removed under reduced pressure to give light yellow oil. The 
oil was triturated with methanol to give 2,5-dibromo-6-methoxy-1,1,3,3-
tetramethylisoindoline 171 as a yellow solid (2.307 g, 87%). Mp. 97-98 oC. HPLC 
purity (93%). 1H NMR (CDCl3, 400 MHz): δ = 1.41 (s, 6 H, CH3), 1.44 (s, 6 H, 
CH3), 3.91 (s, 3 H, OCH3), 6.66 (s, 1 H, Ar-H), 7.3 (s, 1 H, Ar-H). 13C NMR 
(CDCl3, 100 MHz): δ = 28.1 ( C-CH3), 28.3 ( C-CH3), 56.5 (OCH3), 69.2 (C-CH3), 
69.7 (C-CH3), 105.4 (Ar-C), 110.6 (Ar-C), 126.6 (Ar-C), 137.7 (Ar-C), 144.8 (Ar-
C), 155.3 (Ar-C). ATR-FTIR: υmax= 3000 (m, Ar C-H), 1232 (s, C-N), 1034 (C-O) 
cm-1.  
2.4.6 Synthesis of 5-Bromo-6-methoxy-1,1,3,3-tetramethylisoindoline 172 
 
To a suspension of 2,5-dibromo-6-methoxy-1,1,3,3-tetramethylisoindoline 171 (900 
mg, 2.479 mmol, 1 equiv.) and NaHCO3 (208 mg, 2.479 mmol, 1 equiv.) in 
MeOH/DCM (10:5 mL) was added dropwise aqueous H2O2 (30%) until the 
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by the addition of NaOH (5 M). The resulting solution was extracted with DCM (40 
mL x 4) and the combined DCM extracts were washed with brine (50 mL), dried 
over anhydrous Na2SO4, and concentrated under reduced pressure to give 5-bromo-
6-methoxy-1,1,3,3-tetramethylisoindoline 172 as a beige solid (688 mg, 98%). Mp. 
59-60 oC. HPLC purity (>99%). 1H NMR (CDCl3, 600 MHz): δ = 1.42 (s, 6 H, 
CH3), 1.45 (s, 6 H, CH3), 3.91 (s, 3 H, OCH3), 6.62 (s, 1 H, Ar-H), 7.26 (s, 1 H, Ar-
H). ). 13C NMR (CDCl3, 100 MHz): δ = 31.8 (C-CH3), 32.0 (C-CH3), 56.4 (OCH3), 
62.4 (C-CH3), 62.8 (C-CH3), 105.1 (Ar-C), 110.5 (Ar-C), 126.2 (Ar-C), 142.3 (Ar-
C), 149.6 (Ar-C), 155.3 (Ar-C). HRMS (ES): m/z (%) = 184.0723/186.0723 (100) 
[M + H]+; calcd. for C13H18BrNO: 283.0572; found 283.0574. ATR-FTIR: υmax= 
3307 (w, N-H), 2961 (m, Ar C-H), 1307 (s, C-N), 1038 (C-O) 699 (s, C-Br) cm-1. 
2.4.7 Synthesis of 5-Cyano-6-methoxy-1,1,3,3-tetramethylisoindoline 173  
 
A Schlenk vessel that contained a mixture of 5-bromo-6-methoxy-1,1,3,3-
tetramethylisoindoline 172 (2.76 g, 9.72 mmol, 1 equiv.), K4[Fe(CN)6] (837 mg, 
1.94 mmol, 0.2 equiv.), CuI (223 mg, 1.17 mmol, 0.12 equiv.) N-butylimidazole (2.5 
mL, 19.45 mmol, 2 equiv.) in o-xylene (20 mL) was degassed and then refluxed at 
180 oC for 3 d. The resulting mixture was allowed to return to RT before it was 
diluted with water and then extracted with Et2O (60 mL x 4). The combined Et2O 
extracts were washed with brine (50 mL) and dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude residue was purified by silica gel 
column chromatography (EtOAc) and recrystallized from cyclohexane to give 5-
cyano-6-methoxy-1,1,3,3-tetramethylisoindoline 173 as an off-white solid (1.75 g, 
78%). Mp. 138-139 oC. HPLC purity (>99%). 1H NMR (CDCl3, 400 MHz): δ = 1.42 
(s, 6 H, CH3), 1.45 (s, 6 H, CH3), 1.73 (s, 1 H, N-H), 3.94 (s, 3 H, OCH3), 6.66 (s, 1 
H, Ar-H), 7.27 (s, 1 H, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 31.6 (C-CH3), 31.9 
(C CH3), 56.2 (OCH3), 62.4 (C-CH3), 63.2 (C-CH3), 100.8 (C≡N), 104.5 (Ar-C), 
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m/z (%) = 231.156 (100) [M + H]+; calcd. for C14H18N2O: 230.1419; found 
230.1420. ATR-FTIR: υmax= 3326 (w, N-H), 2968 (m, Ar C-H), 2221 (m, C≡N), 
1155 (s, C-N), 1042 (C-O) cm-1. 
2.4.8 Synthesis of 5-Cyano-6-methoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 174 
 
m-Chloroperoxybenzoic acid (1.78 g, 6.43 mmol, 1.3 equiv.) was added to  a solution 
of 5-cyano-6-methoxy-1,1,3,3-tetramethylisoindoline 173 (1.14 g, 4.95 mmol, 1 
equiv.) in DCM (100 mL) at 0 oC. The cooling bath was removed after 30 min and 
the reaction stirred at RT for a further 1.5 h. The DCM layer was washed with HCl (2 
M), NaOH (5 M), and brine solutions (50 mL) and before being dried over 
anhydrous Na2SO4. The DCM was removed under reduced pressure and the solid 
residue obtained was recrystallized from EtOH to give bright yellow needles of 5-
cyano-6-methoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 174 (1.09 g, 90%). Mp. 
200-201 oC. HPLC purity (>99%). HRMS (ES): m/z (%) = 268.1230 (100) [M + 
Na]+; calcd. for C14H17N2O2•: 245.1290; found 245.1286. ATR-FTIR: υmax= 3048 
(w, Ar C-H), 2231 (m, C≡N), 1472 (N-O), 1161 (s, C-N), 1041 (C-O) cm-1. 
2.4.9 Synthesis of 5-Carboxy-6-methoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
175 
 
A suspension of 5-cyano-6-methoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 174 (760 
mg, 3.1 mmol, 1.00 equiv.) in NaOH (5 M, 10 mL)/EtOH (5 mL) was refluxed for 16 
h. The reaction mixture was cooled to RT, then diluted with H2O and washed with 
Et2O (40 mL x 2). The Et2O layer was discarded. The aqueous layer was cooled in 
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The combined Et2O extracts were washed with brine (50 mL) and dried over 
anhydrous Na2SO4 and evaporated under reduced pressure. The residue was 
recrystallized from H2O/EtOH to give 5-carboxy-6-methoxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl 175 as yellow solid (729 mg, 89%). Mp. 244-245 oC 
(dec.). HPLC purity (>99%). HRMS (ES): m/z (%) = 287.1714 (100) [M + Na]+, 
303.0992 (15) [M + K]+; calcd. for C14H18NO4•: 264.1236; found 264.1241. ATR-
FTIR: υmax= 3400-2450 (m, br, OH), 2973 (m, Ar C-H), 1675 (s, C=O), 1360 (s, C-
N), 1202 (C-O) cm-1. 
2.4.10 Synthesis of 5-Carcoxy-6-hydroxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
salicylic acid TMIO 137) via BBr3 Demethylation of 175 
 
BBr3 (1.9 mL, 1.89 mmol, 1 M solution in DCM, 2.5 equiv.) was added dropwise to 
a solution of 5-carboxy-6-methoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 175 (200 
mg, 757 µmol, 1 equiv.) in DCM (15 mL) at -78 oC under Ar atmosphere. The 
reaction was allowed to return to RT while stirring for 18 h. H2O was added to the 
resulting mixture to quench excess BBr3 reagent. The crude product was extracted 
with EtOAc (50 mL x 4) and the combined EtOAc extracts were washed with brine 
(50 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. 
The crude residue was purified by silica gel column chromatography (DCM/MeOH, 
6:0.4) and recrystallized from H2O/EtOH to give 5-carboxy-6-hydroxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl 137 as yellow crystals (76 mg, 40%). Mp. 207-208 oC 
(dec.). HPLC purity (>99%). HRMS (ES): m/z (%) = 152.1186 (45) [M + 2H]+; 
calcd. for C13H16NO4•: 250.1079; found 250.1071. ATR-FTIR: υmax= 3400-2500 (m, 
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2.4.11 Synthesis of 2-Acetoxy-5-carboxy-6-methoxy-1,1,3,3-tetramethylisoindoline 
185 
 
A reaction mixture of 5-carboxy-6-methoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
175 (660 mg, 2.5 mmol, 1 equiv.) and Pd/C (66 mg, 10%, 62.5 µmol, 0.025 equiv.) 
in THF (15 mL) was flushed with Ar for 10 min. Then, a balloon of H2 was 
connected and the reaction mixture stirred for 15 min and then cooled in ice/H2O 
bath. TEA (697 µL, 5 mmol, 2 equiv.) and then AcCl (355 µL, 5 mmol, 2 equiv.) 
were added dropwise and the resulting mixture was stirred for 30 min. The cooling 
bath was removed and stirring was continued for a further 1 h. The reaction mixture 
was filtered through Celite and concentrated in vacuo. The crude residue was stirred 
in aqueous MeOH (10 mL, 2 mL H2O) for 1 h, then diluted with H2O, and extracted 
with EtOAc (50 mL x 4). The EtOAc extracts were washed with brine (40 mL), dried 
over anhydrous Na2SO4, and concentrated in vacuo to give compound 2-acetoxy-5-
carboxy-6-methoxy-1,1,3,3-tetramethylisoindoline 185 as a clear solid (738 mg, 
96%). Although compound 185 was pure enough to be used subsequent step, it was 
further purified by silica gel flash column chromatography (EtOAc/CHCl3, 2:1) and 
recrystallization from cyclohexane. Mp. 149-150 oC. HPLC purity (>99%). 1H NMR 
(CDCl3, 400 MHz): δ = 1.42 (d, 6 H, CH3), 1.48 (d, 6 H, CH3), 2.2 (s, 3 H, 
C=OCH3), 4.1 (s, 3 H, OCH3), 6.78 (s, 1 H, Ar-H), 7.98 (s, 1 H, Ar-H). ), 10.81 (s, 
br, 1 H, CO2H). 13C NMR (CDCl3, 100 MHz): δ = 19.2 (CO-CH3) 25.0, 25.2 (C-
CH3), 28.6, 28.8 (C-CH3), 57.0 (OCH3), 67.9 (C-CH3), 68.4 (C-CH3), 105.0 (Ar-C), 
117.4 (Ar-C), 127.5 (Ar-C), 138.1 (Ar-C), 151.7 (Ar-C), 158.3 (Ar-C), 165.2 
(CO2H), 171.2 (C=OCH3). HRMS (ES): m/z (%) = 330.1401 (20) [M + Na]+, 
346.1140 (24) [M + K]+; calcd. for C16H21NO5: 307.1420; found 307.1418. ATR-
FTIR: υmax= 3267 (m, br, OH), 2973 (m, Ar C-H), 1772 (s, Ac C=O), 1709 
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2.4.12 Synthesis of 2-Acetoxy-5-carboxy-6-hydroxy-1,1,3,3-tetramethylisoindoline 
186 
 
BBr3 (1.4 mL, 1.4 mmol, 1 M solution in DCM, 2.5 equiv.) was added dropwise to a 
solution of 2-acetoxy-5-carboxy-6-methoxy-1,1,3,3-tetramethylisoindoline 185 (170 
mg, 559 µmol, 1 equiv.) in DCM (10 mL) at -78 oC under Ar atmosphere. The 
reaction was allowed to return to RT while stirring for 18 h. H2O was added to the 
resulting mixture to quench excess BBr3 reagent. The crude product was extracted 
with EtOAc (20 mL x 4) and the combined EtOAc extracts were washed with brine 
(20 mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. 
The crude residue was purified by silica gel column chromatography (DCM/MeOH, 
6:0.4) and recrystallized from cyclohexane to give 2-acetoxy-5-carboxy-6-hydroxy-
1,1,3,3-tetramethylisoindoline 186 as a white solid (153 mg, 85%). Mp. 168-169 oC. 
HPLC purity (>98%).1H NMR (CDCl3, 400 MHz): δ = 1.4 (s, 6 H, CH3), 1.48 (s, 6 
H, CH3), 2.2 (s, 3 H, C=OCH3), 6.77 (s, 1 H, Ar-H), 7.64 (s, 1 H, Ar-H), 10.6 (s, br, 
1 H, CO2H). 13C NMR (CDCl3, 100 MHz): δ = 19.2 (CO-CH3) 25, 25.2 ( C-CH3), 
28.6, 28.8 ( C-CH3), 57.0 (OCH3), 67.9 (C-CH3), 68.4 (C-CH3), 105.0 (Ar-C), 117.4 
(Ar-C), 127.5 (Ar-C), 138.07 (Ar-C), 151.7 (Ar-C), 158.3 (Ar-C), 165.2 (CO2H), 
171.2 (C=OCH3). HRMS (ES): m/z (%) = 294.2269 (15) [M + H]+, calcd. for 
C15H19NO5: 293.1263; found 293.1272. ATR-FTIR: υmax= 3095 (m, br, OH), 2973 
(m, Ar C-H), 1737 (s, Ac C=O), 1677 (carboxylic acid C=O), 1160 (C-O) cm-1. 
2.4.13 Synthesis of 5-Carboxy-6-hydroxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
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A suspension of 2-acetoxy-5-carboxy-6-hydroxy-1,1,3,3-tetramethylisoindoline 186 
(136 mg, 464 µmol, 1 equiv.) in H2O/MeOH (2 mL/2 mL) was cooled to 0 oC. LiOH 
(56 mg, 2.3 mmol, 5 equiv.) was added and the reaction mixture stirred overnight 
while allowed to warm to RT. The resulting solution was washed with Et2O and the 
Et2O layer discarded. The aqueous layer was cooled in ice bath, acidified with HCl 
(2 M) and then extracted with Et2O (30 mL x 4). The combined Et2O extracts were 
stirred over PbO2 (28 mg, 116 µmol, 0.25 equiv.) for 20 min, dried over anhydrous 
Na2SO4, filtered and concentrated in vacuo. The crude residue was recrystallized 
from H2O/EtOH to give 5-carboxy-6-hydroxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
137 as yellow crystals (107 mg, 92%). Mp. 207-208 oC (dec.). HPLC purity (>99%). 
HRMS (ES): m/z (%) = 152.1186 (45) [M + 2H]+; calcd. for C13H16NO4•: 250.1079; 
found 250.1071. ATR-FTIR: υmax= 3400-2500 (m, br, OH), 2972 (m, Ar C-H), 1674 
(s, C=O), 1201 (C-O) cm-1.  
2.4.14 Synthesis of 6-Acetoxy-5-caarboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
(Aspirin TMIO 138) 
 
A solution of 5-carboxy-6-hydroxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 137 (89 
mg, 354.4 µmol, 1 equiv.) in THF under Ar was cooled to 0oC. TEA (99 µL, 709 
µmol, 2 equiv.) and then AcCl (50.4 µL, 709 µmol, 2 equiv.) were added dropwise 
and the resulting mixture stirred for 3 h while allowing to return to RT. Water was 
added to the reaction mixture and it was then extracted with DCM (30 mL x 3). The 
DCM extracts were washed with HCl (1 M, 15 mL), brine (20 mL) and dried over 
anhydrous Na2SO4. The combined DCM was removed under reduced pressure and 
the crude residue obtained was recrystallized from H2O/EtOH to give 6-acetoxy-5-
carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 138 as a yellow solid (94 mg, 91%). 
Mp. 206-207 oC. HPLC purity (>99%). HRMS (ES): m/z (%) = 293.1221 (100) [M 







Merged Dual-Action Nitroxide-Aspirin Hybrids 
100  
2600 (m, br, OH), 2972 (m, Ar C-H), 1765 (s, Ac C=O), 1695 (carboxylic acid C=O) 
1184 (C-O) cm-1. 
2.4.15 Synthesis of 6-Acetoxy-5-carboxy-2-methoxy-1,1,3,3-tetramethylisoindoline 
(Aspirin TMIO methoxyamine derivative) 193 
 
A solution of H2O2 (186 µL, 889 µmol, 2 equiv, 30%) was added dropwise (over 10 
min) to a solution of 6-acetoxy-5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 138 
(130 mg, 445 µmol, 1 equiv.) and FeSO4.7H2O (247 mg, 889 µmol, 2 equiv.) in 
DMSO (8 mL). The resulting reaction mixture was stirred for 1 h and then diluted 
with H2O. The aqueous layer was extracted with Et2O (30 mL x 4) and the combined 
Et2O extracts were washed with dilute aqueous HCl (2 M, 20 mL), brine (20 mL), 
and then dried over anhydrous Na2SO4. The solvent was removed under reduced 
pressure and the crude residue purified by short silica gel column chromatography 
(EtOAc) and recrystallization (cyclohexane/EtOAc) to give 6-acetoxy-5-carboxy-2-
methoxy-1,1,3,3-tetramethylisoindoline 193 as white solid (88 mg, 64%). Mp. 215-
217 oC (dec.). HPLC purity (>99%). 1H NMR (CDCl3, 400 MHz): δ = 1.44 (br, s, 12 
H, CH3), 2.34 (s, 3 H, OAc), 3.77 (s, 3 H, OCH3), 6.85 (s, 1 H, Ar-H), 7.82 (s, 1 H, 
Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 21.1 (C=O-CH3), 25.2 (br, C-CH3), 29.7 
(br, C-CH3), 65.6 (OCH3), 66.9 (C-CH3), 67.3 (C-CH3), 117.2 (Ar-C), 121.0 (Ar-C), 
125.8 (Ar-C), 143.2 (Ar-C), 151.0 (Ar-C), 152.9 (Ar-C), 169.4 (CO2H), 169.9 
(C=OCH3). HRMS (ES): m/z (%) = 308.1453 (25) [M + H]+; calcd. for C16H21NO5: 
307.1420; found 307.1417. ATR-FTIR: υmax= 3400-2600 (m, br, OH), 2973 (m, Ar 
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2.4.16 Synthesis of 5-Carboxy-6-hydroxy-2-methoxy-1,1,3,3-
tetramethylisoindoline (Salicylic acid TMIO methoxyamine derivative) 194 
 
Dilute sodium hydroxide solution (2 mL, 2 M) was added to a solution of 6-acetoxy-
5-carboxy-2-methoxy-1,1,3,3-tetramethylisoindoline 193 (50 mg, 163 µmol, 1 
equiv.) in H2O/MeOH (2 mL/2 mL) and the reaction mixture stirred at RT for 3 h. 
The resulting solution was washed with Et2O and the Et2O layer discarded. The 
aqueous layer was cooled in ice bath, acidified with HCl (2 M) and then extracted 
with Et2O (20 mL x 4). The combined Et2O extracts were washed with brine (20 
mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude residue 
was recrystallized from cyclohexane/EtOAc to give 5-carboxy-6-hydroxy-2-
methoxy-1,1,3,3-tetramethylisoindoline 194 as white solid (41.4 mg, 96%). Mp. 210-
212 oC (dec.). HPLC purity (>99%). HRMS (ES): m/z (%) = 266.1530 (100) [M + 
H]+; calcd. for C14H19NO4: 265.3090; found 265.3090. ATR-FTIR: υmax= 3400-
2500 (m, br, OH), 2991 (m, Ar C-H), 1656 (s, C=O), 1209 (C-O) cm-1. 
2.4.17 Synthesis of 5-Bromo-1,1,3,3-tetramethyl-6-nitroisoindoline 67 
 
5-Bromo-1,1,3,3-tetramethylisoindoline 66 (1.9 g, 7.48 mmol) was dissolved in 
H2SO4 (15 mL, 98%) and cooled to 0 °C. Nitric acid (3.75 mL, 70%) was added 
dropwise and the reaction mixture was stirred at 0 °C for 1 h. The cooling bath was 
removed and stirring was continued for 4 h. The reaction mixture was cooled to 0 °C, 
diluted by careful addition ice/H2O and then basified with NaOH solution (10 M). 
The reaction mixture was extracted with Et2O (60 mL x 4) and the combined organic 
extracts were washed with brine (50 mL), dried with anhydrous Na2SO4 and the 
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through a short silica gel column (EtOAc) and recrystallized from hexane/EtOAc 
(5:1) to give 5-bromo-1,1,3,3-tetramethyl-6-nitroisoindoline 67 as yellow crystals 
(1.23 g, 55%). Mp. 135–137 °C, (lit.,51 136–138 °C). 1H NMR (CDCl3, 400 MHz): δ 
= 1.47 (s, 12 H, CH3), 1.6 (br. s, 1 H, NH), 7.42 (s, 1 H, Ar-H), 7.58 (s, 1 H, Ar-H) 
ppm. 13C NMR (CDCl3, 100 MHz): δ = 31.6, 31.6 (C-CH3), 62.8, 62.9 (C-CH3), 
113.3 (Ar-C), 119.2, 128.1 (Ar-C), 149.9 (Ar-C), 154.9 (Ar-C) ppm. 
2.4.18 Synthesis of 5-Cyano-1,1,3,3-tetramethyl-6-nitroisoindoline 187 
 
A Schlenk vessel that contained a mixture of 5-bromo-1,1,3,3-tetramethyl-6-
nitroisoindoline 67 (1.3 g, 4.35 mmol, 1.00 equiv.), K4[Fe(CN)6] (329 mg, 870 
µmol, 0.2 equiv.), CuI (83 mg, 435 µmol, 0.1 equiv.) and N-butylimidazole (1.17 
mL, 8.7 mmol, 2 equiv.) in toluene (15 mL) was degassed and then refluxed at 
150 oC for 2 d. The resulting mixture was allowed to return to RT before it was 
diluted with water and then extracted with EtOAc (50 mL x 4). The combined 
organic extracts were washed with brine (40 mL) and dried over anhydrous Na2SO4 
and concentrated under reduced pressure. The crude residue was purified by silica 
gel column chromatography (EtOAc) and recrystallized from hexane/EtOAc give 5-
cyano-1,1,3,3-tetramethyl-6-nitroisoindoline 187 as a beige powder (726 mg, 68%). 
Mp. 159–160 °C, (lit.,51158–160 °C). 1H NMR (CDCl3, 400 MHz): δ = 1.5 (s, 6 H, 
CH3), 1.51 (s, 6 H, CH3), 1.71 (br, s, 1 H, NH), 7.6 (s, 1 H, Ar-H), 8.04 (s, 1 H, Ar-
H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 31.5, 31.6 (CH3), 63.2, 63.3 (CCH3), 
107.4, (CN), 115.4 (Ar- C), 129.4 (Ar-C), 148.7 (Ar-C), 155.8 (Ar-C), 115.9 (Ar-C) 
ppm. ATR-FTIR: υmax= 3042 (w, N-H), 2980 (m, ArC-H), 2235 (m, C≡N), 1526 (s, 
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2.4.19 Synthesis of 5-Cyano-1,1,3,3-tetramethyl-6-nitroisoindolin-2-yloxyl 188 
 
A solution of 5-cyano-1,1,3,3-tetramethyl-6-nitroisoindoline 187 (500 mg, 2.04 
mmol, 1.00 equiv.) in DCM (100 mL) was treated with mCPBA (595 mg, 2.65  
mmol,  77%, 1.20 equiv.) and stirred for 2 h. The reaction mixture was washed with 
NaOH (2 M, 20 mL x 3) and brine (40 mL), then dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The residue was recrystallized from MeCN to 
give 5-cyano-1,1,3,3-tetramethyl-6-nitroisoindolin-2-yloxyl 188 as orange needles 
(494 mg, 93%). Mp. 230-231 °C (dec), (lit.,51 >230 oC, dec.). ATR-FTIR: υmax= 
2981 (m, ArC-H), 2233 (m, C≡N), 1530 (s, NO2), 1340 (s, C-N), 1163 (s, C-O) cm-
1. 
2.4.20 Synthesis of 5-Amino-6-cyano-1,1,3,3-tetramethylisoindolin-2-yloxyl 189 
 
A suspension of SnCl2·2H2O (403 mg, 1.79 mmol, 3.00 equiv.) in conc. HCl (2 mL) 
was cooled to 0 °C. 5-Cyano-1,1,3,3-tetramethyl- 6-nitroisoindolin-2-yloxyl 188 
(155 mg, 596 µmol, 1 equiv.) was added and the mixture was stirred at 0 °C for 10 
min. The cooling bath was removed and stirring was continued for an additional 3 h. 
The reaction mixture was cooled to 0 °C and basified by careful addition of NaOH (5 
M). The mixture was then extracted with DCM (30 mL x 4) and the combined DCM 
extracts were washed with brine (30 mL), dried with Na2SO4 and the solvent 
evaporated under reduced pressure. The residue was purified by silica gel column 
chromatography (Hexane/EtOAc, 1:1) to give 5-amino-6-cyano-1,1,3,3-
tetramethylisoindolin-2-yloxyl 189 as a pale beige solid (105 mg, 69%). Mp. 199–
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2.4.21 Synthesis of 6-Amino-5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 190 
 
A suspension of 5-amino-6-cyano-1,1,3,3-tetramethylisoindolin-2-yloxyl 189 (100 
mg, 434 μmol, 1.00 equiv.) in 5 M NaOH/EtOH (3 mL/2 mL) was refluxed for 16 h. 
The reaction mixture was cooled to RT and diluted with H2O. It was then washed 
with Et2O (10 mL x 2) and the Et2O layer was discarded. The aqueous layer was 
cooled in an ice bath, acidified with HCl (2 M) and extracted with Et2O (20 mL x 4). 
The combined Et2O extracts were washed with brine (20 mL), dried over anhydrous 
Na2SO4 and evaporated under reduced pressure. The residue was recrystallized from 
H2O/MeCN to give 6-amino-5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 190 
as yellow, voluminous needles (81, 75%). Mp. 230 °C (dec) (lit.,51 >230 oC, dec.). 
ATR-FTIR: υmax= 3472, 3359 (m, N-H2), 2928 (br, O-H), 1666 (s, C=O), 1282 (s, C-
N), 1228 (C-O) cm-1. 
2.4.22 Synthesis of 6-Acetamido-5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
139 
 
A solution of 6-amino-5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 190 (90 mg, 
361 µmol, 1 equiv.) in THF (10 mL), and under Ar, was cooled to 0 oC. TEA (106 
µL, 758 µmol, 2.1 equiv.), then AcCl (51 µL, 722 µmol, 2 equiv.) were added 
dropwise and the resulting mixture stirred for 3 h while allowing it to return to RT. 
Water was added to the reaction mixture, and then extracted with DCM (20 mL x 4). 
The DCM extracts were washed with HCl (1 M, 15 mL), brine and dried over 












Merged Dual-Action Nitroxide-Aspirin Hybrids 
 105 
the crude residue obtained was recrystallized from H2O/MeCN to give 6-acetamido-
5-carboxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 139 as a yellow solid (93 mg, 
88%). Mp. 231-232 oC (dec.). HPLC purity (>98%). HRMS (ES): m/z (%) = 
292.1413 (30) [M + H]+, 314.1232 (70) [M + Na]+; calcd. for C15H19N2O4•: 
291.1345; found 291.1343. ATR-FTIR: υmax= 33400-2600 (br, O-H), 3262 (w, N-H), 
2988 (w, Ar C-H), 1681(s, CO2H C=O), 1590 (s, Ac C=O), 1251 (s, C-N), 1198 (C-
O) cm-1. 
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Chapter 3: Nitroxide-NSAID Conjugates: 
Design, Synthesis and Preliminary Biological 
Evaluation 
3.1 Background 
In the preceding chapter (Chapter 2), the pharmacophore hybridization strategy was 
employed in the design of merged nitroxide-aspirin based hybrids as potential dual 
action therapeutics for inflammatory and oxidative stress related diseases. 
Preliminary evaluation of the antioxidant and anti-inflammatory properties of the 
merged hybrids (Chapter 2) revealed their promising therapeutic potential. In this 
chapter, this hybridization approach is further extended by efforts to combine 
nitroxides with other NSAIDs to generate a series of novel nitroxide-NSAID 
conjugates. In addition to the potential therapeutic outcome, combining a number of 
nitroxide compounds (with various ring classes and substitutions) with NSAIDs 
through ester, amide and amine bonds provides an attractive way to investigate 
structure-activity relationships. Figure 3.1 below shows the representative cleavable 
and non-cleavable target compounds in this chapter. 
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The NSAID pharmacophores to be linked with various nitroxide compounds include 
aspirin, salicylic acid, indomethacin, 5-aminosalicylic acid and 2-hydroxy-5-[2-(4-
trifluoromethylphenyl)-ethylaminobenzoic acid. The synthesis of target compounds 
was carried out primarily by carbodiimide-mediated coupling reactions. 
3.2 Carbodiimide Chemistry 
Carbodiimides are unsaturated compounds that have a heterocumulene (allene type) 
structure with two reactive centres (Figure 3.2).1-3 The central carbon atom is 
electrophilic and so reacts with nucleophiles when one of the nucleophilic terminal 
nitrogen atoms is activated by an electrophile such as a proton donor. The 
carbodiimide coupling reaction is widely used in the synthesis of peptides. 
 
Figure 3.2. Common carbodiimides: EDC (202) and DCC (203). 
The most common carbodiimides used in the synthesis of amides and esters are the 
commercially available N-(3-dimethylaminopropyl)-N′-ethylcarbodiimide 
hydrochloride 202 (EDC) and N',N'-dicyclohexylcarbodiimide 203 (DCC). These 
reagents work by activating carboxylic acids (i, Scheme 3.1) through the formation 
of the unstable O-acylisourea intermediate (v).4-6 The first step involves protonation 
of the nucleophilic nitrogen atom of the carbodiimide (ii) by the carboxylic acid to 
give a carbocation (iv). The resulting carboxylate (iii) then attacks the carbocation 
(iv) to form the O-acylisourea intermediate (v). The formation of amides or esters 
from the O-acylisourea intermediate (v) proceeds through two pathways (a. and b.). 
In the presence of DMAP, the O-acylisourea (v) can directly react with a nucleophile 
(alcohol or amine) to give the desired product (amide or ester) along with the urea 
by-product (vi). The O-acylisourea (v) can also react with a preformed nucleophilic 
carboxylate (iii) to form the anhydride (ix), which in turn reacts with an amine or 
alcohol to give the desired product. The urea by-product (vi) from DCC is usually 
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hand gives a water-soluble urea by-product that is removed by an aqueous wash 
during the workup. 
 
Scheme 3.1. Proposed mechanism for carbodiimide-mediated synthesis of esters 
from carboxylic acids and alcohols. 
In carbodiimide-mediated ester or amide synthesis, the reaction is usually 
accompanied by the formation of an unreactive N-acylurea side product (x). This 
occurs when the O-acylisourea intermediate (v) undergoes an intramolecular O→N 
acyl rearrangement. However, DMAP as a hyperacylation catalyst (acylation 
catalyst) suppresses the formation of the N-acylurea side product (x). These coupling 
reactions are mostly carried out in dichloromethane. 
3.3 Results and Discussion 
The NSAIDs which are intended to be linked with nitroxides include salicylic acid 
135, aspirin 136, 5-amino salicylic acid 149 and indomethacin 151. Figure 3.3 below 
shows the structures of the precursor nitroxide compounds used herein. As 
mentioned earlier in the introductory chapter, cyclic nitroxides such as TEMPOL 102 
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pyrrolidine and piperidines nitroxides are commercially available, the isoindoline 
nitroxides were synthesized as detailed in the subsequent section (except for 

































Figure 3.3. Various nitroxide compounds linked to NSAIDs. 
3.3.1 Synthesis of 5-Amino-1,1,3,3-tetramethylisoindolin-2-yloxyl 
108 
The 5-amino-TMIO 108 was prepared from the precursor 169 following literature 
procedures with a slight modification (Scheme 3.2).7,8 Compound 169 was 
synthesized by exhaustive methylation N-benzylphthalimide 168 with freshly 
prepared methyl Grignard reagent as detailed in Chapter 2 (Section 2.33). 
Palladium-catalyzed hydrogenation of compound 169 was carried out in a Parr 
Hydrogenator to give the secondary amine derivative 207 in 96% yield. Subsequent 
oxidation of compound 207 to the nitroxide derivative 59 was performed with 
mCPBA. Compound 59 was obtained almost quantitatively as a bright yellow solid. 
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Scheme 3.2. Synthesis of 5-amino TMIO 108. Reagents and conditions: a. H2, Pd/C, 
4 h at 50 psi, 96%; b. mCPBA, DCM, 0 oC to RT, 3 h, 94%; c. HNO3, H2SO4, 0 oC, 
5 h, 81%; d. H2, Pd/C, 4 h at 50 psi, MeOH, then PbO2, 88%. 
The nitro derivative 29 was prepared by nitration of compound 59 using concentrated 
sulfuric acid and nitric acid to give a dark brown solution of what was presumed to 
be the oxoammonium salt (the oxoammonium salts obtained when isoindoline 
nitroxides disproportionate are characteristically reddish brown in solution). 
Although the crude nitro product obtained was of sufficient purity, it was further 
purified by recrystallization from ethanol to give bright orange crystals of 29. For 
optimum yield in the next step, recrystallization of the crude nitro compound 29 was 
necessary otherwise, a decrease in the yield of the amino nitroxide 108 from 88% to 
52% was observed when the crude nitro compound 29 was subjected to a palladium-
catalyzed hydrogenolysis. 
The crude product obtained after hydrogenolysis of 29, was a mixture of the desired 
amino nitroxide 108 and the hydroxylamine intermediate. Though the hydroxylamine 
intermediate readily oxidizes to the nitroxide derivative 108 upon exposure to air, the 
crude mixture was stirred for 20 min over 0.025% mole of lead (II) oxide to ensure 
complete oxidation. Copper (II) acetate has equally been reported to facilitate the 
oxidation of the hydroxylamine.9 Compound 108 was obtained as a yellow 
crystalline solid after recrystallization from ethanol. All characterization data 
obtained for compound 108 and its precursors were in agreement with that 
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3.3.2 Synthesis of 5-Carboxy-1,1,3,3-tetraethylisoindolin-2-yloxyl 
206 (CTEIO) 
The tetraethylisoindoline carboxylic acid 206 was synthesized according to literature 
procedures as outlined in Scheme 3.3 below.10 The N-benzylphthalimide 210 was 
obtained quantitatively by refluxing commercially available 4-methylphthalic 
anhydride 209 and benzylamine in acetic acid for 1 h.  
 
Scheme 3.3. Synthesis of CTEIO 206. Reagents and conditions: BnNH2, AcOH, 
reflux, 1 h, 98%; b. EtMgI, PhMe, reflux, 4 h, 32%; c. H2 (50 psi), Pd/C, AcOH, RT, 
4 h, 96%;  d. mCPBA, DCM, RT, 3 h, 84%;  e. AcCl, TEA, 0 ºC, 30 min. to RT, 1 h, 
91%; f. KMnO4 , t-BuOH, MgSO4, 70 oC, 1 d, 60%;  g. NaOH, overnight, 83%. 
The phthalimide 210 was tetraalkylated with freshly prepared ethyl magnesium 
Grignard reagent by refluxing in anhydrous toluene under an argon atmosphere for 4 
h. Purification of the crude tetraalkylated product involved filtration through Celite 
and basic alumina to afford pure 211 as clear oil in 32% yield. Compound 211 was 
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Pd/C in acetic acid. The secondary amine 212, obtained as yellow oil, was oxidized 
with mCPBA to the nitroxide derivative 213 in 84% yield.  
The key step in the synthesis of CTEIO 206 is the oxidation of the aryl methyl group 
with potassium permanganate to the corresponding carboxylic acid. Permanganate 
oxidation is an attractive and convenient method for regio-selective oxidation of 
species bearing mononuclear aromatic hydrocarbons side chains, such as toluene, to 
the corresponding carboxylic acids.11,12  
To successfully carry out this transformation, protection of the nitroxide moiety was 
required due to its reported decomposition under refluxing permanganate oxidation 
conditions.10 Thus, compound 213 was protected with an acetyl protecting group by 
first reducing it to the hydroxylamine derivative through hydrogenolysis, followed by 
in situ reaction with acetyl chloride in the presence of triethylamine to give the N-
acetoxy protected compound 214. The singlets at 2.52 and 2.75 ppm, each 
integrating for 3 protons in the 1H NMR spectrum of 214, were assigned to the N-
acetoxy and the aryl methyl groups respectively.  
Oxidation of the aryl methyl group of 214 was accomplished by allowing it to react 
for 24 hours with refluxing aqueous potassium solution in the presence of 
magnesium sulfate. As permanganate, when heated and/or exposed to air, quickly 
becomes oxidized to the black manganese dioxide residue (MnO2), the oxidation 
reaction was carried out under an argon atmosphere and the permanganate reagent 
was added portionwise over the 24 hours. The N-acetoxy carboxylic acid 215 was 
obtained as a white solid (60%) after purification by column chromatography and 
recrystallization from hexane/ethyl acetate.  
The target nitroxide 206 was readily obtained after deprotection of the nitroxide 
group by basic hydrolysis of 215 with lithium hydroxide. Compound 206 was 
obtained as a yellow crystalline solid after recrystallization from acetonitrile (84%). 
All characterization data obtained for compound 206 and its precursors matched 
previously reported data in the literature.10  
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3.3.3 Approaches to the Synthesis of 5-Carboxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl (CTMIO) 70 
Though the applications of stable nitroxide compounds in various fields have been 
explored primarily with the piperidine and pyrrolidine type nitroxides, 5-carboxy-
1,1,3,3-tetramethylisoindolin-2-yloxyl 70 (CTMIO), an isoindoline-based nitroxide, 
has displayed several promising biological properties in recent years.13,14 Since its 
first reported synthesis 20 years ago, CTMIO possesses low cellular toxicity as well 
as high potential EPR sensitivity.15 Unlike other isoindoline-based nitroxides which 
have limited biological application, the presence of the water solubilizing carboxyl 
group on CTMIO has allowed for its use as a potent antioxidant in a number of 
biological models and systems. In the autosomal recessive, genetic childhood 
disorder, Ataxia telangiectasia (AT), CTMIO significantly reduces oxidative stress in 
AT cells to a greater extent than known antioxidants such as vitamin E or Trolox.16 
CTMIO also acts as an almost-stoichiometric equivalent scavenger of protein 
radicals, thus reducing harmful cellular oxidation reactions and their associated 
damages.17,18  
For synthetic purposes, CTMIO serves as an essential precursor to other isoindoline 
derivatives such as sulfonates and other carboxylic acid derivatives. However, 
CTMIO applications have been somewhat limited as it is not commercially available 
and its synthesis is laborious. Prior to this work, only one synthetic route to CTMIO 
(Scheme 3.4) had been established - a five step synthesis with an overall yield of 
15%.13 The key step involves the double lithiation of bromoamine precursor 66 
followed by subsequent quenching of the dianion with carbon dioxide, to produce an 
in situ zwitterion. This zwitterion is difficult to handle and could not be easily 
isolated due to the presence of excess inorganic salts. Overall the highest yield 
achieved by a member of our research group at QUT over the two steps (d. and e.) 
was 62%. However, this yield was challenging to reproduce.  
In an attempt to improve the yield and provide a practical approach for the synthesis 
of CTMIO, three alternative synthetic routes were explored as part of this project. 
The first two routes used the bromoamine precursor 66 to access CTMIO 70 via 
either the cyano derivative 71 or its benzaldehyde counterpart 73. The third route 
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employed commercially available 4-methylphthalic anhydride 209 as the starting 
material, wherein the methylarene substituent could be subsequently oxidized to the 
desired carboxylic acid. The results are discussed below. 
 
Scheme 3.4. Published synthetic route to CTMIO 70. Reagents and conditions: a. 
BnNH2, AcOH, reflux, 1 h, 98%; b. MeMgI, PhMe, reflux, 4 h, 27%; c. Br2, AlCl3, 
DCM, 0 ºC, 1 h, 91%; d. n-BuLi,  THF, CO2, -78 ºC, 10 min; e. H2O/MeOH, 
NaHCO3, Na2WO4.2H2O, H2O2, RT, 48 h, 62%. 
3.3.3.1 Synthesis of CTMIO 70 from 5-Cyano-1,1,3,3-tetramethylisoindoline 71 
The first route to CTMIO 70 via the aminonitrile 71 is outlined in Scheme 3.5 below. 
Using the copper (I)-catalyzed cyanation of arylbromides reported by Schareina et 
al.,19 bromoamine 66 was treated with K4[Fe(CN)6] in the presence of catalytic CuI 
and N-butylimidazole at elevated temperature to afford the aminonitrile derivative 
71. The FTIR spectrum of 71 showed a distinct sharp and strong C≡N vibration 
stretch at 2226 cm-1 and a weak N-H stretch at 3321 cm-1. In comparison to the 
bromoamine precursor 66, the extra peak in the unsaturated carbon region (111 
ppm) in the 13C NMR spectrum of aminonitrile 71 further supported the formation of 
a cyano functional group. Compound 71 could not be obtained in high purity 
(following analysis by HPLC) due to the presence of what was presumed to be a 
copper-N-butylimidazole complex that could not be completely removed by 
conventional purification techniques. However, the presence of the copper-N-
butylimidazole complex did not affect the subsequent synthetic transformation. Other 
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Scheme 3.5. Synthesis of CTMIO 70 from aminonitrile 71. Reagents and conditions: 
a. K4[Fe(CN)6].3H2O, CuI, N-butylimidazole, o-xylene, 180 ºC, 4 d, sealed vessel; 
b. mCPBA, DCM, 0 ºC 1 h to room temp., 3 h, 78%; c. NaOH, H2O, EtOH, reflux, 
16 h, 95%. 
A mild peroxyl oxidation of the crude aminonitrile 71 with mCPBA afforded the 
corresponding cyano nitroxide 217 in 78% over two steps from 66. The 
transformation was confirmed by the presence of a strong C≡N stretch and the loss 
of the weak N-H absorption at 2227 and 3321 cm-1 respectively in the FTIR 
spectrum of 217. The [M + 2H]+ ion for compound 217 was also observed at m/z 217 
in the HRMS spectrum. Compound 217 was shown to be >95% pure by HPLC 
analysis. Due to significant paramagnetic broadening effect of the nitroxide moiety, 
no NMR spectroscopy data was obtained for compound 217. Basic hydrolysis of 
compound 217 then gave the desired CTMIO 70. The overall yield over three steps 
was 74%. The melting point determined for compound 70 matched that reported in 
the literature.13  
3.3.3.2 Synthesis of CTMIO 70 from Formyl TMI 73 
The second route to CTMIO 70 explored was through the formyl derivative 73 
(Scheme 3.6). Firstly, bromoamine 66 was quantitatively converted to the formyl 
derivative 73 by quenching the resulting doubly lithiated anion (formed upon 
treatment of 66 with n-butyllithium) with DMF.13 The formyl nitroxide 27, obtained 
by mCPBA oxidation of 73, was subsequently oxidized to the desired CTMIO 70 
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yield of 66% for CTMIO 70 from the compound 66 precursor. All characterization 
data obtained for compound 70 and its precursors matched that reported in the 
literature.13 
 
Scheme 3.6. Synthesis of CTMIO 70 from formyl TMI 73. Reagents and conditions: 
a. n-BuLi, THF, DMF, -78 ºC, 1 h to RT, 3 h, 100%; b. mCPBA, DCM, 0 ºC, 1 h, 
then  RT, 3 h, 92%; c. AgNO3, NaOH, H2O, RT, 6 h, 72%. 
3.3.3.3 Synthesis of CTMIO 70 from 4-Methylphthalic Anhydride 209 
The final alternative route to CTMIO 70 was explored using 4-methylphthalic 
anhydride 209 as the starting material (Scheme 3.7). N-Benzyl-4-methylphthalimide 
210 was obtained in excellent yield (98%) after an acetic acid solution of 4-
methylphthalic anhydride 209 and benzylamine was refluxed for 1 h.10 Exhaustive 
methylation of phthalimide 210 with a six fold excess of freshly prepared 
methylmagnesium iodide furnished compound 218 in a modest yield of 34%. The 
two singlets at 1.30 and 1.31 ppm, each integrating for six protons, in the 1H NMR 
spectrum of 218 confirmed the successful transformation. The aryl methyl group and 
benzylic CH2 protons were also evident in the 1H NMR spectrum at 2.39 and 4 ppm 
respectively. The nitroxide 220 was obtained following quantitative debenzylation of 
compound 218 with hydrogen gas and catalytic palladium on activated charcoal, and 

















































Scheme 3.7. Synthesis of CTMIO 70 from 4-methylphthalic anhydride 209. 
Reagents and conditions: a. BnNH2, AcOH, reflux, 1 h, 98%; b. MeMgI, PhMe, 
reflux, 4 h, 34%; c. H2 (50 psi), Pd/C, AcOH, RT, 4 h, 96%; d. mCPBA, DCM, RT, 
3 h, 95%;  e. AcCl, Et3N, 0 ºC, 30 min. to RT, 1 h, 91%; f. KMnO4 ,t-BuOH, 
MgSO4, 70 oC, 1 d, 65%;  g. NaOH, overnight, 97%. 
As mentioned in a preceeding section, nitroxides do not survive permangante 
oxidation.10 It was therefore necessary to protect the nitroxide moiety of compound 
220 with an acetyl protecting group. Hence, Pd/C-catalyzed hydrogenolysis of the 
nitroxide 220 afforded the corresponding hydroxyamine, which was acetylated in situ 
with acetyl chloride in the presence of triethylamine to furnish compound 221 (95%). 
The presence of the N-acetoxy protecting group was verified in the NMR and FTIR 
spectra of 221. The protons of the acetyl group were observed as a singlet at 2.2 ppm 
in the 1H NMR spectrum and a strong C=O stretch was also observed at 1758 cm-1 in 
the FTIR spectrum.  
A regio-selective potassium permanganate side chain oxidation of the aryl methyl 
group of 221 afforded the corresponding carboxylic acid 222 in moderate yield 
(65%). In addition to the N-acetoxy C=O stretch at 1771 cm-1, a strong C=O stretch 
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at 1681 cm-1 and a medium broad O-H stretch (3400 to 2800 cm-1) were observed in 
the FTIR spectrum of 222. These evidently supported the presence of a carboxylic 
acid functional group. The structure of the N-acetoxy protected carboxylic acid 222 
was further confirmed by HRMS, 1H and 13C NMR spectroscopies. The carboxylic 
acid 222 was readily deprotected to give CTMIO 70 after stirring overnight in dilute 
sodium hydroxide solution. The overall yield of CTMIO from this route was 17.4%.  
Athough each of the three new alternative synthetic approaches to CTMIO 70 gave 
comparative overall yields (16-18%), the nitrile route gave the best overall yield 
(18%). However, the fastest route to CTMIO 70 is through the formyl derivative 73. 
3.3.4 Synthesis of 5-Carboxymethyl-1,1,3,3-tetramethylisoindolin-2-
yloxyl 205 
The carboxylic acid 205 was synthesized from the methyl ester intermediate 223 as 
shown in Scheme 3.8 below. The synthesis of methyl ester 223 is discussed in 
Chapter 4. 
 
Scheme 3.8. Synthesis of 5-carboxymethyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 
205. Reagents and conditions: a. mCPBA, DCM, 3 h, 89%; b. MeOH/NaOH, 60 oC, 
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First, methyl ester 223 was readily converted to the nitroxide derivative 224 under 
mild mCPBA oxidation conditions. Compound 224 was obtained as a yellow solid in 
89% yield after purification of the crude product by silica gel column 
chromatography. The identity of 224 was confirmed by HRMS and FTIR analysis. A 
strong C=O stretching frequency was observed at 1737 cm-1 in the FTIR spectrum. In 
addition, the masses observed at m/z 263 and 264 in the HRMS spectrum of 224 
were consistent with the mass of the expected [M + H]+ and [M + 2H]+ ions 
respectively. The purity of compound 224 was assessed by HPLC analysis to be >95% and its melting range was determined to be 100-101 oC.  
The carboxylic acid nitroxide derivative 205 was obtained almost quantitatively by 
basic hydrolysis of the methyl ester 224 with sodium hydroxide. In the FTIR 
spectrum of 205, characteristic broad OH and strong C=O absorptions were observed 
at 3520 and 1650 cm-1 respectively. This evidently supported the presence of the 
carboxylic acid functional group. Also, the molecular ion plus proton [M + H]+ was 
observed at m/z 249 in the HRMS spectrum of 205.  
Likewise, the carboxylic acid nitroxide 205 was also obtained by mCPBA oxidation 
of the corresponding methoxyamine 225. In this case however, it was difficult to 
separate compound 205 from the meta-chorobenzoic acid by-product by 
conventional purification techniques (such as chromatography and recrystallization). 
The next sections explore the synthesis of the novel nitroxide-NSAID conjugates by 
carbodiimide chemistry. 
3.3.5 Synthesis of Nitroxide-Indomethacin Conjugates 
Like aspirin, indomethacin is a conventional NSAID that inhibits both COX-1 and 
COX-2 enzymes. Such nonselectivity towards the COX enzyme is linked to the 
observed gastrointestinal toxicity (GI ulceration and bleeding) that usually arises 
after prolong use of indomethacin even at relatively low doses. Studies have shown 
that slight structural changes in indomethacin (or aspirin) alter its inhibitory action.20-
23 For instance, extending the carboxylic acid side chain or replacing the 4-
chlorobenzoyl moiety with a 4-bromobenzyl group result in high selectivity towards 
the COX-2 enzyme.20 In contrast to the parent indomethacin, amides and ester 
Nitroxide-NSAID Conjugates: Design, Synthesis and Preliminary Biological Evaluation 
124  
derivatives display superior selectively to the COX-2 enzyme with improved GI 
safety profiles even at relatively high doses above their therapeutic efficacy.23,24 
Herein, similar structural modifications were carried out on indomethacin to give 
novel nitroxide-indomethacin cleavable conjugates. As outlined in Scheme 3.9 
below, the preparation of nitroxide-indomethacin conjugate 143 began by reacting 5-
amino TMIO 108 with indomethacin 164 under EDC coupling conditions similar  to 
those used in the preceding sections.  
.  
Scheme 3.9. Synthesis of nitroxide-indomethacin conjugates (143, 226 and 227). 
Reagents and conditions: a. nitroxide (compound 76, 102 or 108), EDC, DMAP, 
DCM, RT, 1 d, 83-91%. 
The amide-linked nitroxide-indomethacin conjugate 143 was obtained as a bright 
yellow crystalline solid in 90% yield following purification by silica gel column 
chromatography and then recrystallization. TEMPOL 102 and 4-amino-TEMPO 76 
were also subjected to similar coupling conditions to give the nitroxide indomethacin 
conjugates 226 and 227 respectively. Characterization data obtained to support the 
successful synthesis of each nitroxide indomethacin conjugate included HRMS, 
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instance showed a weak N-H stretch at 3299 cm-1 along with two characteristic 
amide C=O stretching frequencies at 1677 and 1599 cm-1. 
As mentioned in the preceding section, characterization of nitroxide containing 
compounds by NMR spectroscopy is quite challenging. This is due to the 
paramagnetic line broadening effect commonly observed in the NMR spectrum. The 
broadening effect arises from dipolar interactions between the unpaired electron of 
the nitroxide moiety and nearby nuclei (protons and carbons).25,26 Unlike dipole-
dipole interactions between protons (which are limited to short distances up to 5.5 
Å), the interactions between the unpaired electron of the nitroxide moiety and nearby 
nuclei extends over long distances (up to 25 Å).27 Thus, such proportionate distance-
dependent line broadening means that the paramagnetic effect is more pronounced 
for nuclei in close proximity to the nitroxide spin. However, using lower 
concentration of nitroxide in the samples can in some instances, reduce the line 
broadening effect.  
Hence, for compounds such as the nitroxide-indomethacin conjugates 143, 226 and 
227, it was possible to obtain good structural information for 1H/13C nuclei of 
sufficient distance from the nitroxide radical by NMR spectroscopy. Figure 3.4 
below shows the 1H NMR spectrum obtained from a dilute sample of conjugate 226. 
The singlets at 2.44, 3.7 and 3.86 ppm are characteristic of the methyl, methylene 
and methoxy protons of the indomethacin side chain respectively. The two doublets 
at 6.7 and 6.9 ppm and the adjacent singlet at 6.99 ppm are consistent with the three 
aromatic protons of the indole ring with the expected coupling patterns. The two 
distinct protons of the para-chloro substituted aromatic ring are shown as doublets at 
7.5 and 7.7 ppm. Almost all carbon atoms of the indomethacin structure were 
successfully assigned in the 13C NMR spectrum of 226. A similar trend was observed 
for the nitroxide-indomethacin conjugate 143. Despite a more pronounced line 
broadening effect in the 1H NMR spectrum of the amide conjugate 227, the 
diagnostic proton signals for the indomethacin side chain were also assigned. 
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Figure 3.4. 1H NMR spectrum (400 MHz, CDCl3) of nitroxide-indomethacin 
conjugate 226. 
3.3.6 Synthesis of Nitroxide-Salicylate Conjugates 
The first series of nitroxide-aspirin cleavable conjugates (140, 228 and 229) was 
synthesized by attaching the various nitroxide compounds directly to the carboxylic 
acid group of aspirin 136 through amide and ester linkages. As outlined in Scheme 
3.10 below, 4-amino-TEMPO 76 and 5-amino-TMIO 108 were used to synthesize 
the amide nitroxide-aspirin conjugates 228 and 229 respectively. TEMPOL 102 was 
also succesfully linked to aspirin 136 by esterification to give the ester conjugate 
140. Each of these transformations was achieved by similar carbodiimide coupling 
conditions. Briefly, almost equimolar amounts of nitroxide, aspirin and EDC, and a 
catalytic amount of DMAP were reacted at room temperature for 1 day. Although the 
formation of compound 140 proceeded smoothly, the synthesis of 229 under similar 
coupling conditions was accompanied by the formation of, surprisingly, the ortho-
deacetylated amide 230 (32%). This was verified by the presence of a strong broad 
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around 1640 cm-1 in the FTIR spectrum of 230. Further evidence to support the 
formation of 230 was obtained from the presence of the [M + H]+ ion at m/z 325 in 
the HRMS spectrum. TLC analysis of the reaction mixture indicated that the 
formation of both the desired product 229 and the ortho-phenolic amide side-product 
230 began immediately after the start of the reaction. The mixture was separated by 
silica gel chromatography. 
 
Scheme 3.10. Synthesis of the first series of aspirin nitroxide conjugates (140, 228 and 
229). Reagents and conditions: a. EDC, DMAP, DCM, RT, 1 d, 53-90%. 
The ortho-phenolic amide side-product was likely formed from hydrolysis of the 
ortho-acetate group of either aspirin 136, or the desired product 229, or the o-
acylisourea and anhydride intermediates (see Scheme 3.1). Notably, in the absence 
of the basic  DMAP catalyst, no side reaction was observed. In this case, however, 
less than 8% of starting material was converted to the desired product after four or 
more days. Similar o-deacetylation was observed in the synthesis of the amide 
conjugate 228. This indicated that the hydrolysis is likely facilitated by the presence 
of DMAP as well as the amino nitroxide precursors (76 and 108). 
The cleavable conjugates (140, 228 and 229) were obtained in good to high yields 
(53-90%) after purification by column chromatography. The products were 
characterized by FTIR and HRMS analysis, and their purity assessed by HPLC 
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absorption (at 1546 cm-1) in the FTIR spectrum of 228 supported the presence of an 
amide bond. Also, no characteristic O-H absorption, typical for carboxylic acid (a 
strong, broad band above 3000 cm-1), was present in the FTIR spectrum. This further 
indicated the successful transformation of aspirin to the amide derivative 228. 
Further evidence to confirm the identity of 228 was obtained by HRMS with the 
presence of the [M + H]+ ion at m/z 334. 
For the next series of nitroxide-aspirin conjugates, the aim was to link various 
carboxylic acid containing nitroxides to salicylic acid 135 via ester bonds. The 
carboxylic acid bearing nitroxides used include 4-carboxy TEMPO 8, CTMIO 70, 6-
methoxy-CTMIO 175 and carboxy PROXYL 204. However, as both reactants 
(salicylic acid 135 and the nitroxide) have carboxylic acid functionality, they can 
each react under carbodiimide coupling conditions to independently form the active 
o-acylisourea intermediate (v). This may lead to the formation of unwanted side 
products (such as the stable N-acylurea (x) or a salicylate dimer) and decrease the 
yield of the desired product. To overcome such potential drawbacks, salicylic acid 
135 was first converted to the benzyl salicylate 231 (Scheme 3.11). This was 
achieved by reacting equimolar amounts of salicylic acid 135 and benzyl bromide in 
the presence of sodium bicarbonate. The benzyl salicylate 231 was obtained in 94% 
yield as a clear oil. All characterization data obtained for compound 231 matched 
that in the literature.28  
The benzyl salicylate 231 was then reacted with various carboxylic acid nitroxides 
under EDC/DMAP coupling conditions to give compounds 232-235 in high yields 
(85-90%). The identity of each product was confirmed by 1H NMR and FTIR 
spectroscopy, and HRMS. In the 1H NMR spectrum of compound 234 for instance, 
the strong, broad singlet at 5.25 ppm was assigned to the distinctive CH2 protons of 
the benzylic ester protecting group. Almost all salicylate and benzyl aromatic protons 
were also observed for each benzyl salicylate-nitroxide (232-235) in the 
respective 1H NMR spectrum. The presence of the two characteristic C=O 
absorptions (at 1748 and 1718 cm-1) and the disappearance of an O-H stretch (from 
either reactants, 70 and 231) in the FTIR spectrum indicated successful 
transformation.  




Scheme 3.11. Synthesis of the second series of salicylate nitroxide conjugates via benzyl 
salicylate 231. Reagents and conditions. a. BnBr, NaHCO3, DMF, overnight, 50 oC, 
94%; b. Appropriate carboxylic acid nitroxide (compound 8, 70, 175 or 204), EDC, 
DMAP, DCM, RT, 1 d, 85-90%; c. H2, Pd/C, MeOH, overnight, 41-49%. 
The next step was to debenzylate the o-nitroxide salicylates (232-234) to the 
corresponding acid derivatives (144, 236 and 237). This was achieved using 
palladium catalyzed hydrogenation conditions. Although complete conversion was 
achieved and no side reactions were observed, the isolated yields for each of the 
debenzylated products (144, 236 and 237) was, surprisingly, quite low (41-49%). 
Each target nitroxide-salicylate conjugate (144, 236 and 237) was characterized 
by 1H NMR and FTIR spectroscopy and HRMS. Although the carboxylic acid 
functional group was not observed in the 1H NMR spectra of the target conjugates 
(144, 236 and 237), signals for the four distinct salicylate aromatic ring protons were 
present. The disappearance of the benzyl group protons of the benzyl salicylate 
precursors (232-234) at 5.25 ppm and around 7.26 ppm further supported the 
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spectrum of 236 (3550 to 2500 cm-1) is a characteristic O-H stretch. This, along with 
the two strong C=O stretches (at 1755 and 1716 cm-1), supported the presence of a 
carboxylic acid and an ester. The poor yields were initially attributed to the products 
being lost during the filtration process or trapped within the Pd/C residue. However, 
the yields could not be improved even after several extractions of the Pd/C solid 
residue with dichloromethane and ethyl acetate. The presence of the second ester 
bond linking each nitroxide in the intermediates to the benzyl salicylate, means that it 
is unlikely that these compounds be selectively debenzylated by acid or base 
hydrolysis. 
Therefore, an alternative, but convenient, approach was pursued for the synthesis of 
the salicylate conjugates (144, 236 and 237) starting from salicylaldehyde 238. As 
shown in Scheme 3.12 below, EDC coupling of carboxylic acid nitroxides 
(compound 8, 70 or 204) with salicylaldehyde 238 afforded the nitroxide o-formyl 
phenyl ester derivatives (239-241) in high yields (83-91%). 
 
Scheme 3.12. Synthesis of the second series of salicylate nitroxide conjugates via 
salicylaldehyde 238. Reagents and conditions: a. Appropriate carboxylic acid 
nitroxide (compound 8, 70 or 204), EDC, DMAP, DCM, RT, overnight, 83-91%; b. 
NaClO2, NaH2PO4, H2O2, MeCN, 0 oC-RT, 80-88%. 
The structure and purity of the nitroxide o-formyl phenyl ester derivatives (239-241) 
were verified by HRMS, FTIR and 1H NMR spectroscopy and HPLC. The singlet at 
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proton. The spectrum also confirmed the presence of the four aromatic protons, with 
their expected coupling patterns. The C=O absorption of both the aldehyde and the 
ester functional groups were shown as strong bands at 1749 and 1700 cm-1 
respectively in the FTIR spectrum of 241. 
Although a variety of methods are used to oxidize aldehydes to carboxylic acids, the 
Pinnick oxidation method was employed to convert the o-formyl phenyl esters (239-
241) to the corresponding acid derivatives (144, 236 and 237). The Pinnick oxidation 
reaction uses sodium chlorite (NaClO2) under mild acid conditions as the source of 
the active oxidizing agent.29-31 The acid, most commonly sodium dihydrogen 
phosphate (NaH2PO4), acts as a buffer reacting with NaClO2 to generate the active 
oxidizing agent, chlorous acid. 
Thus, each o-formyl nitroxide (239-241) was oxidized to its salicylate derivative 
(144, 236 and 237) by allowing it to react with NaClO2 in the presence of hydrogen 
peroxide and dihydrogen phosphate. The hydrogen peroxide is employed to quench 
the hypochlorite (HOCl) by-product that is usually generated in this reaction 
condition. Hypochlorite is a stronger oxidant and if not trapped, it can readily oxidize 
the required NaClO2 oxidant and other functional substrates.32 The target salicylate 
conjugates (144, 236 and 237) were obtained in high yields (80-88%) after 
purification by silica gel column chromatography and recrystallization. Alternatively, 
each o-formyl ester (239-241) was readily oxidized to the carboxylic acid derivative 
under mild potassium permanganate oxidation conditions in 1 h. Similar high yields 
were again obtained. The purity and characterization data obtained for  the 
carboxylic acid conjugates (144, 236 and 237) obtained via this route (Pinnick 
oxidation) were identical to those obtained from the benzyl protected intermediates 
(232-234). The lowest overall yield over the two step formyl route was 66% while 
that of the three step benzyl benzoate ester route was 16%. 
3.3.7 Synthesis of Nitroxide-5-Aminosalicylic Acid (5-ASA) 
Conjugates 
In contrast to other conventional NSAIDs, such as aspirin, that cause GI toxicity, 5-
aminosalicylic acid exerts its therapeutic action on inflammatory diseases of the GI 
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track. The four 5-aminosalicylic acid derivatives currently on the drug market 
include mesalamine 242, sulfasalazine 243, balsalazide 244 and olsalazine 245 
(Figure 3.5).33 These derivatives are the mainstay of treatment for inflammatory 
bowel diseases (IBDs) such as ulcerative colitis (UC).34-36 Ulcerative colitis is 
characterized by persistent mucosal inflammation of the colon that leads to 
abdominal pain, anemia, bleeding, diarrhea, and weight loss. Despite the GI 
tolerance of 5-ASA derivatives, combining them with antioxidant agents such as 
stable nitroxides may enhance their anti-inflammatory efficacy by reducing oxidative 
stress. Thus, the following sections will examine the synthesis of amide and amine 
nitroxide conjugates of 5-ASA. 
 
Figure 3.5. Common 5-aminosalicylic acid derivatives: mesalamine 242 (5-ASA), 
sulfasalazine 243, balsalazide 244 and olsalazine 245. 
3.3.7.1 Synthesis of Amide-linked Nitroxide-5-ASA Conjugates 
A number of nitroxides were incorporated into the 5-ASA framework via 
carbodiimide-facilitated amide bond formation starting from methyl 2-hydroxy-5-
nitrobenzoate 246 (Scheme 3.13). The phenol group of methyl 2-hydroxy-5-
nitrobenzoate 246 was first protected with an acetyl group by reacting it with acetyl 
chloride in the presence of triethylamine to furnish the nitro-diester 247. The 
appearance of the characteristic methyl proton singlet of the acetyl protection group 
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acetyl protected methyl benzoate. Compound 247 was then reduced to the amine 
derivative 248 under Pd/C hydrogenolysis. All characterization data (NMR and FTIR 
spectroscopy and melting point) obtained for compound 248 matched that previously 
reported in the literature.37  
 
Scheme 3.13. Synthesis of amide-linked nitroxide-5-ASA conjugates. Reagents and 
conditions: a. AcCl, TEA, 0 ºC, 30 min. to RT, 1 h, 91%; b. H2, Pd/C, EtOAc, 50 psi, 
5 h, 90%; c. Appropriate carboxylic acid (8, 70, 204-206, 258 or 259), EDC, DMAP, 
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The amino ester 248 was then coupled to various carboxylic acid nitroxides under 
EDC coupling conditions to give the amide derivatives (249-253). To compare the 
therapeutic efficacy of the novel nitroxides conjugates to known pharmacophores, 
the 5-ASA conjugates of known antioxidants trolox 258 and cinnamic acid 259 were 
also synthesized (145 and 146). The identity and purity of each product (145, 146, 
249-253) was confirmed by NMR and FTIR spectroscopy, HRMS, and HPLC 
analysis. A mild basic hydrolysis of the amide-diesters (249-253) afforded the 
desired amide salicylates (141, 254-257) in high yields (83-91%). 
3.3.7.2 Synthesis of Amine-Linked Nitroxide-5-ASA Conjugate 
In addition to the amide conjugates, the amino-linked conjugate 142 was the ultimate 
target of this chapter (Figure 3.6). Compound 142 is an intriguing target that is 
similar in structure to 2-hydroxy-5-[2-(4-trifluoromethylphenyl)-ethylaminobenzoic 
acid 260 (AAD-2004). AAD-2004, an amine derivative of 5-ASA (with ethylamino 
linker), is a potent antioxidant that displayed promising neuroprotective action on 
neurodegenerative disorders such as amyotrophic lateral sclerosis (ALS).38,39   
 
Figure 3.6. Chemical structures of AAD-2004 260 and the target nitroxide derivative 
142. 
With the amide derivative 251 in hand, the challenge was to selectively reduce the 
amide bond of conjugate 251 to the corresponding amine derivative without reducing 
the ester groups. Recently, Yoon and coworkers reported the synthesis of AAD-2004 
260 and a series of 5-(N-phenethylamino)salicylic acid derivatives in three steps 
from methyl 2-acetoxy-5-aminosalicylate ester 248 and the corresponding 
phenylacetic acid derivatives (Scheme 3.14).40  
The key step in their approach was the selective reduction of the amide group of the 
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good yield with sodium acyloxyborohydride as the reducing agent. 
Acyloxyborohydrides are versatile synthetic reagents known to selectively reduce 
amides to the corresponding amines.40-42  
 
Scheme 3.14. Synthesis of AAD-2004 via selective amide reduction using the 
sodium acyloxyborohydride reagent. Reagents and conditions: a. Compound 248, 
EDC, DMAP, DCM; b. NaBH4, AcOH, dioxane, reflux, 64%; c. 6 N HCl, AcOH, 
reflux, 85%. 
Sodium acyloxyborohydride is a modified-NaBH4 reagent formed when NaBH4 is 
reacted with a carboxylic acid (most commonly, acetic acid or trifluoroacetic acid) in 
aprotic solvents (Scheme 3.15).42 For amide reduction, the active reducing agent is 
the more reactive acyloxyborohydride (i). Therefore, equimolar amounts of the acid 
and NaBH4 are required for the optimum formation of acyloxyborohydride (i). Also, 
careful (slow) addition of the acid reagent to a suspension of NaBH4 in the 
appropriate solvent reduces the formation of the the less reactive 
triacyloxyborohydride complex (ii). 
NaBH4    +    3RCO2H
NaBH4    +    RCO2H NaBH3RCO2H     +    H2








Scheme 3.15. Sodium acyloxyborohydride formation. Typical reaction conditions: a. 
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To evaluate the selectivity of this reagent on the 5-ASA amide conjugates, a model 
reaction was first attempted with methyl 2-acetoxy-5-(2-(4-
methoxyphenyl)acetamido)benzoate 264 (Scheme 3.16). The methyl 2-acetoxy-5-[2-
(4-methoxyphenyl)acetylamino]benzoate ester 264 was readily synthesized by 
reacting 2-(4-methoxyphenyl)acetic acid 265 with methyl 2-acetoxy-5-
aminobenzoate 248 under EDC coupling conditions. Compound 264 was then 
selectively reduced to the amine derivated 266 by allowing it to react for 25 min with 
a preformed solution of sodium acyloxyborohydride in refluxing dioxane. The 
selective reduction of the amide group was confirmed by the presence of the two 
triplets, each integrating for two protons, at 2.86 and 3.36 ppm in the 1H NMR 
spectrum of 266 (Figure 3.7). 
 
Scheme 3.16. Model reaction for the selective amide reduction with sodium 
acyloxyborohydride reagent. Reagents and conditions: a. Compound 265, EDC, 
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Figure 3.7. Comparison of 1H NMR (600 MHz) spectra of amide precursor 264 and 
its 5-ethylamino derivative 266. 
The methyl protons of both esters (acetotoxy and methyl ester) were also observed in 
the 1H NMR spectrum. Though compound 266 was obtained in 66% yield, the 
reduction of 264 was accompanied by the formation of less than 10% of a mixture of 
the reduced esters as well. This was verified by the 1H NMR spectrum of the crude 
product mixture. 
Having established the optimal conditions for the selective reduction of the 5-ASA 
amide, the next step was to apply these conditions to the synthesis of the nitroxide-5-
ASA amino conjugate 142. Accordingly, when methyl 2-acetoxy-5-[1,1,3,3-
tetramethylisoindolin-2-yloxyl)acetylamino] benzoate ester 251 was subjected to 
similar sodium acyloxyborohydride reduction conditions, the 5-ethylamino 
derivative 267 was obtained in 68% yield following purification by silica gel column 
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Scheme 3.17. Synthesis of amine-linked nitroxide-5-ASA conjugate 142 using 
sodium acyloxyborohydride reduction conditions. Reagents and conditions: a. 
NaBH4, AcOH, dioxane, reflux, 30 min, 68%; b. 0.5 M NaOH/MeOH, overnight, 
72%. 
Characterization data including FTIR, HRMS, and 1H NMR spectra supported the 
successful synthesis of compound 267. Only two distinct C=O stretching frequencies 
were observed (at 1746 and 1715 cm-1) in the FTIR spectrum. This is consistent with 
the presence of the acetyl and methyl benzoate groups. A sharp medium N-H stretch 
of the ethylamino linker was also observed at 3371 cm-1. 
Despite the expected paramagnetic broadening effect of the nitroxide moiety, the 
methyl protons of both esters (acetoxy and methyl ester) were also observed in 
the 1H NMR spectrum of 267 at 2.31 and 3.85 ppm respectively (Figure 3.8). When 
compared to the model compound 266 (Figure 3.7), the weak broad peak at 3.44 
ppm likely represents one of the methylene protons of the ethyleneamino linker. In 
the aromatic region, the broad peaks observed at 6.76, 6.91 and 7.20 ppm represent 
the characteristic salicylate aromatic ring protons. The integration of each proton 
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Figure 3.8. 1H NMR (600 MHz) spectrum of 5-ethylamino-TMIO ester 267. 
The purity of compound 267 was verified by HPLC to be >95%. Mild basic 
hydrolysis of compound 267 afforded the target 5-(N-ethylamino-TMIO) salicylic 
acid conjugate 142 as a yellow solid in 72% yield. The identity of compound 142 
was confirmed following analysis by HRMS  and FTIR spectroscopy. A diagnostic 
mass of the [M + H]+ ion was observed at m/z 370 in the HRMS spectrum. 
Characteristic strong broad OH and strong C=O absorptions at 2500-3500 and 1681 
cm-1 respectively were observed in the FTIR spectrum. 
Having successfully synthesized the targeted nitroxide-NSAID conjugates, their 
antioxidant and anti-inflammatory activities were assessed. 
3.3.8  Antioxidant and Anti-inflammatory Effects of Selected 
Nitroxide-NSAID Conjugates 
The compounds selected for preliminary biological tests are shown in Figure 3.9 
below. The results discussed below were obtained from preliminary studies 
conducted by collaborators in the Center for Cancer Research, a branch of National 



















































Figure 3.9. Selected nitroxide-NSAID conjugates for biological analysis. 
3.3.8.1 Antioxidant Capacity of Nitroxide-NSAID Conjugate 
The antioxidant capacity of the nitroxide-NSAID conjugates was determined by 
evaluating their ability to scavenge reactive oxygen species (ROS) generated by the 
Non-Small Cell Lung Cancer (NSCLC) cells, A549. NSCLC is a type of epithelial 
lung cancer relatively insensitive to chemotherapy and radiation therapy, and 
accounts for over 60% of lung cancers.43 ROS production in A549 cells is initiated 
by the addition of hydrogen peroxide. The quantity of H2O2-induced ROS produced 
by A549 cells is estimated by employing 2′,7′-dichlorofluorescin diacetate (DCFH-
DA). DCFH-DA 269 is a cell-permeable non-fluorescent probe, which is de-
esterified by cellular esterases to the polar, non-fluorescent derivative DCFH 270 
(Scheme 3.18).44-46 
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Scheme 3.18. ROS quantification by DCFH-DA probe: DCFH-DA 269 is 
deacetylated by cellular esterase to the nonfluorescent derivative DCFH 270, which 
is in turn oxidized by ROS to the highly fluorescent DCF 271. 
In the presence of ROS, DCFH 270 is oxidized to the highly fluorescent 2′,7′-
dichlorofluorescein 271 (DCF), the intensity of which is correlated to the amount of 
ROS produced. Thus, A549 cells were placed in black 96 well plates, treated with 10 
μM dichlorofluorescin diacetate for 1 hr and washed thoroughly. Some of the cells 
were treated 10 μM 140 or 100 μM TEMPOL 102, and then 10 μM H2O2 added. 
Fluorescence measurements were taken at various times with excitation and emission 
wavelengths of 485 and 585 nm respectively. Table 3.1 below shows that 5 min after 
addition of H2O2 addition to A549 cells, the ROS significantly increased to 194% of 
the basal fluorescence. TEMPOL 102 or 140 reduced the increase in ROS caused by 
H2O2 but had no effect on basal ROS levels. The results support the proposed strong 
antioxidant capacity of nitroxide-NSAID conjugate 140. Notably, 10 μM of 
compound 140 displayed a similar ROS scavenging ability as 100 μM of TEMPOL 
102 (the most studied antioxidant nitroxide). 
Table 3.1. ROS scavenging action of nitroxide-NSAID-conjugates determined by the 
DCFH-DA probe. 
Addition Relative fluorescence 
(%) 
None 100 ± 5aa 
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H2O2 + 102 (100 μM) 144 ± 12*a 
H2O2 + 140 (10 μM) 155 ± 15*a 
102 (100 μM) 103 ± 6aa 













* The mean value + S.D. of 8 determinations is indicated; *, p < 0.05; ** p < 0.01 relative to control; a p < 0.05; aa p < 0.01 
relative to H2O2 .  This experiment is representative of 2 others. 
3.3.8.2 Anti-inflammatory Capacity of Nitroxide-NSAID Conjugates  
To evaluate the anti-inflammatory capacity of the novel nitroxide-NSAID 
conjugates, studies were carried out using the A549/H1299 NSCLC cells. The target 
protein for this study was the epidermal growth factor receptor (EGFR). EGFR is a 
type of receptor tyrosine kinase (RTK) which is activated when ligands, such as 
epidermal growth factor (EGF), bind to it.47 When activated, EGFR then facilitates 
the activation of multiple downstream signalling pathways within the cell, including 
the cell survival and proliferation pathways. EGFR is a membrane protein that is 
present in a range of cells including NSCLC. It facilitates the fast growth 
(proliferation) of NSCLC. Drugs such as gefitinib,48 erlotinib, and afatinib, used to 
treat advanced NSCLS exert their therapeutic action by primarily blocking the EGFR 
signalling pathway. 
Another downstream effect of the EGFR signalling pathway is that it induces COX-2 
expression which in turn leads to the production of inflammation-related prostanoids 
such as PGE2.49-52  Increased COX-2-induced PGE2 production is involved in 
various aspects of carcinogenesis. It is known to mediate inflammation response and 
can also enhance EGFR activity via a positive feedback loop.49,52 Conventional 
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NSAIDs such as aspirin and indomethacin have displayed promising anti-
carcinogenic effects by reducing PGE2 production and inhibiting NSCLC cell 
growth.49,53,54 Therefore, a rational drug design approach to NSCLC therapy may 
involve developing a multi-target drug that inhibits both EGFR and COX pathways, 
and reduces cellular oxidative stress.  
The novel nitroxide-NSAID conjugates were evaluated for their COX inhibitory 
action on NSCLC cells A549 or H1299. Briefly, selected nitroxide conjugates were 
dissolved in DMSO at a concentration of 30 µM and added to A549 or H1299 cells 
for 30 min. The COX reaction was started by the addition of 20 µg/mL of 
arachidonic acid at 37 oC for 5 min. The COX inhibition action of each compound 
was measured by the ELISA assay which was previously described in Chapter 2.  
As shown in Table 3.2 below, the ester-linked conjugates (140, 144, 233 and 234) 
displayed strong inhibitory capacity of the COX-induced PGE2 production. In 












None  57 + 4 
140 30 31 ± 4* 
143 30 58 ± 3 
144 30 34 ± 6* 
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228 30 54 ± 6 
229 30 45 ± 9 
233 30 23 ± 5* 












































The mean value + S.D. of 3 experiments each repeated in duplicate is shown; p < 0.01, **; p < 0.05, * using the student’s t-test. 
 
Further COX inhibition experiments were conducted at lower concentrations (4 µM) 
of selected conjugates (140 and 228) along with TEMPOL 102 and the parent aspirin 
136. As shown in Table 3.3 below, the ester-linked conjugate 140 significantly 
inhibited PGE2 productions at the lower concentration of 4 μM. The amide-linked 
conjugate 228 showed moderate inhibition at 4 μM. The most interesting result was 
the inhibitory action of the conjugates in comparison to parent aspirin 136. 
Compound 140 was more potent at inhibiting COX-induced PGE2 production in 
NSCLC cells than aspirin 136. 
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Table 3.3. Inhibitory effects of nitroxide-NSAID conjugates on COX-induced PGE2 





None  126 ± 17 
102 90 105 ± 11 
136  90 79 ± 11* 
102 + 136 90 75 ± 14* 
140 4 87 ± 9* 

























The mean value ± S.D. of 4 determination is indicated using NCI-H1299 cells; p < 0.05, * using the Student’s t-test.  This 
experiment is representative of 2 others. 
 
 
The nitroxide-NSAID conjugates were further tested for their inhibitory action on 
NSCLC proliferation using the MMT assay. MTT 272 is a yellow tetrazolium 
compound [3-(4,5-dimethyl-2-thiazolyl)-2,5-diphenyl-2H-tetrazolium bromide] that 
is reduced by various dehydrogenase enzymes to the dark blue MTT formazan 273 
(Scheme 3.19).55,56 The reduction, which involves the cleavage of the tetrazolium 
ring, only occurs in the mitochondria of living cells. Thus, the rate of cell 
proliferation, and conversely, the reduction in cell viability are directly related to 
quantity of MTT formazan produced. The formazan 273 is quantified by measuring 
its absorbance at certain wavelengths (usually between 500 and 600 nm). 

















Scheme 3.19. Mitochondrial reductase-facilitated reduction of MTT 272 to formazan 
273. 
The nitroxide-NSAID conjugates were incubated with A549 cells for 3 days in 0.1 
mL skin irritation test medium using 96 well plates. MTT (1 mg/mL, 15 µL) was 
added for 3 hours, followed by DMSO (150 µL) and the absorbance determined at 
570 nm. The mean value ± S.D. of 8 determinations is indicated. This experiment is 
representative of 2 others.  
As shown in Table 3.4 below, the ester-linked conjugates (140, 144, 233 and 234) 
inhibited A549 cell proliferation with IC50 values in the range of 118-151 µM. In 
contrast, their amide-linked counterparts (143, 228 and 229) displayed moderate cell 
inhibitory potency with IC50 values >300 µM). 




140 130 ± 23 
143 >300 
144 151 ± 8 
228 >300 
229 >300 
233 121 ± 12 
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The mean value + S.D. of 8 determinations is indicated using A549 lung cancer cells; p < 0.05, *; p < 0.01, ** using the 
Student’s t-test.  This experiment is representative of 2 others. 
 
Further A549 cell growth inhibitory studies were conducted with compound 140, 
along with TEMPO 102 and aspirin 136, at different concentrations. The results are 
shown in Table 3.5 below. At a concentration of 180 μM, compound 140 displayed 
strong inhibitory capacity against the growth of A549 cells. However, no significant 
inhibition was observed for compound 140 at a lower concentration (18 μM). In 
contrast, TEMPOL 102 at 90 µM or 900 µM concentrations had little effect on A549 
proliferation. Only a moderate inhibitory action was observed for aspirin 136. 
However, this was only observed at higher aspirin 136 concentrations (900 µM). 
Table 3.5. MMT assay results for nitroxide-NSAID conjugates inhibition of NSCLC 
A549 cell growth. 
Compound Concentration Absorbance 
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(µM) (at 570 nm) 
None  0.663 ± 0.037 
102 90 0.666 ± 0.044 
102 900 0.650 ± 0.060 
136 90 0.682 ± 0.010 
136  900 0.328 ± 0.021* 
140 18 0.652 ± 0.021 

























The mean value + S.D. of 8 determinations is indicated using A549 lung cancer cells; p < 0.05, *; p < 0.01, ** using the 
Student’s t-test.  This experiment is representative of 2 others. 
These results suggest that compound 140 is approximately an order of magnitude 
more potent at inhibiting NSCLC proliferation than aspirin 136. 
The ability of the nitroxide-NSAID conjugates to inhibit the growth of A549 cells in 
the MTT assay was also investigated in the presence of gefitinib. As mentioned 
earlier, gefitinib is an oral, selective anticancer agent known to reversibly inhibit the 
tyrosine kinase, an epidermal growth factor receptor (EGFR) that plays a key role in 
NSCLC carcinogenesis.57-59 It was anticipated that adding gefitinib to the nitroxide-
NSAID conjugates would produce a synergistic inhibitory action on NSCLC cell 
growth. Thus, compound 140, in the presence of gefitinib, was analyzed with the 
MTT assay. As shown in Figure 3.10 below, compound 140 alone had half-
maximum inhibitory action on the proliferation of A549 cells with an IC50 value of 
100 μM. 
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Figure 3.10. MTT assay for the inhibitory effect of nitroxide conjugate 140 (either 
alone or in combination with gefitinib) on NSCLC H1299 cell proliferation. The 
inhibition of cell growth was determined when gefitinib was 0   ( ), 1 μg/mL ( ) and 
3 μg/mL ( ). The mean value ± S.D. of 8 determinations is indicated. 
Upon the addition of 3 μg/mL of gefitinib, compound 140 displayed significant 
inhibitory action with an IC50 value 30 μM. Gefitinib is however known to possess a 
dose-dependent antiproliferation effects on H1299 cells with an IC50 value 40 μM.60 
To further evaluate the additive effect of compound 140 with gefitinib, a clonogenic 
assay was conducted for A549 cells. The clonogenic assay is an in vitro-based cell 
survival assay that tests the ability of a cell to proliferate indefinitely and form a 
large colony.61,62 It is commonly used to determine the ability of a cell to retain its 
unlimited growth after treatment with an agent that inflicts insults on the colony. 
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Thus, large colonies of A549 cells were formed using a clonogenic cell survival 
assay (Figure 3.11 A).  
 
Figure 3.11. Clonogenic assay results for the inhibitory effect of nitroxide-NSAID 
conjugate 140 on A549 cells growth. Colonies of A549 are shown as a function of 
(A) untreated controls, (B) 10 μM 140, (C) 1 μg/mL gefitinib and (D) 10 μM 140 
plus 1 μg/mL gefitinib. 
After the addition of 10 μM of compound 140 or 1 μg/mL of gefitinib, the number 
and size of the colonies were markedly reduced (Figure 3.11 B and C). In the 
presence of gefitinib and 140, few colonies were present (Figure 3.11 D). These 
results suggest that gefitinib and the nitroxide-NSAID conjugates work 
synergistically to inhibit NSCLC growth.  
Due to such promising preliminary results obtained for the selected conjugates, more 
antioxidant and anti-inflammatory studies are currently being carried out with the 
rest of the novel compounds. 
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3.4 Summary of Results 
Using the pharmacophore hybridization strategy, a series of novel potential dual-
acting (antioxidant and anti-inflammatory) nitroxide-NSAID conjugates were 
designed and synthesized. In general, the synthesis involved carbodiimide-facilitated 
coupling of various nitroxide compounds with a number of NSAIDs. The parent 
NSAID templates employed included indomethacin, aspirin, salicylic acid, and 5-
amino salicylic acid. Although the pyrrolidine and piperidines nitroxide precursors 
are commercially available, each isoindoline nitroxide compound was readily 
synthesized. In the synthesis of the water-soluble antioxidant nitroxide, CTMIO, 
three new alternative synthetic routes were developed. Though each new route had a 
modest overall yield (16-18%), the formyl route was the quickest. For the synthesis 
of the AAD-2004 nitroxide analogue 142, the key step involved selective reduction 
of the amide group of 251. This was successfully carried out using an in situ-
generated sodium acyloxyborohydride as the active reducing agent under refluxing 
reaction conditions. 
Nine novel nitroxide-NSAID conjugates were evaluated for their antioxidant and 
anti-inflammatory effects on the A549 Non-Small Cell Lung Cancer cells. Some of 
the nitroxide conjugates displayed significant antioxidant effect on ROS generated 
by A549 cells. Notably, the nitroxide conjugate 140 showed a better ROS scavenging 
activity than the versatile antioxidant, TEMPOL 102. Some of the novel nitroxide 
conjugates displayed promising anti-inflammatory action by inhibiting COX-induced 
PGE2 production by A549 cells. While the ester-linked conjugates (140, 144, 233 
and 234) possessed strong inhibitory effects on the COX enzyme, the amide-linked 
counterparts (143, 228 and 229) displayed only moderate inhibitory effect. Notably, 
the nitroxide conjugate 140 possessed better inhibitory effect on the COX enzyme 
than parent aspirin 136. In addition to the antioxidant and anti-inflammatory effects, 
compound 140 was shown to inhibit the proliferation of A549 NSCLC cells. 
Clonogenic assay studies of A549 cells indicated that combining the conjugate 140 
with anticancer agent gefitinib produced a synergistic effect on inhibiting A549 cells 
growth. The anticancer effect of compound 140 on A549 cell growth is quite 
promising and further studies are currently being undertaken. 
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Another prominent class of drugs in which chronic inflammation and oxidative stress 
play a key role in the pathogenesis and the associated drug-induced cellular damage 
is the sympathomimetic stimulant class of drugs. Due to such noxious effects, long-
term therapeutic benefits of drugs such as such as L-Dopa 147 and Ritalin 148 are 
limited. L-Dopa 147 and Ritalin 148 are the main therapeutic agents used to treat 
Parkinson’s disease and ADHD respectively. The next chapter discusses the use of 
the pharmacophore hybridization approach to synthesize potential hybrid dual-acting 
stimulants by combining antioxidant nitroxides with L-Dopa and Ritalin. 
3.5 Experimental 
3.5.1. Synthesis of 1,1,3,3-Tetramethylisoindoline 207 
 
A reaction mixture of N-benzyl-1,1,3,3-tetramethylisoindoline 169 (5 g, 18.84 mmol, 
1 equiv.) and Pd/C (500 mg,  10% wt.) in glacial acetic acid (50 mL) was shaken 
under hydrogen (50 psi) in a Parr Hydrogenator for 4 h. The mixture was then 
concentrated under reduced pressure and basified with NaOH (2 M, to pH 12). The 
aqueous layer was extracted with Et2O (100 mL x 4) and the combined Et2O extracts 
were washed with brine (60 mL x 2), dried over anhydrous Na2SO4, and 
concentrated under reduced pressure to give 1,1,3,3-tetramethylisoindoline 207 as a 
beige solid (3.17 g, 96%), which was used in the next step without further 
purification. 1H NMR (CDCl3, 400 MHz): δ = 1.48 (s, 12 H, CH3), 1.9 (s, 1 H, N-H), 
7.15 (m, 2 H, Ar-H), 7.27 (m, 2 H, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 31.9 
(C-CH3), 62.8 (C-CH3), 121.4 (Ar-C), 127.1 (Ar-C), 148.8 (Ar-C). 
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mCPBA (6.16 g, 22.25 mmol, 1.3 equiv.) was added to a solution of 1,1,3,3-
tetramethylisoindoline 207 (3 g, 17.1 mmol, 1 equiv.) in DCM (200 mL) at 0 oC. The 
cooling bath was removed after 30 min and the reaction stirred at RT for further 2 h. 
The DCM layer was washed with HCl (2 M, 50 mL), NaOH (2 M, 50 mL x 2), and 
brine solutions (50 mL) and before being dried over anhydrous Na2SO4. The DCM 
was removed under reduced pressure and the residue obtained was purified by a short 
silica gel column chromatography (Hexane/DCM, 1:1) to give 1,1,3,3-
tetramethylisindolin-2-yloxyl 59 as yellow solid (3.058 g, 94%). Mp. 128-129 oC 
(Lit.,63 128-129 oC).  
3.5.3. Synthesis of 5-Nitro-1,1,3,3-tetramethylisoindolin-2-yloxyl 29 
 
1,1,3,3-Tetramethylisoindolin-2-yloxyl 59 (2 g, 1.05 mmol) was dissolved in H2SO4 
(15 mL, 98%) and cooled to 0 °C. Nitric acid (3.75 mL, 70%) was added dropwise 
and the reaction mixture was stirred at 0 °C for 1 h. The cooling bath was removed 
and stirring was continued for 4 h. The reaction mixture was cooled to 0 °C, diluted 
by careful addition ice/H2O and then basified with NaOH solution (10 M). The 
reaction mixture was extracted with Et2O (60 mL x 4) and the combined organic 
extracts were washed with brine (60 mL), dried with anhydrous Na2SO4 and the 
solvent evaporated under reduced pressure. The residue was purified by filtration 
through a short silica gel column (EtOAc) and recrystallized from EtOH to afford 
bright orange prisms of 5-nitro-1,1,3,3-tetramethylisoindolin-2-yloxyl 29 (2 g, 81%). 
Mp. 161-162 °C (lit.,8 160-162°C). 
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A reaction mixture of 5-nitro-1,1,3,3-tetramethylisoindolin-2-yloxyl 29 (1.5 g, 6.38 
mmol, 1 equiv) and Pd/C (150 mg,  10% wt.) in MeOH (25 mL) was stirred under 
hydrogen (50 psi) in a Parr Hydrogenator for 4 h. The mixture was then shaken for 
further 20 min in open air in the presence of PbO2 (19 mg, 80 µmol, 0.0125 equiv.). 
The mixture was then filtered through Celite and concentrated under reduced 
pressure. The crude residue was recrystallized from EtOH to give 5-amino-1,1,3,3-
tetramethylisoindolin-2-yloxyl 108 as yellow solid (1.15 g, 88%). Mp. 196-198 °C 
(Lit.,64 198 °C). 
3.5.5. Synthesis of N-Benzyl-5-methylphthalimide 210 
 
4-Methylphthalic anhydride 209 (10 g, 61.70 mmol, 1 equiv.) was dissolved in 
glacial acetic acid (50 mL). To this was added benzylamine (10 mL, 92.60 mmol, 1.5 
equiv.) and the resulting solution refluxed for 1 hr. The reaction mixture was cooled 
to room temperature, poured onto ice/water (150 mL) and stirred to give a white 
precipitate which was then filtered and recrystallized from ethanol to give fluffy 
white crystals of N-benzyl-5-methylphthalimide 210 (15.21 g, 98%). Mp. 128-130 oC 
(Lit.,10 130 oC). 1H NMR (CDCl3, 400 MHz) δ = 2.50 (s, 3H, CH3), 4.83 (s, 2H, 
CH2), 7.26-7.33 (m, 3H, Ar-H). 
3.5.6. Synthesis of N-Benzyl-1,1,3,3-tetraethyl-5-methyl isoindoline 211  
 
A solution of N-benzyl-5-methylphthalimide 210 (20 g, 80 mmol, 1 equiv.) in 
anhydrous toluene (200 mL) was added to a freshly prepared with ethylmagnesium 
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turnings (23.36 g, 940 mmol, 12 equiv.) in Et2O (200 mL)]. The Et2O was distilled 
off using a Dean–Stark and the reaction mixture was refluxed for 4 h and then 
allowed to cool to RT. The mixture was diluted with hexane and filtered through 
Celite and washed thoroughly with extra hexane. Air was bubbled through the filtrate 
overnight and the crude residue was passed through a short column of basic alumina 
and concentrated in vacuo to afford N-benzyl-1,1,3,3-tetraethyl-5-methylisoindoline 
211 as a colourless oil (9 g, 34%). 1H NMR (CDCl3, 400 MHz): δ = 0.78 (t, J = 7.36, 
3.04, 12 H, CH3), 1.45–1.62 (m, 4 H, CH2), 1.85–1.95 (m, 4 H, CH2), 2.37 (s, 3 H, 
CH3), 4 (s, 2 H, CH2), 6.86 (s, 1 H, Ar-H), 6.94 (d, 1 H, J = 7.7 Hz, Ar-H), 7.02 (d, 1 
H, J = 7.7 Hz, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 9.59 (CH3), 9.62 
(CH3), 21.5 (CH3), 30.32 (CH2), 30.34 (CH2), 46.8 (CH2), 71.0 (CCH3), 71.2 
(CCH3), 123.1 (Ar-C), 123.9 (Ar-C), 126.47 (Ar-C), 126.48 (Ar-C), 127.7 (Ar-C), 
129.2 (Ar-C), 135.0 (Ar-C), 141.7 (Ar-C), 142.5 (Ar-C), 144.7 (Ar-C) ppm. 
3.5.7. Synthesis of 1,1,3,3-Tetraethyl-5-methylisoindoline 212 
 
A reaction mixture of N-benzyl-1,1,3,3-tetraethyl-5-methylisoindoline 211 (5 g, 
14.91 mmol, 1 equiv.) and Pd/C (500 mg,  10% wt.) in glacial acetic acid (50 mL) 
was shaken under hydrogen (50 psi) in a Parr Hydrogenator for 4 h. The mixture was 
then concentrated under reduced pressure and basified with NaOH (2 M, to pH 12). 
The aqueous layer was extracted with Et2O (100 mL x 4) and the combined Et2O 
extracts were washed with brine (50 mL x 2), dried over anhydrous Na2SO4, and 
concentrated under reduced pressure to give 1,1,3,3-tetraethyl-5-methylisoindoline 
212 (3.51 g, 96%), which was used in the next step without further purification. 1H 
NMR (CDCl3, 400 MHz): δ = 0.9 (m, 12 H, CH2CH3), 1.7 (m, 8 H, CH2), 2.38 (s, 3 
H, Ar-CH3), 6.89 (s, 1 H, Ar-H), 6.98 (d, 1 H, Ar-H), 7.05 (d, 1 H, Ar-H). 13C NMR 
(CDCl3, 100 MHz): δ = 9.0 (CH3), 21.4 (Ar-CH3), 33.78 (CH2), 33.79 (CH2), 68.0 
NH
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(Cquat.), 68.2 (Cquat), 122.2 (Ar-C), 123.1 (Ar-C), 127.4 (Ar-C), 136.1 (Ar-C), 144.7 
(Ar-C), 147.7 (Ar-C). 
3.5.8. Synthesis of 1,1,3,3-Tetraethyl-5-methylisoindolin-2-yloxyl 213 
 
m-Chloroperoxybenzoic acid (4.4 g, 15.89 mmol, 1.3 equiv.) was added to  a solution 
of 1,1,3,3-tetraethyl-5-methylisoindoline 212 (3 g, 12.22 mmol, 1 equiv.) in DCM 
(250 mL) at 0 oC. The cooling bath was removed after 30 min and the reaction stirred 
at RT for further 2 h. The DCM layer was washed with HCl (2 M, 50 mL), NaOH (2 
M, 50 mL x 3), and brine (50 mL x 2) solutions and before being dried over 
anhydrous Na2SO4. The DCM was removed under reduced pressure and the residue 
obtained was purified by a short silica gel column chromatography (Hexane/DCM, 
1:1) to give 1,1,3,3-tetraethyl-5-methylisoindolin-2-yloxyl 213 as yellow solid (2.67 
g, 84%). HRMS (ES): m/z (%) = 261.2049 (10) [M + H]+; calcd. for C17H26NO•: 
260.2014; found 260.2015. 
3.5.9. Synthesis of 2-Acetoxy-1,1,3,3-tetraethyl-5-methyl isoindoline 214 
 
A reaction mixture of 1,1,3,3-tetraethyl-5-methylisoindolin-2-yloxyl 213 (1 g, 3.84 
mmol, 1 equiv.) and Pd/C (100 mg, 10% wt.) in THF (25 mL) was flushed with Ar 
for 10 min.  Then, a balloon containing H2 was connected and the reaction mixture 
stirred for 20 min. The reaction mixture was cooled in ice/H2O bath followed by the 
addition of TEA (1.1 mL, 7.68 mmol, 2 equiv.) and then AcCl (545 µL, 7.68 mmol, 
2 equiv.) dropwise. The cooling bath was removed after 30 min and stirring was 
N O
N OAc
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continued for further 1 h. The reaction mixture was filtered through Celite and 
concentrated in vacuo. The crude residue was dissolved in EtOAc (150 mL) and 
washed with brine (40 mL), dried over anhydrous Na2SO4, and concentrated in 
vacuo. Purification of the crude product by silica gel column chromatography 
(Hexane/EtOAc, 5:1) gave 2-acetoxy-1,1,3,3-tetraethyl-5-methylisoindoline 214 as a 
clear solid (1.06 mg, 91%). Mp. 76–78 oC (Lit.,10 76–78 °C). 1H NMR (CDCl3, 400 
MHz): δ = 0.79 (t, 6 H, CH2CH3), 0.96 (t, 6 H, CH2CH3), 1.62 (m, 2 H, CH2), 1.75 
(m, 2 H, CH2), 1.86 (m, 2 H, CH2), 1.96 (m, 2 H, CH2), 2.1 (s, 3 H, CH3), 2.37 (s, 3 
H, CH3), 6.86 (s, 1 H, Ar-H), 6.94 (d, 1 H, Ar-H), 7.06 (dd, 1 H, Ar-H) ppm. 13C 
NMR (CDCl3, 100 MHz): δ = 8.6 (CH3), 9.4 (CH3), 19.4 (CH3), 21.6 (CH3), 28.9 
(CH2), 30.3 (CH2), 73.5 (CCH2), 73.6 (CCH2), 123.4 (Ar-C), 124.0 (Ar-C), 127.5 
(Ar-C), 136.2 (Ar-C), 136.7 (Ar-C), 138.8 (Ar-C), 141.8 (Ar-C), 170.5 (C=O) ppm. 
ATR-FTIR: υmax= 2956 (m, Ar C-H), 1770 (s, C=O), 1190 (s, C-O) cm-1. 
3.5.10. Synthesis of 2-Acetoxy-5-carboxy-1,1,3,3-tetraethylisoindoline 215 
 
MgSO4 (169 mg, 1.65 mmol, 0.5 equiv) and freshly prepared KMnO4 solution (32.7 
mL, 13.2 mmol, 4 equiv, 0.4 M) were added to a solution of N-acetoxy-1,1,3,3-
tetraethyl-5-methylisoindoline 214 (1 g, 3.3 mmol, 1 equiv) in tert-butyl alcohol (20 
mL) and the resulting reaction mixture was stirred at 70 oC for 1 d. The reaction 
mixture was cooled to RT, treated with iPrOH (10 mL) and stirred overnight. The 
mixture was filtered through Celite and the solvent removed in vacuo. The resulting 
residue was picked up in EtOAc (150 mL), washed with water and brine (40 mL), 
dried over anhydrous Na2SO4 and the filtrate concentrated in vacuo. Purification of 
the resulting residue by silica gel flash chromatography (eluent: initial: 
(DCM/EtOAc, 3:2) gave 2-acetoxy-5-carboxy-1,1,3,3-tetraethylisoindoline 215 as a 
white solid (660 mg, 60%). Mp. 168–170 °C (Lit.,10 168–170 °C). 1H NMR (CDCl3, 
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CH2), 2.12 (s, 3 H, CH3), 7.17 (d, 1 H, Ar-H), 7.81 (1 H, Ar-H), 8.03 (d, 1 H, Ar-H) 
ppm. 13C NMR (CDCl3, 100 MHz): δ = 8.5 (CH3), 9.4 (CH3), 19.3 (CH3), 28.9 
(CH2), 30.2 (CH2), 73.7 (CCH3), 74.0 (CCH3), 123.7 (Ar-C), 125.4 (Ar-C), 128.0 
(Ar-C), 128.9 (Ar-C), 142.3 (Cquat), 148.3 (Ar-C), 170.3 (C=O), 172.1 (C=O) ppm. 
3.5.11. Synthesis of 5-Carboxy-1,1,3,3-tetraethylisoindolin-2-yloxyl 206 
 
A suspension of 2-acetoxy-5-carboxy-1,1,3,3-tetraethylisoindoline 215 (500 mg, 1.5 
mmol, 1 equiv.) in H2O/MeOH (5 mL/5 mL) was cooled to 0 oC. LiOH (182.6 mg, 
7.5 mmol, 5 equiv.) was added and the reaction mixture was stirred overnight while 
allowed to warm to RT. The resulting solution was diluted with H2O (20 mL), 
washed with Et2O (20 mL x 2) and the Et2O layer discarded. The aqueous layer was 
cooled in ice bath, acidified with HCl (2 M) and then extracted with Et2O (30 mL x 
4). The combined Et2O extracts were stirred over PbO2 (90.5 mg, 375 µmol, 0.25 
equiv.) for 20 min, dried over anhydrous Na2SO4, filtered and concentrated in vacuo. 
The crude residue was recrystallized from MeCN to give 5-carboxy-1,1,3,3-
tetraethylisoindolin-2-yloxyl 206 as yellow crystals (362 mg, 83%). Mp. 97-99 oC 
(Lit.,10 97-99 oC). 
3.5.12. Synthesis of 5-Cyano-1,1,3,3-tetramethylisoindoline 71 
 
A Schlenk vessel that contained a mixture of 5-bromo-1,1,3,3-tetramethylisoindoline 
66 (500 mg, 1.97 mmol, 1 equiv.), K4[Fe(CN)6] (207.5 mg, 984 µmol, 0.25 equiv.), 
CuI (45 mg, 472 µmol, 0.12 equiv.) N-butylimidazole (825 µL, 3.934 mmol, 2 
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resulting mixture was allowed to return to RT before it was diluted with water and 
then extracted with EtOAc (60 mL x 4). The combined EtOAc extracts were washed 
with brine (50 mL) and dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by silica gel column 
chromatography (EtOAc) to give 71 as a mixture with the N-butylimidazole complex 
(458 mg) which was used in subsequent steps without further purification. 1H NMR 
(CDCl3, 400 MHz): δ = 1.46 (s, 12 H, 4 x CH3), 1.71 (br. s, 1 H, NH), 7.20 (d, 1 H, J 
= 7.6 Hz, Ar-H), 7.40 (s, 1 H, J = 7.6 Hz, Ar-H), 7.53 (d, 1 H, Ar-H). 13C NMR 
(CDCl3, 100 MHz): δ = 31.6 (CH3), 31.8 (CH3), 62.8 (Cquat), 63.2 (Cquat), 111.0 
(CquatN), 119.3 (Ar-C), 122.5 (Ar-C), 125.6 (Ar-C), 131.5 (Ar-C), 150.1 (Ar-C), 
154.2 (Ar-C). HRMS (ES): m/z (%) = 201 (100, M+H); Calcd. for C13H16N2 [M + 
H]+: 201.1313; found 201.1317. ATR-FTIR: υmax= 3321 (w, N-H), 2226 (m, s, 
C≡N).  
3.5.13. Synthesis of 5-Cyano-1,1,3,3-tetramethylisoindol-2-yloxyl 217 
 
 m-Chloroperoxybenzoic acid (864 mg, 2.96 mmol, 1.3 equiv., 77 %) was added to 
an ice-cold solution of the crude 5-cyano-1,1,3,3-tetramethylisoindoline 71 (458 mg, 
2.28 mmol, 1.0 equiv.) in DCM (200 mL). The resulting solution was stirred for 1 h 
at 0 °C. The cooling bath was removed and stirring was continued at RT for a further 
1.5 h with additional dichloromethane added to dissolve the formed precipitate. The 
bright-yellow organic phase was washed successively with HCl (0.5 M (50 mL), 
NaOH (2 M (50 mL) and brine (50 mL) solutions and dried with anhydrous Na2SO4. 
The filtrate was concentrated in vacuo and the resultant solid recrystallized from 
cyclohexane to afford 5-cyano-1,1,3,3-tetramethylisoindol-2-yloxyl 217 as a bright-
yellow solid (330 mg, 78 % from 66). Mp. 127 °C. FTIR (ATR): max = 2227 (m, 
C≡N) cm–1. HRMS (ES): m/z (%) = 217 (80) [M + 2H]+; calcd. for C13H16N2O [M 
+ 2H]+ 217.1341; found 217.1281. 
N O
NC
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3.5.14. Synthesis of CTMIO 70 from 5-Cyano-1,1,3,3-tetramethylisoindol-2-yloxyl 
217 
 
A suspension of 5-cyano-1,1,3,3-tetramethylisoindol-2-yloxyl 217 (150 mg, 698 
μmol, 1.0 equiv.) in NaOH (3 mL, 2 M aqueous solution) and EtOH (0.6 mL) was 
heated at reflux for 16 h. The reaction was cooled to room temperature, diluted with 
water (5 mL), washed with Et2O (3 × 10 mL) and then acidified to pH 1 with HCl (2 
M aqueous solution). The acidic aqueous layer was extracted with Et2O (4 × 20 mL) 
and the combined organic layers washed with brine (15 mL), dried with anhydrous 
Na2SO4 and filtered. The filtrate was concentrated in vacuo and recrystallized from 
MeCN to obtain CTMIO 70 as a yellow solid (155 mg, 95 %). Mp. 211 °C (Lit.,14 
214–218 °C).  
3.5.15. Synthesis of 5-Formyl-1,1,3,3-tetramethylisoindoline 73  
 
n-Butyllithium (1.6 M in hexanes, 5.45 mL, 8.72 mmol, 2.2 equiv.) was added 
dropwise to a solution of 5-bromo-1,1,3,3-tetramethylisoindoline 66 (1 g, 3.94 
mmol) in dry THF (11 mL) at -78°C under argon. After 10 minutes the reaction was 
quenched by the addition of DMF (0.915 mL, 11.8 mmol, 3 equiv.). The resulting 
mixture was allowed to warm to room temperature and then diluted with H2O. The 
aqueous phase was acidified with HCl (2 M) and extracted with Et2O (40 mL x 4) to 
remove non-basic impurities. The aqueous phase was then basified (pH >10) with 
NaOH (5 M) and extracted with Et2O (60 mL x 4). The combined Et2O extracts were 
washed with brine (50 mL), dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by silica gel column 
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crystalline solid. 1H NMR (CDCl3): δ = 1.50 (s, 6 H, 2 x CH3), 1.51 (s, 6 H, 2 x 
CH3), 7.29 (d, 1 H, J = 7.8 Hz, Ar-H), 7.68 (d, 1 H, J = 2.2 Hz, Ar-H), 7.80 (dd, 1 H, 
J = 7.8 Hz, 2.2 Hz, Ar-H), 10.03 (s, 1 H, O=CH). 
3.5.16. Synthesis of 5-Formyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 27 
 
A solution of mCPBA (1.483 g, 5.09 mmol, 1.1 equiv., 77%) in DCM (10 mL) was 
added dropwise to a solution of 5-formyl-1,1,3,3-tetramethylisoindoline 73 (1 g, 4.62 
mmol) in DCM (200 mL) at 0 oC. The reaction mixture was stirred for 2 h the 
resulting bright yellow solution was washed with dilute HCl (0.5 M, 20 mL), NaOH 
(2 M, 20 mL) and brine (20 mL) solutions and then dried over anhydrous Na2SO4. 
The filtrate was concentrated in vacuo and the residue purified by flash column 
chromatography (Hexane/EtOAc, 4:1) to give compound 27 as a bright yellow solid 
(928 mg, 92%). Mp. 138-140°C (Lit.,13 139-141°C).  
3.5.17. Synthesis of CTMIO 70 from 5-Formyl-TMIO 27 
 
NaOH (29.3 mg, 733 μmol, 4.0 equiv.) and AgNO3 (62.3 mg, 366.5 μmol, 2.0 
equiv.) were added to water (3 mL) and stirred at room temperature for 30 min. A 
solution of 5-formyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 27 (40 mg, 183.3 μmol, 
1 equiv.) in ethanol (1.5 mL) was added to the resulting mixture and the reaction 
mixture stirred for 6 h. The solution was acidified (pH < 2) by careful addition of 
HCl (2 M aqueous solution). The aqueous layer was extracted with Et2O (3 × 20 mL) 
and the combined ether layers were washed with brine (15 mL), dried with 
anhydrous Na2SO4 and the filtrate concentrated in vacuo and recrystallized from 
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3.5.18. Synthesis of N-Benzyl-1,1,3,3,5-pentamethylisoindoline 218 
 
A solution of N-benzyl-5-methylphthalimide 209 (55.834 g, 222.2 mmol, 1 equiv) in 
dry toluene (500 mL) was added slowly to a freshly prepared methylmagnesium 
iodide solution [formed from methyl iodide (83 mL, 1.33 mol, 6 equiv) and 
magnesium turnings (40 g, 1.55 mol, 7 equiv)] in dry Et2O. The Et2O was distilled 
off ether through a Dean Stalk and the reaction mixture refluxed at 110 oC for 4 h. 
The mixture was cooled to RT, filtered through Celite and washed several times with 
excess hexane. Air was bubbled through the filtrate overnight and the resulting 
residue filtered through a short basic alumina column (eluent:  Hexane) to separate 
product from the purple intractable material. Concentration in vacuo afforded 
compound N-benzyl-1,1,3,3,5-pentamethylisoindoline 218 as a white solid which 
was readily recrystallized from methanol or pentane (15.67 g, 34%).  Mp. 58-59 oC. 
HPLC purity (>95%). 1H NMR (400 MHz, CDCl3): = δ 1.30 (s, 6 H, CH3),1.31 (s, 6 
H, CH3), 2.39 (s, 3 H, C5-CH3), 4.00 (s, 2 H, CH2), 6.96 (s, 1H, C4-H), 7.06 (q, 2 H, 
J = 7.68, Ar-H), 7.20 - 7.25 (m, 1 H, Ar-H), 7.27 - 7.32 (m, 3 H, Ar-H), 7.48 (d, 2 H 
J = 7.37 Hz, Ar- H). 13C NMR (100 MHz, CDCl3): δ = 21.4 (Ar-CH3), 28.4 (CH3), 
28.5(CH3), 46.3 (CH2), 64.9 (Cquat), 65.1 (Cquat), 121.1 (Ar-C), 121.9 (Ar-C), 126.4-
128.3 (Ar-CH, 3 C), 136.4 (Ar-Cquat), 143.5 (Ar-Cquat’), 145.1 (Ar-Cquat).148.0 (Ar-
Cquat). HRMS (ES): m/z (%) = 180 (100, M+H), 269/71 (48/46) [M+2H]+. Calc. for 
C20H25N [M]+: 179.1980; found 179.1987. ATR-FTIR: υmax= 3290 (w, Ar C-H). 
3.5.19. Synthesis of 1,1,3,3,5-Pentamethylisoindoline 219 
 
A mixture of N-benzyl-1,1,3,3,5-pentamethylisoindoline 218 (5.0 g, 17.91 mmol, 1.0 
equiv.) and palladium (476 mg, 448 μmol, 0.025 equiv., 10 % on carbon) in glacial 
N Bn
NH
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acetic acid (120 mL) was shaken under hydrogen gas (50 psi) for 4 h. The reaction 
mixture was then filtered through Celite and concentrated in vacuo. The resulting 
residue was basified with NaOH (5 M, pH ≥12) and extracted with Et2O (60 mL x 
5). The combined Et2O extracts were washed with brine (50 mL), dried over 
anhydrous Na2SO4, filtered and concentrated in vacuo to afford white crystals of 
1,1,3,3,5-pentamethylisoindoline 219 (3.26 g, 96 %), which was used in subsequent 
reactions without further purification. Mp. 52 °C. 1H NMR (400 MHz, CDCl3): δ = 
1.43 (s, 6 H, CH3),1.44 (s, 6 H, CH3), 1.78 (s, NH) 2.37 (s, 3 H, CH3), 6.93 (s, 1 H, 
Ar-H), 7.01 (d, J = 7.6 Hz, 1 H, Ar-H), 7.06 (d, J = 7.6 Hz, 1 H, Ar-H) ppm. 13C 
NMR (100 MHz, CDCl3): δ = 21.3 (Ar-CH3), 31.9 (CCH3), 32.0 (CCH3), 62.5 
(CCH3), 62.6 (CCH3), 121.2 (Ar-C), 122.0 (Ar-C), 128.0 (Ar-C), 136.8 (Ar-C), 
146.0 (Ar-C), 149.0 (Ar-C) ppm. HRMS (ES): m/z (%) = 190 (25) [M + H]+; calcd. 
for C13H19N [M + H]+ 190.1596; found 190.1590. 
3.5.20. Synthesis of 1,1,3,3,5-Pentamethylisoindol-2-yloxyl 220 
 
m-Chloroperoxybenzoic acid (5.02 g, 17.21 mmol, 1.2 equiv., 77 %) was added to an 
ice-cooled solution of 1,1,3,3,5-pentamethylisoindoline 219 (2.72 g, 14.35 mmol, 1.0 
equiv.) in DCM (80 mL). The resulting solution was stirred for 1 h at 0 °C and then 
at RT for a further 2 h. Excess DCM was added to dissolve the precipitate that 
formed during the reaction. The bright-yellow organic phase was washed 
successively with aqueous HCl (0.5 M, 40 mL), NaOH (2 M, 40 mL x 3) and brine 
(50 mL) solutions, then dried over anhydrous Na2SO4 and filtered. The filtrate was 
concentrated in vacuo to give 1,1,3,3,5-pentamethylisoindol-2-yloxyl 220 as a bright-
yellow solid (2.78 g, 95 %). Mp. 90 °C. HPLC purity (>95%). HRMS (ES): m/z (%) 
= 227 (40) [M + Na]+; calcd. for C13H18NNaO [M + Na]+ 227.1286; found 227.1290. 
3.5.21. Synthesis of N-Acetoxy-1,1,3,3,5-pentamethyl isoindoline 221 
N O
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A mixture of 1,1,3,3,5-pentamethylisoindol-2-yloxyl 220 (1.0 g, 4.90 mmol, 1 
equiv.) and palladium (130 mg, 122 μmol, 0.025 equiv., 10 % on carbon) in dry THF 
(25 mL) was stirred under a balloon of hydrogen gas for 20 min. The reaction 
mixture was then cooled to 0 °C and Et3N (1.37 mL, 9.79 mmol, 2.0 equiv.) and 
AcCl (869 μL, 12.24 mmol, 2.5 equiv.) were added dropwise. The resulting solution 
was stirred at 0 °C for 30 min and then at RT for a further 1 h. The mixture was then 
filtered through Celite and concentrated in vacuo. The residue was dissolved in 
EtOAc (150 mL) and washed with brine (40 mL). The organic phase was dried with 
anhydrous Na2SO4 and filtered. The filtrate was concentrated in vacuo to give N-
acetoxy-1,1,3,3,5-pentamethylisoindoline 221 as a white solid (1.10 g, 91 %). Mp. 
113 °C. 1H NMR (400 MHz, CDCl3): δ = 1.38 (br. s, 6 H, 2 CH3), 1.47 (br. s, 6 H, 2 
CH3), 2.21 (s, 3 H, CH3), 2.39 (s, 3 H, CH3), 6.93 (s, 1 H, Ar-H), 7.00 (d, J = 8.0 Hz, 
1 H, Ar-H), 7.07 (d, J = 8.0 Hz, 1 H, Ar-H) ppm. 13C NMR (100 MHz, CDCl3): δ = 
19.3, 21.5, 25.4, 28.9, 68.0, 68.2, 121.3, 122.1, 128.5, 137.4, 141.0, 143.9, 171.9 
ppm. HRMS (ES): m/z (%) = 248 (95) [M + H]+; calcd. for C15H23NO2 [M + H]+ 
248.1651; found 248.1645. FTIR (ATR): max = 1758 (s, C=O) cm–1. 
3.5.22. Synthesis of 2-Acetoxy-1,1,3,3-tetramethylisoindoline-5-carboxylic Acid 
222 
 
A solution containing N-acetoxy-1,1,3,3,5-pentamethylisoindoline 221 (690 mg, 2.79 
mmol, 1.0 equiv.), MgSO4 (169 mg, 1.39 mmol, 0.5 equiv.) and a freshly prepared 
aqueous KMnO4 solution (27.6 mL, 11.16 mmol, 4.0 equiv., 0.4 M) was stirred at 70 
°C in tBuOH (15 mL) for 1 d. The reaction mixture was cooled to RT, treated with 
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the solvent removed in vacuo. The resulting residue was dissolved in EtOAc (200 
mL), washed brine (50 nL) and dried over anhydrous Na2SO4. The solution was 
filtered and the filtrate concentrated in vacuo. Purification of the resulting residue by 
silica gel flash chromatography (eluent: CHCl3 to CHCl3/EtOAc, 9:1) afforded 2-
acetoxy-1,1,3,3-tetramethylisoindoline-5-carboxylic Acid 222 as a pale-yellow solid 
(498 mg, 65 %). Mp.129 °C. 1H NMR (400 MHz, CDCl3): δ = 1.45 (br. s, 6 H, 2 
CH3), 1.54 (br. s, 6 H, 2 CH3), 2.23 (s, 3 H, CH3), 7.25 (d, J = 7.6 Hz, 1 H, Ar-H), 
7.91 (s, 1 H, Ar-H), 8.06 (d, J = 7.6 Hz, 1 H, Ar-H) ppm. 13C NMR (100 MHz, 
CDCl3): δ = 19.3 (C=OCH3), 25.2 (CCH3), 25.3 (CCH3), 28.7 (CCH3), 28.9 
(CCH3), 68.2 (CCH3), 68.4 (CCH3), 121.9 (Ar-C), 123.8 (Ar-C), 129.4 (Ar-C), 
130.4 (Ar-C), 144.6 (Ar-C), 150.2 (Ar-C), 171.5 (C=O), 171.7 (C=O) ppm. HRMS 
(ES): m/z (%) = 278 (89) [M + H]+; calcd. for C15H20NO4 [M + H]+ 278.1392; found 
278.1383. FTIR (ATR): max = 3400–2800 (br, m, O–H), 1771 (s, C=O), 1686 (s, 
C=O) cm–1. 
3.5.23. Synthesis of CTMIO 70 from 2-Acetoxy-1,1,3,3-tetramethylisoindoline-5-
carboxylic Acid 222 
 
2-Acetoxy-1,1,3,3-tetramethylisoindoline-5-carboxylic acid 222 (100 mg, 360 μmol) 
was stirred in a solution of NaOH (3 mL, 1 M) and EtOH (1 mL) at 0 °C for 30 min. 
The cooling bath was removed and the reaction was stirred at RT overnight. The 
aqueous layer was diluted with H2O (25 mL) and washed with Et2O (10 mL) and 
then acidified to pH 1 with HCl (2 M). The acidic aqueous layer was extracted with 
Et2O (4 × 30 mL) and the combined organic extracts washed with brine (30 mL), 
dried over anhydrous Na2SO4 and filtered. The filtrate was concentrated in vacuo 
and recrystallized from MeCN to give CTMIO 70 as a yellow solid (82 mg, 97 %). 
Mp. 211 °C (Lit.,14 214–218 °C). 
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m-Chloroperoxybenzoic acid (471 mg, 1.62 mmol, 1.5 equiv., 77%) was added to a 
solution of methyl 2-methoxy-5-methoxycarbonylmethyl-1,1,3,3-
tetramethylisoindoline 223 (300 mg, 1.08 mmol, 1 equiv.) in DCM (150 mL) at 0 oC. 
The reaction mixture was stirred for 30 min and then at RT for further 3.5 h. The 
resulting solution was washed with saturated NaHCO3 (30 mL x 2) and brine 
solutions and dried over anhydrous Na2SO4. The filtrate was concentrated in vacuo 
and the crude residue purified by flash column chromatography (Hexane/EtOAc, 4:1) 
to give 5-methoxycarbonylmethyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 224 as  
bright yellow solid (253 mg, 89%). Mp. 96-96.5 °C. HPLC purity (>95%).  HRMS 
(ES): m/z (%) = 263.1500 (100) [M + H]+, 264.1555 (30) [M + 2H]+; calcd. for 
C15H20NO3•: 262.1443; found 262.1426. ATR-FTIR: υmax= 2976 (m, Ar C-H), 1737 
(s, C=O), 1155 (s, C-O) cm-1. 
3.5.25. Synthesis of 5-Carboxymethyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 205 
 
NaOH (4 mL, 2 M) was added to a solution of 5-methoxycarbonylmethyl-1,1,3,3-
tetramethylisoindolin-2-yloxyl 224 (250 mg, 953 μmol, 1 equiv.) in MeOH (6 mL) 
and the resulting reaction mixture was stirred for 2 h at 60 oC. The reaction mixture 
was cooled to RT and diluted with H2O (30 mL). The aqueous layer was washed 
with Et2O (30 mL) and acidified (pH 1) with HCl (2 M). The aqueous layer was 
extracted with Et2O (60 mL x 3) and the combined organic extracts were washed 
with brine (40 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give 
5-carboxymethyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 205 as yellow solid (222 
mg, 94%). Mp. 123-124 °C. HPLC purity (>95%).  HRMS (ES): m/z (%) = 
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FTIR: υmax= 3000 (s, br, O-H), 2977 (m, Ar C-H), 1729 (s, C=O), 1144 (s, C-O) cm-
1. 
3.5.26. Synthesis of 2-(1-(4-Chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-
(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)acetamide 143 
 
A solution of indomethacin 163 (162 mg, 453 μmol, 1 equiv.), 5-amino-1,1,3,3-
tetramethylisoindolin-2-yloxyl 108 (102.24 mg, 498 μmol, 1.1 equiv.), EDC (95.5 
mg, 498 μmol, 1.1 equiv.), and DMAP (11 mg, 90.6 μmol, 0.2 equiv.) in DCM (10 
mL) was stirred under Ar overnight. The resulting reaction mixture was diluted 
(DCM, 150 mL), washed with HCl (1 M, 30 mL x 2) and brine (40 mL), then dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue 
was purified by silica gel column chromatography (Hexane/EtOAc, 3:1) and 
recrystallized from cyclohexane/EtOAc give 2-(1-(4-chlorobenzoyl)-5-methoxy-2-
methyl-1H-indol-3-yl)-N-(1,1,3,3-tetramethylisoindolin -2-yloxyl-5-yl)acetamide 
143 as light yellow crystals (228 mg, 92%). Mp. 164-166 oC. HPLC purity 
(>95%). 1H NMR (CDCl3, 400 MHz): δ = 2.49 (br, s, 3 H, CH3), 3.83 (br, s, 3 H, 
OCH3), 3.88 (br, s, 2 H, CH2), 6.74 (br, d, 1 H, J = 8.4 Hz, Ar-H), 6.9 (br, d, 1 H, J = 
8.4 Hz, Ar-H), 6.96 (br, s, 1 H, Ar-H), 7.51 (br, d, 2 H, J = 6 Hz, Ar-H), 7.7 (br, d, 2 
H, J = 6 Hz, Ar-H). HRMS (ES): m/z (%) = 567.1942 (100) [M + Na]+; calcd. for 
C31H31ClN3NaO4•: 567.1901; found 567.1942; calcd. for C31H31ClN3O4•: 544.2003; 
found 544.2010. ATR-FTIR: υmax= 3299 (w, N-H), 2973 (m, Ar C-H), 1677 (s, 
C=O), 1599 (C=O), 1313 (C-N), 1223 (C-O) cm-1.  
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A solution of indomethacin 163 (200 mg, 559 μmol, 1 equiv.), TEMPOL 102 (106 
mg, 615 μmol, 1.1 equiv.), EDC (118 mg, 615 μmol, 1.1 equiv.), and DMAP (14 mg, 
112 μmol, 0.2 equiv.) in DCM (10 mL) was stirred under Ar overnight.  The 
resulting reaction mixture was diluted (DCM, 150 mL), washed brine (40 mL), dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue 
was purified by silica gel column chromatography (Hexane/EtOAc, 3:1) to give 2-(1-
(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-(2,2,6,6-
tetramethylpiperidin-1-yloxyl-yl) acetate 226 as a pale orange solid (278 mg, 97%). 
Mp. 71-72 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 2.44 (br, s, 3 
H, CH3), 3.70 (br, s, 2 H, CH2), 3.86 (br, s, 3 H, OCH3), 6.69 (br, d, 1 H, J = 7.8 Hz, 
Ar-H), 6.87 (br, d, 1 H, J = 8.4 Hz, Ar-H), 6.99 (br, s, 1 H, Ar-H), 7.49 (br, d, 2 H, J 
= 6 Hz, Ar-H), 7.67 (br, d, 2 H, J = 6.6 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 
21.0 (CH3), 30.9 (CH2), 52.2 (OCH3), 117.3 (Ar-C), 117.31 (Ar-C), 120.0 (Ar-C), 
123.3 (Ar-C), 124.4 (Ar-C), 142.5 (Ar-C), 144.3 (Ar-C), 165.1 (Ar-C), 170.4 (C=O), 
207.0 (C=O). HRMS (ES): m/z (%) = 512.1929 (100) [M + H]+; calcd. for 
C28H32ClN2O5•: 511.2000; found 511.1925. ATR-FTIR: υmax= 2973 (m, Ar C-H), 
1732 (s, C=O), 1680 (C=O), 1314 (C-N), 1141 (C-O) cm-1. 
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A solution of indomethacin 163 (209 mg, 539 μmol, 1 equiv.), 5-amino-TEMPO 76 
(110 mg, 642 μmol, 1.1 equiv.), EDC (123 mg, 642 μmol, 1.1 equiv.), and DMAP 
(14.3 mg, 117 μmol, 0.2 equiv.) in DCM (10 mL) was stirred under Ar overnight.  
The resulting reaction mixture was diluted (DCM, 150 mL), washed with HCl (1 M, 
30 mL x 2) and brine (40 mL), then dried over anhydrous Na2SO4 and evaporated 
under reduced pressure. The crude residue was purified by silica gel column 
chromatography (Hexane/EtOAc, 3:1) and recrystallized from MeOH give reddish 
brown crystals of 2-(1-(4-chlorobenzoyl)-5-methoxy-2-methyl-1H-indol-3-yl)-N-
(2,2,6,6-tetramethylpiperidin-1-yloxyl-4-yl)acetamide 227 (259 mg, 87%). Mp. 199-
201 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 2.46 (br, s, 3 H, 
CH3), 3.7 (br, s, 2 H, CH2), 3.91 (br, s, 3 H, OCH3), 5.28 (br, s, 2 H, Ar-H), 6.69 (br, 
d, 2 H, Ar-H), 7.28 (br, s, 2 H, Ar-), 7.6 (br, d, 2 H, Ar-). HRMS (ES): m/z (%) = 
511.5199 (10) [M + H]+, 522.2062 (50) [M + Na]+; calcd. for C28H33ClN3O4•: 
510.2160; found 510.2158. ATR-FTIR: υmax= 1079 (w, N-H), 2973 (m, Ar C-H), 
1636 (s, C=O), 1555 (C=O), 1350 (C-N), 1111 (C-O) cm-1. 
3.5.29. General Procedure for the Synthesis of Salicylic Acid Derivatives 140, 228 
































Nitroxide-NSAID Conjugates: Design, Synthesis and Preliminary Biological Evaluation 
170  
A solution of aspirin 136 (150 mg, 833 μmol, 1 equiv.), appropriate nitroxide 76, 102 
or 108 (1 mmol, 1.2 equiv.), EDC (191.5 mg, 1 mmol, 1.2 equiv.), and DMAP (13 
mg, 104 μmol, 0.125 equiv.) in DCM (10 mL) was stirred under Ar for 1 d. The 
resulting reaction mixture was diluted (DCM, 150 mL), washed HCl (2 M, 30 mL) 
and brine (30 mL) solutions, dried over anhydrous Na2SO4 and evaporated under 
reduced pressure. The crude residue was purified by silica gel column 
chromatography (CHCl3) and then recrystallization from cyclohexane/EtOAc 
(except 228) to give the corresponding salicylate-nitroxide.  
Compound 140: Reddish brown solid (251 mg, 90%). Mp. 52-53 oC. HPLC purity 
(>95%).  HRMS (ES): m/z (%) = 335.1688 (10) [M + H]+; calcd. for C18H24NO5•: 
334.1654; found 334.1654. ATR-FTIR: υmax= 2977 (w, ArC-H), 1724 (s, C=O), 
1255 (s, C-O) cm-1. 
Compound 228: Reddish brown solid (153 mg, 55%). Mp. 50-52 oC. HPLC purity 
(>95%).  HRMS (ES): m/z (%) = 334.1850 (25) [M + H]+; calcd. for C18H25N2O4•: 
333.1814; found 333.1817. ATR-FTIR: υmax= 3314 (m, N-H), 2976 (w, ArC-H), 
1640 (s, C=O), 1546 (s, C=O), 1229 (s, C-O) cm-1. 
Compound 229: Yellow solid (162 mg, 53%). Mp. 101-102 oC. HPLC purity 
(>95%).  HRMS (ES): m/z (%) = 168.1689 (20) [M + H]+; calcd. for C21H23N2O4•: 
367.1658; found 367.1660. ATR-FTIR: υmax= 3340 (m, N-H), 2971 (w, ArC-H), 
1681 (s, C=O), 1543 (s, C=O), 1255 (s, C-O) cm-1. 
 
3.5.30. Synthesis of Benzyl 2-hydroxybenzoate 231 
 
NaHCO3 (1.46 g, 17.4 mmol, 1.2 equiv.) was added to a solution salicylic acid 135 
(2 g, 14.5 mmol, 1 equiv.) in DMF (20 mL) and the resulting mixture was stirred at 
70 oC for 10 min. The temperature was reduced to 50 oC followed by the addition of 
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for 4 h and then allowed to cool to RT. H2O (50 mL) was added and the crude 
product was extracted with EtOAc (60 mL x 4). The combined EtOAc extracts were 
washed with brine (50 mL), dried over anhydrous Na2SO4 and evaporated under 
reduced pressure. Purification of the crude residue by silica gel chromatography 
(Hexane/EtOAc, 5:0.2) afforded compound 231 as clear oil (3.11 g, 94%). HPLC 
purity (>99%). 1H NMR (CDCl3, 400 MHz): δ = 5.42 (s, 2 H, CH2), 6.9 (m, 1 H, 
Ar-H), 7.4 (m, 6 H, Ar-H), 7.91 (q, 1 H, Ar-H), 10.78 (s, 1 H, O-H). 13C NMR 
(CDCl3, 100 MHz): δ = 66.98 ( CH2), 112.4 (Ar-C), 117.6 (Ar-C), 119.2 (Ar-C), 
128.3 (Ar-C), 128.6 (Ar-C), 128.7 (Ar-C), 130.0 (Ar-C), 135.3 (Ar-C), 135.8 (Ar-C), 
161.8 (Ar-C), 170.0 (C=O). ATR-FTIR: υmax= 3188 (m, br, O-H), 3000 (m, Ar C-H), 
1670 (s, C=O), 1086 and 1133 (s, C-O) cm-1.28 
3.5.31. Synthesis of 2-(Benzyloxy)carbonyl)phenyl-2,2,5,5-tetramethylpyrrolidin-1-
yloxyl-3-carboxylate 232 
 
A solution of benzyl salicylate 231 (135 mg, 591 μmol, 1.1 equiv.), carboxy-
PROXYL 204 (100 mg, 537 μmol, 1 equiv.), EDC (113 mg, 591 μmol, 1.1 equiv.), 
and DMAP (14.4 mg, 118 μmol, 0.2 equiv.) in DCM (10 mL) was stirred under Ar 
for 1 day. The resulting reaction mixture was diluted (DCM, 100 mL), washed brine 
(40 mL), dried over anhydrous Na2SO4 and evaporated under reduced pressure. The 
crude residue was purified by silica gel column chromatography (Hexane/EtOAc, 
5:1) to give 2-(benzyloxycarbonyl)phenyl-2,2,5,5-tetramethylpyrrolidin-1-yloxyl-3-
carboxylate 232 as yellow oil (183 mg, 78%). HPLC purity (>95%). 1H NMR 
(CDCl3, 600 MHz): δ = 5.33 (s, br, 2 H, CH2), 6.9 (s, br, 1 H, Ar-H), 7.4 (br, m, 7 H, 
Ar-H), 7.62 (s, br, 1 H, Ar-H), 8.1 (d, br, 1 H, J = 7.6 Hz, Ar-H). HRMS (ES): m/z 
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ATR-FTIR: υmax= 2975 (w, ArC-H), 1761 (s, C=O), 1719 (s, C=O), 1251 (s, C-N), 
1134 and 1075 (s, C-O) cm-1. 
3.5.32. Synthesis of 2-(Benzyloxycarbonyl)phenyl-6-methoxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl-5-carboxylate 235 
 
A solution of benzyl salicylate 231 (60 mg, 262 μmol, 1.1 equiv.), 5-carboxy-6-
methoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 175 (63 mg, 238.4 μmol, 1 equiv.), 
EDC (50.3 mg, 262 μmol, 1.1 equiv.), and DMAP (6 mg, 48 μmol, 0.2 equiv.) in 
DCM (10 mL) was stirred under Ar for 1 day. The resulting reaction mixture was 
diluted (DCM, 100 mL), washed brine (40 mL), dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The crude residue was purified by silica gel 
column chromatography (Hexane/EtOAc, 5:1) and then recrystallization from 
cyclohexane/EtOAc to give 2-(benzyloxycarbonyl)phenyl-6-methoxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl-5-carboxylate 235 as a yellow solid (82 mg, 73%). 
Mp. 142-143 oC. HPLC purity (>95%). 1H NMR (CDCl3, 600 MHz): δ = 4.21 (br, s, 
3 H, OCH3), 5.27 (s, br, 2 H, CH2), 7.27 (s, br, 2 H, Ar-H), 7.4 (br, m, 2 H, Ar-H), 
7.62 (s, br, 1 H, Ar-H), 8.11 (d, br, 1 H, J = 7.8 Hz, Ar-H). HRMS (ES): m/z (%) = 
497.1806 (40) [M + Na]+; calcd. for C28H28NO6•: 474.1917; found 474.1920. ATR-
FTIR: υmax= 2979 (w, ArC-H), 1748 (s, C=O), 1718 (s, C=O), 1294 (s, C-N), 1192 
(s, C-O) cm-1. 
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A solution of benzyl salicylate 231 (63 mg, 275 μmol, 1.1 equiv.), carboxy-TEMPO 
8 (50 mg, 250 μmol, 1 equiv.), EDC (53 mg, 275 μmol, 1.1 equiv.), and DMAP (6 
mg, 50 μmol, 0.2 equiv.) in DCM (8 mL) was stirred under Ar for 1 day. The 
resulting reaction mixture was diluted (DCM, 100 mL), washed brine (40 mL), dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue 
was purified by silica gel column chromatography (Hexane/EtOAc, 5:1) and then 
recrystallization from cyclohexane to give 2-(benzyloxycarbonyl)phenyl-2,2,6,6-
tetramethylpiperidin-1-yloxyl-4-carboxylate 233 as a light reddish-brown fluffy solid  
(73 mg, 71%). Mp. 112-113 oC. HPLC purity (>95%). 1H NMR (CDCl3, 600 MHz): 
δ = 5.34 (s, br, 2 H, CH2), 7.1 (d, br, 1 H, Ar-H), 7.34 (br, m, 7 H, Ar-H), 7.6 (s, br, 1 
H, Ar-H), 8.1 (d, br, 1 H, J = 7.2 Hz, Ar-H). HRMS (ES): m/z (%) = 412.2126 (30) 
[M + 2H]+, 433.1872 [M + Na]+, 449.2757 [M + K]+; calcd. for C24H28NO5•: 
410.1967; found 410.1967. ATR-FTIR: υmax= 2981 (w, ArC-H), 1745 (s, C=O), 
1722 (s, C=O), 1257 (s, C-N), 1085 (s, C-O) cm-1. 
3.5.34. Synthesis of 2-(Benzyloxycarbonyl)phenyl-1,1,3,3-tetramethylisoindolin-2-
yloxyl-5-carboxylate 234 
 
A solution of benzyl salicylate 231 (70 mg, 305.4 μmol, 1.1 equiv.), CTMIO 70 (65 
mg, 278 μmol, 1 equiv.), EDC (59 mg, 305.4 μmol, 1.1 equiv.), and DMAP (7 mg, 
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reaction mixture was diluted (DCM, 100 mL), washed brine (40 mL), dried over 
anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue was 
purified by silica gel column chromatography (Hexane/EtOAc, 5:1) and then 
recrystallization from cyclohexane/EtOAc to give 2-(benzyloxycarbonyl)phenyl-
1,1,3,3-tetramethylisoindolin-2-yloxyl-5-carboxylate 234 as a yellow crystalline 
solid (90 mg, 72%). Mp. 97-98 oC. HPLC purity (>95%). 1H NMR (CDCl3, 600 
MHz): δ = 5.25 (s, br, 2 H, CH2), 7.26 (s, br, 7 H, Ar-H), 7.42 (br, s, 1 H, Ar-H), 
7.66 (s, br, 1 H, Ar-H), 8.17 (d, br, 1 H, J = 7.2 Hz, Ar-H). HRMS (ES): m/z (%) = 
446.1880 (20) [M + 2H]+; calcd. for C27H26NO5•: 444.1811; found 444.1813. ATR-
FTIR: υmax= 3038 (w, ArC-H), 1744 (s, C=O), 1705 (s, C=O), 1290 (s, C-N), 1192 
(s, C-O) cm-1. 
3.5.35. General Procedure for the Synthesis of Carboxylic Acid Nitroxides (144, 
236 and 237) via Debenzylation of Benzyl Benzoates 232-234 
 
A solution of benzyl benzoate nitroxide 232-234 (377 µmol, 1 equiv.) in MeOH (10 
mL) was hydrogenated at 30 psi over 10% Pd/C for 4 h in a Parr Hydrogenator. The 
solution was filtered through Celite and the filtrate stirred over PbO2 (94.25 μmol, 
0.25 equiv.) for 20 min. The solution was filtered and concentrated under reduced 
pressure. The crude residue was purified by purified by silica gel column 
chromatography (EtOAc and 0.2% AcOH) and then recrystallization from 
H2O/MeOH to give the corresponding carboxylic acid nitroxide (144, 236 and 237). 
2-((2,2,5,5-Tetramethylpyrrolidin-1-yloxyl-3-carbonyl)oxy)benzoic acid 144 from 
232: yellow crystalline solid (57 mg, 49%). Mp. 161-162 oC. HPLC purity 
(>95%). 1H NMR (CDCl3, 600 MHz): δ = 7.18 (s, br, 1 H, Ar-H), 7.4 (br, s, 1 H, 
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307.1377 (15) [M + H]+; calcd. for C16H20NO5•: 306.1341; found 306.1341. ATR-
FTIR: υmax= 3500-2400 (m, br, O-H), 2976 (w, ArC-H), 1766 (s, C=O), 1713 (s, 
C=O), 1204 (s, C-N), 1126 (s, C-O) cm-1. 
2-((2,2,6,6-Tetramethylpiperidin-1-yloxyl-4-carbonyl)oxy)benzoic acid 236 from 
233: light reddish-brown solid (56 mg, 46%). Mp. 149 oC (dec.). HPLC purity 
(>95%). 1H NMR (CDCl3, 600 MHz): δ = 7.17 (s, br, 1 H, Ar-H), 7.4 (s, br, 1 H, 
Ar-H), 7.67 (s, br, 1 H, Ar-H), 8.1 (s, br, 1 H, Ar-H). HRMS (ES): m/z (%) = 
321.1532 (100) [M + H]+; calcd. for C17H22NO5•: 320.1498; found 320.1499. ATR-
FTIR: υmax= 3500-2400 (m, br, O-H), 1755 (s, C=O), 1716 (s, C=O), 1241 (s, C-N), 
1145 (s, C-O) cm-1. 
2-((1,1,3,3-Tetramethylisoindolin-2yloxyl-5-carbonyl)oxy)benzoic acid 237 from 
234: yellow crystalline solid (55 mg, 41%). Mp. 193 oC (dec.). HPLC purity 
(>95%).1H NMR (CDCl3, 600 MHz): δ =  7.27 (s, br, 1 H, Ar-H), 7.41 (s, br, 1 H, 
Ar-H), 7.68 (s, br, 1 H, Ar-H), 8.12 (s, br, 1 H, Ar-H). HRMS (ES): m/z (%) = 
356.1409 (30) [M + 2H]+; calcd. for C20H20NO5•: 354.1341; found 354.1341. ATR-
FTIR: υmax= 3350-2400 (m, br, O-H), 1734 (s, C=O), 1688 (s, C=O), 1288 (s, C-N), 
1196 (s, C-O) cm-1. 
3.5.36. General Procedure for the Synthesis of Formyl-Nitroxides 239-241 
 
A solution of salicylaldehyde 238 (1.31 mmol, 1.05 equiv.), appropriate carboxy-
nitroxide 8, 70 and 204 (1.25 mmol, 1 equiv.), EDC (1.37 mmol, 1.1 equiv.), and 
DMAP (156 μmol, 0.125 equiv.) in DCM (10 mL) was stirred under Ar overnight. 
The resulting reaction mixture was diluted (DCM, 100 mL), washed brine (40 mL), 
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residue was purified by silica gel column chromatography (CHCl3 or 
Hexane/EtOAc, 3:1) and then recrystallization from cyclohexane/EtOAc to give the 
corresponding formyl-o-nitroxides (239-241).  
2-Formylphenyl 2,2,5,5-tetramethylpyrrolidin-1-yloxyl-3-carboxylate 239: yellow 
crystalline solid (319 mg, 88%). HPLC purity (>95%). 1H NMR (CDCl3, 600 MHz): 
δ = 7.19 (s, br, 1 H, Ar-H), 7.47 (d, br, 1 H, Ar-H), 7.7 (s, br, 1 H, Ar-H), 7.9 (s, br, 1 
H, Ar-H), 10.1 (s, br, HC=O). HRMS (ES): m/z (%) = 291.1428 (30) [M + H]+; 
calcd. for C16H20NO4•: 290.1392; found 290.1395. ATR-FTIR: υmax= 3350-2400 (m, 
br, O-H), 1734 (s, C=O), 1688 (s, C=O), 1288 (s, C-N), 1196 (s, C-O) cm-1. 
2-Formylphenyl 2,2,6,6-tetramethylpiperidin-1-yloxyl-4-carboxylate 240: light 
reddish-brown, fluffy crystals (327 mg, 86%). Mp. 94-95 oC. HPLC purity 
(>95%). 1H NMR (CDCl3, 600 MHz): δ = 7.18 (s, br, 1 H, Ar-H), 7.47 (d, br, 1 H, 
Ar-H), 7.69 (s, br, 1 H, Ar-H), 7.91 (d, br, 1 H, J = 7.2 Hz, Ar-H), 10.1 (s, br, 
HC=O). HRMS (ES): m/z (%) = 327.1442 (100) [M + Na]+; calcd. for C17H22NO4•: 
304.1549; found 304.1550. ATR-FTIR: υmax= 3079 (m, ArC-H), 1745 (s, C=O), 
1699 (s, C=O), 1230 (s, C-N), 1154 (s, C-O) cm-1. 
2-Formylphenyl 1,1,3,3-tetramethylisoindolin-2-yloxyl-5-carboxylate 241: yellow 
crystalline solid (372 mg, 88%). Mp. 151-152 oC. HPLC purity (>95%). 1H NMR 
(CDCl3, 600 MHz): δ = 7.34 (d, br, 1 H, J = 7.2 Hz, Ar-H), 7.49 (t, br, 1 H, J = 7.2 
Hz, Ar-H), 7.72 (t, br, 1 H, Ar-H), 7.98 (d, br, 1 H, J = 7.2 Hz, Ar-H), 10.21 (s, br, 
HC=O). HRMS (ES): m/z (%) = 361.1292 (50) [M + Na]+; calcd. for C20H20NO4•: 
338.1392; found 338.1391. ATR-FTIR: υmax= 2978 (m, ArC-H), 1749 (s, C=O), 
1708 (s, C=O), 1234 (s, C-N), 1197 (s, C-O) cm-1. 
3.5.37. General Procedure for the Oxidation of Formyl Nitroxides 239-241 to the 
Corresponding Carboxylic Acids 144, 236 and 237 
Method A 
KH2PO4 (48.3 mg, 355 µmol, 2 equiv. in 0.5 mL H2O) and H2O2 (30 µL, 355 µmol, 
1.5 equiv. 30% in H2O) were added to a solution of appropriate formyl nitroxide 
239-241 (177.3 µmol, 1 equiv.) in MeCN (5 mL) at 0 oC. NaClO2 (40.3 mg, 356 
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µmol, 2 equiv. in 0.5 mL H2O) was then added dropwise and the resulting solution 
stirred for 2 h. The reaction mixture was diluted with H2O and the aqueous layer 
extracted with DCM (30 mL x 3). The DCM extract was washed with brine, dried 
over anhydrous Na2SO4 and evaporated under reduced pressure. The crude residue 
was purified by silica gel column chromatography (EtOAc/0.01%AcOH) and then 
recrystallization from H2O/MeOH to give the corresponding carboxylic acid 
nitroxide (144, 236 and 237). 
2-((2,2,5,5-Tetramethylpyrrolidin-1-yloxyl-3-carbonyl)oxy)benzoic acid 144 from 
239: yellow crystalline solid (319 mg, 88%). Mp. 161-162 oC. HPLC purity 
(>95%). 1H NMR (CDCl3, 600 MHz): δ = 7.18 (s, br, 1 H, Ar-H), 7.7.4 (br, s, 1 H, 
Ar-H), 7.66 (s, br, 1 H, Ar-H), 8.1 (d, br, 1 H, Ar-H). HRMS (ES): m/z (%) = 
307.1377 (15) [M + H]+; calcd. for C16H20NO5•: 306.1341; found 306.1341. ATR-
FTIR: υmax= 3500-2400 (m, br, O-H), 2976 (w, ArC-H), 1766 (s, C=O), 1713 (s, 
C=O), 1204 (s, C-N), 1126 (s, C-O) cm-1. 
2-((2,2,6,6-Tetramethylpiperidin-1-yloxyl-4-carbonyl)oxy)benzoic acid 236 from 
240: light reddish-brown, fluffy crystals (327 mg, 86%). Mp. 149 oC (dec.). HPLC 
purity (>95%).  1H NMR (CDCl3, 600 MHz): δ = 7.17 (s, br, 1 H, Ar-H), 7.4 (s, br, 
1 H, Ar-H), 7.67 (s, br, 1 H, Ar-H), 8.1 (s, br, 1 H, Ar-H). HRMS (ES): m/z (%) = 
321.1532 (100) [M + H]+; calcd. for C17H22NO5•: 320.1498; found 320.1499.  ATR-
FTIR: υmax= 3500-2400 (m, br, O-H), 1755 (s, C=O), 1716 (s, C=O), 1241 (s, C-N), 
1145 (s, C-O) cm-1. 
2-((1,3,3-Tetramethylisoindolin-2-yloxyl-5-carbonyl)oxy)benzoic acid 237 from 
241: yellow crystalline solid (372 mg, 88%). Mp. 193 oC (dec.). HPLC purity 
(>95%). 1H NMR (CDCl3, 600 MHz): δ =  7.27 (s, br, 1 H, Ar-H), 7.41 (s, br, 1 H, 
Ar-H), 7.68 (s, br, 1 H, Ar-H), 8.12 (s, br, 1 H, Ar-H). HRMS (ES): m/z (%) = 
356.1409 (30) [M + 2H]+; calcd. for C20H20NO5•: 354.1341; found 354.1341. ATR-
FTIR: υmax= 3350-2400 (m, br, O-H), 1734 (s, C=O), 1688 (s, C=O), 1288 (s, C-N), 
1196 (s, C-O) cm-1. 
Method B 
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KMnO4 (56 mg, 355 µmol, 2 equiv.) was added to a solution of appropriate formyl 
nitroxide 239-241 (177.3 µmol, 1 equiv.) in acetone (5 mL) at 0 oC under Ar. The 
reaction mixture was stirred for 2 h, followed by the addition of dilute H2SO4 (0.5 
M). The aqueous layer was extracted with DCM and the combined DCM extracts 
washed with brine, dried over anhydrous Na2SO4 and evaporated under reduced 
pressure. The crude residue was recrystallization from H2O/MeOH to give the 
corresponding carboxylic acid nitroxide (144 (86%), 236 (85%) and 237 (85%). 
3.5.38. Synthesis of Methyl 2-acetoxy-5-nitrobenzoate 233 
 
A suspension of methyl 2-hydroxy-5-nitrobenzoate 246 (650 mg, 3.3 mmol, 1 equiv.) 
in THF (15 mL) under Ar was cooled to 0 °C. TEA (1.15 mL, 8.24 mmol, 2.5 equiv.) 
and then AcCl (459 µL, 6.59 mmol, 2 equiv.) were added dropwise and the resulting 
mixture stirred for 2 h. The reaction mixture was diluted with H2O and the aqueous 
layer extracted with DCM (60 mL x 4). The combined DCM extracts were washed 
brine (50 mL) and dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The crude residue was purified by silica gel column chromatography 
(CHCl3/Hexane, 1:1) and then recrystallization from cyclohexane to give methyl 2-
acetoxy-5-nitrobenzoate 247 as a white crystalline solid (91%). Mp. 75-76 oC (Lit.,37 
73-74 oC). 1H NMR (CDCl3, 400 MHz): δ = 2.4 (s, 3 H, C=OCH3), 3.94 (s, 3 H, 
OCH3), 7.3 (d, 1 H, J = 8.4 Hz, Ar-H), 8.42 (dd, 1 H, J = 8.4 Hz, 2.8 Hz, Ar-H), 8.9 
(d, 1 H, J = 2.8 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 20.9 ( C=OCH3), 52.8 
(OCH3), 124.4 (Ar-C), 125.3 (Ar-C), 127.4 (Ar-C), 128.5 (Ar-C), 145.3 (Ar-C), 
155.3 (Ar-C), 163.0 (C=O), 168.8 (C=O). ATR-FTIR: υmax= 3102 (w, Ar C-H), 1759 
(s, C=O), 1727 (s, C=O), 1529 (s, NO2), 1190 (s, C-O) cm-1. 
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A solution of methyl 2-acetoxy-5-nitrobenzoate 247 (500 mg, 2.09 mmol, 1 equiv.) 
in EtOAc (20 mL) was hydrogenated at 50 psi over 10% Pd/C (50 mg) for 4 h in a 
Parr Hydrogenator. The resulting solution was filtered through Celite and the filtrate 
was concentrated under reduced pressure. Methyl 2-acetoxy-5-aminobenzoate 248 
was obtained as a light brown solid (394 mg, 90%) and was used in the next step 
without further purification but readily recrystallizes from cyclohexane/EtOAc. Mp. 
107 oC (dec.), (Lit.,37 103-105 oC). HPLC purity (>95%). 1H NMR (CDCl3, 400 
MHz): δ = 2.31 (s, 3 H, C=OCH3), 3.74 (s, 2 H, NH2), 3.84 (s, 3 H, OCH3), 6.82 
(dd, 1 H, J = 8.4 Hz, 3 Hz,  Ar-H), 6.88 (d, 1 H, J = 8.4 Hz, Ar-H), 7.28 (d, 1 H, J = 
3 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 21.0 (C=OCH3), 52.2 (OCH3), 117.5 
(Ar-C), 120.0 (Ar-C), 123.3 (Ar-C), 124.4 (Ar-C), 142.5 (Ar-C), 144.4 (Ar-C), 165.1 
(C=O), 170.4 (C=O).  
3.5.40. General Procedure for the Synthesis of Methyl Benzoate Amide Conjugates 
145, 146, 249-253 
 
A solution of methyl 2-acetoxy-5-aminobenzoate 248 (124 mg, 591 µmol, 1.1 
equiv.), appropriate carboxylic acid 8, 70, 204-206, 258 or 259 (537 µmol, 1 equiv.), 
EDC (123.5 mg, 599 µmol, 1.2 equiv.), and DMAP (8.2 mg, 67 μmol, 0.125 equiv.) 
in DCM (10 mL) was stirred under Ar overnight. The resulting reaction mixture was 
diluted (DCM, 100 mL), washed brine (40 mL), dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The crude residue was purified by silica gel 
column chromatography (CHCl3 or Hexane/EtOAc, 3:1) to give the corresponding 

















Beige solid (206.3 mg, 87%). Mp. 123-124 oC. HPLC purity (>95%). 1H NMR 
(CDCl3, 600 MHz): δ = 1.58 (s, 3 H, CH3), 1.96 (m, 1 H, CH2), 2.21 (s, 3 H, CH3), 
2.27 (s, 3 H, CH3), 2.33 (s, 3 H, CH3), 2.4 (s, 3 H, CH3), 2.42 (m, 1 H, CH2), 2.65 
(m, 2 H, CH2), 3.86 (s, 3 H, OCH3), 4.32 (s, 1 H, NH), 7.05 (d, 1 H, J = 9 Hz, Ar-H), 
7.75 (dd, 1 H, J = 9 Hz, 3 Hz, Ar-H), 8.08 (d, 1 H, J = 3 Hz, Ar-H), 8.38 (s, 1 H, 
OH). 13C NMR (CDCl3, 100 MHz): δ = 11.3 (CH3), 12.1 (CH3), 12.3 (CH3), 20.4 
(CH3), 20.9 (CH3), 24.2 (CH2), 29.5 (CH2), 52.4 (OCH3),  118.0 (Ar-C), 119.1 (Ar-
C), 121.6 (Ar-C), 121.9 (Ar-C), 122.4 (Ar-C), 123.5 (Ar-C), 124.4 (Ar-C), 124.8 
(Ar-C), 135.3 (Ar-C), 143.9 (Ar-C), 146.0 (Ar-C), 146.8 (Ar-C), 164.5 (C=O), 169.8 
(C=O), 172.9 (C=O). HRMS (ES): m/z (%) = 442.1789 (35) [M + H]+; calcd. for 
C24H27NO7: 441.1788; found 441.1788. ATR-FTIR: υmax= 3478 (m, O-H), 3364 (m, 
N-H), 2929 (m, ArC-H), 1762, 1728 (s, C=O), 1671 (s, C=O), 1531 (s, C=O), 1184 
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Beige solid (233.5 mg, 93%). Mp. 181-182 oC. HPLC purity (>95%). 1H NMR 
(CDCl3, 400 MHz): δ = 1.48 (s, 18 H, C(CH3)3), 2.36 (s, 3 H, CH3), 3.86 (s, 3 H, 
OCH3), 5.52 (s, 1 H, NH), 6.35 (d, 1 H, J = 15.6 Hz, CH=CH), 7.07 (d, 1 H, J = 7.8 
Hz, Ar-H), 7.41 (d, 3 H, Ar-H), 7.72 (d, 1 H, J = 15.6 Hz, CH=CH), 7.96 (d, 1 H, J = 
7.8 Hz, Ar-H), 8.13 (s, 1 H, OH). 13C NMR (CDCl3, 100 MHz): δ = 21 (CH3), 30.12 
(C(CH3)3), 34.36 (C(CH3)3), 52.3 (OCH3),  116.83 (Ar-C), 122.65 (Ar-C), 123.2 
(Ar-C), 124.3 (Ar-C), 125.16 (Ar-C), 125.41 (CH=CH), 125.8 (Ar-C), 136.28 (Ar-
C), 136.38 (CH=CH), 144.02 (Ar-C), 146.5 (Ar-C), 156.07 (Ar-C), 164.5 (C=O), 
164.57 (C=O), 170.23 (C=O). HRMS (ES): m/z (%) = 468.2339 (100) [M + H]+; 
calcd. for C27H33NO6: 467.2308; found 467.2308. ATR-FTIR: υmax= 3623 (m, br, 
O-H), 3305 (m, br, N-H), 2954 (m, ArC-H), 1726 (s, C=O), 1621 (s, C=O), 1540 (s, 




Yellow solid (170 mg, 84%). Mp. 69-70 oC. HPLC purity (>95%). 1H NMR 
(CDCl3, 600 MHz): δ = 2.37 (s, 3 H, C=OCH3), 3.89 (s, 3 H, OCH3), 7.12 (br, s, 1 
H, Ar-H), 7.84 (br, s, 1 H, Ar-H), 8.04 (br, s, 1 H, Ar-H). HRMS (ES): m/z (%) = 
378.1744 (30) [M + H]+; calcd. for C19H25N2O6•: 377.1713; found 377.1711. ATR-
FTIR: υmax= 3330 (m, N-H), 2975 (m, ArC-H), 1768 (s, C=O), 1726 (s, C=O), 1540 
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Light reddish-brown solid (156 mg, 74%). Mp. 205 oC (dec.). HPLC purity 
(>95%). 1H NMR (CDCl3, 600 MHz): δ = 2.39 (s, 3 H, C=OCH3), 3.85 (s, 3 H, 
OCH3), 7.28 (br, dd, 1 H, Ar-H), 7.73 (br, d, 1 H, Ar-H), 8.14 (br, d, 1 H, Ar-H). 
HRMS (ES): m/z (%) = 392.1927 (15) [M + H]+, 414.1760 (100) [M + Na]+; calcd. 
for C20H27N2O6•: 391.1869; found 391.1871. ATR-FTIR: υmax= 3339 (m, N-H), 
2977 (m, ArC-H), 1765, 1727 (s, C=O), 1691 (s, C=O), 1548 (s, C=O), 1176 (s, C-




Yellow solid (224.2 mg, 95%). Mp. 215 PoPC (dec.). HPLC purity (>95%). P1 PH NMR 
(CDClR3R, 600 MHz): δ = 2.34 (s, 3 H, C=OCH R3R), 3.85 (s, 3 H, OCHR3R), 4.21 (br, s, 2 
H, CHR2R), 7.7.09 (br, s, 1 H, Ar-H), 7.86 (br, s, 1 H, Ar-H), 7.95 (br, s, 1 H, Ar-H). 
HRMS (ES): m/z (%) = 440.1939 (30) [M + H]P+ P; calcd. for CR24RH R27RNR2RO R6RP•P: 439.1869; 
found 439.1869. ATR-FTIR: υRmaxR= 3273 (m, N-H), 2976 (m, ArC-H), 1760, 1729 (s, 
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Yellow solid (190 mg, 83%). Mp. 122-124 oC. HPLC purity (>95%). 1H NMR 
(CDCl3, 600 MHz): δ = 2.3 (s, 3 H, C=OCH3), 3.79 (s, 3 H, OCH3), 7.05 (br, s, 1 H, 
Ar-H), 7.92 (br, s, 1 H, Ar-H), 8.09 (br, s, 1 H, Ar-H). 13C NMR (CDCl3, 100 MHz): 
δ = 21.3 (C=OCH3), 52.6 (OCH3), 123.52 (Ar-C), 124.7 (Ar-C), 135.5 (Ar-C), 147.2 
(Ar-C), 164.8 (C=O), 170.1 (C=O). HRMS (ES): m/z (%) = 426.1794 (10) [M + H]+, 
148.1606 (100) [M + Na]+; calcd. for C23H25N2O6•: 425.1713; found 425.1716. 
ATR-FTIR: υmax= 3376 (m, N-H), 2980 (m, ArC-H), 1735, 1725 (s, C=O), 1664 (s, 




Yellow solid (209.5 mg, 81%). Mp. 122-124 oC. HPLC purity (>95%). 1H NMR 
(CDCl3, 600 MHz): δ = 2.41 (s, 3 H, C=OCH3), 3.91 (s, 3 H, OCH3), 7.17 (br, s, 1 
H, Ar-H), 8.05 (br, s, 1 H, Ar-H), 8.22 (br, s, 1 H, Ar-H). 13C NMR (CDCl3, 100 
MHz): δ = 21.15 (C=OCH3), 52.49 (OCH3), 123.5 (Ar-C), 124 (Ar-C), 135.67 (Ar-
C), 147.13 (Ar-C), 164.48 (C=O), 170.07 (C=O). HRMS (ES): m/z (%) = 481.2410 
(20) [M + H]+; calcd. for C27H33N2O6•: 481.2339; found 481.2341. ATR-FTIR: 
υmax= 3369 (m, N-H), 2971 (m, ArC-H), 1743, 1719 (s, C=O), 1675 (s, C=O), 1534 
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3.5.41. General Procedure for the Hydrolysis of Methyl Benzoate Amide 
Conjugates 249-253 
 
A solution of NaOH (3 mL, 1 M) was added to a solution of appropriate amide (235-
239) in THF (5 mL) and the reaction mixture was stirred at RT overnight. THF was 
removed under pressure and the aqueous layer washed with DCM, then cooled in 
ice/H2O bath and acidified (to pH 1) with HCl (2 M). The precipitate formed was 
isolated by filtration and purified by recrystallization from H2O/MeOH to give the 
corresponding salicylic acid derivative (141, 254-257). 
2-Hydroxy-5-(1,1,3,3-tetraethylisoindolin-2-yloxyl-5-carboxamido)benzoic acid 141 
 
Yellow solid (209.5 mg, 81%). Mp. 208 oC (dec.). HPLC purity (>95%). HRMS 
(ES): m/z (%) = 426.2091 (45) [M + H]+; calcd. for C24H29N2O5•: 425.2076; found 
425.2081. ATR-FTIR: υmax= 3295 (m, br, O-H), 2968 (m, ArC-H), 1686, 1637 (s, 
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Yellow solid (170 mg, 84%). Mp. 171 oC (dec.). HPLC purity (>95%). HRMS (ES): 
m/z (%) = 321.1452 (20) [M], 322.1510 (20) [M + H]+, 323.1590 (100) [M + 2H]+; 
calcd. for C16H21N2O5•: 321.1450; found 321.1452. ATR-FTIR: υmax= 3200 (m, br, 




Light reddish-brown solid (156 mg, 74%). HPLC purity (>95%). HRMS (ES): m/z 
(%) = 336.1729 (15) [M + H]+, 337.1753 (100) [M + 2H]+; calcd. for C17H23N2O5•: 
335.1607; found 335.1607. ATR-FTIR: υmax= 3200 (m, br, O-H), 3921 (m, ArC-H), 




Yellow solid (224.2 mg, 95%). Mp. 115 oC (dec.). HPLC purity (>95%). HRMS 
(ES): m/z (%) = 385.1834 (20) [M + 2H]+; calcd. for C21H23N2O5•: 383.1607; found 
383.1611. ATR-FTIR: υmax= 3263 (m, br, O-H), 2923 (m, ArC-H), 1674, 1647 (s, 
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Yellow solid (190 mg, 83%). Mp. 207 oC (dec.). HPLC purity (>95%). HRMS (ES): 
m/z (%) = 392.3146 (100) [M + Na]+; calcd. for C20H21N2O5•: 369.1450; found 
369.1460. ATR-FTIR: υmax= 3100 (m, br, O-H), 2954 (m, ArC-H), 1676, 1644 (s, 
C=O), 1565 (s, C=O), 1187 (s, C-O) cm-1. 
3.5.42. Synthesis of Methyl 2-acetoxy-5-(2-(4-methoxyphenyl acetamido)benzoate 
264 
 
A solution of methyl 2-acetoxy-5-aminobenzoate 248 (124 mg, 591 µmol, 1.1 
equiv.), 2-(4-methoxyphenyl)acetic acid 265 (89 mg, 537 µmol, 1 quiv.), EDC 
(123.5 mg, 599 µmol, 1.2 equiv.), and DMAP (8.2 mg, 67 μmol, 0.125 equiv.) in 
DCM (10 mL) was stirred under Ar overnight.  The resulting reaction mixture was 
diluted (DCM, 100 mL), washed brine (40 mL), dried over anhydrous Na2SO4 and 
evaporated under reduced pressure. The crude residue was purified by silica gel 
column chromatography (CHCl3 or Hexane/EtOAc, 3:1) to give methyl 2-acetoxy-5-
(N-(4-methoxyphenylacetamide))benzoate ester 264 as a white solid (155, 81%). Mp. 
49-51 oC. 1H NMR (CDCl3, 400 MHz): δ = 2.32 (s, 3 H, C=OCH3), 3.69 (s, 2 H, 
CH2), 3.839 (s, 3 H, OCH3), 3.84 (s, 3 H, OCH3), 6.95 (d, 2 H, J = 8.4 Hz, Ar-H), 
7.02 (d, 1 H, J = 9 Hz, Ar-H), 7.13 (s, 1 H, NH), 7.24 (d, 2 H, J = 8.4 Hz, Ar-H), 
7.84 (m, 2 H, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 20.9 (C=OCH3), 34.9 (CH2), 
52.3 (OCH3), 55.2 (OCH3), 114.8 (Ar-C), 122.4 (Ar-C), 123.3 (Ar-C), 124.4 (Ar-C), 
125.1 (Ar-C), 125.9 (Ar-C), 130.7 (Ar-C), 135.6 (Ar-C), 146.7 (Ar-C), 159.3 (Ar-C), 
164.5 (C=O), 169.6 (C=O), 169.8 (C=O). HRMS (ES): m/z (%) = 358.1286 (30) [M 
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ATR-FTIR: υmax= 3371 (m, N-H), 2934 (w, Ar C-H), 1718 (s, C=O), 1698 (s, C=O), 
1540 (s, C=O), 1296 (s, C-N), 1191 (s, C-O) cm-1. 
3.5.43. Synthesis of Methyl 2-acetoxy-5-((4-methoxyphenethyl) amino)benzoate 
266 
 
Anhydrous acetic acid (40 µL, 700 µmol, 5 equiv.) was added dropwise to a 
suspension of NaBH4 (27 mg, 707 µmol, 5.05 equiv.) and methyl 2-acetoxy-5-(2-(4-
methoxyphenylacetamido)benzoate 264 (50 mg, 140 µmol, 1 equiv.) in dry dioxane 
(3 mL). The resulting reaction mixture was refluxed for 25 min and then allowed to 
return to RT. H2O was added and the resulting aqueous solution was extracted with 
EtOAc (30 mL x 4). The combined organic layer was washed with brine (30 mL), 
dried over anhydrous Na2SO4, and concentrated in vacuo. The crude product was 
purified silica gel column chromatography (Hexane/EtOAc, 3:1) to give methyl 2-
acetoxy-5-((4-methoxyphenethyl)amino)benzoate 266 as a white solid (32 mg, 66%). 
Mp. 49-51 oC (Lit.,40 49-50 oC). 1H NMR (CDCl3, 600 MHz): δ = 2.31 (s, 3 H, 
C=OCH3), 2.86 (t, 2 H, J = 6.6 Hz, CH2), 3.36 (t, 2 H, J = 6.6 Hz, CH2), 3.8 (s, 3 H, 
OCH3), 3.84 (s, 3 H, OCH3), 6.73 (dd, 2 H, J = 9 Hz, 3 Hz, Ar-H), 6.87 (m, 3 H, Ar-
H), 7.13 (d, 2 H, J = 8.4 Hz, Ar-H), 7.18 (d, 1 H, J = 3 Hz, Ar-H). 13C NMR (CDCl3, 
100 MHz): δ = 20.2 (C=OCH3), 34.9 (CH2), 52.3 (OCH3), 55.4 (OCH3), 114.8 (Ar-
C), 122.4 (Ar-C), 123.3 (Ar-C), 124.4 (Ar-C), 125.1 (Ar-C), 125.9 (Ar-C), 130.7 
(Ar-C), 135.5 (Ar-C), 146.7 (Ar-C), 159.3 (Ar-C), 164.5 (C=O), 169.6 (C=O). 
HRMS (ES): m/z (%) = 344.1455 (50) [M + H]+; calcd. for C19H21NO5: 343.1420; 
found 343.1422. ATR-FTIR: υmax= 3393 (m, N-H), 2951 (w, Ar C-H), 1758 (s, 
C=O), 1718 (s, C=O), 1189 (s, C-O) cm-1. 
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Anhydrous acetic acid (42 µL, 728 µmol, 5 equiv.) was added dropwise over 10 min 
to a suspension of NaBH4 (28 mg, 735 µmol, 5.05 equiv.) and methyl 2-acetoxy-5-
(2-(1,1,3,3-tetraethylisoinolin-2-yloxyl-5-yl)acetamido)benzoate 251 (64 mg, 146 
µmol, 1 equiv.) in dry dioxane (3 mL). The resulting reaction mixture was refluxed 
for 30 min and then allowed to return to RT. H2O was added and the resulting 
aqueous solution was extracted with EtOAc (30 mL x 4). The combined organic 
layer was washed with brine (30 mL), dried over anhydrous Na2SO4, and 
concentrated in vacuo. The crude product was purified silica gel column 
chromatography (Hexane/EtOAc, 3:1) to give methyl 2-acetoxy-5-((2-(1,1,3,3-
tetramethylisoindolin-2yloxyl-5-yl)amino)benzoate 267 as yellow solid (42 mg, 
68%). Mp. 85-87 oC. HPLC purity (>95%). 1H NMR (CDCl3, 600 MHz): δ = 2.31 
(s, 3 H, C=OCH3), 3.45 (br, s, 2 H, CH2), 3.85 (s, 3 H, OCH3), 6.76 (br, s, 1 H, Ar-
H), 6.92 (br, s, 1 H, Ar-H), 7.08 (br, s, 1 H, Ar-H). HRMS (ES): m/z (%) = 426.2111 
(40) [M + H]+; calcd. for C24H29N2O5•: 425.2076; found 425.2076. ATR-FTIR: 
υmax= 3371 (m, N-H), 2972 (w, Ar C-H), 1746 (s, C=O), 1715 (s, C=O), 1195 (s, C-
O) cm-1. 
3.5.45. Synthesis of 2-Hydroxy-5-((2-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)ethyl)amino)benzoic acid 142 
 
NaOH (2 mL, 0.5 M) was added to a solution of methyl 2-acetoxy-5-((2-(1,1,3,3-
tetramethyl isoindolin-2yloxyl-5-yl)amino)benzoate 267 (40 mg, 94 µmol) in MeOH 
(2 mL) and the reaction mixture was stirred at RT overnight. MeOH was removed 
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ice/H2O bath and acidified (to pH 3) with HCl (2 M). The precipitate formed was 
isolated by filtration and purified by recrystallization from H2O/MeOH to give 2-
hydroxy-5-((2-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)ethyl)amino)benzoic acid 
142 as brownish yellow solid (25 mg, 72%). Mp. 200 oC (dec.). HRMS (ES): m/z 
(%) = 370.1847 (15) [M + H]+; calcd. for C21H25N2O4•: 369.1814; found 369.1817. 
ATR-FTIR: υmax= 3500-2500 (m, br, O-H), 2975 (m, Ar C-H), 1681 (s, C=O), 1215 
(s, C-O) cm-1. 
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Chapter 4: Synthesis of L-Dopa and Ritalin 
Nitroxide Analogues 
4.1 Background 
L-Dopa 147 and Ritalin (or Methylphenidate, MPH) 148 (Figure 4.1) are two 
sympathomimetic drugs identified as the standard-of-care treatment for Parkinson’s 
disease (PD) and attention deficit hyperactivity disorder (ADHD) respectively.1-5 
Like most sympathomimetic amine stimulants, L-Dopa and Ritalin share a common 
phenethylamine core. They exert their therapeutic action by mainly altering or 
mimicking the sympathetic nervous system functions. PD is a chronic, progressive 
neurodegenerative disorder caused primarily by the loss of dopamine-producing cells 
(dopaminergic neurons) within the substantia nigra of the central nervous system.4,6,7 
Dopamine 152 is a neurotransmitter that regulates diverse, normal physiological 
functions (movement, reward, motivation, and learning). 
 
Figure 4.1. L-Dopa 147 and methylphenidate 148 chemical structures. 
The characteristic PD motor symptoms such as tremor, rigidity and bradykinesia 
(slowness of movement) are attributed to dopamine depletion in the substantia nigra 
of the central nervous system. Dopamine 152 biosynthesis from L-tyrosine 274 takes 
place in the cytosol catecholaminergic neurons (Scheme 4.1).8  
 
Scheme 4.1. Biosynthesis of dopamine 152 from L-tyrosine 274: a. tyrosine 
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Enzymes such as tyrosine hydroxylase (TH) and aromatic L-amino acid 
decarboxylase (AADC) successively catalyze the dopamine biosynthetic pathway. 
Since the pathogenesis of PD is mainly linked to the loss of dopaminergic neurons 
(which in turn leads to decreased amounts of available physiological dopamine), a 
rational strategy to manage PD should involve a direct dopamine replacement 
therapy. However, dopamine does not cross the blood brain barrier. For this reason, 
L-Dopa, a biosynthetic precursor to dopamine that readily crosses the blood brain 
barrier, is used for PD management. 
ADHD is a common childhood behavioural disorder that affects 5–10% of the 
general population.9,10 It is characterized by a number of behavioural symptoms such 
as small attention span, impulsivity, and hyperactivity. Ritalin relieves ADHD-
behavioural symptoms by blocking the reuptake of dopamine and noradrenaline by 
presynaptic neurons thereby increasing the intrasynaptic concentrations of dopamine 
and noradrenaline. 11-13 
Despite the therapeutic benefits of L-Dopa and Ritalin, long-term use of these 
sympathomimetic agents often leads to side effects such as dyskinesia (difficulty in 
performing voluntary movements, in PD) and oxidative brain damage (in ADHD).14-
16 Notably, oxidative stress is identified as a major contributor to the pathology of PD 
and ADHD as well as their associated drug-induced cytotoxicity.8,17-22 In nigral cells, 
dopamine spontaneously oxidizes to a dark pigment known as neuromelanin.8 The 
dopamine-autoxidation process also generates free radicals (such as hydroxyl and 
superoxide radicals) and neurotoxic semiquinone and quinone metabolites. The 
dopamine-derived quinoids are strong electrophiles which, when attacked by 
nucleophiles such as the sulfhydryl group, induce damage to biomolecules like 
proteins in the midbrain.8,23 Redox active metals found in large quantities in the 
substantia nigra of PD patients also promote dopamine-induced autoxidative 
neuronal damage.24 Iron for instance induces cellular damage by forming reactive 
complexes with the catechol group of dopamine and dopamine-metabolites. The 
implication of oxidative stress in PD pathology is further supported by reports of 
decreased levels of reduced-glutathione (GSH) along with the increase in the 
activities of GSH-associated metabolizing enzymes including GSH peroxidase 
observed in the substantia nigra of PD patients.25-29 Glutathione is natural antioxidant 
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that protects dopaminergic neurons by detoxifying ROS generated in the midbrain. 
Dopaminergic neurons in PD patients also display a high rate of basal lipid 
peroxidation.30,31 This, along with depleted levels of nigral endogenous antioxidant 
enzymes (such as SOD and catalase) evidently support the role of oxidative stress in 
PD pathogenesis.30-34 
Similarly, Ritalin-induced oxidative stress is well documented.16,35-38 Thus, the 
continuing vulnerability of dopaminergic neurons to both drug-induced and 
pathological oxidative stress evidently suggest a clear need for an antioxidant 
therapeutic intervention. In a recent PD model study, the antioxidant nitroxide 
TEMPOL was shown to protect dopaminergic mesencephalic cells from 6-
hydroxydopamine (a dopamine metabolite)-induced apoptosis. As part of a wider 
strategy towards the use of the antioxidant nitroxides as a potential remedy for 
oxidative stress-related diseases, this chapter further explores the antioxidant 
capacity of stable nitroxide compounds in neurodegenerative disorders, particularly 
PD and ADHD. The aim here is to use the pharmacophore hybridization strategy to 
design and synthesize new hybrid dual acting nitroxide-based anti-PD and anti-
ADHD agents 149 and 150, by overlapping the functional components of L-Dopa 















Figure 4.2. Chemical structures of merged target compounds: L-Dopa TMIO 149, 
Ritalin TMIO 150 and the rigid alkyne-linked α-amino acid 151. 
In addition to the L-Dopa and Ritalin nitroxide analogues 149 and 150, the rigid 
alkyne-linked α-amino acid nitroxide 151 is the final target compound in this 
chapter. The synthesis of compound 151 will be carried out by taking advantage of 
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the Schöllkopf’s approach that would be employed in the asymmetric synthesis of 
the target L-Dopa nitroxide analogue 149. Unlike the L-Dopa and Ritalin nitroxides 
149 and 150, compound 151 is designed as a potential site-directed spin label 
(SDSL) for studying the structure and conformational dynamics of peptides and 
proteins. Furthermore, 151 could also be used as a tool for monitoring ROS-induced 
cellular oxidative stress in diseases such as PD by both EPR and fluorescence 
techniques. 
4.2 Results and Discussion 
4.2.1 Schöllkopf’s Synthesis of Merged L-Dopa-TMIO 149 
Since D-dopa is not a substrate for the AADC enzyme (which metabolizes L-Dopa to 
dopamine),39-41 L-Dopa is administered as a single enantiomer in dopamine 
replacement therapy. Hence, the challenge herein is to employ a synthetic approach 
that will predominantly afford the target compound 149 in its optically active L-
isomer form. Though a variety of methods are available to asymmetrically prepare 
chiral nonproteogenic α-amino acids,42-44 Schöllkopf’s approach was employed in the 
synthesis of the target L-Dopa nitroxide.45 
The Schöllkopf methodology is an asymmetric nucleophilic derivatization approach 
used to prepare chiral amino acids. The asymmetric induction for the Schöllkopf 
approach is usually greater than 95%.45-48 The method uses bis-lactim ethers such as 
(2R)-2,5-dihydro-3,6-dimethoxy-2-isopropylpyrazine 275 as precursors to a masked 
glycine synthetic equivalents (enolates). Bis-lactim ether substrates, also referred to 
as Schöllkopf chiral auxiliaries, are commonly prepared by cyclizing glycine with a 
chiral auxiliary. α-Amino acids such as R-valine are the most common chiral 
auxiliaries employed.49 The bis-lactim ether 275 has two acidic protons at C2.  
Deprotonation at C2 by a strong base generates the planar masked glycine enolate 
276 (Scheme 4.2). The in situ generated carbanion 276 is then alkylated 
diastereoselectively to give the alkyl dihydropyrazine intermediate 277. In the 
presence of an electrophile, the side chain (isopropyl group) of 276 acts as a chiral 
inducing centre that directs electrophilic attack from the opposite side of the planar 
enolate 276. The bis-lactim ether 275 also contains two hydrolyzable sites (at the two 
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nitrogen atoms). Following alkylation, the dihydropyrazine ring can be readily 
hydrolyzed to furnish an optically pure free amino methyl ester 178 along with the 
methyl D-valinate chiral auxiliary 279. Scheme 4.3 below outlines the proposed 
synthetic route for the synthesis of the target L-Dopa nitroxide 149 via the 
Schöllkopf’s approach. 
 
Scheme 4.2. The Schöllkopf’s approach for asymmetric synthesis of chiral α-amino 
acids. Reagents and conditions: a. nBuLi, -78 oC; b. RCHX (X = Br, Cl or I); c. HCl. 
 
Scheme 4.3. Proposed synthetic route to L-Dopa nitroxide 149. Reagents and 
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However, in order to conveniently assess the diastereoselectivity of this approach 
by 1H NMR spectroscopy, the alkylation of bis-lactim ether 275 was first attempted 
with the methoxyamine derivative 283 of the benzyl bromide nitroxide 280. 
4.2.1.1 Synthesis of Benzyl Bromide Methoxyamine 283 
The benzyl bromide methoxyamine 283 was synthesized in seven steps from 
bromoamine precursor 66 as depicted below in Scheme 4.4. The bromoamine 
intermediate 66 was obtained in three steps from phthalic anhydride 167 by 
following the previous literature procedures discussed in Chapter 2.50 Bromoamine 
66 was oxidized to the corresponding nitroxide 28 under mild mCPBA oxidation 
conditions. Compound 28 was obtained almost quantitatively as yellow solid 
following purification by trituration with hexane to remove the small (less than 5%) 
5,6-dibromo nitroxide impurity 284, which is usually formed during the bromination 
step. All characterization data obtained for 28 matched that previously reported in the 
literature.50 
 
Scheme 4.4. Synthesis of benzyl bromide N-methoxyamine 283. Reagents and 
conditions: a. mCPBA, DCM, 0 oC-RT, 2 h, 87%; b. FeSO4.7H2O, H2O2, DMSO, 
RT, 1 h, 93%; c. nBuLi, THF, -78 oC, 15 min, then DMF, 3 h, 96%; d. NaBH4, 
MeOH, 0 oC, 1.5 h, 97%; e. MsCl, TEA, 0 oC, 2 h, THF, Ar, then LiBr, Me2CO, 
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Since the nitroxide moiety can react with n-butyllithium to give the hydroxylamine, 
amine and alkoxyamine derivatives,51,52 it was necessary to first protect the 5-
bromonitroxide 28 prior to subjecting it to lithiation conditions. Thus 28 was 
converted to its methoxyamine derivative 23 by reacting it in situ with methyl 
radicals formed by the typical Fenton reaction of hydrogen peroxide and iron (II) 
sulfate with DMSO.53 The methoxy protons of 23 were observed as a singlet at 3.8 
ppm in the 1H NMR spectrum. Other spectroscopic data obtained for 23 matched that 
reported in the literature.53,54  
To synthesize the formyl derivative 22, bromomethoxyamine 23 was first lithiated 
with n-butyllithium and subsequently quenched with DMF to furnish formyl 22 
quantitatively. Evidence to support this transformation was obtained by the presence 
of the characteristic formyl proton signal as a singlet at 9.98 ppm in the 1H NMR 
spectrum of 22. A strong C=O absorption was also observed at 1690 cm-1 in the FTIR 
spectrum of 22. The identity of 22 was further confirmed by the presence of the 
molecular ion plus proton [M + H]+ at m/z 234 in the HRMS spectrum. The purity of 
22 was assessed by analytical HPLC to be >95%.  
The formyl methoxyamine 22 was then reduced by sodium borohydride to the 
corresponding benzyl alcohol 285 in 97% yield. The loss of the formyl proton signal 
at 9.98 ppm as well as the appearance of the benzylic CH2 proton signal as a singlet 
at 4.68 ppm in the 1H NMR spectrum of the isolated product supported the formation 
of 285. In the FTIR spectrum of 285, the presence of a strong-broad O-H absorption 
at 3393 cm-1 and the absence of a strong formyl C=O stretch at 1690 cm-1 further 
supported this successful transformation. The HRMS analysis also confirmed the 
identity of compound 285 with the molecular ion plus proton [M + H]+ peak at m/z 
326. Compound 285 was determined to be >95% pure by HPLC analysis. 
In general, primary alcohols are not good leaving groups in bimolecular nucleophilic 
substitution reactions with halides. A common approach around this involves first 
converting the hydroxyl group into a good leaving sich as a mesylate, which is in 
turn readily substituted with the desired halide. Following a similar approach, 
compound 285 was first converted to the methanesulfonate ester intermediate by 
reacting with methanesulfonyl chloride in the presence of triethylamine. The 
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mesylate was then reacted in situ with lithium bromide to furnish compound 283. 
Although TLC analysis of the reaction mixture (after two hours) showed complete 
consumption of the starting material 285 and the formation of a single new 
component, analysis of the isolated product by HPLC, HRMS and 1H NMR 
spectroscopy revealed a two component mixture of the desired benzyl bromide 283 
and its chloride derivative 286 (≤ 11%, Figure 4.3). The unexpected formation of the 
benzyl chloride 286 side-product could be explained by competing nucleophilic 
substitution of the mesylate by chloride ions (produced during in situ generation of 
the mesylate). 
 
Figure 4.3. Chemical structures of benzyl bromide 283 and benzyl chloride 286 TMI 
methoxyamines. 
Qi and co-workers also reported similar nucleophilic substitution of a series of 
benzylic sulfonate esters by chloride ions in modest yields.55 However, since 
bromides are better nucleophiles than their chloride counterparts, the desired 
benzylic bromide 283 was obtained exclusively when the benzylic halide mixture 
was refluxed in acetone in the presence of excess lithium bromide for two hours. 
Compound 283 was obtained in high yield (81%) as a white solid following 
purification by flash column chromatography. The product isolated was 
characterized by HRMS, FTIR, 1H and 13C NMR spectroscopy. The molecular ion 
[M + H]+, with the characteristic isotopic pattern for the presence of a single bromine 
atom, was observed at m/z 298/300 in the HRMS spectrum. The disappearance of a 
strong O-H absorption above 3393 cm-1 in the FTIR spectrum of 283 further 
supported the transformation. HPLC analysis of compound 283 showed a single 
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4.2.1.2 Alkylation of Schöllkopf’s Bis-lactim Ether Chiral Auxiliary 275 
With the benzyl bromide intermediate 283 in hand, the key step in the synthesis of 
the target L-Dopa-nitroxide analogue 149 was the subsequent asymmetric alkylation 
of the commercially available bis-lactim ether chiral auxiliary (2R)-2,5-dihydro-3,6-
dimethoxy-2-isopropylpyrazine 275 with benzyl bromide 283. Freshly purchased 
compound 275 had a designated purity of 96% by GCMS. The 1H NMR spectrum of 
275 showed about 5% impurities. The impurities were reported to be the ethoxy 
derivatives of 275, namely (2R)-2,5-dihydro-3-ethoxy-6-methoxy-2-
isopropypiperazine and (2R)-2,5-dihydro-6-ethoxy-3-methoxy-2-
isopropypiperazine.49 These ethoxy contaminants are reportedly formed from an 
impurity in the triethyloxonium tetrafluoroborate reagent used in the synthesis of 
275. However, it was also stated that their presence does not affect the outcome of 
the alkylation step and they are readily separated from the desired product by 
chromatography. 
Thus, the chiral auxiliary 275 was deprotonated at C5 with equimolar amount of n-
butyllithium to generate the enolate 276 (Scheme 4.5). As mentioned in the 
preceding section, one of the diastereotopic sides at C5 of the planar enolate ion is 
strongly shielded by the bulky isopropyl group. This ensures electrophilic attack at 
C5 to occur exclusively on the opposite face to the isopropyl group, thus resulting in 
the formation of the 2R, 5S diastereomer. 
 
Scheme 4.5. Alkylation of bis-lactim ether 275 with benzyl bromide N-
methoxyamine 283. Reagents and conditions: a. nBuLi, -78 oC, 15 min, THF, then 
283, 3 h, 80%. 
Upon quenching anion 276 with the benzyl bromide methoxyamine 283, the single 
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chromatography). The diastereomeric purity of the isolated product 287 was 
confirmed by 1H NMR spectroscopy to be >99%. The single proton of the central 
carbon of the isopropyl group was shown as a multiplet at 2.11 ppm while the 
benzylic protons (CH2) were observed at 3.07 ppm. Three distinct aromatic protons 
were also observed at 7.11 and 7.26 ppm. This was consistent with the presence of 
the three protons of the isoindoline aromatic ring. 
The dihydropyrazine proton of 287 labelled Ha in Figure 4.4 below was also 
observed as a doublet at 3 ppm. This was, interestingly, much further upfield than the 
Ha proton of the chiral auxiliary starting material 275 which was observed at 4 ppm. 
As was the case with some benzyl-alkylated dihydropyrazines reported in the 
literature,47,56 such marked difference in chemical shift suggests that compound 287 
probably adopts an “aryl-inside” conformation (287a in Figure 4.4). In this 
conformation, the Ha proton of 287 is situated in the shielding cone of the 







Observed at 3 ppm: an upfield shift in 

















Figure 4.4. Chemical structure of 275, 287 and the aryl-inside conformation of 287 
(287a). 
Good evidence to support the “aryl-inside” conformation of 287 was obtained 
from 1H NMR ROESY analysis (Figure 4.5) which showed a clear spatial 
correlation between the dihydropyrazine ring Ha proton at 3 ppm and the isoindoline 
aromatic protons at 7.11 and 7.26 ppm (as highlighted in the ROESY spectrum 
Figure 4.5). Such a correlation also indicates that the isopropyl group and the 
isoindoline fragment are anti to each other with reference to the dihydropyrazine ring 
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plane. The evidence from ROESY spectrum is however inconclusive because the 
highlighted spatial correlation with the isoindoline aromatic protons could as well 
arise from the benzylic protons at 3.07 ppm which overlap the Ha proton signal at 3 
ppm. Other characterization data obtained to support the identity of 287 included 
HRMS, FTIR and 13C NMR spectra.  
 
Figure 4.5. ROESY spectrum of 287 (400 MHz at 300 ms spin lock): showing the 
correlation between dihydropyrazine C5 proton (red) and isoindoline aromatic 
protons (blue). 
The strong C=N stretch of the dihydropyrazine ring was observed at 1695 cm-1 in the 
FTIR spectrum of 287. The presence of the two C=N group of the dihydropyrazine 
ring was also confirmed by the carbon signals at 162 and 164 ppm in the 13C NMR 
spectrum of 287. In addition the molecular ion [M + H]+ was observed at m/z 402 in 
the HRMS spectrum of 287. Compound 287 was assessed to be >95% pure by 
HPLC with a melting range of 62-63 oC.  
Having confirmed that compound 287 was a single diastereomer (2S, 5R), the next 
step was to deprotect the nitroxide moiety. 
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4.2.1.3 Synthesis of Dihydropyrazine TMIO 281 via Oxidation of the 
Methoxyamine Derivative 287 
Oxidation of dihydropyrazine methoxyamine 287 to the corresponding nitroxide 181 
was achieved under mild mCPBA oxidation conditions (Scheme 4.6) in the presence 
of sodium bicarbonate. To avoid a potential acid hydrolysis of the dihydropyrazine 
rings of 281 and 287, sodium bicarbonate was employed to neutralize the m-
chlorobenzoic acid by-product of the mCPBA reagent. The deprotection proceeded 
smoothly to furnish compound 281 as a yellow solid in high yield (81%) after 
purification by silica gel column chromatography.  
 
Scheme 4.6. Synthesis of dihydropyrazine nitroxide 281 via mCPBA demethylation 
of N-methoxyamine dihydropyrazine 287. Reagents and conditions: a. mCPBA, 
NaHCO3, DCM, 0 oC, 3 h, 81%. 
As expected, a paramagnetic broadening effect of the nitroxide moiety was observed 
in the 1H NMR spectrum of 281. Despite that, however, each dihydropyrazine ring 
proton signal was conveniently observed and properly assigned. The isopropyl group 
protons were observed as broad singlets at 0.61 (CH3), 0.85 (CH3) and 2.14 (CH) 
ppm. The C2, C5 and the dimethoxy protons were also observed at 3.19 (1 H), 3.5 (1 
H), and 3.72 (6 H) respectively. A diagnostic molecular ion plus sodium [M + Na]+ 
was observed at m/z 409 in the HRMS spectrum of 281. The purity of 281 was 
assessed by HPLC to be >95% and its measured melting range was 85-86 °C. 
Having successfully employed (diastereoselectively) the Schöllkopf’s approach in 
the alkylation of bis-lactim ether 275 with the benzyl bromide methoxyamine 283, 
the next section explores the use of similar conditions for the alkylation of bis-lactim 
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4.2.1.4 Synthesis of Dihydropyrazine TMIO 181 via Benzyl Bromide TMIO 280 
As mentioned earlier, benzyl bromide methoxyamine 283 was used in the synthesis 
of the dihydropyrazine nitroxide 181 to conveniently assess, by 1H NMR 
spectroscopy, the enantioselectivity of the alkylation step of the Schöllkopf 
methodology. Having established the diastereoselectivity of the Schöllkopf’s 
alkylation step, a similar reaction was also attempted with benzylic nitroxide 280 in 
place of methoxyamine 283. As outlined in Scheme 4.7 below, the benzylic nitroxide 
280 was obtained in 4 steps from the bromoamine precursor 66.  
 
Scheme 4.7. Synthesis of benzyl bromide TMIO 280. Reagents and conditions: a. 
nBuLi, THF, -78 oC, 15 min, then DMF, 3 h, 100%; b. mCPBA, DCM, 0 oC-RT, 2 h, 
92%; c. NaBH4, MeOH, 0 oC, 1.5 h, 86%; d. MsCl, TEA, 0 oC, 2 h, THF, Ar, then 
LiBr, Me2CO, reflux, 2 h, 75%. 
As detailed in Chapter 3, the formyl nitroxide 27 was obtained in two steps from the 
bromoamine 66. First, the dianion generated from the lithaiation of 66 was quenched 
with DMF to quantitatively furnish 5-formyl amino derivative 73. This was followed 
by a mild mCPBA oxidation of 73 to give the formyl nitroxide 27. Subsequent 
reduction of compound 27 to the corresponding benzyl alcohol 288 was facilitated by 
sodium borohydride in one hour. The benzyl alcohol 288 was obtained in 86% yield 
after purification by column chromatography and recrystallization from cyclohexane. 
In the FTIR spectrum of 288, the presence of a strong-broad OH absorption at 3425 
cm-1 and the absence of a strong formyl C=O stretch around 1600-1700 cm-1 
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Like the methoxyamine counterpart 283, the benzyl bromide nitroxide 280 was 
obtained by reacting benzyl alcohol 288 with methanesulfonyl chloride in the 
presence of triethylamine to produce a mesylate derivative. The mesyl group was 
then readily displaced in situ by bromide ions by reacting with lithium bromide to 
furnish the desired benzyl bromide derivative 280. Compound 280 was characterized 
by HRMS and FTIR spectroscopy and its purity was assessed by HPLC (>95%).  
Following similar alkylation conditions as described in Scheme 4.5 above, the bis-
lactim ether chiral auxiliary 275 was first lithiated with n-butyllithium and the 
resulting anion 276 was then reacted with benzyl bromide nitroxide 280 to furnish 
the dihydropyrazine nitroxide 281 in 78% yield (Scheme 4.8). To avoid a potential 
reaction of the bromide or the nitroxide moiety of 280 with n-butyllithium, a slight 
excess of the chiral auxiliary 275 was used. 
 
Scheme 4.8. Synthesis of dihydropyrazine nitroxide 281 via alkylation of bis-lactim 
ether 275 with benzyl bromide TMIO 280. Reagents and conditions: a. nBuLi, -
78 oC, 15 min, THF, then 280, 3 h, 78%. 
All characterization data obtained for dihydropyrazine 281 from the benzyl bromide 
nitroxide 280 route were consistent with those obtained from the benzyl bromide 
methoxyamine 283 route (Scheme 4.5 and Scheme 4.6).  
Although both routes give comparatively good yields, compound 281 was obtained 
via the benzyl bromide nitroxide 180 route in five steps from bromoamine precursor 
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4.2.1.5 Hydrolysis of Dihydropyrazine 281 to Furnish L-Dopa-Nitroxide TMIO 
149 
A mild acid hydrolysis of the dihydropyrazine nitroxide 281 furnished the crude 
amino methyl ester 282 as a mixture with the D-valine methyl ester 279 (Scheme 
4.9). Purification of the crude product mixture by silica gel column chromatography 
completely removed the D-valine methyl ester 279 side product. Compound 282 was 
obtained as a yellow solid (76%) and was determined to be >95% pure by HPLC. 
 
Scheme 4.9. Hydrolysis of dihydropyrazine nitroxide 281 to the target L-Dopa TMIO 
149. Reagents and conditions: a. HCl, THF/H2O, 3 h, 76%; b. LiOH, THF/H2O, 2 h, 
89%. 
The characteristic primary amine (NH2) stretching frequency was observed as two 
weak bands at 3382 and 3319 cm-1 in the FTIR spectrum of 282. In addition, the 
strong C=O absorption observed at 1730 cm-1 confirmed the presence of methyl ester 
carbonyl group in 282. The identity of 282 was further confirmed by the presence of 
the diagnostic [M + H]+ and [M + Na]+ ions at m/z 292 and 314 respectively in the 
HRMS spectrum. The significant paramagnetic broadening effects of the nitroxide 
moiety limited the characterization of 282 by 1H NMR spectroscopy. 
The target L-Dopa nitroxide 149 was obtained when a solution of the amino methyl 
ester 282 and three molar equivalents of lithium hydroxide were stirred at room 
temperature for 2 h. The amino acid 149 was obtained as a yellow precipitate at pH 7 
in 89% yield. The identity of compound 149 was confirmed by the presence of the 
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carboxylic acid O-H stretch was also observed at 3376 cm-1 in the FTIR spectrum of 
149. Compound 149 decomposed above 121 oC.  
Having successfully employed the Schöllkopf methodology to synthesize the L-Dopa 
nitroxide analogue 149, the approach was further employed in the synthesis of the 
novel rigid alkyne-linked α-amino acid nitroxide 151 as discussed in the next section. 
Compound 151 was designed as a potential site directed spin label for 
macromolecules such as peptides and proteins. 
4.2.2 Schöllkopf Synthesis of the Rigid Alkyne-linked α-Amino Acid 
Nitroxide 151 as a Potential SDSL for Peptides and Proteins 
Site-directed spin labelling (SDSL) is an effective technique used in combination 
with EPR spectroscopy to study the structure and conformational dynamics of 
macromolecules such as proteins, nucleic acids and carbohydrates.57-62 The technique 
involves covalent attachment of a spin label to a site of interest on a target 
biomolecule. This enables structural and dynamic information to be obtained under 
conditions close to the physiological or actual functional state of the system under 
investigation. 
For structural elucidation of peptides and proteins, the methanethiosulfonate spin 
label 290 (MTSL) is the most widely used nitroxide compound in SDSL 
experiments.63 In general, the protocol involves incorporating unique cysteine 
residues at selected sites of interest within the protein under study by cysteine 
substitution mutagenesis (Scheme 4.10). This is performed with minimal functional 
















Scheme 4.10. Disulfide-linked MTSL-protein complex formation for SDSL studies. 
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Under appropriate conditions, sulfhydryl groups of mutated cysteine residues can 
react with MTSL 290 to form the disulfide-linked MTSL-protein complex 291.65 
Despite the extensive use of the MTSL in SDSL-EPR experiments, the approach 
suffers from some notable drawbacks.66 Firstly, the newly formed disulfide bond can 
be easily cleaved in the presence of a range of reducing agents such as dithiothreitol 
(DTT). Also, in some proteins, native cysteine residues are essential for their 
optimum structural and functional dynamics. Therefore modification of such cysteine 
residues with the MTSL to form a disulfide may not provide accurate structural and 
dynamic information regarding the native protein under study. Furthermore, the 
rotational flexibility along the five single bonds (between the pyrroline ring of the 
MTSL and the α-carbon of the protein backbone) often leads to increasing mobility 
of the spin label.67 This consequently makes the position of the spin label more 
difficult to define. The rotation freedom along the five single bonds can also lead to 
isomerization about the disulfide bond. This in turn leads multiple undesirable 
motional components (such as decoupling of the motion of the spin label and protein) 
in the EPR spectra. 
The most common alternative strategies to the MTSL that are used to introduce 
nitroxide spin labels within macromolecules are solid-phase peptide synthesis and 
click chemistry.57,68-71 The first and the most widely used α-amino acid spin probe 
incorporated in a peptide via a peptide bond (solid phase peptide synthesis) is the 
paramagnetic 2,2,6,6-tetramethyl-N-oxyl-4-amino-4-carboxylic acid or TOAC 294 
(Figure 4.6).72-74  
 
Figure 4.6. Common Cα-tetrasubstituted α-amino acids: Aminoisobutyric acid (Aib) 
292, 1-aminocyclohexane-1-carboxylic acid 293 (Ac6c) and TOAC 294. 
TOAC-coupled peptides show significant conformational restrictions.75,76 This 
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spin label experiments give good structural information. However, the achiral nature 
of TOAC spin means other TOAC conformations do exist.77,78 This may affect the 
secondary structure of peptides and alter spatial intermolecular and/or intramolecular 
distance measurements between two TOAC paramagnetic centres.79 Thus, the aim of 
this work was to develop a new spin label that could minimize the drawbacks 
associated with rotational mobility, isomerization, multiple conformers, and achiral 
effects. 
The target novel-rigid-chiral α-amino acid nitroxide spin label 151 could accurately 
provide relevant structural and dynamic information about a peptide under study. 
The design of this spin label is based on the more rigid isoindoline nitroxide ring 
class bridged to an L-phenylalanine α-amino acid by an alkyne linker. Due to its 
rigidity and chirality, biomolecular structural information could be obtained with 
compound 151 with minimal drawbacks associated with rotational mobility, 
isomerization, multiple conformers and achiral effects. Compound 151 could also be 
used to monitor cellular ROS-induced oxidative stress damage of peptides and 
proteins. Due to its expected high fluorescent quenching potential, 151 could also be 
used as a fluorescent probe to deduce more structural information of peptides and 
proteins. Under appropriate conditions, fluorescence would be restored when 151 is 
oxidized or reduced to its oxoammonium ion or hydroxylamine derivatives 
respectively. 
The synthesis of compound 151 was carried out using the Schöllkopf’s bis-lactim 
ether approach and palladium-catalyzed Sonogashira coupling reactions as discussed 
below.45,46 
4.2.2.1 Alkylation of Schöllkopf’s Bis-lactim Ether 275 
As outlined in Scheme 4.11 below, the first step towards compound 151 involved 
lithiation of the bis-lactim ether (2R)-2,5-dihydro-3,6-dimethoxy-2-
isopropylpyrazine 275 with n-butyllithium, followed by the reaction of the resulting 
enolate 276 with 4-iodobenzyl bromide 295 to furnish the alkylated dihydropyrazine 
296 in 86% yield. Compound 296 was obtained in its pure form as a single 
diasteromer and its identity was confirmed by NMR spectroscopy, HRMS and FTIR 
analysis. Like 287, compound 296 also adopts an “aryl-inside” conformation. This 
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was verified by the difference in the chemical shift for the C5 proton of 296 
(observed at 3.4 ppm) and the starting material 275 (observed at 4 ppm)- an upfield 
shift of 0.6 ppm. Further confirmation was obtained by the spatial correlation 
between the C5 proton and the para-substituted aromatic ring protons in the ROESY 























Scheme 4.11. Alkylation of bis-lactim ether 275 with 4-iodobenzyl bromide 295. 
Reagents and conditions: a. nBuLi, THF, -78oC, 15 min, then 295, 4 h, 86%. 
4.2.2.2 Synthesis of Alkyne TMIO 90 
Following successful diastereoselective alkylation of Schöllkopf’s chiral auxiliary 
275, the next step was to synthesize alkyne TMIO 90 by following previous literature 
procedures as outlined in Scheme 4.12 below.80,81 The bromoamine starting material 
66 was synthesized from commercially available phthalic anhydride 167 in 3 steps as 
described in Chapter 2. Lithiation of bromoamine 66 with n-butyllithium resulted 
into the formation of a dianion which, upon quenching with iodine, furnished the 
crude 2,5-diiodoisoindoline compound 298. The diiodo compound 298 was then 
reduced by aqueous hydrogen peroxide solution in the presence of sodium 
bicarbonate to afford the 5-iodoisoindoline derivative 68. The 5-iodo nitroxide 61 
was obtained almost quantitatively by subjecting compound 68 to mild mCPBA 
oxidation conditions. Then a palladium-catalyzed copper-free Sonogashira coupling 
reaction of 5-iodo nitroxide 61 with a fivefold excess of 2-methyl-3-butyn-2-ol 
furnished the protected acetylene nitroxide 297 in 70% yield. Compound 297 was 
deprotected with potassium hydroxide in refluxing anhydrous toluene to give the 
desired alkyne TMIO 90 as a bright yellow solid in 93% yield. All characterization 
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Scheme 4.12. Synthesis of alkyne TMIO 90. Reagents and conditions: a. nBuLi, 
THF, -78oC, 10 min, then I2, NaHCO3, H2O2, 80%; b. mCPBA, DCM, 0 oC, 3 h, 
87%; c. 2-methyl-3-butyn-2-ol, DABCO, Pd(OAc)2, MeCN, Ar, reflux, 24 h, 70%; 
d. KOH, toluene, reflux, 30 min, 93%. 
With the alkyne TMIO 90 and the 4-iodobenzyl dihydropyrazine 296 in hand, the 
synthesis of the target compound 151 from these two intermediates was 
accomplished via two routes as described below.  
4.2.2.3 Synthesis of Alkyne-linked α-Amino Acid Nitroxide 151 via Sonogashira 
Coupling 
In the first route (Scheme 4.13), 4-iodobenzyl dihydropyrazine 296 was first 
hydrolyzed under acidic conditions to give an equimolar mixture of the (S)-4-
iodophenylalanine 291 and D-valine 279 methyl esters as verified by IH NMR 
spectroscopy. Both amino esters were then protected with Boc groups by allowing 
the crude mixture to react with Boc-anhydride in the presence of triethylamine. 
Purification of the crude product by silica gel chromatography afforded (S)-(N-t-
butoxycarbonyl)-4-iodophenylalanine methyl ester 300 as a white solid in 66% yield 
(over the two steps from 296). The t-butoxy protons of the Boc-protecting group 
were shown as a singlet at 1.42 ppm that integrated for 9 protons in the 1H NMR 
spectrum of 300. 


















































Scheme 4.13. Synthesis of the rigid alkyne-linked α-amino acid SDSL 151 via 
Sonogashira coupling of Boc-protected phenylalanine methyl ester 300 with alkyne 
TMIO 90. Reagents and conditions: a. TFA, MeCN/H2O, 3 h; b. (Boc)2O, TEA, RT, 
O/N, (66% from 296); c. 90, PdCl2(PPh3)2, CuI, TEA, RT, O/N, 66%; d. LiOH, 
H2O/THF, 2 h, 93%; e. HCl, dioxane/H2O, O/N, 96%. 
Also, the methylene (CH2) group protons were observed as two doublet of doublets 
at 2.95 and 3 ppm. The singlet at 3.72 ppm (3 protons) and the broad doublet at 4.56 
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ppm (1 proton) were assigned to the methoxy protons of the methyl ester group and 
C2 (α-carbon CH) proton respectively. The two doublets in the aromatic region (at 
6.78 and 7.61 ppm), each integrating for 2 protons, were assigned to the para-
substituted phenyl ring protons. Further evidence to support the identity of 300 was 
obtained from the presence of two strong C=O stretching frequencies observed at 
1735 and 1684 cm-1 in the FTIR spectrum of 300. This was consistent with the 
presence of the methyl ester and the Boc-protecting group. A medium NH stretch (of 
the Boc-NH group) was also observed at 3343 cm-1. Other characterization data 
obtained to further support the identity of 300 included 13C NMR spectroscopy and 
HRMS analysis. Compound 300 was determined to be >95% pure by HPLC 
analysis. 
Bis(triphenylphosphine)palladium (II) dichloride facilitated Sonogashira reaction of 
300 with the alkyne TMIO 90 in the presence of triethylamine and catalytic copper 
(I) iodide afforded the rigid alkyne TMIO-linked Boc-protected phenylalanine 
methyl ester 301. Although the coupling proceeded smoothly, it was however 
accompanied by the formation of the homodimer alkyne TMIO side product 303 as 
verified by HRMS analysis. Hence the alkyne TMIO 90 was used in slight excess. 
Compound 301 was obtained in 66% yield as a yellow solid after the crude residue 
was subjected to flash column chromatography. The identity of compound 301 was 
confirmed by the presence of the characteristic [M + H]+, [M + 2H]+ and [M + Na]+ 
ions at m/z 492, 493 and 514 respectively in the HRMS spectrum of 301. Despite the 
paramagnetic broadening effect of the nitroxide moiety, the N-Boc phenylalanine 
methyl ester fragment protons were assigned in the 1H NMR spectrum of 301. 
Compound 301 was assessed to be >95% pure by HPLC and its melting range was 
determined to be 183-184 oC.  
The methyl ester group of 301 was then hydrolyzed with lithium hydroxide to give 
the corresponding carboxylic acid 302 in 93% yield. Although the carboxylic acid 
proton could not be assigned, the loss of the methoxy protons signal around 3.7 ppm 
in the 1H NMR spectrum of 302 evidently supported the successful transformation. 
Furthermore, a characteristic broad O-H stretching absorption of the carboxylic acid 
group was observed in the FTIR spectrum of 302 (ranging from 2500 to 3500 cm-1). 
The HRMS spectrum of 302 showed the distinct [M + H]+ mass at m/z 462. The 
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purity of 302 was confirmed by HPLC analysis to be >95%. The Boc-protecting 
group of 302 was then removed under mild hydrochloric acid conditions to furnish 
the target alkyne-linked α-amino acid nitroxide 151 as a yellow precipitate in 96% 
yield. HRMS analysis confirmed the identity of target compound 151 by the presence 
of the diagnostic [M + 2H]+ ion at m/z 379. 
Alternatively, the target compound 151 was obtained by first subjecting the 4-
iodobenzyl dihydropyrazine 296 and the alkyne TMIO 90 to similar Sonogashira 
coupling conditions (used in the synthesis of 301 above) prior to hydrolysis of the 




























Scheme 4.14. Synthesis of the rigid alkyne-linked α-amino acid SDSL 151 via 
Sonogashira coupling of dihydropyrazine 296 with the alkyne TMIO 90. Reagents 
and conditions: a. PdCl2(PPh3)2, CuI, TEA, RT, O/N, 73%; b. HCl, MeCN, 2 h, 
93%; c. LiOH, H2O/THF, 2 h, 86%. 
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The alkyne-linked dihydropyrazine 304 was obtained as a yellow solid in 73% yield 
after purification by silica gel chromatography. Evidence to support the synthesis of 
304 was obtained from HRMS, FTIR and 1H NMR spectroscopy. Despite the 
paramagnetic broadening effect of the nitroxide moiety, each proton of the benzyl 
dihydropyrazine fragment was correctly assigned in the 1H NMR spectrum of 304. 
Protons of the isopropyl group were observed as broad doublets at 0.62 (CH3), 0.96 
(CH3) and 2.17 (CH) ppm. The C5 and C2 protons were also observed as broad 
singlets at 3.38 (1 H) and 4.34 (1 H) ppm respectivel. The two singlets at 3.69 and 
3.73 ppm (each integrated for 3 H) were assigned to the two methoxy groups of the 
dihydropyrazine ring. The broad doublets at 7.11 and 7.37, each integrated for 2 
protons, were assigned to the para-substituted phenyl ring protons. In the FTIR 
spectrum of 304, the C=N stretch of the dihydropyrazine ring was observed as a 
strong band at 1693 cm-1. The HRMS spectrum of 304 further confirmed its identity 
by the presence of the [M + H]+ and [M + Na]+ masses at m/z 487 and 509 
respectively. The purity of compound 304 was assessed by HPLC to be >95% and 
its measured melting range was 85-86 °C.  
Hydrolysis of the dihydropyrazine ring of 304 with dilute hydrochloric acid 
furnished the amino methyl ester 305 in 99% yield. The two medium absorptions at 
3309 and 3369 cm-1 in the FTIR spectrum of 305 are the characteristic NH stretch of 
the primary amino group. In addition, a strong C=O stretches of the methyl ester was 
also observed at 1741 cm-1. The protons of the phenylalanine methyl ester fragment 
were accounted for in the 1H NMR spectrum of 305. Further evidence to support the 
identity of 305 was obtained from HRMS analysis. The purity of compound 305 was 
assessed by HPLC to be >95%.   
The target alkyne-linked α-amino acid nitroxide 151 was obtained almost 
quantitatively when the phenylalanine methyl ester 305 was reacted with three molar 
equivalents of aqueous lithium hydroxide at room temperature. All characterization 
data obtained for 151 via this route matched that obtained by the first route. Although 
each of the two routes furnished the target compound 151 in comparatively good 
yields, the second route (Scheme 4.14) had two fewer steps than the first (Scheme 
4.13). The overall yield for routes 1 and 2 were 60 and 64% respectively. Compound 
151 will be assessed for its potential spin label application in peptides and proteins. 
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4.2.3 The Attempted Synthesis of Ritalin-TMIO Analogue 150 
Methylphenedate 148 (MPH, Ritalin) is the most common medication for the 
treatment of ADHD. Structurally, MPH has four stereoisomers due to the presence of 
two stereocentres (Figure 4.7). While the threo-isomers possess significant 
therapeutic effect, the erythro counterparts display very little activity.82 The toxic 
hypertensive side effects of MPH are known to arise mainly from the use of the 
erythro isomers. Although the D-threo isomer is up to 38 times more potent than the 
L-threo counterpart, Ritalin is currently administered as a racemic mixture of both 
threo isomers.83-85 Despite such significant difference in therapeutic efficacy, there is 
currently not many reported enantioselective synthesis of the D-threo isomer in the 
literature. 
Threo is the most active form (Up to 38x more 
active than erythreo). Prescribed as racemate
(D and L). D is 13x more active than L.
L may have undesirable side effects.
2R, 2'S
Very few therapeutic properties.
























Figure 4.7. Erythro and threo isomers of methylphenedate (MPH). 
The synthesis of the target nitroxide-Ritalin derivative described here is based on the 
highly regio-, diastereoselective rhodium-catalyzed intermolecular C-H insertion 
approach that employs metal cabenoid intermediates.86-88 Developed by Davies and 
coworkers, the approach uses a dirhodium catalyst such as Rh2(S-DOSP)2 to insert 
methyl phenyldiazoacetate 307 into N-Boc-piperidine 306 to give the D-threo-
methylephenedate 148 in 86% diastereomeric excess (Scheme 4.15). The mechanism 
for this reaction is given in the review article by Davies and coworkers.88  
A similar approach was attempted for the synthesis of the target Ritalin nitroxide 
analogue 150 as outlined in Scheme 4.16 below. However, to determine the 
diastereoselectivity of this method by 1H NMR spectroscopy, the dirhodium-
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catalyzed intermolecular C-H insertion was first attempted on the methoxyamine 
derivative 309 of methyl diazoacetate TMIO 308. Since the required N-Boc-
piperidine 306 and diazoacetate methoxyamine 309 starting materials were not 
readily available, their syntheses are discussed below. 
 
Scheme 4.15. Dirhodium-catalyzed asymmetric synthesis of Ritalin 148. Reagents 
and conditions: a. Rh2(S-DOSP)2, hexane, -50 oC; then TFA. 
 
Scheme 4.16. Proposed asymmetric synthesis of 150 via dirhodium-catalyzed 
intermolecular C-H insertion of methyl aryldiazoacetate 308. Reagents and 
conditions: a. Rh2(S-DOSP)2, hexane, -50 oC; then TFA. 
4.2.3.1 Synthesis of N-Boc Piperidine 306  
Piperidine 310 was readily converted to the N-Boc-protected derivative 306 by 
allowing it to react at room temperature with Boc-anhydride for two hours (Scheme 
4.17). The crude product was purified by Kugelrohr distillation to give compound 
306 as clear oil in 95% yield. All characterization data obtained for compound 306 
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Scheme 4.17. Synthesis of N-Boc piperidine 306. Reagents and conditions: a. 
Boc2O, 0 oC-RT, THF, 2 h, 95%. 
4.2.3.2 Synthesis of Methyl Diazoacetate Methoxyamine 309 
Scheme 4.18 below depicts the proposed route for the synthesis of diazoacetate 309 
from the benzyl bromide intermediate 283. Compound 283 was synthesized as per 
Scheme 4.4. 
 
Scheme 4.18. Synthesis of methyl diazoacetate methoxyamine 309. Reagents and 
conditions: a. TMSCN, TBAF, MeCN, reflux; b. 5 M KOH, reflux; c. MeOH, 
H2SO4 (98%), reflux; d. DBU, p-ABSA, MeCN, RT, Ar. 
4.2.3.3 Synthesis of Benzylcyanide Methoxyamine 311 via Cyanation of 283 
Cyanation of benzyl bromide 283 was facilitated by trimethylsilyl cyanide (TMSCN) 
as the cyanide source. TMSCN is a stabilized hydrogen cyanide that is commonly 
employed (in the place of NaCN or KCN) for direct nucleophilic substitution of alkyl 
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an additive such as a fluoride compound, Lewis acid or a metal oxide.90-93 DeShong 
and coworkers employed tetrabutylammonium fluoride (TBAF) as an additive to 
successfully cyanate a range of benzylic halides and azides in excellent yield 
(Scheme 4.19).93 In that study, TBAF (ii) was reported to form a hypervalent 
cyanosilicate intermediate (iii) with TMSCN (i) which in turn facilitates the 












X = Br, Cl, Ii iiiii iv  
Scheme 4.19. Proposed mechanism for the cyanation of benzylic halides with 
TMSCN in the presence of TBAF. Adapted from DeShong et al.93 
Following a similar protocol, the benzyl bromide methoxyamine 283 was 
successfully converted to the corresponding benzyl cyanide 311 in 81% yield and 
was obtained as a white solid. The procedure involved refluxing a reaction mixture 
of benzyl bromide 283, TMSCN and TBAF in anhydrous acetonitrile (Scheme 4.20). 
Complete conversion was observed (by TLC analysis) after three hours. 
 
Scheme 4.20. Synthesis of benzyl cyanide methoxyamine 311 via TMSCN 
facilitated cyanation of benzylbromide methoxyamine 283. Reagents and conditions: 
a. TMSCN, TBAF, MeCN, reflux, 3 h, 81%. 
Evidence to support the transformation was obtained from the appearance of a 
characteristic C≡N stretch at 2250 cm-1 in the FTIR spectrum of 311. In comparison 
to the benzyl bromide methoxyamine precursor 283, an extra carbon peak was 
observed at 117.9 ppm in the 13C NMR spectrum of 311. This further supported the 
presence of a cyano group. Compound 311 was also characterized by HRMS and 1H 
NMR spectroscopy and its purity was verified by HPLC analysis to be >95%. The 
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4.2.3.4 Synthesis of 2-Methoxy-5-methoxycarbonylmethyl-1,1,3,3-
tetramethylisoindoline 223 via Hydrolysis of Benzyl Cyanide 311 
Nitriles are commonly hydrolyzed to the corresponding carboxylic acids under 
refluxing basic or acidic conditions. However, basic hydrolysis of 311 in refluxing 
potassium hydroxide solution (Scheme 4.21) furnished almost an equal mixture of 
the desired product 225 and, surprisingly, CTMIO methoxyamine derivative 312 as 
verified by the 1H NMR and HRMS spectra of the crude product.  A similar result 
was obtained with the benzyl cyanide nitroxide counterpart. Attempts to separate the 
crude mixture using conventional separation techniques (chromatography, trituration 
and recrystallization) were unsuccessful. 
 
Scheme 4.21. Basic hydrolysis of benzyl cyanide N-methoxamine 311. Reagents and 
conditions: a. 5 M, KOH, reflux, O/N. 
The unexpected formation of compound 312 under such basic hydrolysis conditions 
can be rationalized as follows (Scheme 4.22). The benzylic protons (CH2) are the 
most acidic in the nitrile intermediate 311. Gokel et al. proposed that the anion 313 
generated by the deprotonation of the nitrile precursor 311 could likely be oxidized 
by molecular oxygen to give the acyl cyanide intermediate 314.94 The acyl cyanide 
intermediate 314 can then be readily cleaved by potassium hydroxide to give the 
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Scheme 4.22. Gokel et al. proposed mechanism for oxidative hydrolysis and 
cleavage of nitrile 311 to the carboxylic acid 312.94 Reagents and conditions: a. 
KOH; b. O2; c. KOH, H2O. 
Similar oxidative hydrolysis (and cleavage) of nitriles are reported in the 
literature.94,95 However, the nitrile methoxyamine 311 was successfully hydrolyzed 
exclusively to the desired carboxylic acid 225 (as verified by 1H NMR spectroscopy 
and HRMS analysis) by refluxing in concentrated sulfuric acid solution (Scheme 
4.23). The carboxylic acid 225 was obtained in as a white solid in 84% yield. The 
transformation was supported by the presence of a strong C=O and a broad OH 
absorptions at 1737 and 3382 cm-1 respectively in the FTIR spectrum of 225. The 
mass of the molecular ion plus proton [M + H]+ was observed at m/z 264 in the 
HRMS spectrum. Compound 225 was >94% pure by HPLC analysis and its melting 
range was determined to be 115-116 oC. 
The methyl ester 223 was readily obtained by refluxing the carboxylic acid 225 in 
methanol in the presence of a catalytic amount of concentrated sulfuric acid. The 
methylene and the two methoxy protons were observed at 3.61, 3.69 and 3.77 ppm 
respectively in the 1H NMR spectrum of 223. Also, the loss of the carboxylic acid 
OH stretch in the FTIR spectrum of 223 further supported the successful 
esterification of 225. Notably, the methyl ester 223 was also obtained directly from 
the benzyl cyanide 311, in comparatively high yield (85%), when the acid hydrolysis 


































Scheme 4.23. Acid hydrolysis of benzyl cyanide N-methoxamine 302. Reagents and 
conditions: a. H2SO4 (98%), reflux, O/N, 84%; b. MeOH, H2SO4 (98%), reflux, 
O/N, 87%; d. MeOH, H2SO4 (98%), reflux, O/N, 85%. 
Although the methyl ester 223 was obtained from benzyl bromide precursor 283 in 
three steps, however, the total number of steps to 223 from the bromomethoxyamine 
23 precursor was six. Based on a recent palladium-catalyzed decarboxylative 
coupling of aryl halides with malonates developed by Lui and coworkers,96 the 
methyl ester 223 was, alternatively, readily obtained directly from the 
bromomethoxyamine 23 in one step. The protocol is discussed in the next section. 
4.2.3.5 Synthesis of Methyl Ester 223 from Bromomethoxyamine 23 
Alternatively, compound 223 was obtained directly from bromomethoxyamine 23 
via a palladium-catalyzed decarboxylative coupling reported by Lui and coworkers.96 
In that study, a series of α-aryl nitriles were successfully synthesized in high yields 
from readily available cyanoacetate salts and appropriate aryl halides. The coupling 
was facilitated by allyl palladium chloride dimer and a phosphine ligand such as 2,2′-
bis(diphenylphosphino)-1,1′-binaphthalene (BINAP) or 2-dicyclohexylphosphino-
2′,6′-dimethoxybiphenyl (S-Phos). To apply a similar decarboxylative coupling 
protocol in the synthesis of methyl ester 223 from the bromoamine precursor 23, 
potassium malonate 316 was employed in the place of the cyanoacetate salts. First, 
the malonate monoester salt 316 was readily prepared by reacting equimolar amounts 
of methyl malonate 315 with potassium hydroxide in methanol (Scheme 4.24). The 
salt 316 was obtained quantitatively as a white powdery solid after washing the crude 
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precipitate with diethyl ether and drying in a vacuum oven. All characterization data 
obtained for 316 were in agreement with the literature.96 
 
Scheme 4.24. Synthesis of potassium malonate 316. Reagents and conditions: a. 
KOH, MeOH, 0 oC-RT, O/N, 97%. 
To access the methyl ester 223, the oxidative decarboxylative coupling protocol 
involved refluxing a degassed reaction mixture of bromomethoxyamine 23 and 
malonate 316 in the presence of catalytic amounts of allyl palladium chloride dimer, 
BINAP, and DMAP (Scheme 4.25). Compound 223 was obtained in 54% after 
purification by silica gel column chromatography. All characterization data obtained 
herein were in agreement with those obtained via Scheme 4.23 above. 
 
Scheme 4.25. Synthesis of methyl ester 223 via palladium-catalyzed oxidative-
decarboxylative coupling of bromomethoxyamine 23 and potassium malonate 316. 
Reagents and conditions: a. [Pd(Allyl)Cl]2, BINAP, DMAP, mesitylene, reflux, Ar, 
1d, 54%. 
The methyl ester 223 was obtained in 54% via the single oxidative decarboxylative 
coupling step whereas in comparison the nitrile hydrolysis route (Scheme 4.4, 
Scheme 4.20 and Scheme 4.23) gave an overall yield of 52% in five or six steps 
from 23. 
4.2.3.6 Synthesis of Methyl Diazoacetate Methoxyamine 309 
α-Diazo carbonyl compounds are versatile building blocks widely employed in a 
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cycloaddition, cyclization of unsaturated substrates and catalytic C-H insertion 
reactions.97 Due to their structure and high nitrogen content, diazo compounds are 
highly reactive. Diazo compounds are thermally unstable and acid labile. Under most 
reaction conditions, they generally decompose to give the thermodynamically stable 
dinitrogen. One approach commonly used to access diazo carbonyl compounds is the 
Regitz diazo transfer reaction.98 The approach generally involves a base-catalyzed 
reaction of p-toluenesulfonyl (tosyl) azide with an active methylene group (next to 
electron withdrawing groups). DBU is the most common base employed in the 
Regitz diazo transfer reaction. Despite the wide use of tosyl azide as the source of 
nitrogen in the diazo transfer reactions, the p-acetamidobenzenesulfonyl azide (p-
ABSA) derivative has also been successfully employed.99 As shown in Scheme 4.26 
below, p-ABSA was employed as the diazo transfer reagent in the synthesis of the 










Scheme 4.26. Synthesis of methyl diazoacetate methoxyamine 309 via Regitz’s 
diazo transfer reaction of methyl ester 223. Reagents and conditions: a. p-ABSA, 
DBU, MeCN, RT, Ar, 1 d, 86%. 
Thus, the α-diazo methyl ester 309 was prepared in excellent yield when compound 
223 was allowed to react with p-ABSA in the presence of DBU for one day. 
Compound 309 was obtained as a bright yellow solid in 86% yield following 
purification by silica gel column chromatography. The characteristic ‘diazo band’ 
(CN≡N stretch) was observed as a strong signal at 2107 cm-1 in the FTIR spectrum 
of 300. Also, the loss of the distinct methylene (CH2) protons signal of 223 at 3.61 
ppm in the 1H NMR spectrum of the isolated product further supported the formation 
of the α-diazo methyl ester 309. HRMS analysis of 309 confirmed the presence of 
the [M + H]+ ion at m/z 304. Compound 309 was >95% pure by HPLC analysis and 
its melting range was determined to be 91-92 oC. Notably, the α-diazo methyl ester 
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309 was slightly unstable at room temperature and decomposed over time to the 
methyl ester 223. This was verified by TLC and 1H NMR spectroscopy analysis. 
4.2.3.7 Attempted Synthesis of Methoxyamine Derivative of Ritalin-Nitroixide 
150 via Dirhodium-Catalyzed Intermolecular C-H Insertion 
As mentioned earlier, the key and ultimate step in the enantioselective synthesis of 
the target Ritalin-methoxyamine derivative 317 is the dirhodium-catalyzed 
intermolecular C-H insertion reaction between N-Boc piperidine 306 and a transient 
metal carbene generated in situ by a metal-induced extrusion of nitrogen from α-
diazo methyl ester 309.100 Thus, α-diazo methyl ester 309 and N-Boc piepridine 306 
were allowed to react in the presence of catalytic amount of Rh2(S-DOSP)2 under an 
argon atmosphere at −50 oC (Scheme 4.27).  
 
Scheme 4.27. Attempted dirhodium-catalyzed intermolecular C-H insertion reaction 
of α-diazo methyl ester 309 and N-Boc piperidine 306. Reagents and conditions: a. 
Rh2(S-DOSP)2, hexane, Ar, 14 h, -50 oC. 
TLC analysis of the reaction mixture indicated complete consumption of the starting 
α-diazo compound 300 after fourteen hours of reaction. However, a complex mixture 
of products was observed by TLC and in the 1H NMR spectrum of the isolated 
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techniques (chromatography and recrystallization) were unsuccessful. Despite the 
complexity of the crude product mixture, neither the starting α-diazo methyl ester 
309 nor the estimated proton signals of the desired product were present in the 1H 
NMR spectrum. As mentioned in the preceding section, the α-diazo methyl ester 309 
is unstable and decomposes over time to give the methyl ester precursor 223. 
However, this was not the case under the dirhodium-catalyzed intermolecular C-H 
insertion reaction conditions because the 1H NMR spectrum of the crude mixture did 
not contain any characteristic proton signals that matched those of the methyl ester 
223 protons. 
In addition, HRMS analysis of the crude mixture further indicated the formation of 
the desired product 317 was unsuccessful. Attempts to optimize the reaction 
conditions including performing the reaction at different temperatures (-78 oC, room 
temperature and 50 oC), increasing or decreasing the catalytic load (from 1% mol to 
5% or 0.5% mol) and using different solvents (cyclohexane) produced similar results. 
While no other dirhodium catalyst was employed, it would be interesting to examine 
other catalysts in the future. 
4.3 Summary of Results 
As part of a wider strategy towards developing novel dual action antioxidant 
nitroxides, the pharmacophore hybridization approach was successfully employed 
herein to synthesize the novel, merged L-Dopa nitroxide analogue 149. The target 
chiral α-amino acid 149 was prepared via the Schöllkopf’s bis-lactim ether 
asymmetric synthesis of α-amino acids. The key step in this approach involved 
diastereoselective alkylation of the Schöllkopf chiral auxiliary 275 with benzyl 
bromide intermediates (280 and 283) in high yields. As a potential dual acting 
therapeutic, it is anticipated that compound 149 could retain the beneficial anti-
Parkinson’s effects while at the same time provide remedy for the drug-induced 
cellular oxidative stress-related damages that usually accompanies PD drugs such as 
L-Dopa. 
The Schöllkopf’s bis-lactim ether approach in combination with the palladium-
catalyzed Sonogashira coupling reaction was also successfully employed to 
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synthesize the rigid alkyne-linked chiral α-amino acid 151. Due to its rigidity and 
chirality, compound 151 was designed as a potential site directed spin label for 
studying the structure and dynamics of macromolecules, specifically proteins, with 
minimal drawbacks associated with rotational mobility, isomerization, multiple 
conformers and achiral effects. As a potent radical scavenger, compound 151 could 
also be used to monitor ROS-induced cellular oxidative stress-related damages to 
peptides and proteins under study. 
In addition to successfully synthesizing target compounds 149 and 151, attempts 
were made to synthesize the Ritalin-nitroxide analogue 150 via a highly regio-, 
diastereoselective rhodium-catalyzed intermolecular C-H insertion of methyl 
phenyldiazoacetate 309 into N-Boc-piperidine 206 to give the D-threo-
methylephenedate TMIO methoxyamine derivative 317. Despite successful synthesis 
of the diazoacetate intermediate 309, unfortunately, the intermolecular C-H insertion 
step produced a complex mixture of products. Evidence for the desired product 317 
or the starting diazoacetate 209 could not be found in either the 1H NMR or HRMS 
spectra of the isolated product. Attempts to optimize the reaction conditions were 
unsuccessful. 
At present both targets α-amino acids (149 and 151) are being considered for 
appropriate biological evaluation of their therapeutic and/or spin labelling effects. 
The final results and discussion section of this thesis (Chapter 5) uses the 
pharmacophore hybridization approach to synthesize novel dual acting catechol and 
1,3-benzodioxole-based isoindoline TMI and TMIO compounds (154-161). The 
target compounds (154-161) are the first examples of catechol-based nitroxides that 
could function as potential dual antioxidant therapeutics as well as synthetic 
templates to build functional materials. 
Synthesis of L-Dopa and Ritalin Nitroxide Analogues 
 229 
4.4 Experimental 
4.4.1 Synthesis of 5-Bromo-1,1,3,3-tetramethylisoindolin-2-yloxyl 28 
 
mCPBA (11 g, 37.8 mmol, 1.2 equiv, 77%) was added to a solution of 5-bromo-
1,1,3,3-tetramethylisoindoline 66 (8 g, 31.5 mmol) in DCM (300 mL) at 0 oC. The 
reaction mixture was stirred for 30 min and then at RT for a further 1.5 h. The 
resulting solution was washed with dilute HCl (0.5 M, 50 mL), NaOH (2 M, 50 mL x 
3) and brine (50 mL) solutions and then dried over anhydrous Na2SO4. The filtrate 
was concentrated in vacuo and the residue purified by trituration from hexane to give 
compound 28 as a bright yellow solid (7.37 g, 87%). Mp. 138-140°C (Lit.,50 139-
141°C).  
4.4.2 Synthesis of 5-Bromo-2-methoxy-1,1,3,3-tetramethylisoindoline 23 
 
A solution of H2O2 (6.68 mL, 32 mmol, 2 equiv, 30%) was added dropwise (over 30 
min) to a solution of 5-bromo-1,1,3,3-tetramethylisoindolin-2-yloxyl 28 (4.31 g, 16 
mmol, 1 equiv.) and FeSO4.7H2O (6.68 g, 24 mmol, 2 equiv.) in DMSO (40 mL). 
The resulting reaction mixture was stirred for 1 h and then diluted with H2O (100 
mL). The aqueous layer was extracted with Et2O (70 mL x 4) and the combined 
Et2O extracts were washed with NaOH (2 M, 50 mL), brine (50 mL), and then dried 
over anhydrous Na2SO4. The solvent was removed under reduced pressure and the 
crude residue purified by filtering through a short silica gel column (hexane) to give 
5-bromo-2-methoxy-1,1,3,3-tetramethylisoindoline 23 as a colourless oil (4.232 g, 
93%). 1H NMR (CDCl3, 400 MHz): δ = 1.40 (br, s, 12 H, CH3), 3.60 (s, 3 H, 
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Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 25.0 (br, CH3), 29.9 (br, CH3), 65.5 
(OCH3), 66.9 (C-CH3), 70.0 (C-CH3), 120.7  (Ar-C), 123.3 (Ar-C), 124.8 (Ar-C), 
130.2 (Ar-C), 144.2 (Ar-C), 147.5 (Ar-C). 
4.4.3 Synthesis of 5-Formyl-2-methoxy-1,1,3,3-tetramethylisoindoline 22  
 
n-Butyllithium (3.57 mL, 5.72 mmol, 1.2 equiv, 1.6 M in hexanes) was added 
dropwise to a solution of 5-bromo-2-methoxy-1,1,3,3-tetramethylisoindoline 23 
(1.354 g, 4.76 mmol, 1 equiv.) in dry THF (20 mL) at -78°C under Ar. DMF (1.1 
mL, 14.3 mmol, 3 equiv.) was added after 15 min and the resulting mixture was 
allowed to warm to RT over 3 h. The reaction was quenched with H2O (30 mL) and 
stirred for a further 15 min. The aqueous phase was extracted with Et2O (60 mL x 4) 
and the combined Et2O extracts were washed with HCl (2 M, 40 mL), NaOH (2 M, 
40 mL), and brine (50 mL). The Et2O layer was dried over anhydrous Na2SO4 and 
concentrated under reduced pressure. The crude residue was purified by flash column 
chromatography (Hexane/DCM, 2:1) to afford 5-formyl-2-methoxy-1,1,3,3-
tetramethylisoindoline 22 as white solid (1 g, 96%). Mp. 71-72 oC. HPLC purity 
(>95%). 1H NMR (CDCl3, 400 MHz): δ = 1.42 (d, 6 H, CH3), 1.46 (br, s, 6 H, 
CH3), 3.78 (s, 3 H, OCH3), 7.26 (d, 1 H, J = 7.8 Hz, Ar-H), 7.64 (d, 1 H, J = 1.2 Hz, 
Ar-H), 7.75 (dd, 1 H, J = 7.8 Hz, 1.2 Hz, Ar-H), 9.98 (s, 1 H, HC=O). 13C NMR 
(CDCl3, 100 MHz): δ = 24.4 (br, CH3), 29.9 (br, CH3), 65.6 (OCH3), 67.0 (C-CH3), 
67.3 (C-CH3), 122.2 (Ar-C), 122.6 (Ar-C), 130.1 (Ar-C), 136.1 (Ar-C), 146.5 (Ar-
C), 152.5 (Ar-C), 192.0 (C=O). HRMS (ESI): m/z (%) = 234.1450 (20) [M + H]+; 
calcd. for C14H19NO2: 233.1416; found 233.1416. ATR-FTIR: υmax= 2987 (m, Ar C-
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4.4.4 Synthesis of 5-Hydroxymethyl-2-methoxy-1,1,3,3-tetramethylisoindoline 
285 
 
Sodium borohydride (175.1mg, 4.63 mmol, 1.5 equiv.) was added to a solution 5-
formyl-2-methoxy-1,1,3,3-tetramethylisoindoline 23 (720 mg, 3.09 mmol, 1 equiv.) 
in methanol (10 mL) at 0 oC. The reaction mixture was stirred for 1.5 h and then 
concentrated in vacuo. The crude was residue picked up in Et2O (60 mL x 4) and 
washed with brine (50 mL). The Et2O layer was dried over anhydrous Na2SO4, 
concentrated under reduced pressure and the residue obtained was purified by 
purified by flash column chromatography (Hexane/EtOAc, 4:1) to afford 5-
hydroxymethyl-2-methoxy-1,1,3,3-tetramethylisoindoline 285 as white solid (701 g, 
96%). Mp 63-64 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 1.43 (s, 
12 H, CH3), 3.78 (s, 3 H, OCH3), 4.68 (s, 2 H, CH2), 7.09 (d, 1 H, J = 7.8 Hz, Ar-H), 
7.12 (s, 1 H, Ar-H), 7.23 (d, 1 H, J = 7.8 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ 
= 28.0 (w, br, C-CH3), 30.0 (w, br, C-CH3), 65.5 (OCH3), 65.6 (CH2), 67.0 (C-
CH3), 67.1 (C-CH3), 120.3 (Ar-C), 121.7 (Ar-C), 126.2 (Ar-C), 140.0 (Ar-C), 144.9 
(Ar-C), 145.7 (Ar-C). HRMS (ESI): m/z (%) = 236.1608 (15) [M + H]+; calcd. for 
C14H21NO2: 235.1572; found 235.1573. ATR-FTIR: υmax= 3393 (br, OH), 2988 (m, 
Ar C-H), 1026 (C-O) cm-1. 
4.4.5 Synthesis of 5-Bromomethyl-2-methoxy-1,1,3,3-tetramethylisoindoline 283 
 
TEA (812 µL, 5.82 mmol, 2 equiv.) and then MsCl (450 µL, 5.82 mmol, 2 equiv.) 
were added dropwise to a solution of 5-hydroxymethyl-2-methoxy-1,1,3,3-
tetramethylisoindoline 285 (685 mg, 2.91 mmol, 1 equiv.) and LiBr (758 mg, 8.73 
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2 h, the resulting reaction mixture was then diluted with Et2O (150 mL) and filtered. 
The filtrate was washed with brine (40 mL), dried over anhydrous Na2SO4, and the 
solvent removed under reduced pressure. LiBr (505.6 mg, 5.82 mmol, 2 equiv.) was 
added to a solution of the crude residue in acetone (10 mL) and the resulting mixture 
was refluxed for 2 h.  The reaction mixture was concentrated and taken up in Et2O 
(60 mL x 4). The Et2O layer was washed with brine (40 mL), dried over anhydrous 
Na2SO4, and the solvent removed under reduced pressure. The residue obtained was 
purified on a short flash column (Hexane/Et2O, 6:0.2) to give 5-bromomethyl-2-
methoxy-1,1,3,3-tetramethylisoindoline 283 as a white solid (703 mg, 81%). Mp. 97-
98 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 1.43 (s, 12 H, CH3), 
3.78 (s, 3 H, OCH3), 4.51 (s, 2 H, CH2), 7.06 (d, 1 H, J = 8 Hz, Ar-H), 7.11 (d, 1 H, 
J = 1.6 Hz, Ar-H), 7.26 (dd, 1 H, J = 8 Hz, 1.6 Hz, Ar-H). 13C NMR (CDCl3, 100 
MHz): δ = 34.0 (CH2), 65.5 (OCH3), 67.0 (C-CH3), 67.0 (C-CH3), 121.9 (Ar-C), 
122.2 (Ar-C), 128.2 (Ar-C), 136.8 (Ar-C), 145.7 (Ar-C), 145.9 (Ar-C). HRMS (ESI): 
m/z (%) = 298.0759/300.0751 (5) [M + H]+; calcd. for C14H20BrNO: 297.0728; 
found 279.0726. ATR-FTIR: υmax= 2971 (m, Ar C-H), 1051 (C-O), 653 (s, C-Br) 
cm-1. 
4.4.6 Synthesis of 5-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-
yl)methyl)-2-methoxy-1,1,3,3-tetramethylisoindoline 287 
 
A solution of (R)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine 275 (300 µL, 1.67 
mmol, 1 equiv.) in  freshly distilled THF (10 mL) under Ar was cooled to -78 oC. 
nBuLi (1.1 mL, 1.76 mmol, 1.6 M, 1.05 equiv.) was added dropwise and the reaction 
mixture was stirred for 15 min. A solution 5-bromomethyl-2-methoxy-1,1,3,3-
tetramethylisoindoline 283 (549 mg, 1.84 mmol, 1.1 equiv.) in THF (5 mL) was then 
added and stirring was continued for 3 h while allowing the reaction to return to RT. 
The reaction was quenched with H2O and extracted with Et2O (60 mL x 4). The 
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Na2SO4 and concentrated in vacuo. The crude residue was purified by silica gel 
column chromatography (hexane/CHCl3, 1:1) to give 5-(((2S,5R)-5-isopropyl-3,6-
dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-2-methoxy-1,1,3,3-
tetramethylisoindoline 287 as a white solid (535 mg, 80%). Mp. 62-63 oC. HPLC 
purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 0.59 (d, 3 H, J = 7.2 Hz, CH3), 
0.91 (d, 3 H, J = 7.2 Hz, CH3), 1.38 (s, 12 H, CH3), 2.11 (m, 1 H, CH), 3 (d, 1 H, 
CH), 3.07 (d, 2 H, J = 4.8 Hz, CH2), 3.71 (s, 6 H, 2 x OCH3), 3.77 (s, 3 H, OCH3), 
4.33 (q, 1 H, CH), 7.06 (d, 1 H, Ar-H), 7.11 (d, 1 H, Ar-H), 7.26 (dd, 1 H, Ar-H). 13C 
NMR (CDCl3, 100 MHz): δ = 16.4 (CH3), 19.0 (CH3), 30.9 (C(CH3)2), 40.0 (CH2), 
52.1 (OCH3), 52.4 (OCH3), 56.8 (CH),  60.1 (CH),  65.4 (OCH3), 66.89 (C-CH3), 
66.92 (C-CH3), 120.9 (Ar-C), 123.4 (Ar-C), 128.8 (Ar-C), 136.0 (Ar-C), 143.3 (Ar-
C), 144.5 (Ar-C), 162.4 (C=N), 164.2 (C=N). HRMS (ES): m/z (%) = 402.2775 
(100) [M + H]+; calcd. for C23H35N3O3: 401.2678; found 401.2679. ATR-FTIR: 
υmax= 2971 (m, Ar C-H), 1695 (s, C=N), 1235 and 1224 (s, C-N), 1047 and 1016 (C-
O) cm-1. 
4.4.7 Synthesis of 5-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-
yl)methyl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 269 via oxidation of 281 
 
NaHCO3 (74 mg, 882 μmol, 1.5 equiv.) and mCPBA (177 mg, 882 µmol, 1.5 equiv, 
77%) were added to a solution of 5-(((2S,5R)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazin-2-yl)methyl)-2-methoxy-1,1,3,3-tetramethylisoindoline 287 (236 mg, 
588µmol, 1 equiv.) in DCM (20 mL) at 0 oC. The cooling bath was removed after 30 
min and the reaction mixture was stirred at RT for further 2.5 h. The resulting 
solution was diluted (DCM, 100 mL), washed with NaOH (0.1 M, 30 mL), brine (40 
mL) and then dried over anhydrous Na2SO4. The solvent was removed under 
reduced pressure and the crude residue obtained was purified by flash column 
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281 as a yellow solid (184 mg, 81%). Mp. 85-86 °C. HPLC purity (>95%). 1H NMR 
(CDCl3, 400 MHz): δ = 0.61 (br, s, 3 H, CH3), 0.85 (br, s, 3 H, CH3), 2.14 (br, s, 1 
H, CH), 3.19 (br, s, 1 H, CH), 3.5 (br, t, 1 H, CH), 3.72 (br, s, 3 H, OCH3), 3.73 (br, 
s, 3 H, OCH3), 4.39 (br, s, 1 H, CH2). HRMS (ES): m/z (%) = 409.2320 (70) [M + 
Na]+; calcd. for C22H32N3O3•: 386.2444; found 386.2444. ATR-FTIR: υmax= 2971 
(m, Ar C-H), 1694 (s, C=N), 1235 and 1224 (s, C-N), 1047 and 1016 (C-O) cm-1. 
4.4.8 Synthesis of 5-Formyl-1,1,3,3-tetramethylisoindoline 73 
 
n-Butyllithium (1.6 M in hexanes, 5.45 cm3, 8.72 mmol, 2.2 equiv.) was added 
dropwise to a solution of 5-bromo-1,1,3,3-tetramethylisoindoline 66 (1 g, 3.94 
mmol) in dry THF (11 mL) at -78°C under argon. After 10 minutes the reaction was 
quenched by the addition of dry DMF (0.915 mL, 11.8 mmol, 3 equiv.). The 
resulting mixture was allowed to warm to room temperature and then diluted with 
H2O (100 mL). The aqueous phase was acidified with HCl (2 M) and extracted with 
Et2O (40 mL x 2) to remove non-basic impurities. The aqueous phase was then 
basified (pH >10) with NaOH (5 M) and extracted with Et2O (60 mL x 4). The 
combined Et2O extracts were washed with brine (40 mL), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The crude residue was purified by 
silica gel column chromatography (0.2% MeOH/CHCl3) to afford compound 73 (800 
mg, 100%) as an off-white crystalline solid. 1H NMR (CDCl3): δ = 1.50 (s, 6 H, 2 x 
CH3), 1.51 (s, 6 H, 2 x CH3), 7.29 (d, 1 H, J = 7.8 Hz, Ar-H), 7.68 (d, 1 H, J = 2.2 
Hz, Ar-H), 7.80 (dd, 1 H, J = 7.8 Hz, 2.2 Hz, Ar-H), 10.03 (s, 1 H, O=CH). 
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A solution of mCPBA (1.483 g, 5.09 mmol, 1.1 equiv, 77%) in DCM (10 mL) was 
added dropwise to a solution of 5-formyl-1,1,3,3-tetramethylisoindoline 73 (1 g, 4.62 
mmol) in DCM (150 mL) at 0 oC. The reaction mixture was stirred for 2 h the 
resulting bright yellow solution was washed with dilute HCl (0.5 M, 40 mL), NaOH 
(2 M, 40 mL x 2) and brine solutions and then dried over anhydrous Na2SO4. The 
filtrate was concentrated in vacuo and the residue purified by flash column 
chromatography (Hexane/EtOAc, 4:1) to give compound 27 as a bright yellow solid 
(928 mg, 92%). Mp. 138-140°C (Lit: 139-141°C).101 
4.4.10 Synthesis of 5-hydroxymethyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 280 
 
Sodium borohydride (60.31 mg, 1.59 mmol, 1.5 equiv.) was added to a solution 5-
formyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 27 (232 mg, 1.06 mmol, 1 equiv.) in 
methanol (5 mL) at 0 oC and the reaction mixture was stirred for 1.5 h. The reaction 
mixture was concentrated in vacuo and the residue taken up in Et2O (150 mL). The 
Et2O layer was washed with brine (40 mL), dried over anhydrous Na2SO4, and 
concentrated under reduced pressure to afford 5-hydroxymethyl-1,1,3,3-
tetramethylisoindolin-2-yloxyl 288 as a yellow solid which could be readily 
recrystallized from cyclohexane (200 mg, 86%). Mp. 110 (Lit.,102 108-110 oC). 
HPLC purity (>99%). FTIR (ATR): υmax = 3425 (s, O-H), 1426 (m, N-O), 1027 (s, 
C-O) cm-1. HRMS (ESI): m/z (%) = 221.1373 (15) [M + H]; calcd. for C13H18NO2• 
220.1338; found 220.1341. 
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Compound 280 was obtained from 288 by following similar procedure as per 
Section 4.4.5 above. Yellow solid, 75%. Mp. 110 (Lit.,102 108-110 oC). HPLC purity 
(>95%). HRMS (ESI): m/z (%) = 283.0488/285.0491 (30) [M + H]+; calcd. for 
C13H17BrNO•: 282.0494; found 282.0497. 
4.4.12 Synthesis of 5-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-
yl)methyl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 281 via benzyl bromide nitroxide 
280 
 
A solution of (R)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine 275 (226 µL, 1.26 
mmol, 1.1 equiv.) in  freshly distilled THF (10 mL) under Ar was cooled to -78 oC. 
nBuLi (775 μL, 1.24 mmol, 1.6 M, 1.08 equiv.) was added dropwise and the reaction 
mixture was stirred for 15 min. A solution 5-bromomethyl-1,1,3,3-
tetramethylisoindoline 280 (325 mg, 1.15 mmol, 1 equiv.) in THF (5 mL) was then 
added and stirring was continued for 3 h while allowing the reaction to return to RT. 
The reaction was quenched with H2O and extracted with Et2O (60 mL x 4). The 
combined Et2O extracts were washed with brine (50 mL), dried over anhydrous 
Na2SO4 and concentrated in vacuo. The crude residue was purified by silica gel 
column chromatography (Hexane/EtOAc, 1:0.1) to give 5-(((2S,5R)-5-isopropyl-3,6-
dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 
281 yellow solid (346 mg, 78%). All data obtained were consistent with those from 
Section 4.4.7. 
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Dilute HCl (2 mL, 0.5 M) was added to a solution of 5-(((2S,5R)-5-isopropyl-3,6-
dimethoxy-2,5-dihydropyrazin-2-yl)methyl)-1,1,3,3-tetramethylisoindolin-2-yloxyl 
281 (170 mg, 440 µmol, 1 equiv.) in MeCN (5 mL) at 0 oC. The resulting reaction 
mixture was allowed to return to RT while stirring overnight and diluted with H2O 
(20 mL). The aqueous layer was washed with DCM (15 mL), then cooled to 0 oC, 
and basified with saturated Na2CO3 solution to pH 11. The basic solution was 
extracted with DCM (30 mL x 4) and the combined DCM extracts were washed with 
brine (30 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
residue was purified by silica gel column chromatography (DCM/4%MeOH) to give 
(S)-2-amino-3-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)propanoate 282 as a 
yellow solid (96 mg, 76%). Mp. 88-90 oC. HPLC purity (>95%) HRMS (ES): m/z 
(%) = 292.1724 (70) [M + H]+, 314.2094 (100) [M + Na]+; calcd. for C16H23N2O3•: 
291.1709; found 291.1709. ATR-FTIR: υmax= 3382, 3319 (w, NH2), 2974 (m, Ar C-
H), 1730 (s, C=O), 1195 (s, CN), 1118 (s, C-O) cm-1. 
4.4.14 Synthesis of (S)-2-Amino-3-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)propanoic acid (L-Dopa-TMIO) 149 
 
A solution of (S)-2-amino-3-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)propanoate 
282 (78 mg, 268 µmol, 1 equiv.) in THF/H2O (3 mL/1 mL) was cooled to 0 oC. 
LiOH (19.23 mg, 803 µmol, 3 equiv.) was added and the reaction mixture was stirred 
for 10 min and then at RT for 2 h. The resulting solution was concentrated under 
reduced pressure and the residue obtained was purified by trituration with THF to 
give (S)-2-amino-3-(1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)propanoic acid 149 
as a yellow solid (96 mg, 76%). Mp. 121 oC (dec). HRMS (ES): m/z (%) = 300.1432 
(20) [M + Na]+; calcd. for C15H21N2O3•: 277.1552; found 277.1552. ATR-FTIR: 
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4.4.15 Synthesis of (2S,5R)-2-(4-Iodobenzyl)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazine 296 
 
A solution of (R)-2-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine  275 (200 µL, 1.12 
mmol, 1 equiv.) in  freshly distilled THF (5 mL) under Ar was cooled to -78 oC. To 
that was added dropwise nBuLi (761 µL, 1.22 mmol, 1.6 M, 1.05 equiv.) and the 
reaction mixture was stirred for 15 min. Then a solution 4-iodobenzyl bromide 295 
(398 mg, 1.34 𝜇mol, 1.2 equiv.) in THF (3 mL) was added and stirring was 
continued for 1h at -78 oC before allowing it to return to room temperature (3 h). The 
reaction was quenched with H2O (100 mL) and extracted with Et2O (60 mL x 4). 
The combined Et2O extracts were washed with brine (40 mL), dried over anhydrous 
Na2SO4 and concentrated in vacuo. The crude residue was purified by silica gel 
column chromatography (Hexane/EtOAc, 4:0.2) to give (2S,5R)-2-(4-iodobenzyl)-5-
isopropyl-3,6-dimethoxy-2,5-dihydropyrazine 296 (384 mg, 86%) as a white solid. 
Mp. 96-96.5 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 0.61 (d, 3 
H, J = 6.8 Hz, CH3), 0.96 (d, 3 H, J = 6.8 Hz, CH3), 2.16 (m, 1 H, CH), 3.02 (d, 1 H, 
J = 3 Hz, CH2), 3.4 (d, 1 H, CH), 3.67 (s, 3 H, OCH3), 3.71 (s, 3 H, OCH3), 4.28 (d, 
1 H, J = 4 Hz, CH), 6.85 (d, 2 H, J = 7.6 Hz, Ar-H), 7.53 (d, 2 H, J = 7.6 Hz, Ar-
H). 13C NMR (CDCl3, 100 MHz): δ = 16.5 (CH3), 19.0 (CH3), 31.4 (C(CH3)2), 39.4 
(CH2), 52.2 (OCH3), 52.4 (OCH3), 56.3 (CH),  60.1 (CH),  91.8 (Ar-C), 132.0 (Ar-
C), 136.9 (Ar-C), 137.1 (Ar-C), 162.2 (C=N), 164.0 (C=N). HRMS (ES): m/z (%) = 
401.0653 (100) [M + H]+; calcd. for C16H21IN2O2: 400.0648; found 400.0650. ATR-
FTIR: υmax= 2964 (m, Ar C-H), 1689 (s, C=N), 1224 (s, C-N), 1008 (C-O) cm-1. 
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n-Butyllithium (1.6 M in hexane, 5.45 mL, 8.72 mmol, 2.2 equiv.) was added 
dropwise to a solution of 5-bromo-1,1,3,3-tetramethylisoindoline 66 (1 g, 3.94 mmol 
1 equiv.) in dry THF (15 mL) at -78°C under argon. After 10 minutes the reaction 
was quenched by the addition of iodine (3g in 10 mL THF, 11.8 mmol, 3 equiv.) in 
dry THF (10 mL). The resulting mixture was allowed to warm to room temperature 
and then diluted with H2O (40 mL). The aqueous phase was basified with NaOH (5 
M) and extracted with DCM (60 mL x 4). The combined DCM extracts were washed 
with brine (40 mL) and the aqueous phase was then basified (pH >10) with NaOH (5 
M) and extracted with DCM (60 mL x 4). The combined DCM extracts were washed 
with brine (40 mL), dried over anhydrous Na2SO4 and concentrated under reduced 
pressure. The crude residue obtained was dissolved in MeOH/DCM (10:1 mL) and 
NaHCO3 (100 mg) added. Aqueous hydrogen peroxide solution (1 mL, 30 wt. % in 
H2O) was added dropwise and the resulting solution acidified with H2SO4 (30 mL, 2 
M). Acid aqueous layer was washed with DCM (20 mL x 2) and the combined DCM 
layers were extracted with H2SO4 (3 x 15 mL, 2 M). The combined H2SO4 extracts 
were then washed with DCM (20 mL) and basified with NaOH (10 M). The basic 
layer was extracted with DCM (60 mL x 4) and the combined DCM layers were 
washed with brine (40 mL), dried over anhydrous Na2SO4 and concentrated under 
reduced pressure to give 5-iodo-1,1,3,3-tetramethylisoindoline 68 as golden oil (950 
mg, 80%). 1H NMR (400 MHz, CDCl3) δ 1.42 (s, 6 H, CH3), 1.44 (s, 6 H, CH3), 6.9 
(d, 1 H, Ar-H), 7.45 (d, 1 H, Ar-H), 7.56 (dd, 1 H, Ar-H). 13C NMR (100 MHz, 
CDCl3) δ 31.7 (CH3), 31.8 (CH3), 62.6 (CCH3), 62.7 (CCH3), 92.2 (Ar-C), 123.5 
(Ar-C), 130.8 (Ar-C), 136.0 (Ar-C), 138.6 (Ar-C), 151.4 (Ar-C).  
4.4.17 Synthesis of 5-Iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl 6180 
 
m-Chloroperoxybenzoic acid (1.3 g, 4.48 mmol, 1.5 equiv., 77%) was added to a 
solution of 5-iodo-1,1,3,3-tetramethylisoindoline 68 (900 mg, 3 mmol, 1 equiv.) in 
DCM (200 mL) at 0 oC. The reaction mixture was stirred for 30 min and then at RT 
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mL), NaOH (2 M, 40 mL x 2) and brine (50 mL) solutions and dried over anhydrous 
Na2SO4. The filtrate was concentrated in vacuo and the crude residue purified by 
flash column chromatography (Hexane/DCM, 1:1) to give 5-iodo-1,1,3,3-
tetramethylisoindolin-2-yloxyl 61 as  a yellow solid (825 mg, 87%). Mp. 132-135 °C 
(Lit.,81 132-135 °C). 
4.4.18 Synthesis of 5-(3-Hydroxy-3-methyl)butynyl-1,1,3,3-tetramethylisoindolin-
2-yloxyl 29780 
 
A reaction mixture of 5-iodo-1,1,3,3-tetramethylisoindolin-2-yloxyl 61 (800 mg, 
2.53 mmol), DABCO (852 mg, 7.59 mmol, 3 equiv.), Pd(OAc)2 (16 mg, 76 µmol, 3 
mol%), 2-methyl-3-butyn-2-ol 9 (1.21 mL, 12.65 mmol, 5 equiv.) in MeCN (15 mL) 
was refluxed under Ar for 24 h. The mixture was concentrated in vacuo and the 
crude residue purified by silica gel flash column chromatography (Hexane/EtOAc, 
1:1) to give  5-(3-hydroxy-3-methyl)butynyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 
297 as a brown–orange oil (482 mg, 70%). ATR-FTIR: υmax= 3387 (OH), 2976 
(ArCH) cm-1.  
4.4.19 Synthesis of 5-Ethynyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 90 
 
A suspension of KOH (924 mg, 14.3 16.52 mmol, 10 equiv.) in toluene (150 mL) 
was heated to reflux until the solid KOH was almost completely dissolved.  5-(3-
Hydroxy-3-methyl)butynyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 297 (450 mg, 1.65 
mmol, 1 equiv.) in  toluene (20 mL) was the added and the resulting solution was 
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and washed with brine (15 mL x 2), dried over anhydrous Na2SO4 and concentrated 
under reduced pressure. The residue obtained was purified by silica gel flash column 
chromatography (Hexane/EtOAc, 4:1) to give 5-ethynyl-1,1,3,3-
tetramethylisoindolin-2-yloxyl 90 as a pale yellow crystalline solid (329 mg,  93%). 
Mp. 126–128 C (Lit.,80 126–128 oC). 
4.4.20 Synthesis of (S)-Methyl 2-amino-3-(4-iodophenyl)propanoate 
hydrochloride 299 
 
A solution of (2S,5R)-2-(4-iodobenzyl)-5-isopropyl-3,6-dimethoxy-2,5-
dihydropyrazine 296 (220 mg, 550 µmol, 1 equiv.) in MeCN/H2O (5 mL/0.5 mL) 
was cooled to 0 oC. A solution of TFA (128 µL, 1.65 mmol, 3 equiv.) in DCM (1 
mL) was added dropwise and the resulting mixture was stirred at 0 oC for 30 min and 
then at RT for a further 2.5 h. The reaction mixture was then cooled in an ice bath 
and basified with saturated NaHCO3 solution (ca. pH 10). The resulting mixture was 
extracted with DCM (60 mL x 4) and the combined DCM extracts were washed with 
brine (40 mL), dried over anhydrous Na2SO4 and concentrated in vacuo. The crude 
residue was obtained as a mixture of (S)-4-iodophenylalanine 299 and D-valine 279 
methyl esters as determined by IH NMR spectroscopy (140 mg). This crude mixture 
was used in the next step without further purification. 1H NMR (CDCl3, 400 MHz): 
Peaks for 299; δ = 0.90 (d, 3 H, J = 4 Hz, CH3), 0.97 (d, 3 H, J = 4 Hz, CH3), 2.02 
(m, 1 H, CH), 2.81 (dd, 1 H, J = 12 Hz, 4 Hz, CH2), 3.03 (dd, 1 H, J = 12 Hz, 4 Hz, 
CH2), 3.31 (d, 1 H, J = 4 Hz, CH), 3.72 (s, 3 H, OCH3), 6.95 (d, 2 H, J = 8 Hz, Ar-
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A mixture of (S)-4-iodophenylalanine 299 and D-valine 279 methyl esters (140 mg) 
in DCM (5 mL) was cooled in an ice bath. TEA (192 µL, 1.37 mmol, 2.5 equiv.) and 
then (Boc)2O (240 mg, 1.1 mmol, 2 equiv.) were added and the resulting mixture 
was stirred overnight while allowing it to return to RT. The reaction mixture was 
diluted with H2O then extracted with DCM (60 mL x 4). The combined DCM 
extracts were washed with brine (40 mL), dried over anhydrous Na2SO4, and 
concentrated under vacuum. The crude residue obtained was purified by silica gel 
column chromatography (Hexane/EtOAc, 5:0.6) to give (S)-2-((tert-
butoxycarbonyl)amino)-3-(4-iodophenyl)propanoate 300 as a white solid (140 mg, 
66% over the two steps from 296). Mp. 77.5-78 oC (Lit.,104 78.5-80 oC). HPLC purity 
(>95%). 1H NMR (CDCl3, 400 MHz): δ = 1.42 (s, 9 H, C(CH3)3),  2.95 (dd, 1 H, J = 
14.4 Hz, 6 Hz, CH2), 3.06 (dd, 1 H, J = 14.4 Hz, 6.4 Hz, CH2), 3.72 (s, 3 H, OCH3), 
4.56 (br, d, 1 H, CH), 4.96 (br, d, 1 H, NH), 6.87 (d, 2 H, J = 8 Hz, Ar-H), 7.61 (d, 2 
H, J = 8 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ =  28.3 (CH3), 37.92 (CH2), 
37.93 (C(CH3)2), 52.3 (OCH3), 54.2 (CH),  92.5 (Ar-C), 131.3 (Ar-C), 135.7 (Ar-C), 
137.6 (Ar-C), 155.0 (C=O), 172.1 (C=O). HRMS (ES): m/z (%) = 390.0489 (40) [M 
+ H]+; calcd. for C15H20INO2: 389.0488; found 389.0488. ATR-FTIR: υmax= 3343 
(m, N-H), 2967 (m, Ar C-H), 1735 (s, C=O), 1684 (s, C=O), 1159 (C-O) cm-1. 
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4.4.22  Synthesis of Methyl (S)-2-((tert-butoxycarbonyl)amino)-3-(4-((1,1,3,3-
tetramethylisoindolin—2-yloxyl-5-yl)ethynyl)phenyl)propanoate 301 
 
Degassed TEA (200 µL) was added to a degassed reaction mixture of (S)-2-((tert-
butoxycarbonyl)amino)-3-(4-iodophenyl)propanoate 300 (100 mg, 247 µmol, 1 
equiv.), 5-ethynyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 90 (63.44 mg, 296 µmol, 
1.2 equiv.), Pd(PPh3)3 (4.33 mg, 6.18 µmol, 0.025 equiv.), and CuI (1.17 mg, 6.18 
µmol, 0.025 equiv.) in THF (10 mL) under Ar. The reaction mixture was stirred at 
RT for 1 d and then concentrated in vacuo. The crude residue obtained was purified 
by silica gel column chromatography (hexane/EtOAc, 5:1) to give methyl (S)-2-
((tert-butoxycarbonyl)amino)-3-(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)ethynyl)phenyl)propanoate 301 as a yellow solid (81 mg, 66%). Mp. 183-184 oC. 
HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 1.43 (s, 9 H, C(CH3)3),  3.10 
(d, 1 H, J = 3.6 Hz, CH2), 3.15 (d, 1 H, J = 4 Hz, CH2), 3.73 (s, 3 H, OCH3), 4.6 (br, 
d, 1 H, J = 2.4 Hz, CH), 4.50 (br, d, 1 H, J = 7.2 Hz, NH), 7.15 (br, d, 2 H, J = 5.2 
Hz,  Ar-H), 7.44 (br, d, 2 H, J = 5.2 Hz, Ar-H). HRMS (ES): m/z (%) = 492.2455 (5) 
[M + H]+, 493.2577 (15) [M + 2H]+, 514.2381 (100) [M + Na]+; calcd. for 
C29H35N2O5•: 491.2546; found 491.2450. ATR-FTIR: υmax= 3336 (w, N-H), 2975 
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4.4.23 Synthesis of (S)-2-((tert-Butoxycarbonyl)amino)-3-(4-((1,1,3,3-
tetramethylisoindolin-2-yloxyl-5-yl)ethynyl)phenyl)propanoic acid 302 
 
LiOH (6.44 mg, 269 µmol, 3 equiv.) was added to a solution of (S)-2-((tert-
butoxycarbonyl)amino)-3-(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)ethynyl)phenyl) propanoate 301 (44 mg, 90 µmol, 1 equiv.) in H2O/THF (1 mL/3 
mL). The reaction mixture was stirred for 2 h and then diluted with H2O (15 mL). 
The resulting solution was washed with Et2O (15 mL) and the Et2O layer discarded.  
The aqueous layer was cooled in ice bath, neutralized with saturated NH4Cl, 
acidified with HCl (0.5 M, pH 3) and then extracted with EtOAc (40 mL x 4). The 
combined EtOAc extracts were washed with brine (30 mL), dried over anhydrous 
Na2SO4, and concentrated in vacuo give (S)-2-((tert-butoxycarbonyl)amino)-3-(4-
((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)ethynyl)phenyl)propanoic acid 302 as 
yellow solid (40 mg, 93%). Mp. 70-70.5 oC. HPLC purity (>95%). 1H NMR 
(CDCl3, 400 MHz): δ = 1.43 (s, 9 H, C(CH3)3),  3.14 (br, s, 1 H, CH2), 3.25 (br, s, 1 
H, CH2), 4.59 (br, s, 1 H, CH), 4.98 (br, s, 1 H, NH), 7.22 (br, s, 2 H, Ar-H), 7.45 
(br, s, 2 H, Ar-H). HRMS (ES): m/z (%) = 462.2445 (20) [M + H]+; calcd. for 
C28H33N2O4•: 461.2440; found 461.2440. ATR-FTIR: υmax= 3500-2500 (m, br, O-
H), 2975 (m, Ar C-H), 1710 (s, br, C=O), 1161 (C-O) cm-1. 
4.4.24 Synthesis of (S)-2-Amino-3-(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
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HCl (0.2 mL, 4 M in dioxane) was added to a solution of (S)-2-((tert-
butoxycarbonyl)amino)-3-(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)ethynyl)phenyl)propanoic acid 302 (35 mg, 73 µmol, 1 equiv.) in dioxane/H2O (2 
mL/0.1 mL). The reaction mixture was stirred overnight and concentrated in vacuo. 
The crude residue was washed with Et2O (5 mL), dissolved in MeOH (2 mL) and 
precipitated by dropwise addition of THF. The precipitate was collected to give (S)-
2-amino-3-(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)ethynyl)phenyl)propanoic acid 151 as a yellow solid (29 mg, 96%). Mp. 162-
163 oC (dec.). HRMS (ES): m/z (%) = 379.1989 (100) [M + 2H]+; calcd. for 
C23H25N2O3•: 475.2597; found 475.2597. ATR-FTIR: υmax= 3384 (s, br, OH), 2974 
(m, Ar C-H), 1614 (s, C=O), 1119 (C-O) cm-1. 
4.4.25 Synthesis of 5-[4-(((2S,5R)-5-Isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-
2-yl)methyl)phenyl)ethynyl] -1,1,3,3-tetramethylisoindolin-2-yloxyl 304 
 
Degassed TEA (300 µL) was added to a degassed reaction mixture of (2S,5R)-2-(4-
iodobenzyl)-5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazine 296 (150 mg, 374 
µmol, 1 equiv.), 5-ethynyl-1,1,3,3-tetramethylisoindolin-2-yloxyl 90 (120 mg, 560 
µmol, 1.5 equiv.), PdCl2(PPh3)2 (13 mg, 19 µmol, 0.05 equiv.) and CuI (3.5 mg, 19 
µmol, 0.05 equiv.)  in THF (10 mL) under Ar. The reaction mixture was stirred at RT 
overnight and then concentrated in vacuo. The crude residue obtained was purified 
by silica gel column chromatography (Hexane/EtOAc, 4:0.4) to give 5-[4-(((2S,5R)-
5-isopropyl-3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)phenyl)ethynyl]-1,1,3,3-
tetramethylisoindolin-2-yloxyl 304 as a yellow solid (133 mg, 73%). Mp. 85-86 oC. 
HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 0.62 (d, 3 H, J = 6.8 Hz, 
CH3), 0.96 (d, 3 H, J = 6.8 Hz, CH3), 2.17 (br, d, 1 H, J = 3.2 Hz, CH), 3.14 (br, d, 2 
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4.34 (br, d, 1 H, J = 4 Hz, CH), 7.11 (br, d, 2 H, J = 6.4 Hz, Ar-H), 7.37 (br, d, 2 H, J 
= 6.4 Hz, Ar-H). HRMS (ES): m/z (%) = 487.2791 (100) [M + H]+, 509.2616 (60) 
[M + Na]+; calcd. for C30H36N3O3•: 486.2757; found 486.2758. ATR-FTIR: υmax= 
2972 (m, Ar C-H), 1693 (s, C=N), 1237 (C-N), 1013 (C-O) cm-1. 
4.4.26 Synthesis of methyl (S)-2-Amino-3-(4-((1,1,3,3-tetramethylisoindolin-2-
yloxyl-5-yl)ethynyl)phenyl)propanoate 305 
 
Aqueous HCl (0.1 mL, 1 M) was added to a solution of 5-[4-(((2S,5R)-5-isopropyl-
3,6-dimethoxy-2,5-dihydropyrazin-2-yl)methyl)phenyl)ethynyl]-1,1,3,3-
tetramethylisoindolin-2-yloxyl 304 (75 mg, 154 µmol, 1 equiv.) in MeCN (3 mL) 
and the reaction mixture was stirred vigorously for 2 h. The reaction mixture was 
diluted with H2O and washed with DCM. The DCM wash layer was discarded and 
the aqueous layer was cooled in ice bath, basified with saturated NaHCO3 (pH 10) 
and extracted with DCM (40 mL x 4). The combined DCM extracts were wash with 
brine, dried over anhydrous Na2SO4, and concentrated in vacuo. The crude residue 
obtained was purified by silica gel column chromatography (DCM/MeOH, 96:4) to 
give methyl (S)-2-amino-3-(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)ethynyl)phenyl) propanoate 305 as a yellow solid (55 mg, 92%). Mp. 120-121 oC. 
HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 2.29 (br, dd, 1 H, J = 13.6 
Hz, 7.6 Hz, CH2), 3.13 (br, dd, 1 H, J = 13.6 Hz, 5.2 Hz, CH2), 3.73 (s, 3 H, OCH3), 
3.76 (br, s, 1 H, CH), 7.22 (br, d, 2 H, Ar-H), 7.46 (br, d, 2 H, Ar-H). HRMS (ES): 
m/z (%) = 392.2055 (100) [M + H]+, 414.1875 (40) [M + Na]+; calcd. for 
C24H27N2O3•: 391.2022; found 391.2022. ATR-FTIR: υmax= 3369 and 3309 (m, 
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4.4.27 Synthesis of (S)-2-Amino-3-(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-
yl)ethynyl)phenyl)propanoic acid 151 
 
LiOH (3.7 mg, 153 µmol, 2 equiv.) was added to a solution of methyl (S)-2-amino-3-
(4-((1,1,3,3-tetramethylisoindolin-2-yloxyl-5-yl)ethynyl)phenyl)propanoate 305  (30 
mg, 77 µmol, 1 equiv.) in H2O/THF (0.1 mL/3 mL). The reaction mixture was stirred 
for 2 h and then acidified to pH 3 with HCl (2 M) to give a compound 151 as a 
yellow precipitate that was filtered off. The remaining 151 was recovered by 
removing the solvent and triturating with cold MeOH/THF to removed NaCl.  
Compound 151 was obtained as a yellow solid (25 mg, 86%). Mp. 162-163 oC (dec.). 
HRMS (ES): m/z (%) = 379.1989 (100) [M + 2H]+; calcd. for C23H25N2O3•: 
475.2597; found 475.2597. ATR-FTIR: υmax= 3384 (s, br, OH), 2974 (m, Ar C-H), 
1614 (s, C=O), 1119 (C-O) cm-1. 
4.4.28 Synthesis of 5-Cyanomethyl-2-methoxy-1,1,3,3-tetramethylisoindoline 311 
 
TMSCN (201.5 µL, 1.61 mmol, 2 equiv.) was added drop wise to a solution of 5-
bromomethyl-2-methoxy-1,1,3,3-tetramethylisoindoline 283 (240 mg, 805 μmol, 1 
equiv.) and TBAF (1.61 mL, 1.61 mmol, 2 equiv., 1 M solution in THF) in MeCN (8 
mL) under Ar, and the reaction mixture refluxed for 3 h and allowed to cool to RT. 
The mixture was diluted with Et2O (150 mL) and washed with HCl (0.1 M, 20 mL), 
NaOH (0.1 M, 20 mL) and brine (40 mL), and dried over anhydrous Na2SO4. The 
solvent was removed under reduced pressure and the residue was purified by a flash 
column chromatography (Eluent: Hexane/EtOAc, 5:1) to give 5-cyanomethyl-2-
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58 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 1.43 (br, s, 12 H, 
CH3), 3.74 (s, 2 H, CH2), 3.78 (s, 3 H, OCH3), 7.05 (s, 1 H, Ar-H), 7.10 (d, 1 H, J = 
8 Hz, Ar-H), 7.18 (d, 1 H, J = 8 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 23.6 
(CH2), 25.0 (br, C-CH3), 29.0 (w, br, C-CH3), 65.5 (OCH3), 66.9 (C-CH3), 67.1 (C-
CH3), 118.0 (C≡N), 121.1 (Ar-C), 122.3 (Ar-C), 127.0 (Ar-C), 128.8 (Ar-C), 145.3 
(Ar-C), 146.4 (Ar-C). HRMS (ES): m/z (%) = 245.1582 (30) [M + H]+; calcd. for 
C15H20N2O: 244.1576; found 244.1576. ATR-FTIR: υmax= 2972 (m, Ar C-H), 2250 
(m, C≡N), 1051(s, C-O) cm-1.  
4.4.29 Synthesis of 5-Carboxymethyl-2-methoxy-1,1,3,3-tetramethylisoindoline 
225 via hydrolysis of 311  
 
Conc. H2SO4 (3 mL, 98%) was added to a suspension of 5-cyanomethyl-2-methoxy-
1,1,3,3-tetramethylisoindoline 311 (250 mg, 1.03 mmol, 1 equiv.) in H2O (3 mL). 
and the reaction mixture was refluxed overnight. The reaction mixture was cooled in 
an ice bath and diluted with water. The aqueous layer was extracted with Et2O (60 
mL x 4) and the combined Et2O extracts were washed with brine (40 mL), dried over 
anhydrous sodium sulfate, and concentrated in vacuo. The crude residue was purified 
by a short silica gel column chromatography (EtOAc) to give 5-carboxymethyl-2-
methoxy-1,1,3,3-tetramethylisoindoline 225 as a white solid (226 mg, 84%). Mp. 
115-116 oC. HPLC purity (>94%).  1H NMR (CDCl3, 400 MHz): δ = 1.42 (br, s, 12 
H, CH3), 3.63 (s, 2 H, CH2), 3.77 (s, 3 H, OCH3), 7.00 (s, 1 H, Ar-H), 7.04 (d, 1 H, J 
= 7.6 Hz, Ar-H), 7.15 (d, 1 H, J = 7.6 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 
25.0 (br, C-CH3), 29.0 (w, br, C-CH3), 40.9 (CH2), 65.5 (OCH3), 66.9 (C-CH3), 
67.0 (C-CH3), 121.7 (Ar-C), 122.5 (Ar-C), 128.3 (Ar-C), 132.2 (Ar-C), 144.4 (Ar-
C), 145.7 (Ar-C), 176.9 (C=O). HRMS (ES): m/z (%) = 264.1519 (15) [M + H]+; 
calcd. for C15H21NO3: 263.1521; found 263.1521. ATR-FTIR: υmax= 3382 (s, br, 
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4.4.30 Synthesis of 2-Methoxy-5-methoxycarbonylmethyl-1,1,3,3-
tetramethylisoindoline 223 from 225 
 
A solution of 5-carboxymethyl-2-methoxy-1,1,3,3-tetramethylisoindoline 225 (100 
mg, 380 µmol, 1 equiv.) and 2 drops of H2SO4 (98%) in MeOH (5 mL) was refluxed 
overnight. The reaction mixture was cooled to RT and diluted with H2O (30 mL). 
The aqueous layer was extracted Et2O (60 mL x 4) and the organic extract was 
washed with brine (40 mL), dried over anhydrous Na2SO4, and concentrated in 
vacuo. The crude residue obtained was purified by silica gel column chromatography 
(Hexane/EtOAc, 5:0.2) to give 2-methoxy-5-methoxycarbonylmethyl-1,1,3,3-
tetramethylisoindolin 223 as a white solid (92 mg, 87%). Mp. 79-80 oC. HPLC purity 
(>99%). 1H NMR (CDCl3, 400 MHz): δ = 1.42 (br, s, 12 H, CH3), 3.61 (s, 2 H, 
CH2), 3.69 (s, 3 H, OCH3), 3.77 (s, 3 H, OCH3), 7.00 (s, 1 H, Ar-H), 7.05 (d, 1 H, J 
= 8 Hz, Ar-H), 7.14 (d, 1 H, J = 8 Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 25.3 
(w, br, CH3), 29.7 (w, br, CH3), 41.2 (CH2), 52.1 (OCH3), 65.5 (OCH3), 66.9 (C-
CH3), 67.1 (C-CH3), 121.7 (Ar-C), 122.4 (Ar-C), 128.2 (Ar-C), 132.9 (Ar-C), 144.1 
(Ar-C), 145.6 (Ar-C), 172.2 (C=O). HRMS (ES): m/z (%) = 278.1680 (15) [M + H]+; 
calcd. for C16H23NO3: 277.1678; found 277.1678. ATR-FTIR: υmax= 2975 (m, Ar C-
H), 1736 (s, C=O), 1206 and 1143 (s, C-O) cm-1. 
4.4.31 Synthesis of Methyl Potassium Malonate 316 
 
A solution of methyl malonate 315 (5 mL, 43.75 mmol, 1 equiv.) in MeOH (30 mL) 
was cooled to 0 oC. KOH (2.455 g, 43.75 mmol, 1 equiv.) was added and the reaction 
mixture was allowed to return to RT while stirring overnight. The resulting solution 
was concentrated under reduced pressure and the residue obtained was washed with 
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316 as a white solid (6.63 g, 97%). 1H NMR (CD3OD, 400 MHz): 3.33 (s, 3 H, 
OCH3), 4.65 (s, 2 H, CH2). 13C NMR (D2O, 100 MHz): δ = 44.4 (CH2), 52.5 
(OCH3), 172.1 (C=O), 174.2 (C=O). 
4.4.32 Synthesis of 2-Methoxy-5-methoxycarbonylmethyl-1,1,3,3-
tetramethylisoindoline 223 from 23 and 316 
 
A Schlenk tube containing 5-bromo-2-methoxy-1,1,3,3-tetramethylisoindoline 23 
(316 mg, 1.11 mmol, 1 equiv.), potassium methyl malonate 316 (434.13 mg, 2.78 
mmol, 2.5 equiv.), allylpalladium (II) chloride dimer (8.14 mg, 22 µmol, 0.02 
equiv.), BINAP (41.54 mg, 67 µmol, 0.06 equiv.), and DMAP (13.6 mg, 11 µol, 0.01 
equiv.) in mesitylene (10 mL) was degassed and then heated for 1 d at 140 oC. The 
resulting mixture was concentrated under reduced pressure. The crude residue 
obtained was purified by silica gel column chromatography (Hexane/EtOAc, 5:0.2) 
to give 2-methoxy-5-methoxycarbonylmethyl-1,1,3,3-tetramethylisoindoline 223 as a 
white solid (164 mg, 54%). Mp. 79-80 oC. HPLC purity (>95%). 1H NMR (CDCl3, 
400 MHz): δ = 1.42 (br, s, 12 H, CH3), 3.61 (s, 2 H, CH2), 3.69 (s, 3 H, OCH3), 3.77 
(s, 3 H, OCH3), 7.00 (s, 1 H, Ar-H), 7.05 (d, 1 H, J = 8 Hz, Ar-H), 7.14 (d, 1 H, J = 8 
Hz, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 25.3 (w, br, CH3), 29.7 (w, br, CH3), 
41.2 (CH2), 52.1 (OCH3), 65.5 (OCH3), 66.9 (C-CH3), 67.1 (C-CH3), 121.7 (Ar-C), 
122.4 (Ar-C), 128.2 (Ar-C), 132.9 (Ar-C), 144.1 (Ar-C), 145.6 (Ar-C), 172.2 (C=O). 
HRMS (ES): m/z (%) = 278.1680 (15) [M + H]+; calcd. for C16H23NO3: 277.1678; 
found 277.1678. ATR-FTIR: υmax= 2975 (m, Ar C-H), 1736 (s, C=O), 1206 and 
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4.4.33 Synthesis of Methyl 2-diazo-2-(2-methoxy-1,1,3,3-tetramethylisoindolin-5-
yl)acetate 309 
 
DBU (116 µL, 772 µmol, 1.2 equiv.) was added dropwise to a solution of 2-
methoxy-5-methoxycarbonylmethyl-1,1,3,3-tetramethylisoindoline 223 (179 mg, 644 
µmol, 1 equiv.) and 4-acetamidobenzenesulfonyl azide (178 mg, 740 µmol, 1.15 
equiv.) in MeCN (3 mL) under Ar. The resulting reaction mixture was stirred for 1 
day and then concentrated under reduced pressure. The residue obtained was purified 
by silica gel column chromatography (Hexane/EtOAc, 8:0.2) to afford 2-diazo-2-(2-
methoxy-1,1,3,3-tetramethylisoindolin-5-yl)acetate 309 as a bright yellow solid (168 
mg, 86%). Mp. 91-92 oC. HPLC purity (>95%).   1H NMR (CDCl3, 400 MHz): δ = 
1.41(br, s, 12 H, CH3), 3.76 (s, 3 H, OCH3), 3.85 (s, 3 H, OCH3), 7.10 (d, 1 H, J = 8 
Hz, Ar-H), 7.25 (d, 1 H, J = 8 Hz, Ar-H), 7.27 (s, 1 H, Ar-H). 13C NMR (CDCl3, 100 
MHz): δ = 25.0 (w, br, C-CH3), 30.0 (w, br, C-CH3), 52.0 (OCH3), 65.5 (OCH3), 
66.9 (C-CH3), 67.2 (C-CH3), 77.2 (N2+=C), 117.6 (Ar-C), 122.1 (Ar-C), 123.2 (Ar-
C), 124.1 (Ar-C), 143.4 (Ar-C), 146.2 (Ar-C), 165.8 (C=O). HRMS (ES): m/z (%) = 
304.1591 (10) [M + H]+; calcd. for C16H21N3O3: 303.1583; found 303.1583. ATR-
FTIR: υmax= 2970 (m, Ar C-H), 2107 (s, C=N2), 1691 (s, C=O), 1047 (s, C-O) cm-1.  
4.4.34 Synthesis of N-Boc Piperidine 306 
 
A solution of di-tert-butyl dicarbonate (3 g, 13.75 mmol, 1 equiv.) in THF (15 mL) 
under an Ar atmosphere was cooled to 0 oC. Piperidine 310 (1.63 mL, 16.49 mmol, 
1.2 equiv.) was added dropwise and the resulting solution stirred at RT for 2 h. 10% 
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x 4). The Et2O extract was washed with brine (40 mL), dried over anhydrous 
Na2SO4 and concentrated under reduced pressure. The residue obtained was purified 
by Kugelrohr distillation to give compound 306 as colourless oil (2.42 mg, 95%). 1H 
NMR (CDCl3, 400 MHz): δ = 1.43(s, 9 H, CH3), 1.48 (m, 4 H, CH2), 1.53 (t, 2 H, 
CH2), 3.33 (t, 4 H, CH2). 13C NMR (CDCl3, 100 MHz): δ = 24.5 (CH3), 25.7 (CH2), 
28.5 (CH2), 44.6 (OCMe3), 79.1 (N-CH2), 154.9 (C=O).  
 
4.4.35 Attempted Synthesis of tert-Butyl (R)-2-((R)-2-methoxy-1-(2-methoxy-
1,1,3,3-tetramethylisoindolin-5-yl)-2-oxoethyl)piperidine-1-carboxylate 317 
 
A solution of Rh2(S-DOSP)4 (3.125 mg, 1.65 μmol, 0.01 equiv.) and N-Boc 
piperidine 306 (63.4 μL, 330 μmol, 2 equiv.) in dry hexane (1 mL) was added 
dropwise (over 30 min) to a solution of 2-diazo-2-(2-methoxy-1,1,3,3-
tetramethylisoindolin-5-yl)acetate 309 (50 mg, 165 μmol, 1 equiv.) in hexane (2 mL) 
at -50 oC under Ar. The resulting reaction mixture was stirred for 14 h at -50 oC and 
concentrated in vacuo. Attempts to purify the crude residue with silica gel column 
chromatography (Hexane/EtOAc, 4:1), trituration or recrystallization from methanol 
were unsuccessful. 
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Chapter 5: Synthesis of Novel Catechol-Based 
Nitroxides as Potential Multifunctional 
Antioxidants 
5.1 Background 
The catechol moiety is an integral structural and functional subunit of a number of 
biologically relevant endogenous compounds. Catecholamine neurotransmitters such 
as adrenaline 319, noradrenaline, and dopamine 152 (Figure 5.1), are involved in 
various cell signalling pathways. 
 
Figure 5.1. Chemical structure of catechol 318, dopamine 152 and adrenaline 319. 
Most natural antioxidant compounds, particularly those derived from fruits and 
vegetables, are rich in catecholic functionality. Flavonoids for instance are a class of 
phenolic compounds isolated from edible plants.1 They possess a variety of 
biological activities including antioxidant, antimicrobial, anticarcinogenic and anti-
inflammatory actions.1-4 Polyphenolic antioxidants like catechols exert their 
antioxidant effect mainly via a radical scavenging action that involves redox 
chemistry with the phenol moiety. As depicted in Scheme 5.1 below, the antioxidant 
activity of catecholinic compounds is attributed to the reversible redox triad between 
the catechol moiety 318 and its oxidation products, namely the semiquinone 320 and 
the quinone 321 derivatives.5 
Although catechols do spontaneously oxidize (autoxidation) under standard 
atmospheric conditions,6 the reaction is usually slow and most commonly, enzymes 
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oxidizing agents (sodium periodate, NaIO4)8 are employed for more rapid oxidation 
of catechols to their quinone counterparts. The resonance stabilized nature of the 
semiquinone radical 320 further accounts for the increased antioxidant action of 
catechol compounds (Scheme 5.2).9  
 
Scheme 5.1. Redox triad of catechols: catechol 318, semiquinone 320 and quinone 
321. 
 
Scheme 5.2. Resonance hybrids of the semiquinone radical 320. 
Owing to their electrophilic and redox characteristics, the highly reactive quinone 
species are extensively used as substrates to further modify and functionalize 
materials (Scheme 5.3). Such catechol-based functional materials are built 
exclusively via irreversible covalent bonds such as a Michael-type addition reaction 
to form thioethers and alkyl/aryl substituted amines, or a radical mediated 
homocoupling to form polymeric catechols.10 Catechols, in the form of 
polydopamine-based quinones like 327 for example, are identified as the integral 
component of the protein secreted and used by mussels for attachment to a variety of 
surfaces.11 Such strong adhesive properties of polydopamine have been utilized to 
build novel bioinspired and versatile adherent materials that can bind to both organic 
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of modified zwitterionic poly(carboxybetaine)-catechol polymer surfaces 
(Au@pCB2-catechol2) which were used to directly immobilize anti-activated 






























Scheme 5.3. Dopaquinone residue 322 as a substrate for building functional 
materials: a. Michael type addition reaction; b. Metal chelation; c. Schiff base 
reaction with amines (imine formation); d. Oxidative coupling reaction. Adapted and 
modified from Deming et al.10,19,20 
Catechols and their o-quinone derivatives also serve as ideal substrates that form 
stable functional complexes 324 with a variety of di and trivalent metal ions.20 Such 
complexes are commonly employed to build magnetic, sensing and electronic 
devices. 
Like their catechol counterparts, the methylenedioxyphenyl group (or 1,3-
benzodioxole) 328 is widely distributed in nature and it is also found in many 
pharmaceutical products (Figure 5.2).21-23 Safrole 329 is a benzodioxole containing 
natural product used as a starting material to synthesize insecticides, fragrances and 
some drugs.24-31 The illicit drug 3,4-methylenedioxy-N-methylamphetamine 153, 
widely known as Ecstasy or MDMA, is a benzodioxole derivative synthesized from 
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Safrole 329.32 MDMA has strong psychotherapeutic effects which make it a common 
recreational drug that is widely abused by young people.33-37  
 
Figure 5.2. Chemical structures of common 1,3-benzodioxole compounds: parent 
1,3-benzodioxole 328, safrole 329 and MDMA 153. 
Benzodioxole is primarily generated by a base-catalyzed methylation of catechol 
with a dihalomethane. Both the stable electron rich aromatic ring and the 
methylenedioxy protecting group of benzodioxole containing compounds account for 
their lower polarity compared to their catechol counterparts. Such low polarity makes 
benzodioxole-based therapeutics much effective at crossing the blood-brain barrier. 
Like an acetal group, benzodioxole hydrolyzes to catechol under acidic conditions. 
Compounds with benzodioxole functionality are liable to be readily oxidized by 
enzymes and other oxidizing agents. In biological systems, the cytochrome P450 
enzymes frequently catalyze the oxidative cleavage of the methylenedioxy group of 
both dietary and synthetic benzodioxole compounds.38  
Cytotoxic effects associated with their long-term use however have limited any 
therapeutic benefits of catechol and benzodioxole-based pharmacophores. Catecholic 
therapeutics and their oxidative metabolites cause damage to biomolecules by 
oxidative stress. There is therefore a need for effective antioxidant therapeutic 
interventions for drugs that contain this pharmacophore. 
Thus, the present study explores the synthesis of novel isoindoline based-
catecholamines and benzodioxoles, as well as their nitroxide derivatives (Figure 
5.3). As the first examples of catechol-based nitroxides, the target compounds could 
be explored as potential dual antioxidant therapeutics as well as synthetic 
templates/precursors for building functional materials. The target isoindoline-based 
catecholamines such as compound 154 could potentially serve as a new type of 
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to potent therapeutics like L-Dopa 147, dopamine 152 and adrenaline 319. L-Dopa 
147 for instance is identified as the standard-of-care treatment for Parkinson’s 
disease. 
 
Figure 5.3. Target catechol-based compounds: Catecholamines TMI 154 and TEI 
158, catechol TMIO 156 and TEIO 160, benzodioxole TMI 155 and TEI 159, 
benzodioxole TMIO 157 and TEIO 161. 
Compound 154 could also be used as a building block for catechol-containing 
functional materials via synthetic modifications through either the catechol or the 
amino functional group. Along with their nitroxide counterparts (156 and 160), the 
target catecholamines (154 and 158) are also designed as potential substrates for 
building new nanocomposite drug delivery systems. In addition, other 
nanocomposite materials could be built from these hybrid compounds for potential 
applications in sensing and electronic devices, catalysis and (bio)chemical reactions. 
The catechol-nitroxide analogues (156 and 160) are also designed as potential dual 
action antioxidants therapeutics owing to the presence of both the catechol and the 
free radical moieties. It is anticipated that the isoindoline based benzodioxole target 
compounds (155, 157, 159 and 161) may display similar sympathomemitic efficacies 
to their parent templates (328 and 153). In addition to the potential sympathomemitic 
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drug-induced and disease related oxidative stress through their reactive oxygen 
scavenging activities. 
Since increasing the steric bulk at the α-carbon slows the rate with which the 
nitroxide moiety gets reduced in biological system, each class of target compounds 
consists of the tetramethyl and tetraethyl-substituted isoindoline-based catecholic 
compounds. The syntheses are discussed in the subsequent sections. 
5.2 Results and Discussion 
5.2.1 Synthesis of Tetramethyl Isoindoline Analogues of 
Catecholamine, Benzodioxole and their Corresponding Nitroxides. 
5.2.1.1 Attempted Synthesis of Catechol TMIO 143 via Boron Tribromide 
Demethylation Protocol 
As outlined in Scheme 5.4 below, previous attempts to synthesize catechol TMIO 
156 from the dimethoxy TMIO precursor 330 were undertaken using boron 
tribromide as the demethylating reagent.39 Unfortunately, a complex mixture of 
products was obtained under these conditions. 
 
Scheme 5.4. Attempted synthesis of catechol TMIO 156 via boron tribromide 
demethylation of dimethoxy TMIO precursor 330. Reagents and conditions: a. BBr3, 
DCM, -78 oC.  
This was attributed to a nitroxide-mediated degradation of the desired catechol 
TMIO 156 to the highly reactive and unstable semiquinone 331 and quinone 332 
derivatives as outlined in Scheme 5.5 below. Evidence to support the formation of 
these oxidative by-products was obtained by the presence of a strong C=O stretch 
(characteristic of quinones) at 1694 cm-1 in the FTIR spectrum of the isolated product 
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plausible, one should not ignore the role of the boron tribromide reagent into the 
decomposition pathway. 
 
Scheme 5.5. Proposed nitroxide mediated oxidative decomposition of catechol 156 
to semiquinone 331 and quinone 332. 
As mentioned in Section 2.12 (Chapter 2), the nitroxide moiety could potentially 
complex with the boron reagent to generate other reactive radical species that may 
facilitate the degradation process. To avoid such proposed nitroxide-mediated 
decomposition of the target catechol TMIO 156, the initial alternative approach 
employed here (in the synthesis of 156) was to first protect the nitroxide moiety of 
dimethoxy precursor 330 prior to the demethylation step. As outlined in Scheme 5.6 
below, by protecting the nitroxide 330 with an acetyl-protecting group, it was 
envisaged that this might allow the demethylation to be carried out smoothly with no 
associated nitroxide-mediated decomposition of the catechol substrate. 
 
Scheme 5.6. Proposed synthesis of catechol TMIO 156 via N-acetoxy protecting 
group strategy. Reagents and conditions: a. Pd/C, H2, TEA, AcCl, THF, 0 oC; b. 
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The next section discusses the synthesis and N-acetoxy protection of 330 and the 
subsequent demethylation of the resulting acetyl protected intermediate 333. 
5.2.1.2 Synthesis of 5,6-Dimethoxy TMIO 330 
The dimethoxy nitroxide precursor 330 was readily synthesized in five steps from the 
tetramethylated Grignard reaction product 169 by following previous methodologies 
(with slight modifications) developed in the Bottle group at QUT (Scheme 5.7).40  
 
Scheme 5.7. Synthesis of dimethoxy TMIO 330. Reagents and conditions: a. Br2, 
AlCl3, DCM, 0 oC-RT, O/N, 89%; b. H2O2, NaHCO3, MeOH/DCM, 10 min, 100%; 
c. 5 M NaOMe/MeOH, CuI, DMF, reflux, 1 d, 88%; d. mCPBA, DCM, 0 oC-RT, 2 h, 
87%.  
The starting compound 169 was readily obtained in two steps from commercially 
available phthalic anhydride 167 as discussed in Chapter 2 (Section 2.2.1.1). When 
compound 169 was treated with a seven-fold excess of bromine in the presence 
anhydrous aluminium trichloride and pyridine, the crude residue obtained was 
triturated with methanol to give the tribromo compound 335 in 90% yield. The 
trituration step ensured complete separation of compound 335 from the benzaldehyde 
side-product 338 formed during the bromine-facilitated oxidative debenzylation of 
169. Compound 335 was then reduced quantitatively to the corresponding 
dibromoamine 336 by reacting with aqueous hydrogen peroxide in the presence of 
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tribromide intermediate 335 was not isolated. Instead, the crude mixture (of 
tribromide 335 and benzaldehyde 338) was reduced to give a mixture of the desired 
dibromoamine 336 and the benzaldehyde 338 side-product. Pure compound 336 was 
then obtained via successive acid-base extractions of the crude mixture which 
ensured complete removal of the benzaldehyde 338. For optimum yield however, 
several backwashes of the benzaldehyde extracts with sulfuric acid were required. 
Ultimately, purification of 335 by trituration and subsequent reduction to the 
dibromoamine 336 was an equally efficient protocol to furnish 336 that avoided the 
use of large volumes of acid and base (and the neutralization step). 
For the synthesis of dimethoxyamine 337, dibromoamine 336 was subjected to the 
copper-catalyzed nucleophilic substitution of aryl halides with an alkoxide as 
discussed is Section 2.2.1.3. The methanolysis protocol involved refluxing the aryl 
halide in a 25 mol% sodium methoxide solution in the presence of catalytic copper 
(I) iodide and DMF as cosolvent. The dimethoxy derivative 337 was obtained in 88% 
yield and was used in the subsequent step without further purification. Compound 
337 was then converted to the nitroxide derivative 330 under a mild mCPBA 
oxidation conditions in 87% yield. All characterization data obtained for compounds 
330 and 335-327 were consistent with those reported in the literature.39,40 
5.2.1.3 N-Acetyl Protection of Dimethoxy TMIO 330 and Subsequent Attempted 
Boron Tribromide Demethylation 
Due to the ease of introduction and removal, the acetyl protecting group strategy is a 
convenient way to mask a nitroxide moiety. Moreover, the protection and 
deprotection steps are generally quantitative transformations. In the synthesis of 
compound 333, the nitroxide precursor 330 was first hydrogenated to give the 
hydroxylamine 339 (Scheme 5.8). The hydroxylamine intermediate 339 was then 
allowed to react in situ with acetyl chloride in the presence of triethylamine for two 
hours. The desired N-acetoxy dimethoxy compound 333 was obtained in 95% yield 
following purification of the crude product by silica gel column chromatography. 
The most diagnostic feature in the 1H NMR spectrum of 333 was the characteristic 
N-acetoxy protons that were observed as a singlet at 2.2 ppm (3 H). The two singlets 
at 1.38 and 1.46 ppm, each integrating for 6 protons corresponds to the two sets of 
Synthesis of Novel Catechol-Based Nitroxides as Potential Multifunctional Antioxidants 
268  
CH3 groups. The non-equivalence observed for the two sets of CH3 groups arises 
from a combination of a slow nitrogen inversion on the NMR time scale. The 
equivalent dimethoxy and aryl protons were also observed as singlets at 3.88 (6 H) 
and 6.61 ppm (2 H) respectively. The strong C=O stretching frequency observed at 
1753 cm-1 in the FTIR spectrum of 333 was consistent with the presence of an acetyl 
functionality. Compound 333 was >95% pure by HPLC analysis and its melting 
range was determined to be 84-85 oC.   
 
Scheme 5.8. Synthesis of N-acetoxy protected dimethoxyamine 333. Reagents and 
conditions: a. Pd/C, H2, TEA, AcCl, THF, 0 oC-RT, 2 h, 95%. 
Having successfully synthesized the N-acetoxy protected dimethoxy derivative 333, 
the next step was to deprotect the dimethoxy group using mild boron tribromide 
demethylation conditions to furnish the corresponding N-acetoxy catechol 334 
(Scheme 5.9). Upon treating 333 with three molar equivalents of boron tribromide, 
TLC analysis of the reaction mixture indicated complete consumption of the starting 
material after one day. 
 
Scheme 5.9. Attempted boron tribromide demethylation of N-acetoxy protected 
dimethoxyamine 333. Reagents and conditions: a. BBr3, DCM, -78 oC-RT, 1 d; b. 1 
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1H NMR analysis of the crude product indicated the loss of the singlet corresponding 
to the dimethoxy protons at 3.88 ppm. This, evidently, supported the successful 
demethylation of compound 333. However, no phenolic proton signal was observed 
in the 1H NMR spectrum of the isolated crude product. This could be attributed to a 
likely complexation between the catechol moiety of compound 334 and the boron 
tribromide. Like most trisubstituted boron centres, the boron atom of boron 
tribromide is sp2 hybridized and has a trigonal planar geometry and an empty p 
orbital. The presence of the empty p orbital gives boron tribromide its weak Lewis 
acid characteristics. This therefore allows boron tribromide to be susceptible to 
nucleophilic attack by a variety of nucleophiles including hydroxide, cyanide, 
fluoride, α-hydroxy-carboxylic acids, dicarboxylic acids, and diols. Under 
appropriate conditions, trisubstituted boron compounds such as boronic acids can 
rapidly react with catechols to form stable boronic esters.41,42 The resulting 
cycloboronates have tetrahedral geometry with an sp3 hybridization at the boron 
centre.  
Attempt to purify the crude product isolated from the boron tribromide 
demethylation reaction by silica gel chromatography were unsuccessful as no 
product was recovered from the column even when more polar eluents 
(DCM/MeOH) were used. In this case, it is likely that the catechol moiety of 334 
formed a complex with the silica gel particles. Also, purification of the crude product 
by trituration or recrystallization was unsuccessful. Therefore, the crude product was 
subsequently hydrolyzed to the corresponding nitroxide 156 under basic conditions. 
Unfortunately, a complex mixture of products was isolated from the hydrolysis 
reaction as verified by TLC. In the FTIR spectrum of the hydrolysis product mixture, 
a strong C=O absorption was observed at 1740 cm-1. This suggested the likely 
decomposition of the desired product 156 to the highly reactive quinone derivative 
332. Also, no characteristic HRMS signal could be obtained for the crude mixture. 
This suggested that the target catechol TMIO 156 could have undergone an oxidative 
self-polymerisation to give polyquinoline derivatives under such basic hydrolysis 
conditions. 
Thus, due to its high reactivity and redox characteristic, the target catechol TMIO 
156 could not be isolated following the attempted boron tribromide demethylation of 
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333 and the subsequent hydrolysis reaction. As a result of the likely complexation 
and redox nature of the target catechol 156, any alternative demethylation conditions 
should preferably exclude the use of Lewis acid reagents. The following sections 
discuss the synthesis of catecholamine TMI compound 154 and its catechol nitroxide 
156 as well as the methylenedioxy derivatives (155 and 157) via demethylation of 
the dimethoxyamine precursor 337 under Bronsted acid conditions. 
5.2.1.4 Synthesis of Catecholamine TMI 154 
Besides Lewis acids, Bronsted acids are the other frequently used ether cleavage 
reagents. The most common Bronsted acids employed include hydrogen halides such 
as hydrochloric and hydrobromic acids. The demethylation protocol generally 
involves refluxing the ether substrate in concentrated Bronsted acid solutions. Such 
harsh reaction conditions were, however, not attempted on the acetyl protected 
dimethoxy substrate 333 or the nitroxide precursor 330. This was due to the likely 
hydrolysis of the acetyl protecting group of 333 and subsequent acid-catalyzed 
decomposition of the nitroxide intermediate 330. However, Bronsted acid reagents 
could readily be employed in the synthesis of the target catecholamine TMI 
compound 154 via demethylation of the dimethoxyamine precursor 337. 
Successfully synthesis of catecholamine TMI 154 may provide an alternative route to 
access the target catechol TMIO 156 via a mild peroxy acid oxidation of the 
catecholamine 154. In addition, catecholamine 154 could also serve as a precursor to 
target methylenedioxy TMI 155 and TMIO 157 compounds. 
Thus when dimethoxyamine 337 was refluxed in concentrated hydrobromic acid 
solution, complete demethylation was achieved after twelve hours (Scheme 5.10). 
The target catecholamine 154, isolated as the hydrobromide salt, was obtained as a 
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Scheme 5.10. Synthesis of catecholamine TMI 154. Reagents and conditions: a. HBr 
(45% wt./v in H2O), reflux, O/N, 84%.  
Evidence to support this transformation was obtained from the loss of the dimethoxy 
protons signal at 3.88 ppm in the 1H NMR spectrum of 154. The equivalent aryl and 
diphenolic protons signals of 154 were also observed as singlets at 6.63 and 9.23 
ppm respectively. In the FTIR spectrum of 154, a characteristic strong broad OH 
stretch observed at 3147 cm-1 also supported the presence of phenol functionality. 
The identity of 154 was further confirmed by the presence of the molecular ion of the 
protonated amine at m/z 202 in the HRMS spectrum. Catecholamine 154 
decomposed at temperatures above 331-333 oC. 
5.2.1.5 Synthesis of Catechol TMIO 156 from Catecholamine TMI 154 
With the catecholamine derivative 154 in hand, synthesis of the catechol TMIO 156 
was then attempted under mild peroxy acid oxidation conditions. However, upon 
subjecting compound 154 to sodium tungstate-hydrogen peroxide oxidation 
conditions (Scheme 5.11), FTIR analysis of the isolated product indicated the 
presence of a characteristic strong C=O stretching absorption at 1740 cm-1. In 
addition, no characteristic OH stretch was observed above 3000 cm-1 in the FTIR 
spectrum. 
 
Scheme 5.11. Attempted synthesis of catechol TMIO 156 via peroxy acid oxidation 
of catecholamine TMI 154. Reagents and conditions: a. H2O2, H2O/MeOH, RT; or 
mCPBA, DCM/MeOH. 
This, evidently, indicated the target catechol TMIO 156 was likely oxidized to the 
quinone derivative under such oxidation conditions. The reddish-brown appearance 
of the isolated product is a further characteristic indication of the presence of a 
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analysis. A similar result was also obtained when mCPBA was used in the place of 
hydrogen peroxide.  
At this stage, it was difficult to determine whether such oxidative decomposition of 
the preformed-catechol TMIO 156 to the quinone derivative 332 was primarily a 
spontaneous process (autoxidation facilitated by both catechol and the free radical 
moieties), or facilitated by the hydrogen peroxide (or mCPBA) as the active 
oxidizing agent, or a combination of both. 
In a final attempt to synthesize compound 156, it was thought necessary to protect 
the catechol moiety of catecholamine 154 prior to attempting the oxidation step. This 
may ensure smooth oxidation of the catechol-protected amine to the corresponding 
nitroxide which in turn could be deprotected to give the desired catechol TMIO 156. 
However, since the oxidation of catechols to quinones usually occurs under both 
oxidizing and basic conditions, the choice of protecting group herein should exclude 
protecting groups that are removed under such reaction conditions (oxidizing 
conditions or conditions above pH 8). Since silyl ether protecting groups are 
commonly removed under neutral or mild acidic conditions, t-butyldimethylsilyl 
group (TBDMS) was the protecting group of choice used in this case.  
As outlined in Scheme 5.12 below, silylation of 154 was achieved by allowing it to 
react with tert-butyldimethylsilyl chloride (TBDMS-Cl) in the presence of excess 
imidazole for four days. The silyl ether 340 was determined to be slightly unstable 
when the crude isolated product was subjected to standard column chromatography 
purification. Attempts to purify the isolated crude silyl ether 340 by silica gel 
chromatography produced a complex mixture of desilylated products as verified 
by 1H NMR spectroscopy. However, after several mild aqueous base washes with 0.5 
M sodium hydroxide solution, compound 340 was of sufficient purity by 1H NMR 
spectroscopy and was used in the subsequent step without further purification.  
The loss of the characteristic diphenol protons signal (singlet at 9.23 ppm) in the 1H 
NMR spectrum of 340 evidently indicated successful transformation. The protons of 
the di-tert-butyldimethylsilyl group were also observed as singlets at 0.19 (12 H) and 
0.99 ppm (18 H). HRMS analysis further confirmed the identity of 340 by the 
presence of the molecular ion plus proton [M + H]+ mass at m/z 436. The FTIR 
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spectrum of 340 also confirmed the loss of a strong broad OH stretching frequency at 





















156 341  
Scheme 5.12. Synthesis of catechol TMIO 156 via TBDMS protection of 
catecholamine TMI 154. Reagents and conditions: a. TBDMSCl, imidazole, DMF, 4 
d, 64%; b. mCPBA, DCM, 2 h, 83%; c. TBAF, THF, 30 min, 79%. 
The aminosilyl ether 340 was then converted to the corresponding nitroxide 341 
under mild mCPBA oxidation conditions. To avoid potential acid-catalyzed cleavage 
of the silyl ether-protecting group by the resulting m-chlorobenzoic acid by-product, 
the oxidation of 340 was carried out in the presence of sodium hydrogen carbonate. 
The silyl-protected nitroxide 341 was obtained as a yellow solid in 83% yield. The 
identity of 341 was confirmed by the presence of the [M + H]+ and [M + Na]+ ions at 
m/z 436 and 450 respectively in the HRMS spectrum. The melting range determined 
for the isolated product was 142-143 °C.  
Subsequent deprotection of the silyl ether 341 was carried out with a one molar 
solution of tetrabutylammonium fluoride (TBAF) in tetrahydrofuran. As anticipated, 
the deprotection proceeded smoothly in 30 minutes to afford target catechol TMIO 
156 as a yellow solid in 79% yield. The identity of 156 was confirmed by HRMS 
analysis with the [M + H]+ ion observed at m/z 223. A strong broad OH stretching 
frequency for the diphenol group was observed at 3055 cm-1 in the FTIR spectrum. 
The melting range determined for 156 was 225-227 °C (decomposed). 
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The above results thus indicated that the likely decomposition of catechol TMIO 156 
to the quinone derivative 322 proposed in the preceding sections is not primarily a 
nitroxide-mediated process. Instead, it appears to be primarily facilitated by the 
presence of an oxidizing agent (mCPBA or H2O2), a base (NaOH) or via the 
formation of stable catecholborane complexes with BBr3. Furthermore, no C=O 
stretching frequencing was observed in the FTIR spectrum of 156. This thus 
indicated that compound 156 is fairly stable and does not spontaneously decompose 
to generate the highly reactive quinone oxidative by-product 332 as was initially 
proposed. 
With the targets catecholamine TMI 154 and catechol TMIO 156 in hand, the next 
section discusses the synthesis of the tetramethyl-substituted methylenedioxy 
derivatives 155 and 157. 
5.2.1.6 Synthesis of Benzodioxole TMI 155 and TMIO 157 
Methylenation of catechols to the corresponding methylenedioxy groups is 
commonly performed with methylene halides as the methylenating reagent in the 
presence of a base.43,44 The reaction is generally carried out in a refluxing dipolar 
aprotic solvent such as dimethylformamide. Scheme 5.13 below outlines the 
synthetic route undertaken to furnish methylenedioxy TMI 155 and the 























Scheme 5.13. Synthesis of benzodioxole TMI 155 and TMIO 157. Reagents and 
conditions: a. DCM, NaOH, DMSO, reflux, 2 h, 71%; b. mCPBA, DCM, 2 h, 89%. 
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Initially, when a solution of catecholamine 154 and two equivalents of 
dibromomethane in DMSO was refluxed for two hours in the presence of sodium 
hydroxide, the product isolated was predominantly the N-methyl methylenedioxy 
derivative 342, as confirmed by HRMS, 1H and 13C NMR spectroscopies. When the 
reaction was carried out with excess dichloromethane in the place of 
dibromomethane, an almost equimolar mixture of the target methylenedioxy TMI 
155 and the N-methyl derivative 342 was obtained as verified by 1H NMR analysis. 
Although there are examples in the literature for the reaction of dichloromethane 
with secondary amines under similar basic conditions, the products isolated in those 
cases were the N-(chloromethyl) derivatives (no N-methyl derivative was isolated).45-
47 The mechanism for the formation of the unexpected N-methyl derivative 341 
herein is at this stage elusive and was not further investigated because optimum 
conditions were established for the exclusive formation of the desired 
methylenedioxy TMI 155. The optimum condition for the synthesis of 
methylenedioxy TMI 155 required the use of 2.5 molar equivalents of 
dichloromethane and a two-hour reflux. Under these conditions, the target 
methylenedioxy TMI 155 was obtained in 71% yield following purification by 
column chromatography. The identity of compound 155 was confirmed by FTIR, 
HRMS, 1H and 13C NMR spectroscopies. In the 1H NMR spectrum of 155, the 
methylenedioxy group protons were shown as a singlet at 6.55 ppm (2 H). The mass 
of the [M + H]+ ion was also observed at m/z 220 in the HRMS spectrum of 155. 
Compound 155 was determined to be >95% pure by HPLC analysis.  
Subsequent oxidation of 155 to the corresponding nitroxide 157 was achieved under 
mild mCPBA conditions. Compound 157 was obtained as a yellow solid in 89% 
yield after purification by silica gel column chromatography. The structure of 157 
was also confirmed by the presence of the [M + 2H]+ and [M + Na]+ ions at m/z 236 
and 257 respectively in the HRMS spectrum. Compound 157 was >95% pure by 
HPLC analysis. 
Having established the optimum conditions for the synthesis of the tetramethyl-
substituted target catechols (154 and 156) and methylenedioxy compounds (255 and 
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157), the next section details the use of similar conditions for the synthesis of the 
tetraethyl-substituted counterparts (158-161). 
5.2.2 Synthesis of Tetraethyl-substituted Isoindoline Analogues of 
Catecholamine, Benzodioxole and their Corresponding Nitroxides. 
As noted in the introductory chapter, the stability of the nitroxide moiety partly 
depends on steric effects at the carbon α to the radical centre. This, therefore, makes 
tetraethyl-substituted nitroxides reduced at a much slower rate than their tetramethyl 
counterparts under biological conditions. Thus, synthesising the tetraethyl versions of 
catecholamine and the corresponding nitroxide compounds may provide robust 
antioxidant systems as well as provide more insights into the structural-activity 
relationship when compared to the tetramethyl counterparts. 
5.2.2.1 Synthesis of 5,6-Diiodo-TEI 335 
5,6-Diiodo-1,1,3,3-tetraethylisoindoline 335 was synthesized by following literature 
procedures as outlined in Scheme 5.14 below.48,49 The benzyl phthalimide 168 was 
generated by refluxing commercially available phthalic anhydride 167 and 




















Scheme 5.14. Synthesis of diiodo TEI 345. Reagents and conditions: a. BnNH2,  
AcOH, reflux, 1 h, 98%; b. EtMgI, Et2O, toluene, reflux, 4 h, 38%; c. H2, Pd/C, 50 
psi, 3 h, 94%; d. H5IO6, KI, conc. H2SO4, 0 °C to RT, 3 h, 80%.  
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Exhaustive alkylation of compound 168 with a sixfold excess of freshly prepared 
ethylmagnesium Grignard furnished the tetraethylated product 343 in modest yield of 
38%. Subsequent palladium catalyzed hydrogenolysis of the Grignard reaction 
product 343 furnished the debenzylated secondary amine 344 almost quantitatively. 
Allowing 344 to react with periodic acid and potassium iodide in cold concentrated 
sulfuric acid facilitated the successful di-iodination of compound 344. The periodic 
acid and potassium iodide reagents act as a source of a strongly electrophilic 
iodonium ion known to facilitate the iodination.49 Compound 345 was obtained in 
80% yield following purification by silica gel chromatography. All characteristic 
data obtained were consistent with the literature.49 
5.2.2.2 Synthesis of Catecholamine TEI 158  
Diiodo TEI 345 was subjected to similar copper-catalyzed methanolysis conditions 
employed for the synthesis of 337 (Scheme 5.7) as outlined in Scheme 5.15 below. 
The 5,6-dimethoxyamine derivative 346 was obtained in 82% yield following 
purification by silica gel flash column chromatography. The identity of compound 
346 was confirmed by FTIR, HRMS, 1H and 13C NMR spectroscopy. The dimethoxy 
protons were observed as a singlet at 3.87 ppm (6 H) while the [M + H]+ ion was 
observed at m/z 192 in the 1H NMR and HRMS spectra of 346 respectively. 
Compound 346 was >95% pure by HPLC analysis and its melting range was 

















Scheme 5.15. Synthesis of catecholamine TEI 158. Reagents and conditions: a. 
NaOMe, CuI, DMF, reflux, 1 d, 82%; b. HBr (45% wt./v in H2O), reflux, O/N, 83%. 
Demethylation of 346 to the corresponding catecholamine derivative 158 was 
achieved under refluxing conditions with concentrated aqueous hydrobromic acid 
solution (48% in water). The target catecholamine 158 was obtained as the 
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hydrobromide salt as a light grey precipitate in 83% yield. The loss of the singlet at 
3.87 ppm for the dimethoxy group protons of 346 and the appearance of the diphenol 
protons signal as singlet at 9.23 ppm in the 1H NMR spectrum of 158 were 
supporting evidence for successful demethylation of 346. Further evidence was 
obtained by the presence of a characteristic strong broad OH absorption at 3343 cm-1 
in the FTIR spectrum of 158. The mass of the molecular ion [M]+ was observed at 
m/z 264 in the HRMS spectrum of 158. Compound 158 decomposed at temperatures 
above 251-252 oC. 
5.2.2.3 Synthesis of Catechol TEIO 160  
Like the tetramethyl counterpart 154, attempted oxidation of the tetraethyl-
substituted catecholamine 158 with either mCPBA or hydrogen peroxide (Scheme 
5.16) resulted in the formation of oxidative quinone by-products similar to those 
previously observed, as verified by FTIR spectroscopy. The isolated product had 
similar quinone characteristics with a C=O absorption at 1750 cm-1 in the FTIR 
spectrum. 
 
Scheme 5.16. Attempted synthesis of catechol TEIO 160 via peroxy acid oxidation 
of catecholamine TEI 158. Reagents and conditions: a. H2O2, H2O/MeOH, RT; or 
mCPBA, DCM/MeOH. 
Thus, the successful synthesis of catechol TEIO 160 could only be accomplished via 
the silyl ether protecting group strategy as outlined in Scheme 5.17 below. When the 
catecholamine 158 was reacted with tert-butyldimethylsilyl chloride in the presence 
of imidazole, the product isolated was a mixture of the mono- and di-silyl protected 
ethers (347 and 348) as verified by 1H NMR analysis. Although subsequent oxidation 
of the mixture (347 and 348) to the corresponding nitroxides (349 and 350) 
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protected ether 348 was obtained when the crude product mixture (of 347 and 348) 
was washed with a dilute 0.5 M sodium hydroxide solution. The silyl ether nitroxide 
mixture (349 and 350) was then deprotected with a 1 M tetrabutylammonium 
fluoride solution to give the desired catechol TEIO 160. Compound 160 was 
obtained as a bright orange solid in 67% yield over the three steps from 158. A 
strong OH stretch was observed at 3354 cm-1 in the FTIR spectrum of 160. The [M + 
H]+ and [M + Na]+ ions were observed at m/z 279 and 301 respectively in the HRMS 





















R = H (347 and 349)
349, 350
R = TBDMS (348 and 350)  
Scheme 5.17. Synthesis of catechol TEIO 160 via TBDMS protection of 
catecholamine TEI 158. Reagents and conditions: a. TBDMSCl, imidazole, DMF, 4 
d; b. mCPBA, DCM, 2 h; c. TBAF, THF, 30 min, 67% (over the 3 steps). 
5.2.2.4 Synthesis of Benzodioxole TEI 159 and TEIO 161 
The tetraethyl methylenedioxy derivatives (159 and 161) were readily obtained from 
catecholamine precursor 158 as depicted in Scheme 5.18 below. When a solution of 
158 and three molar equivalents of dichloromethane in DMSO was refluxed for three 
hours, the crude residue obtained was purified by column chromatography to give 
methylenedioxy TEI 159 in 68% yield. The most diagnostic feature as a supporting 
evidence for this transformation was the presence of a singlet at 6.05 ppm in the 1H 
NMR spectrum of 159. This was consistent with the presence of the characteristic 
methylenedioxy proton (CH2) signal. 
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Scheme 5.18. Synthesis of benzodioxole TEI 159 and TEIO 161. Reagents and 
conditions: a. DCM, NaOH, DMSO, reflux, 2 h, 68%; b. mCPBA, DCM, 2 h, 85%. 
Also, neither a phenolic proton signal nor its characteristic OH absorption was 
observed in the 1H NMR and FTIR spectra of 159 respectively. The extra 
methylenedioxy carbon was also observed at 69 ppm in the 13C NMR spectrum. The 
[M + H]+ ion for compound 159 was observed at m/z 276 in the HRMS spectrum and 
159 was >95% pure by HPLC. Subsequent oxidation of 146 to the corresponding 
nitroxide 161 was facilitated by mCPBA. Catechol TEIO 161 was obtained as a 
yellow solid in 85% yield and its identity was verified by FTIR and HRMS analysis. 
5.3 Summary of Results 
The synthesis of a series of isoindoline-based catecholamine and methylenedioxy 
compounds (154-161) was described. The target compounds comprised of both the 
tetramethyl and the tetraethyl-substituted secondary amines and the corresponding 
nitroxides. Notably, the target compounds are the first examples of catechol-based 
nitroxide compounds synthesized. The target catecholamine derivatives (154 and 
158) were readily obtained by demethylation of the dimethoxyamine precursors (337 
and 345) under refluxing Bronsted acid conditions with concentrated hydrobromic 
acid.  
Initial attempts to synthesize the catechol nitroxides (156 and 160) via either boron 
tribromide demethylation of the N-acetoxy protected dimethoxy derivative 333 or 
direct peroxy acid oxidation of the catecholamine derivatives (154 and 158) resulting 
in the formation of presumably the highly reactive quinone derivatives as verified by 
FTIR spectroscopy. The target catechol nitroxides (156 and 160) were however 
obtained via a silyl ether protection of the catecholamines (154 and 158) followed by 
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in turn readily deprotected with TBAF to furnish the desired catechol nitroxides (156 
and 160). 
The methylenedioxyamine derivatives (155 and 159) were prepared by base-
catalyzed methylation of catecholamines (154 and 158) with dichloromethane. 
Although the N-methyl methylenedioxyamine derivative 342 was initially obtained 
under the base-catalyzed methylation conditions (with dibromomethane or excess 
DCM), optimum conditions for the synthesis of the desired methylenedioxyamine 
compounds (155 and 159) required the use of 2.5-3 molar equivalents of DCM and a 
refluxing time of three hours or less. The methylenedioxy nitroxides (157 and 161) 
were readily obtained by a mild mCPBA oxidation of the methylenedioxyamine 
derivatives (155 and 159). 
5.4 Experimental 
5.4.1. Synthesis of 2,5,6-Tribromo-1,1,3,3-tetramethyl isoindoline 335  
 
Bromine (2.7 mL, 52.75 mmol, 7 equiv.) was added dropwise to a solution of 2-
benzyl-1,1,3,3-tetramethylisoindoline 169 (2 g, 7.54 mmol, 1.00 equiv.) and pyridine 
(200 µL, 2.49 mmol, 0.33 equiv.) in DCM (40 mL) at 0 °C under an Ar atmosphere. 
The reaction mixture was stirred for 15 min followed by the addition of anhydrous 
AlCl3 (3 g, 22.61 mmol, 3.00 equiv.). Stirring was continued overnight while 
allowing the reaction mixture to return to RT. The reaction was cooled in ice bath 
and then basified with 10 M NaOH (25 mL) and stirred vigorously (10 min) until the 
solution was almost clear. The mixture was extracted with DCM (70 mL x 4) and the 
combined DCM extracts were washed with brine (50 mL), dried over anhydrous 
Na2SO4, and concentrated in vacuo to give yellowish brown oil. The crude residue 
was then purified by triturating with methanol to give 2,5,6-tribromo-1,1,3,3-
tetramethylisoindoline 335 as a pale yellow solid (2.76 g, 89%). Mp. 109-110 oC 
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H, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 28.0 (C-CH3), 69.3 (C-CH3), 
123.2 (Ar-C), 127.1 (Ar-C), 145.4 (Ar-C) ppm. 
5.4.2. Synthesis of 5,6-Dibromo-1,1,3,3-tetramethylisoindoline 336 
 
Hydrogen peroxide (998 µL, 9.7 mmol, 30% in H2O, 2.00 equiv.) was added 
dropwise to a suspension of 2,5,6-tribromo-1,1,3,3-tetramethylisoindoline 335 (2 g, 
4.85 mmol, 1 equiv.) and NaHCO3 (612 mg, 7.28 mmol, 1.5 equiv.) in MeOH/DCM 
(10:2 mL) and the resulting reaction mixture was stirred for 10 min and concentrated 
in vacuo. The residue obtained was taken up in Et2O (150 mL), washed with brine 
(40 mL), dried over anhydrous Na2SO4 and concentrated in vacuo to give 5,6-
dibromo-1,1,3,3-tetramethylisoindoline 336 as a beige solid (1.61 g, 100%). Mp. 76–
77 oC (Lit.,50 76-77°C). 1H NMR (CDCl3, 400 MHz): δ = 1.41 (s, 12 H, CH3), 1.94 
(s, 1 H, NH), 7.34 (s, 2 H, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 33.7 ( C-
CH3), 62.6 (C-CH3), 122.9 (Ar-C), 126.8 (Ar-C), 150.2 (Ar-C) ppm. 
5.4.3. Synthesis of 5,6-Dimethoxy-1,1,3,3-tetramethyl isoindoline 337 
 
A reaction mixture containing 5,6-bromo-1,1,3,3-tetramethylisoindoline 336 (3 g, 9 
mmol, 1 equiv.), CuI (206 mg, 1.1 mmol, 0.12 equiv.),  DMF (2 mL) and NaOMe 
(10 mL, 25% wt./v in MeOH) was refluxed for 24 h under an Ar atmosphere. The 
reaction was allowed to cool to RT, then diluted with water (15 mL) and extracted 
with Et2O (70 mL x 4). The combined Et2O extracts were washed with brine (50 
mL), dried over anhydrous Na2SO4, and concentrated in vacuo to give 5,6-
dimethoxy-1,1,3,3-tetramethylisoindoline 337 as a white solid (1.86 g, 88%). The 
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purification. Mp. 71-72 oC. 1H NMR (CDCl3, 400 MHz): δ = 1.44 (s, 12 H, CH3), 
3.89 (s, 6 H, OCH3), 6.60 (s, 2 H, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 
32.0 ( C-CH3), 56.1 (OCH3), 62.8 (C-CH3), 104.4 (Ar-C), 140.3 (Ar-C), 148.8 (Ar-
C) ppm. 
5.4.4. Synthesis of 5,6-Dimethoxy-1,1,3,3-tetramethyl isoindolin-2-yloxyl 330 
 
m-Chloroperoxybenzoic acid (1.85 g, 6.37 mmol, 1.5 equiv, 77%) was added to a 
solution of 5,6-dibromo-1,1,3,3-tetramethylisoindoline 337 (1 g, 4.25 mmol, 1 
equiv.) in DCM (200 mL) at 0 oC. The cooling bath was removed after 30 min and 
stirring continued then at RT for a further 1.5 h. The resulting solution was washed 
with dilute HCl (0.5 M, 40 mL), NaOH (2 M, 40 mL x 2) and brine solutions and 
then dried over anhydrous Na2SO4. The filtrate was concentrated in vacuo and the 
crude residue was purified by flash column chromatography (Hexane/EtOAc, 5:1) to 
give 5,6-dimethoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 330 as a bright yellow 
solid (925 mg, 87%). Mp. 202-203 °C (Lit.,51 201-203 °C).  
5.4.5. Synthesis of 2-Acetoxy-5,6-dimethoxy-1,1,3,3-tetramethylisoindoline 333 
 
A reaction mixture containing 5,6-dimethoxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 
330 (500 mg, 2 mmol, 1 equiv.) and Pd/C (50 mg, 10% wt.) in THF (15 mL) was 
flushed with Ar for 10 min.  Then, a balloon of H2 was connected and the reaction 
mixture was stirred for 20 min. The mixture was cooled in ice/H2O bath followed by 
dropwise additions of TEA (558 µL, 4 mmol, 2 equiv.) and AcCl (284 µL, 4 mmol, 2 
equiv.). The cooling bath was removed after 30 min and stirring was continued for a 
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vacuo. The crude residue was dissolved in EtOAc (150 mL) and washed with brine 
(40 mL), dried over anhydrous Na2SO4, and concentrated in vacuo. Purification of 
the crude product by silica gel column chromatography (Hexane/EtOAc, 5:1) gave 2-
acetoxy-5,6-dimethoxy-1,1,3,3-tetramethylisoindoline 333 as a clear solid (557 mg, 
95%). Mp. 84-85 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 1.38 
(s, 6 H, CH3), 1.46 (s, 6 H, CH3), 2.20 (s, 3 H, C=OCH3), 3.88 (s, 6 H, OCH3), 6.61 
(s, 2 H, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 19.3 (CO-CH3) 25.4 ( C-
CH3), 29.0 ( C-CH3), 56.2 (OCH3), 68.3 (C-CH3), 104.7 (Ar-C), 135.6 (Ar-C), 
149.3 (Ar-C), 171.8 (C=OCH3) ppm. HRMS (ES): m/z (%) = 294.1659 (100) [M + 
H]+, calcd. for C16H23NO4: 293.1625; found 293.1627. ATR-FTIR: υmax = 2973 (m, 
ArC-H), 1753 (s, C=O), 1204 (s, C-N), 1170 (s, C-O) cm-1. 
5.4.6. Attempted Boron Tribromide Demethylation of 2-Acetoxy-5,6-dimethoxy-
1,1,3,3-tetramethylisoindoline 333 
BBr3 (2.56 mL, 2.56 mmol, 1 M solution in DCM, 3 equiv.) was added dropwise to a 
solution of 2-acetoxy-5,6-dimethoxy-1,1,3,3-tetramethylisoindoline 333 (250 mg, 
852 μmol, 1 equiv.) in DCM (10 mL) at -78 oC under Ar. The resulting reaction 
mixture was allowed to return to RT. TLC analysis of the reaction mixture showed 
complete consumption of the starting material after 22 h. The excess BBr3 reagent 
was quenched by careful addition of ice cold H2O. The crude product was extracted 
with DCM (60 mL x 4) and the combined DCM extracts were washed with brine (40 
mL), dried over anhydrous Na2SO4, and concentrated under reduced pressure. 1H 
NMR analysis of the crude residue obtained showed complete demethylation. 
Attempts at purifying the crude mixture by column chromatography were 
unsuccessful. 
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A solution of 5,6-dimethoxy-1,1,3,3-tetramethylisoindoline 337 (500 mg, 2.12 mmol, 
1 equiv.) in HBr (10 mL, 45% wt./v in H2O) was refluxed overnight and then 
allowed to cool to RT. The resulting precipitate was filtered, washed with Et2O (10 
mL x 3) and dried under high vacuum to give 5,6-dihydroxy-1,1,3,3-
tetramethylisoindoline hydrobromide 154 as grey solid (514 mg, 84%). Mp. 331-
333 oC (dec.). 1H NMR ((CD3)2SO, 400 MHz): δ = 1.58 (s, 12 H, CH3), 6.63 (s, 2 H, 
Ar-H), 9.11 (s, 2 H, NH2), 9.23 (s, 2 H, OH) ppm. 13C NMR ((CD3)2SO, 100 MHz): 
δ = 29.1 ( C-CH3), 67.7 (C-CH3), 108.4 (Ar-C), 132.9 (Ar-C), 147.0 (Ar-C) ppm. 
HRMS (ES): m/z (%) = 208.1308 (100) [M]+, calcd. for C12H18NO2+: 208.1332; 
found 208.1308. ATR-FTIR: υmax = 3147 (s, br, OH), 3008 (m, ArC-H), 1347 (s, C-
N), 1237 (s, C-O) cm-1. 
5.4.8. Synthesis of 5,6-Bis((tert-butyldimethylsilyl)oxy)-1,1,3,3-
tetramethylisoindoline 340 
 
A solution of 5,6-dihydroxy-1,1,3,3-tetramethylisoindoline hydrobromide 154 (100 
mg, 347 µmol, 1 equiv.), TBDMSCl (261.5 mg, 1.74 mmol, 5 equiv.) and imidazole 
(118 mg, 1.74 mmol, 5 equiv.) in DMF (10 mL) was stirred under Ar for 4 days. The 
resulting reaction mixture was diluted with H2O and basified to pH 10 with saturated 
NaHCO3 solution. The aqueous layer was then extracted with Et2O (60 mL x 4) and 
the combined Et2O extracts were washed with dilute NaOH (0.5 M, 40 mL) and 
brine (30 mL x 5) solutions, dried over anhydrous Na2SO4 and concentrated under 
reduced pressure to give 5,6-bis((tert-butyldimethylsilyl)oxy)-1,1,3,3-
tetramethylisoindoline 340 as a white solid (97 mg, 64%). The isolated product was 
of sufficient purity, as determined by 1H NMR spectroscopy, and was used in the 
subsequent step without further purification. Mp. 105-107 o C. 1H NMR (CDCl3, 400 
MHz): δ = 0.18 (s, 12 H, Si(CH3)2), 0.99 (s, 18 H, SiC(CH3)3), 1.38 (s, 12 H, 
CCH3), 6.50 (s, 2 H, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 4.1 (Si(CH3)2), 
18.4 (SiC(CH3)2, 26.0 (SiC(CH3)3), 31.8 ( C-CH3), 62.7 (C-CH3), 113.6 (Ar-C), 
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calcd. for C24H45NO2Si2: 435.2989; found 435.2987. FTIR (ATR): υmax = 3100 (w, 
N-H), 2962 (m, ArC-H), 1233 (s, C-N), 1032 (s, C-O) cm-1. 
5.4.9. Synthesis of 5,6-Bis((tert-butyldimethylsilyl)oxy)-1,1,3,3-
tetramethylisoindolin-2-yloxyl 341  
 
m-Chloroperoxybenzoic acid (68 mg, 234 µmol, 1.2 equiv, 77%) was added to a 
reaction mixture containing 5,6-bis((tert-butyldimethylsilyl)oxy)-1,1,3,3-
tetramethylisoindoline 340 (85 mg, 195 µmol, 1 equiv.) and NaHCO3 (25 mg, 293 
µmol, 1.5 equiv.) in DCM (15 mL) at 0 oC. The cooling bath was removed after 30 
min and the stirring was continued RT for a further 1.5 h. The resulting solution was 
diluted (DCM, 100 mL), washed with dilute NaOH (0.5 M, 40 mL x 2) and brine (40 
mL) solutions and then dried over anhydrous Na2SO4. The filtrate was concentrated 
in vacuo to give 5,6-bis((tert-butyldimethylsilyl)oxy)-1,1,3,3-tetramethylisoindolin-
2-yloxyl 341 as bright yellow solid (73 mg, 83%). Mp. 142-143 °C. HRMS (ESI): 
m/z (%) = 436.2821 (70) [M + H]+, 450.2775 (100) [M + Na]+; calcd. for 
C24H4NO3Si2•: 450.2860; found 436.2854. FTIR (ATR): υmax = 2927 (m, ArC-H), 
1343 (s, C-N), 1192 (s, C-O) cm-1. 
5.4.10. Synthesis of 5,6-Dihydroxy-1,1,3,3-tetramethylisoindolin-2-yloxyl 156 
 
TBAF (2.44 mL, 2.44 mmol, 10 equiv., 1 M solution in THF) was added dropwise to 
a solution of 5,6-bis((tert-butyldimethylsilyl)oxy)-1,1,3,3-tetramethylisoindolin-2-
yloxyl 341 (110 mg, 244 µmol, 1 equiv.) in THF (10 mL) and the resulting reaction 
mixture was stirred for 30 min at RT. The reaction mixture was concentrated under 
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layer was washed with dilute HCl (0.5 M, 20 mL) and brine (40 mL), and then dried 
over anhydrous Na2SO4. The filtrate was concentrated in vacuo and the crude 
product obtained was triturated with hexane to give 5,6-dihydroxy-1,1,3,3-
tetramethylisoindolin-2-yloxyl 156 as yellow solid (43 mg, 79%). Mp. 225-227 °C 
(dec.). HRMS (ESI): m/z (%) = 223.0926 (18) [M + H]+; calcd. for C12H16NO3•: 
222.1130; found 222.1090. FTIR (ATR): υmax = 3055 (s, br, O-H), 2961 (m, ArC-H), 
1303 1234 (s, C-O) cm-1. 
5.4.11. Synthesis of 6,7-Dihydro-5H-[1,3]dioxolo[4,5-f]-5,5,7,7-
tetramethylisoindoline (Methylenedioxy TMI) 155 
 
A solution of 5,6-dihydroxy-1,1,3,3-tetramethylisoindoline hydrobromide 154 (200 
mg, 694 µmol, 1 equiv.), DCM (111 µL, 1.74 mmol, 2.5 equiv.) and NaOH (139 mg, 
3.47 mmol, 5 equiv.) in DMSO was refluxed for 2 h and the resulting reaction 
mixture was allowed to cool to RT and then diluted with H2O (50 mL). The crude 
product was extracted with DCM (60 mL x 4) and the combined DCM extracts were 
washed with brine (40 mL), dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by silica gel column 
chromatography (DCM/5%MeOH) to give methylenedioxy TMI 155 as a white solid 
(108 mg, 71%). Mp. 125.5-126.5 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 
MHz): δ = 1.49 (s, 12 H, CH3), 5.96 (s, 2 H, OCH2), 6.55 (s, 2 H, Ar-H) ppm. 13C 
NMR (CDCl3, 100 MHz): δ = 32.0 (C-CH3), 62.6 (C-CH3), 101.2 (Ar-C), 101.9 
(CH2), 141.7 (Ar-C), 147.2 (Ar-C) ppm. HRMS (ESI): m/z (%) = 220.1312 (100) [M 
+ H]+; calcd. for C13H17NO2: 219.2840; found 219.2838. FTIR (ATR): υmax = 3327 




Synthesis of Novel Catechol-Based Nitroxides as Potential Multifunctional Antioxidants 
288  
5.4.12. Synthesis of 6,7-Dihydro-5H-[1,3]dioxolo[4,5-f]-5,5,6,7,7-
pentamethylisoindoline (N-Methyl methylenedioxy TMI) 342 
 
A solution of 5,6-dihydroxy-1,1,3,3-tetramethylisoindoline hydrobromide 154 (200 
mg, 694 µmol,  1 equiv.), dibromomethane (97 µL, 1.39 mmol, 2 equiv.) and NaOH 
(139 mg, 3.47 mmol, 5 equiv.) in DMSO was refluxed for 2 h and the resulting 
reaction mixture was allowed to cool to RT and then diluted with H2O (40 mL). The 
crude product was extracted with DCM (60 mL x 4) and the combined DCM extracts 
were washed with brine, dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by silica gel column 
chromatography (DCM) to give N-methyl methylenedioxy TMI 342 as low melting 
beige solid (118 mg, 73%). HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 
1.28 (s, 12 H, CH3), 2.39 (s, 3 H, NCH3), 5.93 (s, 2 H, OCH2), 6.59 (s, 2 H, Ar-H) 
ppm. 13C NMR (CDCl3, 100 MHz): δ = 26.9 (C-CH3), 27.1 ( N-CH3), 64.3 (C-CH3), 
101.0 (OCH2), 102.1 (Ar-C), 140.8 (Ar-C), 146.8 (Ar-C) ppm. HRMS (ESI): m/z 
(%) = 234.1451 (18) [M + H]+; calcd. for C14H19NO2: 233.1416; found 233.1418. 
FTIR (ATR): υmax = 2960 (m, ArC-H), 1304 (s, C-N), 1038 (s, C-O) cm-1. 
5.4.13. Synthesis of 6,7-Dihydro-5H-[1,3]dioxolo[4,5-f]-5,5,6,7,7-
pentamethylisoindolin-6-yloxyl (Methylenedioxy TMIO) 157 
 
m-Chloroperoxybenzoic acid (258 mg, 889 µmol, 1.3 equiv, 77%) was added to a 
reaction mixture containing methylenedioxy TMI 154 (150 mg, 684 µmol, 1 equiv.) 
and NaHCO3 (86 mg, 1 mmol, 1.5 equiv.) in DCM (100 mL) at 0 oC. The cooling 
bath was removed after 30 min and the mixture was stirred at RT for a further 1.5 h. 
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then dried over anhydrous Na2SO4. The filtrate was concentrated in vacuo and the 
crude residue was purified by flash column chromatography (Hexane/EtOAc, 5:1) to 
give methylenedioxy TMIO 157 as a bright yellow solid (143 mg, 89%). Mp. 188-
189 °C. HPLC purity (>95%). HRMS (ESI): m/z (%) = 236.1612 (55) [M + 2H]+, 
257.0991 (100) [M + Na]+; calcd. for C13H16NO3•: 234.1130; found 234.1132. FTIR 
(ATR): υmax = 2978 (m, ArC-H), 1303 (s, C-N), 1036 (s, C-O) cm-1.  
5.4.14. Synthesis of 1,1,3,3-Tetraethylisoindoline 344 
 
A suspension of 2-benzyl-1,1,3,3-tetraethylisoindoline 343 (2 g, 6.22 mmol, 1 
equiv.) and Pd/C (200 mg, 10% wt.) in AcOH (30 mL) was shaken under an 
atmosphere of H2 (50 psi in a Parr apparatus) for 3 h. The resulting mixture was 
filtered through Celite, concentrated under reduced pressure and basified with NaOH 
(1 M). The residue was extracted with DCM (60 mL x 4) and the DCM layer was 
washed with brine (40 mL). The DCM layer was dried over anhydrous Na2SO4 and 
concentrated under reduced pressure to give 1,1,3,3-tetraethylisoindoline 344 as pale 
yellow oil (1.35 g, 94%). The product was of sufficient purity by 1H NMR 
spectroscopy and was used in the subsequent step without further purification. 1H 
NMR (CDCl3, 400 MHz): δ = 0.88 (t, 12 H, J = 7.2 Hz, CH3), 1.70 (m, 8 H, J = 7.2 
Hz, CH2), 7.07 (m, 2 H, Ar-H), 7.21 (m, 2 H, Ar-H) ppm. 13C NMR (CDCl3, 100 
MHz): δ = 8.9 (CH3), 33.8 (CH2), 68.3 (C-CH2), 122.4 (Ar-C), 126.5 (Ar-C), 147.5 
(Ar-C) ppm.344 
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A solution of H5IO6 (969 mg, 3.49 mmol, 0.8 equiv.) in H2SO4 (15 mL, 98%) was 
cooled to 0 oC. KI (1.95 g, 11.77 mmol, 2.7 equiv.) was then added portionwise and 
the resulting dark-brown iodinium solution was stirred for 20 min. The iodinium 
solution was then added dropwise to a solution of 1,1,3,3-tetraethylisoindoline 344 
(1.2 g, 4.36 mmol, 1 equiv.) in H2SO4 (10 mL, 98%). The resulting mixture was 
stirred for 3 h and then poured onto ice (200 mL) with care. The solution was 
basified with NaOH (10 M) and extracted with DCM (60 mL x 4). The combined 
DCM extracts were washed with saturated Na2S2O3 (30 mL x 2) and brine (40 mL) 
solutions, and then dried over anhydrous Na2SO4. The solvent was removed under 
reduced pressure and the crude residue obtained was purified by silica gel 
chromatography (DCM) to give 5,6-diiodo-1,1,3,3-tetraethylisoindoline 345 as an 
off-white solid (1.68 g, 80%). Mp. 80–81 °C (Lit.,49 80–81 °C). 1H NMR (CDCl3, 
400 MHz): δ = 0.85 (t, 12 H, J = 7.6 Hz, CH3), 1.60 (m, 8 H, J = 7.6 Hz, CH2), 7.55 
(s, 2 H, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 8.8 (CH3), 33.5 (CH2), 68.1 
(CCH2), 105.1 (Ar-C), 133.4 (Ar-C), 150.3 (Ar-C) ppm.  
5.4.16. Synthesis of 5,6-Dimethoxy-1,1,3,3-tetraethylisoindoline 346  
 
A reaction mixture containing 5,6-iodo-1,1,3,3-tetramethylisoindoline 345 (2.5 g, 
5.17 mmol, 1 equiv.), CuI (118 mg, 620 μmol, 0.12 equiv.), DMF (5 mL) and 
NaOMe (15 mL, 25% wt./v in MeOH) were refluxed for 24 h under an Ar 
atmosphere. The reaction was allowed to cool to room temperature, then diluted with 
water and extracted with Et2O (60 mL x 4). The combined Et2O extracts were 
washed with brine (40 mL), dried over anhydrous Na2SO4, and concentrated in 
vacuo. The crude residue was purified by silica gel column chromatography (CHCl3) 
to give 5,6-dimethoxy-1,1,3,3-tetraethyl isoindoline 346 as a white solid (1.236 g, 
82%). Mp. 58-59 oC. HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 0.87 
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6.55 (s, 2 H, Ar-H) ppm. 13C NMR (CDCl3, 100 MHz): δ = 9.0 (CH3), 33.9 (CH2), 
56.1 (OCH3), 68.3 (C-CH2), 120.3 (Ar-C), 105.5 (Ar-C), 139.2 (Ar-C), 148.3 (Ar-C) 
ppm. FTIR (ATR): υmax = 3380 (w, N-H), 2960 (m, ArC-H), 1218 (s, C-N), 1162 (s, 
C-O) cm-1. HRMS (ESI): m/z (%) = 192.2229 (100) [M + H]+; calcd. for 
C18H29NO2: 191.2198; found 191.2196. 







A solution of 5,6-dimethoxy-1,1,3,3-tetraethylisoindoline 346 (250 mg, 858 µmol, 1 
equiv.) in aqueous HBr (5 mL, 48%) was refluxed overnight and the reaction mixture 
allowed to return to RT. The resulting precipitate was filtered, washed with Et2O (10 
mL x 3) and dried under high vacuum to give a grey powder of 5,6-dihydroxy-
1,1,3,3-tetraethylisoindoline 158 as the hydrobromide salt (243 mg, 83%). Mp. 251-
252 oC (dec.). 1H NMR ((CD3)2SO, 400 MHz): δ = 0.92 (t, 12 H, J = 8 Hz, CH3), 
1.91 (m, 8 H, J = 8 Hz, CH2), 6.6 (s, 2 H, Ar-H), 8.48 (s, 2 H, NH2), 9.23 (s, 2 H, 
OH) ppm. 13C NMR ((CD3)2SO, 100 MHz): δ = 8.7 (CH3), 30.1 (CH2), 74.6 (C-
CH2), 110.2 (Ar-C), 131.4 (Ar-C), 146.5 (Ar-C) ppm. HRMS (ES): m/z (%) = 
264.1955 (100) [M]+, calcd. for C16H26NO2+: 264.1958; found 264.1955. ATR-
FTIR: υmax = 3343 (s, br, OH), 2968 (m, ArCH), 1303 (s, C-N), 1174 (s, C-O) cm-1. 
Synthesis of Novel Catechol-Based Nitroxides as Potential Multifunctional Antioxidants 
292  
5.4.18. Synthesis of 5-Hydroxy-6-((tert-butyldimethylsilyl)oxy)-1,1,3,3-





R = H (347), TBDMS (348)
O
  
A solution of 5,6-dihydroxy-1,1,3,3-tetraethylisoindoline hydrobromide 158 (100 
mg, 290 µmol, 1 equiv.), TBDMSCl (219 mg, 1.45 mmol, 5 equiv.), imidazole (99 
mg, 1.45 mmol, 5 equiv.) in DMF (10 mL) was stirred under Ar for 4 days. The 
resulting reaction mixture was diluted with H2O and basified to pH 9 with saturated 
NaHCO3 solution. The aqueous layer was then extracted with Et2O (60 mL x 4) and 
the combined Et2O extracts were washed with brine (30 mL x 5), dried over 
anhydrous Na2SO4 and concentrated under reduced pressure. The crude product 
isolated was a mixture of mono- and di- silyl ether protected compounds 347 and 348 
(123 mg) as verified by 1H NMR spectroscopy and HRMS. 1H NMR (CDCl3, 400 
MHz): δ = [mono silyl ether 347 peaks] 0.1 (s, Si(CH3)2), 0.85 (t, CH2CH3), 0.91 (s, 
SiC(CH3)3), 1.6 (m, CH2CH3), 6.47 (s, 2 H, Ar-H) ppm; [di silyl ether 348 peaks] 
0.096 (s, Si(CH3)2), 0.85 (t, CH2CH3), 0.91 (s, SiC(CH3)3), 1.62 (m, CH2CH3), 6.56 
(s, 2 H, Ar-H) ppm.  HRMS (ESI): m/z (%) = [mono silyl ether 347] 378.2746 (100) 
[M + H]+; calcd. for C22H39NO2Si: 377.2750; found 377.2750; [di silyl ether 348] 
492.3651 (100) [M + H]+; calcd. for C28H53NO2Si2: 491.3615; found 491.3618. 
FTIR (ATR): υmax = 3236 (m, br, O-H), 2929 (m, ArC-H), 1349 (s, C-N), 1249 (s, C-
O) cm-1. 
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5.4.19. Synthesis of 5-Hydroxy-6-((tert-butyldimethylsilyl)oxy)-1,1,3,3-





R = H (349), TBDMS (350)
O
 
m-Chloroperoxybenzoic acid (110 mg, 377 µmol, 1.3, 77%) was added to a reaction 
mixture containing NaHCO3 (37 mg, 435 µmol) and the crude silyl ether TEI 
(mixture of 347 and 348, 123 mg) in DCM (50 mL) at 0 oC. The cooling bath was 
removed after 30 min and stirring was continued at RT for a further 1.5 h. The 
resulting solution was washed with dilute NaOH (0.5 M, 30 mL) and brine solutions 
and dried over anhydrous Na2SO4. The filtrate was concentrated in vacuo to give the 
silyl ether TEIO mixture of 349 and 350 as a bright yellow solid (98 mg). HRMS 
(ESI): m/z (%) = [mono silyl ether 349] 394.2587 (100) [M + 2H]+; calcd. for 
C22H38NO23Si: 392.2621; found 392.2619; [di silyl ether 350] 529.3377 (70) [M + 
Na]+; calcd. for C28H52NO3Si2•: 506.3486; found 506.3485. FTIR (ATR): υmax = 
3235 (m, br, O-H), 2969 (m, ArC-H), 1331 (s, C-N), 1250 (s, C-O) cm-1. 
5.4.20. Synthesis of 5,6-Dihydroxy-1,1,3,3-tetraethylisoindolin-2-yloxyl 160 
(catechol TEIO) 
 
TBAF (2.9 mL, 2.9 mmol, 1 M solution in THF) was added dropwise to a solution of 
the silyl ether TEIO mixture (of 349 and 350, 98 mg) in THF (10 mL) and stirred for 
30 min at RT. The resulting reaction mixture was concentrated under reduced 
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was washed with dilute HCl (0.5 M, 40 mL) and brine (40 mL) and then dried over 
anhydrous Na2SO4. The filtrate was concentrated in vacuo and the crude product 
obtained was triturated with hexane to give 5,6-dihydroxy-1,1,3,3-
tetraethylisoindolin-2-yloxyl 160 as a bright yellow solid (54 mg, 67% from 158). 
Mp. 150-151 °C. HRMS (ESI): m/z (%) = 279.1792 (32) [M + H]+, 301.1705 (40) 
[M + Na]+; calcd. for C16H24NO3•: 278.1756; found 278.1811. FTIR (ATR): υmax = 
3354 (s, br, O-H), 2972 (m, ArC-H), 1219 (s, C-O) cm-1. 
5.4.21. Synthesis of 6,7-Dihydro-5H-[1,3]dioxolo[4,5-f]-5,5,7,7-
tetraethylisoindoline (Methylenedioxy TEI) 159 
 
A solution of 5,6-dihydroxy-1,1,3,3-tetraethylisoindoline hydrobromide 158 (100 
mg, 291 µmol, 1 equiv.), DCM (32 µL, 726 µmol, 2.5 equiv.) and NaOH (58 mg, 
1.45 mmol, 5 equiv.) in DMSO (5 mL) was refluxed for 2 h and the resulting 
reaction mixture was allowed to cool to RT and then diluted with H2O. The crude 
product was extracted with DCM (60 mL x 4) and the combined DCM extracts were 
washed with brine (40 mL), dried over anhydrous Na2SO4 and concentrated under 
reduced pressure. The crude residue was purified by silica gel column 
chromatography (CHCl3) to give methylenedioxy TEI 159 as a clear oil (low melting 
solid) (54 mg, 68%). HPLC purity (>95%). 1H NMR (CDCl3, 400 MHz): δ = 0.89 (t, 
12 H, J = 7.6 Hz, CH3), 1.67 (m, 8 H, J = 7.6 Hz, CH2), 6.05 (s, 2 H, OCH2), 6.59 
(s, 2 H, Ar-H). 13C NMR (CDCl3, 100 MHz): δ = 8.9 (CH3), 33.8 (CH2), 68.2 (C-
CH2), 101.1 (Ar-C), 102.8 (CH2), 140.3 (Ar-C), 146.7 (Ar-C) ppm. HRMS (ESI): 
m/z (%) = 276.1937 (100) [M + H]+; calcd. for C17H25NO2: 275.1885; found 
275.1887. FTIR (ATR): υmax = 3400 (w, N-H), 2950 (m, ArC-H), 1375 (s, C-N), 
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5.4.22. Synthesis of 6,7-Dihydro-5H-[1,3]dioxolo[4,5-f]-5,5,7,7-
tetraethylisoindolin-6-yloxyl (MethylenedioxyTEIO) 161 
 
m-Chloroperoxybenzoic acid (68.5 mg, 236 µmol, 1.3 equiv., 77%) was added to a 
reaction mixture of methylenedioxy TEI 159 (50 mg, 182 µmol, 1 equiv.) and 
NaHCO3 (23 mg, 273 µmol, 1.5 equiv.) in DCM (50 mL) at 0 oC. The resulting 
mixture was stirred for 30 min and then at RT for a further 1.5 h. The resulting 
solution was washed with dilute NaOH (2 M, 20 mL) and brine (30 mL) and then 
dried over anhydrous Na2SO4. The filtrate was concentrated in vacuo and the crude 
residue purified by flash column chromatography (Hexane/EtOAc, 6:1) to give 
methylenedioxy TEIO 161 as a bright yellow solid (45 mg, 85%). Mp. 75-76 °C. 
HPLC purity (>95%). FTIR (ATR): υmax = 2968 (m, ArC-H), 1264 (s, C-N), 1037 
(s, C-O) cm-1. HRMS (ESI): m/z (%) = 313.1648 (100) [M + Na]+; calcd. for 
C17H24NO3•: 290.1956; found 290.1749. 
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Chapter 6: Conclusion and Future Work 
6.1 Conclusion 
As a wider strategy towards developing new therapeutics for managing chronic 
inflammation and oxidative stress-related diseases/disorders, the main aim of this 
PhD research project was to employ the pharmacophore hybridization strategy to 
design, synthesize and evaluate the therapeutic efficacy of novel potential dual-acting 
hybrid nitroxide-based antioxidants. The approach combines various nitroxide 
compounds with known pharmacophores - mainly the NSAID and the 
sympathomemitic stimulants class of drugs. The hybrid agents were constructed by 
either merging/overlapping the two structural subunits or via cleavable (ester and 
amide bonds) and non-cleavable (amine bond) linkers. 
By taking advantage of the structural similarities of the parent templates, the novel 
overlapped nitroxide-salicylate hybrid agents (137, 138 and 139) were designed and 
synthesized by merging the parent pyrroline nitroxide 3 with salicylic acid 135 and 
acetylsalicylic acid 136 templates. The cleavable and non-cleavable nitroxide-
NSAID conjugates such as 140, 141 and 143 were designed by linking various 
nitroxide compounds with selected NSAIDs (salicylic acid 135, aspirin 136, 
indomethacin 164 and 5-ASA 242). 
As anticipated, the merged analogues (137 and 138) displayed moderate antioxidant 
effect by inhibiting the MPO-mediated hypochlorous acid production system. Results 
from preliminary anti-inflammatory efficacy studies indicated that the merged 
hybrids (137 and 138) were less effective in the COX enzyme inhibitory assay than 
the parent aspirin 136. Although the results are encouraging, notably, such COX 
inhibitory effects were only significant after longer incubation times. Thus, this result 
indicated that the merged nitroxide-salicylate derivatives are slow-time dependent 
COX inhibitors. 
Studies to evaluate the antioxidant and anti-inflammatory effects of the novel 
nitroxide-NSAID conjugates (including 140, 143, 144, 233 and 234) were conducted 
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on the A549 Non-Small Cell Lung Cancer cells. In contrast to the merged 
counterparts, the nitroxide-NSAD conjugates displayed significant antioxidant and 
COX inhibitory effects similar to or in some instances better than the parent aspirin. 
Notably, the nitroxide conjugate 140 showed a better ROS scavenging activity than 
the versatile antioxidant, TEMPOL. The ester-linked conjugates (140, 144, 233 and 
234) possessed strong inhibitory effects on the COX enzyme than the amide-linked 
counterparts (228, 229 and 143). Notably, the nitroxide conjugate 140 possessed 
better inhibitory effect on the COX enzyme than parent aspirin 136. In addition to the 
antioxidant and anti-inflammatory effects, compound 140 was shown to inhibit the 
proliferation of A549 NSCLC cells. Clonogenic assay studies of A549 cells indicated 
that combining the conjugate 140 with anticancer agent gefitinib produced a 
synergistic effect on inhibiting A549 cells growth. The anticancer effect of 
compound 140 on A549 cell growth is quite promising and further studies are 
currently being undertaken. 
In addition to the nitroxide-NSAID derivatives, this PhD project also explored the 
design and synthesis of novel merged nitroxide-sympathomemitic stimulants namely 
the nitroxide analogues of L-Dopa 147 and Ritalin 148. Although the key and 
ultimate step (dirhodium-catalyzed intermolecular C-H insertion of methyl 
phenyldiazoacetate 309 into N-Boc-piperidine 306 to give the D-threo-
methylephenedate TMIO methoxyamine derivative 317) in the synthesis of the 
Ritalin-nitroxide analogue 150 was unsuccessful, the Schöllkopf’s bis-lactim ether 
asymmetric synthesis of α-amino acids approach was successfully employed to 
synthesize the target L-Dopa nitroxide derivative 145. By combining the 
Schöllkopf’s methodology with the palladium-catalyzed Sonogashira coupling 
reaction, the rigid alkyne-linked chiral α-amino acid SDSL 151 was also synthesized. 
The synthesis of both the L-Dopa TMIO 149 and the alkyne-linked chiral α-amino 
acid SDSL 151 proceeded smoothly with high enantiomeric purity as verified by 
the 1H NMR spectroscopy analysis of their respectively diastereomeric precursors 
287 and 296.  
The dual-acting hybrid pharmacophore approach was also extended to catecholamine 
and benzodioxole-based compounds. In Chapter 5, the synthesis of a series of 
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isoindoline-based catecholamine and methylenedioxy compounds (154-161) was 
described. As the first class of catechol-based nitroxides, the target nitroxide-
catecholinic-hybrids were mainly designed as potential dual-acting antioxidant 
therapeutics which could also be readily employed as synthetic templates/precursors 
for building functional materials. The target nitroxide-catecholinic-hybrids were 
designed to provide effective antioxidant intervention since the therapeutic benefits 
of common catechol and benzodioxole-based pharmacophores have been limited by 
the oxidative stress-induced cellular damaged linked to their long term use.  
Some synthetic transformations carried out in this work that should be highlighted 
include  
 Optimization of the copper-catalyzed methanolysis and cyanation of aryl 
halides. 
 The use of the acetyl protecting group strategy under boron tribromide 
mediated demethylation conditions. 
 Sodium aceloxyborohydride facilitated-chemoselective reduction of aryl 
amide to the corresponding amine in the presence of esters (employed in the 
synthesis of AAD-2004 TMIO analogue 142). 
 The Schöllkopf’s asymmetric nucleophilic derivatization approach used in 
the synthesis of the novel chiral α-amino acids (149 and 151). 
 The palladium-catalyzed Sonogashira coupling reaction conditions for the 
synthesis of the rigid alkyne-linked α-amino acid nitroxide (151). 
 The palladium-catalyzed decarboxylative coupling of bromoamine precursor 
23 and potassium malonate 316 in the synthesis of methyl ester 223. 
 The Regitz diazo transfer reaction employed in the synthesis of the diazo 
ester 309. 
 The dirhodium-catalyzed intermolecular C-H insertion reaction between N-
Boc piperidine 306 and the transient metal carbene generated in situ from α-
diazo methyl ester 309 in the attempted synthesis of Ritalin-nitroxide 
analogue 150.  
 The silyl ether protecting group approach employed in the synthesis of 
catechol nitroxides 156 and 160. 
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6.2 Future work 
The findings in this PhD project have certainly contributed to the use of the 
pharmacophore hybridization strategy as a practical and cost effective rational drug 
design and development approach. Since the results obtained from the design and 
development of the novel potential dual-acting nitroxide-based drug candidates were 
encouraging, it is therefore anticipated that this work could serve as a useful template 
for future drug design research that could further explore the antioxidant capacity of 
stable nitroxide compounds. Despite the successful synthesis of almost all of the 
target compounds (except Ritalin-TMIO analogue) in this work, only a few selected 
NSAID-nitroxide analogues were evaluated for their therapeutic efficacy. Therefore, 
the ongoing and future work in this project is centred mainly on evaluating the dual-
acting therapeutic effects of the novel hybrid agents and/or their functional 
application. For instance, to fully determine the extent of the inhibitory effects of the 
merged nitroxide-NSAID hybrids (137-139) on the COX enzyme (and whether they 
are slow-time dependent COX inhibitors as was proposed), it is vital to run the COX 
inhibition experiments with these hybrids with incubation (over 20 min). Although 
the preliminary results obtained for the antioxidant and anti-inflammatory effects of 
the nitroxide-NSAID conjugates were conducted with only nine selected compounds, 
currently, further experiments are being undertaken (with all target nitroxide-NSAID 
conjugates) to give a thorough insight into their efficacies as well as the structure-
activity relationships. In the case of the overlapped hybrid L-Dopa TMIO, further 
investigation should focus on evaluating its dual therapeutic efficacy: as an anti-
Parkinson agent (potential dopamine replacement therapeutic) that could also provide 
remedy for oxidative stress damage, whether drug-induced or from the PD 
pathogenesis or both. 
Experiments are currently planned through collaborations to incorporate and the rigid 
alkyne-linked chiral α-amino acid SDSL 151 into a peptide and subsequently study 
the structural and dynamic nature of the macromolecule through EPR spectroscopy 
and fluorescence. 
Furthermore, it would be worthwhile to evaluate different dirhodium catalysts (such 
as Rh2(S-biTISP)2) for the intermolecular C-H insertion reaction between N-Boc 
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piperidine 306 and the transient metal carbene generated in situ from α-diazo methyl 
ester 309.  
Also, since the nitroxide-NSAID conjugate 140 possessed synergistic anti-cancer 
effects when combined with the anti-cancer agent gefitinib 350, synthesizing and 
biological evaluation of a gefitinib-nitroxide conjugate such as 351 could be 
intriguing. Scheme 6.1 below outlines the proposed route for the synthesis of the 
gefitinib-nitroxide conjugate 351. 
 
Figure 6.1. Chemical structure of gefitinib 350 and its amino-TEMPO analogue 351. 
 
Scheme 6.1. Proposed synthetic route to gefitinib amino-TEMPO derivative 351. 
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